Quality of life in patients with lung cancer: an epidemiological study by Montazeri Moghaddam, Ali
 
 
 
 
 
 
Montazeri Moghaddam, Ali  (1996) Quality of life in patients with lung 
cancer: an epidemiological study. PhD thesis. 
 
 
 
http://theses.gla.ac.uk/1828/
 
 
 
 
 
 
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given 
 
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk University  of  Glasgow 
Faculty  of  Medicine 
Department  of  Public  Health 
Quality  of  Life  in  Patients  with  Lung 
Cancer: 
An  Epidemiological  Study 
Ali  Montazeri  Moghaddam,  B.  Sc.,  M.  P.  H. 
Thesis  submitted  to  the  Faculty  of  Medicine  of  University 
of  Glasgow  for  the  degree  of 
Doctor  of  Philosophy  (Ph.  D.  ) 
August  1996 
©  Ali  Montazeri  Moghaddam  1996 
- In  the  name  of  God 
... 
Dedicated  to  my  parents,  my  wife,  and  my  children 
and 
In  memory  of  my  beloved  brothers  Reza  and  Elyas 
2 Declaration 
This  thesis  is  submitted  in  fulfilment  of  the  requirements  for  the  degree  of  Doctor 
of  Philosophy  at  the  University  of  Glasgow,  Faculty  of  Medicine,  Department  of 
Public  Health.  Unless  stated  otherwise,  the  work  is  that  of  the  author. Contents 
-  Contents 
...........................................  4  ................................................. 
-  List  of  Tables  9  .................................................................................... 
-  List  of  Figures 
.........................................  12  .......................................... 
-  List  of  Appendices 
............................................................................  13 
-  List  of  publications  14  ........................................................................... 
-  Key  to  the  thesis  16  ............................................................................... 
-  Acknowledgements  17  .......................................................................... 
-  Abstract  19  ............................................................................................. 
-  Introduction  to  the  study  ...................................................................  21 
CHAPTER  ONE:  STUDY  BACKGROUND 
- 
- 
1. 
2. 
3. 
4. 
5. 
6. 
6.1. 
6.1.1. 
6.1.2. 
6.1.3. 
6.2. 
6.2.1. 
6.2.2. 
6.2.3. 
6.3. 
7. 
7.1. 
7.2. 
Summary 
........................................................................................... 
Introduction 
...................................................................................... 
Global  overview  ...............................................................................  Diagnosis  of  lung  cancer  .................................................................. 
Screening  for  lung  cancer  ................................................................. 
Types  of  lung  cancer  ......................................................................... 
Staging  of  disease 
............................................................................. 
Treatment  of  lung  cancer  .................................................................. 
Small  cell  lung  cancer  ...................................................................... 
Surgery 
....................................................................  ......................  Radiotherapy 
..................................................................................... 
Chemotherapy 
...................................................................................  Non-small  cell  lung  cancer  ...............................................................  Surgery 
.............................................................................................. 
Radiotherapy 
..................................................................................... 
Chemotherapy 
................................................................................... 
Supportive  care  ................................................................................. 
Symptoms  of  lung  cancer  ................................................................. 
Disease-related  symptoms  ................................................................ 
Treatment-related  symptoms  (side-effects) 
...................................... 
26 
27 
28 
31 
31 
32 
33 
34 
34 
34 
34 
34 
35 
35 
35 
36 
36 
37 
37 
38 
7.2.1.  Potential  complication  of  surgery  .....................................................  38 
7.2.2. 
7.2.3. 
8. 
9. 
Side-effects  of  radiotherapy  .............................................................. 
Side  effects  of  chemotherapy  ............................................................  Lung  cancer  in  Scotland 
................................................................... 
Lung  cancer  and  socio-economic  deprivation 
.................................. 
38 
39 
40 
41 
10. 
10.1. 
Preliminary  investigations 
................................................................  Communication  with  cancer  patients:  Tak  Tent  study  ..................... 
44 
45 
10.2.  Quality  of  life  in  patients  with  ovarian  cancer  ..................................  45 
11.  Conclusion 
........................................................................................  47 
CHAPTER  TWO:  MEASURING  QUALITY  OF  LIFE: 
EXPERIENCES  FROM  THE  TREATMENT  OF  CANCER 
-  Summary 
...........................................................................................  49 
Introduction 
......................................................................................  50 
1.  Outcome:  measuring  health,  "hard"  and  "soft"  data 
....................... 
50 
4 2.  Quality  of  life:  meaning  and  purposes  ..............................................  52 
3.  Quality  of  life:  controversies  ............................................................  56 
3.1.  The  use  of  objective  measures  ..........................................................  56 
3.2.  Definitions  of  quality  of  life 
.............................................................  58 
3.3.  Differing  approaches  ........................................................................  59 
3.4.  Use  of  general  or  specific  measures  ................................................. 
60 
3.5.  Major  dimensions  to  be  included 
..................................................... 
63 
3.6.  Who  should  measure  ........................................................................  64 
4.  Experiences  from  the  treatment  of  cancer  ........................................ 
67 
4.1.  Quality  of  life  and  survival  ...............................................................  68 
4.2.  Contribution  to  development  of  cancer  treatment  ............................ 
70 
4.3.  Identification  of  psychological  needs  ............................................... 
71 
4.4.  Quality  of  life  and  alternative  therapy  .............................................. 
72 
4.5.  Obtaining  additional  information 
..................................................... 
73 
5.  New  directions 
..................................................................................  74 
6.  Conclusion 
........................................................................................ 
76 
CHAPTER  THREE:  QUALITY  OF  LIFE  IN  PATIENTS  WITH  LUNG 
CANCER 
-  Summary  ...........................................................................................  80 
-  Introduction 
......................................................................................  81 
1.  Quality  of  life  in  lung  cancer  patients  in  general  ..............................  82 
1.1.  Instruments 
....................................................................................... 
83 
1.2.  General  findings 
............................................................................... 
85 
1.2.1.  Performance  status  ............................................................................ 
85 
1.2.2.  Quality  of  life  as  a  prognostic  factor 
................................................  87 
1.2.3.  Psychological  issues 
......................................................................... 
87 
1.2.4.  Symptom  distress 
.............................................................................. 
89 
1.3.  Communication 
................................................................................ 
90 
2.  Quality  of  life  in  patients  with  small  and  non-small  lung  cancer.....  91 
2.1.  Small  cell  lung  cancer  ......................................................................  92 
2.1.1.  Tumour  response  ..............................................................................  92 
2.1.2.  Intensive  versus  less  intensive  therapy  ............................................. 
93 
2.1.3.  Radiotherapy  .....................................................................................  95 
2.2.  Non-small  cell  lung  cancer  ...............................................................  96 
2.2.1.  Chemotherapy 
................................................................................... 
96 
2.2.2.  Chemotherapy  and  best  supportive  care  ........................................... 
97 
2.2.3.  Radiotherapy  .....................................................................................  98 
2.2.4.  Adjuvant  chemotherapy  with  radiotherapy  ....................................... 
99 
2.2.5.  Surgery 
.............................................................................................. 
100 
3.  Discussion  and  conclusions  .............................................................. 
100 
4.  Summary  Tables 
............................................................................... 
105 
CHAPTER  FOUR:  AIMS  AND  OBJECTIVES 
1.  Aims 
................................................................................................. 
128 
2.  Objectives 
......................................................................................... 
128 
3.  Hypotheses 
........................................................................................ 
129 CHAPTER  FIVE:  MATERIALS  AND  METHODS 
-  Summary 
...........................................................................................  131 
-  Introduction 
...................................................................................... 
132 
1.  Setting 
............................................................................................... 
132 
1.1.  Stobhill  Hospital  catchment  area  ..................................................... 
132 
1.2.  Department  of  Respiratory  Medicine  ............................................... 
134 
2.  Design 
............................................................................................... 
135 
2.1.  Baseline  assessment  .......................................................................... 
135 
2.2.  Follow-up  assessment  ....................................................................... 
136 
3.  Patients 
............................................................................................. 
138 
3.1.  Cases 
................................................................................................. 
138 
3.2.  Controls 
............................................................................................ 
138 
4.  Materials  ........................................................................................... 
139 
4.1.  The  Nottingham  Health  Profile  (NHP) 
............................................. 
139 
4.2.  The  European  Organisation  for  Research  and  Treatment  of  Cancer 
Quality  of  Life  Questionnaire  (EORTC  QLQ-C30) 
......................... 
142 
4.3.  The  EORTC  QLQ  Lung  Cancer  Questionnaire  (EORTC  QLQ- 
LC  13) 
................................................................................................ 
144 
4.4.  Study  specific  questionnaires  ........................................................... 
145 
4.4.1.  Socio-demographic  questionnaire  .................................................... 
145 
4.4.2.  Acceptability  questionnaire  ..............................................................  147 
4.4.3.  Quality  of  life:  patients'  perceptions  ................................................ 
148 
4.5.  Additional  study  measures  ............................................................... 
148 
4.5.1.  Clinical  variables  .............................................................................. 
148 
4.5.2.  ECOG  Performance  Scale  ................................................................ 
148 
5.  Data  collection  .................................................................................. 
149 
5.1.  Baseline  data  collection  .................................................................... 
149 
5.2.  Follow-up  data  collection  ................................................................. 
150 
5.3.  Interviewer-administered  approach  .................................................. 
150 
5.4.  Time  spent  interviewing  and  travelling  ............................................ 
151 
5.5.  Other  sources  of  identification  of  cases  ............................................ 
152 
6.  Analysis  ............................................................................................ 
154 
6.1.  Coding 
.............................................................................................. 
154 
6.2.  Presentation  of  data  and  statistical  tests  ........................................... 
155 
6.2.1.  Categorical  data  and  Chi-square  test  ................................................ 
155 
6.2.2.  Numerical  data  and  non-parametric  tests  ......................................... 
155 
6.2.3.  Logistic  regression  analysis  .............................................................. 
156 
6.2.4.  Cox  regression  analysis  .................................................................... 
157 
6.2.5.  Content  analysis  ................................................................................ 
157 
6.3.  Sample  size  and  the  power  of  the  study  ........................................... 
158 
7.  Limitations  and  difficulties 
............................................................... 
158 
7.1.  Study  design 
..................................................................................... 
158 
7.2.  Follow-up  of  controls  ....................................................................... 
159 
7.3.  Interview  settings  .............................................................................. 
159 
7.4.  Blindness 
.......................................................................................... 
159 
7.5.  Samples 
............................................................................................ 
160 
7.6.  Missing  cases  .................................................................................... 
160 
7.7.  Difficulties 
........................................................................................ 
160 
6 CHAPTER  SIX:  RESULTS 
-  Introduction 
......................................................................................  163 
1.  Study  population  ...............................................................................  163 
1.1.  Socio-demographic  characteristics  ...................................................  165 
1.2.  Social  network  and  social  support  .................................................  .. 
167 
1.3.  .  Housing  and  family  structure  ...........................................................  168 
1.4.  Patients'  characteristics,  local,  and  national  figures 
.........................  171 
2.  Baseline  assessments  ........................................................................  172 
2.1.  The  Nottingham  Health  Profile  (NHP) 
.............................................  172 
2.2.  The  European  Organisation  for  Research  and  Treatment  of  Cancer 
Quality  of  Life  questionnaire  (EORTC  QLQ-C30  and  QLQ-LC13)........  175 
2.2.1  Functioning  and  global  quality  of  life 
..............................................  175 
2.2.2  Main  symptoms  ................................................................................  177 
2.3.  Baseline  quality  of  life  and  socio-economic  deprivation 
................. 
178 
2.3.1.  The  NHP  by  Deprivation  Category 
..........................................  . 
178 
2.3.2. 
.......  The  EORTC  questionnaires  by  Deprivation  Category 
.................... 
181 
2.4.  Pain  medication  ................................................................................  184 
2.5.  Prediction  of  baseline  quality  of  life, 
................................................  184 
2.5.1.  Emotional  problems  .........................................................................  185 
2.5.2.  Social  isolation... 
................................  0  .............................................  187 
2.5.3.  Global  quality  of  life.,  .......................................................................  187 
2.6.  Does  interview  setting  matter?  .........................................................  190 
2.7.  Does  knowing  diagnosis  matter?  ....................................  ..................  192 
3.  Follow-up  assessments  .....................................................................  196 
3.1.  Baseline  quality  of  life  as  indicator  of  length  of  survival  ................. 
199 
3.1.1.  Descriptive  analysis  ..........................................................................  199 
3.1.2.  Cox  regression  analysis  ....................................................................  201 
3.1.3  Split  in  survivals  and  non-survivals  .................................................  203 
3.1.4  Cox  regression  analysis-forward  selection  of  variables  ................... 
203 
3.2.  Comparing  baseline  with  follow-up  assessments  .............................  208 
3.2.1.  General  health 
...................................................................................  208 
3.2.2.  Functioning  and  global  quality  of  life 
..............................................  208 
3.2.3.  Symptoms 
.........................................................................................  209 
3.3.  Quality  of  life  and  different  types  of  treatments  ...............................  212 
3.3.1  General  health., 
............................................  o  ....................................  212 
3.3.2.  Functioning  and  global  quality  of  life 
.............................................. 
213 
3.3.3.  Symptoms 
.........................................................................................  213 
3.4.  Small  and  non-small  cell  lung  cancer  and  quality  of  life 
................. 
218 
3.4.1.  Comparing  quality  of  life  in  small  and  non-small  cell  lung  cancer  ..........  218 
3.4.2.  Effects  of  treatment  on  small  and  non-small  cell  lung  cancer..........  222 
3.5.  Limited  and  extensive  diseases  and  quality  of  life, 
...............  0  ..........  226 
3.5.1.  Comparison  between  limited  and  extensive  diseases 
....................... 
226 
3.5.2.  Effects  of  treatment  on  patients  with  limited  and  extensive  disease.........  230 
3.6.  Pain  medication  at  follow-up 
............................................................  233 
3.7.  Prediction  of  global  quality  of  life  at  follow-up  assessments...........  233 
4.  Evaluation  of  study  acceptability  ...................................................... 
239 
5.  Patients'  perceptions  of  quality  of  life 
.............................................. 
244 
5.1.  Definition  of  quality  of  life  by  patients  ............................................ 
244 
7 5.2.  A  good  quality  of  life  as  perceived  by  patients  ................................ 
244 
5.3.  Order  of  importance 
.........................................................................  245 
CHAPTER  SEVEN:  DISCUSSION 
-  Introduction 
......................................................................................  250 
1.  General  discussion 
............................................................................  250 
1.1.  The  study  findings 
............................................................................  250 
1.2.  Quality  of  life 
....................................................................................  251 
1.3.  Methodological  issues 
......................................................................  254 
1.4.  What  should  be  assessed?  .................................................................  260 
1.5.  How  to  influence  clinical  practice  .................................................... 
263 
2.  Study  population  ...............................................................................  264 
2.1.  Representativeness 
........................................................................... 
264 
2.2.  Missing  cases  ....................................................................................  265 
2.3.  Characteristics  of  cases  and  controls  ................................................ 
266 
2.4.  Social  support  ...................................................................................  267 
3.  Baseline  quality  of  life 
......................................................................  268 
3.1.  Quality  of  life  in  cases  and  controls  ................................................. 
269 
3.2.  Quality  of  life  and  deprivation 
..........................................................  273 
3.3.  What  predicts  the  baseline  quality  of  life? 
.......................................  275 
3.4.  Interview  setting  ............................................................................... 
277 
3.5.  Knowing  the  diagnosis  of  cancer  and  its  relation  to  the  outcomes..  279 
4.  Follow-up  assessments  ..................................................................... 
280 
4.1.  Baseline  quality  of  life  as  a  predictor  of  survival  ............................. 
280 
4.2.  Baseline  versus  follow-up  quality  of  life 
.......................................... 
283 
4.3.  Effects  of  different  treatment  policies  ..............................................  285 
4.4.  Small  cell  versus  non-small  cell  lung  cancer  .................................... 
287 
5.  Patients'  reactions  to  the  study  .........................................................  288 
CHAPTER  EIGHT:  CONCLUSIONS  AND  RECOMMENDATIONS 
1.  Conclusions 
......................................................................................  293 
2.  Recommendations 
............................................................................  298 
-  References 
...........................................................................  302 
-  Appendices  ..........................................................................  333 
8 List  of  Tables 
1.1  Main  types  of  lung  cancer  ..................................................................  32 
1.2  Staging  system  for  small  cell  lung  cancer  .......................................... 
33 
1.3  Simplified  staging  system  for  non-small  cell  lung  cancer  ................. 
33 
1.4  Some  common  symptoms  in  lung  cancer  patients  at  presentation....  38 
1.5  Some  common  treatment-related  symptoms  in  lung  cancer  patients.  39 
2.1.  Examples  of  variations  in  purposes  of  quality  of  life  studies............  55 
3.1.  Summary  of  review  papers  of  quality  of  life  studies  in  patients 
with  lung  cancer  ................................................................................. 
107 
3.2  Summary  of  quality  of  life  studies  in  patients  with  lung  cancer........  109 
3.3  Summary  of  quality  of  life  studies  in  patients  with  cancer  including 
lung  cancer  ......................................................................................... 
114 
3.4  Quality  of  life  measures  used  in  lung  cancer  studies  ......................... 
116 
3.5  Summary  of  quality  of  life  studies  in  patients  with  small  cell  lung 
cancer  ................................................................................................. 
118 
3.6  Summary  of  quality  of  life  studies  in  patients  with  non-small  cell 
lung  cancer  ......................................................................................... 
123 
5.1  Population  living  at  differing  levels  of  Deprivation:  Stobhill  catch- 
ment  area,  Greater  Glasgow,  Scotland,  and  England  &  Wales.........  133 
5.2  Census  1991  statistics  for  selected  postcode  sectors  from  Stobhill 
catchment  area  ................................................................................... 
134 
5.3  New  referrals  to  Department  of  Respiratory  Medicine  -  Stobhill 
Hospital,  1995  .................................................................................... 
135 
5.4  Lung  cancer  cases  registered  from  Stobhill  Hospital-1994 
............... 
138 
5.5  Content  of  QLQ-C36  and  QLQ-C30 
.................................................  142 
5.6  ECOG  Performance  Status  Scale 
.......................................................  149 
6.1  Excluded  and  missing  cases  ...............................................................  165 
6.2  Socio-demographic  characteristics  of  study  population  .................... 
166 
6.3  Patients'  social  network  and  social  support  ....................................... 
168 
6.4  Patients'  housing  and  family  structure  170 
6.5  Patients'  characteristics  compared  with  available  local,  and 
national  figures 
.................................................................................. 
171 
6.6  Baseline  scores  on  NHP-Part  I  by  cases  and  controls  ........................ 
174 
6.7  Baseline  functioning  and  global  quality  of  life  scores  on  EORTC 
QLQ-C30  by  cases  and  controls  ........................................................ 
176 
6.8  Baseline  scores  of  main  symptoms  on  EORTC  QLQ-C30  and 
QLQ-LC  13  by  cases  and  controls  ...................................................... 
178 
6.9  Patients'  baseline  scores  on  NHP-Part  I  by  Deprivation  Category 
.... 
180 
6.10  Patients'  baseline  functioning  and  global  quality  of  life  scores  on 
EORTC  QLQ-C30  by  Deprivation  Category 
..................................... 
182 
6.11  Patients'  baseline  scores  of  main  symptoms  on  EORTC  QLQ-C30 
and  QLQ-LC13  by  Deprivation  Category 
.......................................... 
183 
6.12  Patients'  baseline  scores  on  NHP-Part  I  by  interview  settings..........  191 
6.13  Patients'  baseline  functioning  and  global  quality  of  life  scores  on 
EORTC  QLQ-C30  by  interview  settings  ........................................... 
191 
6.14  Patients'  baseline  scores  of  main  symptoms  on  EORTC  QLQ-C30 
and  QLQ-LC  13  by  interview  settings  ................................................ 
192 
9 6.15  Baseline  scores  on  NHP-Part  I  by  patients  who  knew  their  cancer 
diagnosis  and  those  who  did  not  know 
.............................................. 
194 
6.16  Baseline  functioning  and  global  quality  of  life  scores  on  EORTC 
QLQ-C30  by  patients  who  knew  their  cancer  diagnosis  and  those 
who  did  not  know 
..............................................................................  194 
6.17  Baseline  scores  of  main  symptoms  on  EORTC  QLQ-C30  and 
QLQ-LC13  by  patients  who  knew  their  cancer  diagnosis  and  those 
who  did  not  know 
..............................................................................  195 
6.18  Lung  cancer  patients'  demographic  and  clinical  characteristics........  198 
6.19  Lung  cancer  patients'  baseline  scores  on  NHP-Part  I 
........................ 
200 
6.20  Lung  cancer  patients  baseline  functioning  and  global  quality  of  life 
scores  on  EORTC  QLQ-C30 
............................................................. 
200 
6.21  Lung  cancer  patients'  baseline  and  follow-up  scores  on  NHP-Part  I.........  210 
6.22  Lung  cancer  patients'  baseline  and  follow-up  functioning  and 
global  quality  of  life  scores  on  EORTC  QLQ-C30 
........................... 
210 
6.23  Lung  cancer  patients'  baseline  and  follow-up  symptoms  scores  on 
EORTC  QLQ-C30  and  QLQ-LC  13 
................................................... 
211 
6.24  The  changes  in  lung  cancer  patients'  general  health  status  scores  as 
measured  by  NHP-Part  I  before  and  after  treatment  .......................... 
215 
6.25  The  changes  in  lung  cancer  patients'  functioning  and  global  quality 
of  life  scores  as  measured  by  EORTC  QLQ-C30  before  and  after 
treatment  ............................................................................................  216 
6.26  The  changes  in  lung  cancer  patients'  symptoms  scores  as  measured 
by  EORTC  QLQ-C30  and  QLQ-LC13  before  and  after  treatment....  217 
6.27  Comparison  of  small  and  non-small  cell  lung  cancer  patients' 
scores  at  baseline  and  follow-up  assessments  on  NHP-Part  I...........  220 
6.28  Comparison  of  small  and  non-small  cell  lung  cancer  patients' 
functioning  and  global  quality  of  life  scores  at  baseline  and  follow- 
up  assessments  on  EORTC  QLQ-C30 
...............................................  220 
6.29  Comparison  of  small  and  non-small  cell  lung  cancer  patients' 
symptoms  scores  on  EORTC  QLQ-C30  and  QLQ-LC13  at 
baseline  and  follow-up  assessments  ..................................................  221 
6.30  Small  and  non-small  cell  lung  cancer  patients'  general  health  mean 
scores  on  NHP-Part  I  before  and  after  treatment  ............................... 
224 
6.31  Small  and  non-small  cell  lung  cancer  patients'  functioning  and 
global  quality  of  life  mean  scores  on  EORTC  QLQ-30  before  and 
after  treatment  ....................................................................................  224 
6.32  Small  and  non-small  cell  lung  cancer  patients'  symptoms  mean 
scores  on  EORTC  QLQ-C30  and  QLQ-LC13 
................................... 
225 
6.33  Comparison  of  scores  of  patients  with  limited  and  extensive 
disease  on  NHP-Part  I  at  baseline  and  follow-up 
.............................. 
228 
6.34  Comparison  of  functioning  and  global  quality  of  life  scores  of 
patients  with  limited  and  extensive  disease  on  EORTC  QLQ-C30 
at  baseline  and  follow-up 
...................................................................  228 
6.35  Comparison  of  symptoms  scores  of  patients  with  limited  and 
extensive  disease  on  EORTC  QLQ-C30  and  QLQ-LC13  at 
baseline  and  follow-up 
.......................................................................  229 
10 636  Patients'  mean  scores  on  NHP-Part  I  before  and  after  treatment  by 
those  who  had  limited  disease  and  those  with  extensive  disease......  231 
6.37  Patients'  functioning  and  global  quality  of  life  mean  scores  on 
EORTC  QLQ-C30  before  and  after  treatment  by  those  who  had 
limited  disease  and  those  with  extensive  disease 
..............................  231 
6.38  Patients'  symptoms  mean  scores  on  EORTC  QLQ-C30  and  QLQ- 
LC13  before  and  after  treatment  by  those  who  had  limited  disease 
and  those  with  extensive  disease 
.......................................................  232 
6.39  Patients'  reactions  toward  the  study  (acceptability  questionnaire)....  241 
6.40  Patients'  preferences  by  their  demographic  characteristics,  general 
health  status,  global  quality  of  life,  and  interview  setting  ................. 
242 
6.41  Patients'  views  on  why  they  found  being  interviewed  acceptable  by 
their  demographic  characteristics,  general  health  status,  global 
quality  of  life,  and  interview  setting  ..................................................  243 
6.42  Definition  of  quality  of  life  by  lung  cancer  cases  and  chronic 
respiratory  disease  controls  ......................................................... 
247 247 
6.43  A  good  quality  of  life  as  perceived  by  lung  cancer  cases  and 
chronic  respiratory  disease  controls  ................................................... 
247 
6.44  Dimensions  of  life  mentioned  as  a  good  quality  of  life  in  order  of 
importance  (overall  results)  ............................................................... 
248 
6.45  Dimensions  of  life  mentioned  as  a  good  quality  of  life  in  order  of 
importance  by  cases  and  controls  ...................................................... 
248 List  of  Figures 
5.1  A  schematic  view  of  the  study  design 
................................................ 
137 
5.2  The  procedure  of  data  collection  ......................................................... 
153 
6.1  A  schematic  presentation  of  study  samples  ........................................ 
164 
6.2  NHP-Part  I  by  cases  and  controls  ........................................................ 
174 
6.3  EORTC  QLQ-C30  by  cases  and  controls  ........................................... 
176 
6.4  NHP-Part  I  by  Deprivation  Category 
.................................................. 
180 
6.5  EORTC  QLQ-C30  by  Deprivation  Category 
...................................... 
182 
6.6  Logistic  regression  analysis-Baseline  emotional  reactions  ................. 
186 
6.7  Logistic  regression  analysis-Baseline  social  isolation 
........................ 
188 
6.8  Logistic  regression  analysis-Baseline  global  quality  of  life 
................ 
189 
6.9  A  schematic  view  of  study  population  at  follow-up  stage  .................. 
197 
6.10  Cox  regression  analysis-survival  and  hazard  function  by  the 
baseline  general  health  status  as  measured  by  NHP 
...........................  205 
6.11  Cox  regression  analysis-Survival  and  hazard  function  by  baseline 
functioning  as  measured  by  the  EORTC  QLQ-C30 
...........................  206 
6.12  Cox  regression  analysis-Survival  and  hazard  function  by  the  baseline 
global  quality  of  life  as  measured  by  the  EORTC  QLQ-C30 
...................... 
207 
6.13  Logistic  regression  analysis-Follow  up  global  quality  of  life  and 
functioning 
..........................................................................................  236 
6.14  Logistic  regression  analysis-Follow  up  global  quality  of  life  and 
symptoms  ............................................................................................  236 
6.15  Logistic  regression  analysis-Follow  up  global  quality  of  life  and 
prognostic  factors 
................................................................................  237 
6.16  Logistic  regression  analysis-Follow  up  global  quality  of  life  and 
NHP 
....................................................................................................  237 
6.17  Logistic  regression  analysis-Follow-up  global  quality  of  life  and 
socio-demographic,  clinical  and  social  support  variables  ...................  238 
12 List  of  Appendices 
I  Letter  to  Tak  Tent 
.............................................................................. 
334 
II  Tak  Tent:  does  cancer  support  work?  Studies  of  a  cancer  support 
group  .................................................................................................. 
336 
III  Letter  sent  to  General  Practitioners  in  Stobhill  Hospital  catchment 
area  ..................................................................................................... 
361 
IV  Patient  referral  form 
........................................................................... 
364 
V  The  Nottingham  Health  Profile  Part  I  ................................................ 
366 
VI  The  EORTC  QLQ-C30  and  QLQ-LC13 
............................................ 
372 
VII  Correspondence  with  the  EORTC  Quality  of  Life  Unit  and  user's 
agreement  ........................................................................................... 
376 
VIII  Study  specific  questionnaire  .............................................................. 
387 
IX  Acceptability  questionnaire  ............................................................... 
391 
X  Letter  sent  to  lung  cancer  patients  at  follow-up  by  the  chest 
physician  ............................................................................................ 
393 
XI  Letter  sent  to  lung  cancer  patients  at  follow-up  by  the  researcher.....  395 
XII  The  Nottingham  Health  Profile  user's  guide  for  data  analysis..........  397 
XIII  The  EORTC  Quality  of  Life  Questionnaires  user's  guide  for  data 
analysis  .............................................................................................. 
400 
XIV  Distribution  of  patients'.  scores  on  the  NHP 
...................................... 
405 List  of  publications 
The  following  publications  originated  from  this  project  and  have  been  used  in 
this  thesis. 
A.  Papers 
1.  Montazeri  A,  Milroy  R,  Macbeth  F,  McEwen  J,  Gillis  CR  (1996) 
Understanding  patients:  let's  talk  about  it.  A  study  of  cancer  communication. 
Supportive  Care  in  Cancer,  4,97-101. 
2.  Montazeri  A,  McEwen  J,  Gillis  CR  (1996)  Quality  of  life  in  patients  with 
ovarian  cancer:  current  state  of  research.  Supportive  Care  in  Cancer,  4,169-179. 
3.  Montazeri  A.  A  descriptive  study  of  a  cancer  support  group.  European  Journal 
of  Cancer  Care  1996;  4:  32-37. 
4.  Montazeri  A,  Gillis  CR,  McEwen  J  (1996)  Measuring  quality  of  life  in 
oncology:  is  it  worthwhile?  Part  I.  Meaning,  purposes,  and  controversies. 
European  Journal  of  Cancer  Care,  5,159-167. 
5.  Montazeri  A,  Gillis  CR,  McEwen  J  (1996)  Measuring  quality  of  life  in 
oncology:  is  it  worthwhile?  Part  II.  Experiences  from  the  treatment  of  cancer. 
European  Journal  of  Cancer  Care,  5,168-175. 
6.  Montazeri  A,  Milroy  R,  Gillis  CR,  McEwen  J  (1996)  Interviewing  cancer 
patients  in  a  research  setting:  the  role  of  effective  communication.  Supportive 
Care  in  Cancer,  4,447-454. 
7.  Montazeri  A,  Milroy  R,  Gillis  CR,  McEwen  J  (1996)  Quality  of  life: 
perception  of  lung  cancer  patients.  European  Journal  of  Cancer,  32A,  in  press. 
8.  Montazeri  A,  Gillis  CR,  McEwen  J  (1997)  Tak  Tent.  Studies  conducted  in  a 
cancer  support  group,  Supportive  Care  in  Cancer,  5,  in  press. 
B.  Abstracts  and  presentations 
1.  Montazeri  A,  McEwen  J,  Gillis  CR  (1995)  Can  we  add  life  to  years  not  years 
to  life?  Proceedings  of  the  Organisation  of  European  Cancer  Institute  (OECI) 
Conference  on  Cancer  and  Quality  of  Life. 
The  paper  presented  at  the  OECI's  Conference  on  Cancer  and  Quality  of  Life,  12- 
14  May  1995,  Bled,  Slovenia. 
2.  Montazeri  A  (1995)  Quality  of  life  and  cancer.  Department  of  Public  Health, 
University  of  Glasgow,  Glasgow,  25  October. 
14 3.  Montazeri  A,  Milroy  R,  Gillis  CR,  McEwen  J  (1996)  Interviewing  cancer 
patients  in  a  research  setting:  does  communication  matter?  Supportive  Care  in 
Cancer,  4,233. 
The  paper  has  been  accepted  for  presentation  at  the  8th  Symposium  of  the 
Multinational  Association  of  Supportive  Care  in  Cancer  (MASC),  19-22  June 
1996,  Toronto,  Canada. 
4.  Montazeri  A,  Milroy  R,  McEwen  J,  Gillis  CR  (1996)  Feasibility  of  conducting 
a  double  blind  case-control  study  of  quality  of  life  in  patients  with  lung  cancer. 
Proceedings  of  the  XIV  International  Scientific  Meeting  of  the  International 
Epidemiological  Association  (IEA),  p.  209. 
The  paper  has  been  accepted  for  presentation  at  the  XIV  International  Scientific 
Meeting  of  the  IEA,  27-30  August  1996,  Nagoya,  Japan. 
5.  Montazeri  A  (1996)  Quality  of  life  in  patients  with  lung  cancer.  To  be 
presented  at  the  West  of  Scotland  Health  Services  Research  Network  joint 
meeting  with  the  West  of  Scotland  Oncological  Organisation,  Royal  College  of 
Physicians  &  Surgeons  of  Glasgow,  12  November. 
6.  Montazeri  A  (1996)  Measuring  quality  of  life  in  patients  with  lung  cancer.  To 
be  presented  at  the  Department  of  Public  Health,  University  of  Glasgow, 
Glasgow,  20  November. 
7.  Montazeri  A,  Milroy  R,  Gillis  CR,  McEwen  J  (1996)  Quality  of  life  in  patients 
with  lung  cancer:  an  important  prognostic  factor.  Thorax,  51  (Suppl.  3),  A8. 
(accepted  for  presentation  at  the  British  Thoracic  Society  Winter  Meeting, 
London,  9-11  December). 
8.  Milroy  R,  Montazeri  A,  Gillis  CR,  McEwen  J  (1996)  Quality,  of  life  in  patients 
with  lung  cancer:  does  treatment  matter?  Thorax,  51  (Suppl.  3),  A56. 
(accepted  for  presentation  at  the  British  Thoracic  Society  Winter  Meeting, 
London,  9-11  December)., 
C.  Short  Contributions 
1.  Montazeri  A  (1994)  Is  improving  survival  worthwhile?  a  study  of  the  quality 
of  life  in  patients  with  ovarian  cancer.  HSR  News  (West  of  Scotland  Health 
services  Research  Network),  No.  12,4.  (research  proposal) 
2.  Montazeri  A  (1996)  Clinical  oncology  information  network:  is  the  need 
urgent?  Clinical  Oncology,  8,132.  (letter). 
D.  Submitted  papers 
1.  Montazeri  A,  Gillis  CR,  McEwen  J  (1996)  Quality  of  life  in  patients  with  lung 
cancer:  25  years  on.  Part  I.  Lung  cancer  in  general. 
2.  Montazeri  A,  Gillis  CR,  McEwen  J  (1996)  Quality  of  life  in  patients  with  lung 
cancer:  25  years  on.  Part  II.  Small  and  non-small  lung  cancer. 
15 Key  to  the  thesis 
A.  Title  indications 
1.  Titles 
1.1.  Sub-titles 
1.1.1.  Sub-sub-titles 
B.  Abbreviations  and  phrases 
Assessment  Assessment  of  quality  of  life 
Baseline  Prior  to  diagnosis 
CT  Chemotherapy 
Cum  Cumulative 
EORTC  European  Organisation  for  Research  and  Treatment  of  Cancer 
Follow-up  Three  months  after  treatment 
LC  Lung  cancer 
n  Sample  size 
NHP  Nottingham  Health  Profile 
No.  Numbers 
NSCLC  Non-small  cell  lung  cancer 
Obs.  Observer 
p  P  value  (Probability) 
Phyns.  Physicians 
PS  Performance  status 
PT  Palliative  treatment 
Pt(s).  Patient(s) 
(%)  Percentage 
QLQ-C30  Quality  of  Life  Cancer  Core  30-item  Questionnaire 
QLQ-LC13  Quality  of  Life  Lung  Cancer  13-item  Questionnaire 
QOL  (QL)  Quality  of  life 
RT  Radiotherapy 
SC  Supportive  care 
SCLC  Small  cell  lung  cancer 
SD  Standard  Deviation 
Vs.  Versus 
16 Acknowledgements 
I  had  the  advantage  of  having  two  distinguished  scholars  as  my  supervisors,  Dr. 
Charles  Gillis,  Director  of  the  West  of  Scotland  Cancer  Surveillance  Unit,  and 
Professor  James  McEwen,  the  Head  of  the  Department  of  Public  Health, 
University  of  Glasgow.  I  wish  to  express  my  sincere  gratitude  to  them  for  their 
guidance  all  through  the  course  of  my  research.  I  should  acknowledge  that 
without  their  advice,  and  support  it  would  have  been  impossible  for  me  to 
conduct  this  research.  I  gained  considerable  insight  from  Professor  McEwen's 
expertise  in  public  health  in  general,  and  in  measuring  health  in  particular,  and 
Dr.  Gillis's  expertise  in  cancer  epidemiology  in  the  conduct  of  this  investigation. 
Their  long  standing  experience  and  expertise  in  these  fields  provided  me with  a 
lot  of  encouragement  amidst  hardship  during  this  research.  They  were  always 
there  when  I  needed  them  and  were  a  `solution'  to  my  problems  and  difficulties. 
This  project  was  set  up  and  carried  out  with  help  and  support  from  different 
people.  However,  it  was  Dr.  Gillis  who  first  inspired  me  with  the  idea  of  studying 
`quality  of  life'  and  with  him  originated  the  initial  thoughts  for  the  study.  The 
credit  for  the  robust  design  applied  in  this  study  must  go  to  him. 
I  am  indebted  to  the  following: 
Stobhill  Hospital 
Dr.  Robert  Milroy  the  Chest  Consultant  in  the  Stobhill  Hospital,  who  was 
involved  in  the  study  from  the  beginning  and  was  a  great  support  to  the  project. 
Without  his  encouragement  there  was  no  way  to  carry  out  the  research.  I  am  very 
grateful  to  him  for  everything,  especially  for  his  permission  to  participate  in  his 
clinics. 
I  should  also  like  to  thank  Dr  Gavin  Boyd,  the  Stobhill's  leading  Chest 
Consultant  for  granting  me  permission  to  interview  his  patients.  I  am  grateful  for 
the  support  of  the  junior  doctors  and  clinical  staff,  especially  outpatient  and  ward 
nurses  in  the  Department  of  Respiratory  Medicine. 
Although  most  patients  who  participated  in  the  study  are  no  longer  alive,  I  would 
like  to  thank  them  posthumously.  They  kindly  talked  to  me  and  allowed  me  to 
interview  them.  In  addition,  they  kindly  agreed  to  the  inclusion  of  the 
photographs  that  are  included  in  this  thesis.  I  wrote  this  thesis,  sometimes  with 
tears,  while  I  was  thinking  about  them.  I  would  also  like  to  thank  their  families  as 
well,  from  whom  I  received  considerable  help. 
I  would  like  to  thank  Mrs.  Janette  Henderson,  the  study  co-ordinator,  for  her  help 
and  support.  She  made  a  lot  of  effort  to  make  this  project  a  reality,  especially  by 
asking  General  Practitioners'  and  patients'  permission  for  me  to  interview  them. 
Many  thanks  also  go  to  the  GPs  in  the  Stobhill  catchment  area. 
I  am  also  grateful  to  the  Hospital  s'  Ethical  Committee  for  their  permission  to 
carry  out  this  research. 
17 West  of  Scotland  Cancer  surveillance  Unit 
I  would  like  to  thank  Mr.  David  Hole  for  his  statistical  advice  in  the  analysis  of 
the  data  and  also  for  his  involvement  in  the  study  design  and  progress  of  the 
project.  I  would  like  to  thank  all  staff  at  the  West  of  Scotland  Cancer 
Surveillance  Unit  who  helped  me  by  providing  necessary  information  for  this 
project.  Thank  you  to  Mrs.  Norma  Hill,  Secretary  to  Dr.  Gillis,  for  her  kind  co- 
operation. 
Greater  Glasgow  Health  Board 
I  am  indebted  to  Mrs.  Eileen  Kesson,  Area  Clinical  Audit  Facilitator,  for  her  help 
and  support,  and  for  providing  me  with  the  data  extracted  from  the  medical 
records.  There  is  no  doubt  that  she  made  a  great  contribution  to  this  project  and 
was  a  great  support  to  myself. 
Department  of  Public  Health 
Many  thanks  to  the  following  in  the  Department  of  Public  Health,  University  of 
Glasgow: 
-  Dr.  Sarah  McGhee  for  her  assistance  with  proof  reading  and  comments. 
-  Mr.  Harper  Gilmour,  senior  lecturer  in  statistics,  for  his  statistical  advice. 
-  Mr.  Keith  Murray  for  help  with  computing. 
-  Mrs.  Adrienne  Girvan,  Department  Secretary,  for  help  and  support  during  my 
study. 
-  Miss.  Margaret  Ashton,  Postgraduate  Secretary,  for  her  help  during  my  study. 
-  All  Department  staff  who  kindly  helped  me  on  several  occasions  with  my  study, 
especially  Mrs.  Christine  Cole-Hamilton,  the  Departmental  Librarian. 
I  would  like  to  thank  all  my  fellow  Ph.  D.  research  students  for  their  help  and 
support,  especially  John  Ehiri,  Jane  Gow,  Janice  Harper,  Domingo  Eizaguirre, 
and  my  fellow  Iranian,  Amir  Harirchi. 
Special  thanks 
My  special  thanks  go  to  my  sponsors,  Iranian  Ministry  of  Health,  and  Central 
Office  of  J-Daneshgahi.  I  am  very  grateful  for  their  support  and  for  providing  me 
with  the  opportunity  to  undertake  this  programme. 
Finally,  I  wish  to  express  my  heartfelt  gratitude  to  my  parents,  my  wife  and 
children,  whose  sacrifices  and  support  made  this  study  possible.  I  hope  I  should 
be  able  to  reciprocate  these  in  the  future. 
18 Abstract 
A  population-based  study  of  quality  of  life  in  patients  with  lung  cancer  cases  and 
chronic  respiratory  disease  controls  was  carried  out  at  Stobhill  Hospital  in 
Glasgow  between  January  1995  and  April  1996.  A  study-specific  questionnaire 
was  administered  in  addition  to  three  standard  instruments  (the  Nottingham 
Health  Profile-  NHP;  the  European  Organisation  for  Research  and  Treatment  of 
Cancer  Quality  of  Life  Questionnaire-  EORTC  QLQ-C30;  and  its  Lung  Cancer 
complementary  questionnaire-  QLQ-LC13)  used  to  measure  quality  of  life.  The 
aim  was  to  carry  out  baseline  assessments  of  quality  of  life  following  referral  by 
General  Practitioners  but  before  diagnosis  was  made  by  consultants.  The 
researcher  and  patients  were  blind  to  the  diagnosis.  Follow-up  assessments  were 
scheduled  only  for  lung  cancer  patients  but  not  controls  three  months  after  initial 
treatment.  Two-hundred  and  thirty-eight  patients  were  interviewed  both  at  their 
homes  and  in  the  clinic.  Of  these,  129  patients  had  lung  cancer  and  109  were 
patients  with  chronic  respiratory  disease.  There  were  no  significant  differences 
between  the  characteristics  of  cases  and  controls  except  for  age  (mean  age  =  67.5 
±  9.1  and  64.6  ±  10.4  years  respectively).  The  majority  of  cases  and  controls  were 
married  (56%),  retired  (56%),  with  a  low  level  of  education  (95%),  from  severely 
deprived  areas  (60%).  The  main  results  may  be  summarised  as  follows: 
"  There  were  no  significant  differences  between  quality  of  life  in  cases  and 
controls  except  for  pain  and  loss  of  appetite. 
"  Patients  with  different  socio-economic  status  had  different  quality  of  life.  The 
poorer  reported  a  lower  level  of  quality  of  life. 
19 "  Social  support  systems,  social  networks,  and  socio-demographic  status  of  the 
patients  were  found  to  predict  baseline  quality  of  life  prior  to  diagnosis. 
"  Non-medical  factors  (Deprivation  Category  and  marital  status)  were  found  to 
be  significant  predictors  of  patients'  global  quality  of  life  at  follow-up, 
whereas  medical  factors  (cell  type  and  treatment  modalities)  were  not. 
9  Global  quality  of  life  prior  to  diagnosis  was  a  clear  predictor  of  survival. 
"  Treatment  regimens  were  found  to  be  ineffective  regardless  of  cell  type  and 
stage  of  disease  when  comparing  baseline  and  follow-up  assessments  of 
quality  of  life  in  patients  with  lung  cancer. 
"  Patients'  reactions  to  the  study  indicated  that  they  did  not  find  the  study 
intrusive.  However,  they  preferred  to  be  interviewed  at  home  rather  than  to 
fill  in  a  questionnaire  in  the  clinic. 
"  Patients'  perceptions  of  quality  of  life  were  found  to  differ  from  those  of 
health  professionals. 
In  the  light  of  study  findings  it  is  concluded  that  conducting  a  robust 
epidemiological  study  of  quality  of  life  in  patients  with  lung  cancer  is  feasible.  It 
is  essential  that  such  an  assessment  be  carried  out  in  the  context  of  their  socio- 
economic  status.  The  results  suggest  that  quality  of  life  is  a  real  and  useful 
prognostic  factor.  It  predicts  survival  and  it  is  important  to  include  quality  of  life 
measures  in  future  studies  of  outcomes  in  lung  cancer  care. 
The  above  forms  the  basis  of  recommendation  to  improve  lung  cancer  care  and  to 
provide  guidelines  for  further  work. 
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Introduction  to  the  study 
Lung  cancer  is  an  important  public  health  problem  and  the  most  common 
cause  of  cancer  deaths  among  men  and  ranked  fifth  in  females  world-wide 
(Parkin  et  al.,  1993). 
Based  on  comparable  data,  Scotland  is  among  countries  with  the  highest 
recorded  incidence  of  lung  cancer  in  the  world.  Within  Scotland,  the  West  of 
Scotland  has  an  even  higher  rate  as  compared  to  the  Scottish  average.  More 
importantly,  since  1990  the  age  standardised  incidence  of  lung  cancer  in 
females  in  Glasgow  has  over  taken  that  of  breast  cancer  (Gillis  et  al.,  1992). 
The  efficacy  of  treatment  for  lung  cancer  remains  poor  and  most  lung  cancer 
patients  die  with  a  relative  survival  rate  of  approximately  20%  at  one  year 
after  diagnosis  (Black  et  al.,  1993).  With  such  a  low  level  of  cure  on  one  hand, 
and  because  the  disease  and  its  treatment  have  severe  effects  on  patients' 
physical  and  psychological  well-being  on  the  other  hand,  quality  of  life  is  the 
most  relevant  issue  in  lung  cancer  care. 
Quality  of  life  issues  in  lung  cancer  patients  are  discussed  from  two  broad 
perspectives:  first,  in  clinical  decision-making  for  individual  patients 
including  decisions  to  treat  patients  with  curative  or  palliative  intent,  and 
secondly,  in  the  evaluation  of  new  treatment  modalities  in  group  of  patients. 
Yet,  the  question  remains,  what  are  the  factors  that  determine  quality  of 
survival  for  lung  cancer  patients?  It  is  important  to  assess  these  factors 
prospectively  in  order  to  identify,  not  only  the  existence  of  physical  signs  or 
symptoms  but  also  the  factors  that  predispose  to  them  at  a  much  earlier  stage. 
This  question  which  has  not  received  enough  attention  in  previous  work  is  the 
subject  of  this  project. 
21 Introduction  to  the  study 
Definition  of  quality  of  life 
Quality  of  life  has  been  defined  in  many  ways.  One  of  the  most  recent  and 
acceptable  definitions  has  been  offered  by  the  World  Health  Organisation 
Quality  of  Life  Group  (1994): 
"Quality  of  life  is  an  individual's  perception  of  his/her  position  in  life  in  the 
context  of  the  culture  and  value  system  in  which  he/she  lives,  and  in  relation 
to  his/her  goals,  expectations,  standards,  and  concerns'. 
This  definition  is  the  basis  on  which  this  study  is  built.  In  this  respect, 
studying  quality  of  life  in  the  context  of  the  socio-economic  characteristics  of 
patients  becomes  essential.  Thus,  this  study  addresses  quality  of  life  issues  in 
patients  with  lung  cancer  and  the  extent  to  which  social  characteristics 
influence  quality  of  life  of  patients  with  lung  cancer. 
Reasons  for  choosing  lung  cancer 
Given  the  large  number  of  cases  of  lung  cancer  in  Glasgow,  most  of  whom 
come  from  deprived  areas,  and  the  substantial  resources  which  lung  cancer 
cases  consume;  this  is  an  issue  which  commands  significant  attention.  In 
addition,  there  were  two  practical  considerations  which  influenced  the 
decision  to  undertake  this  research: 
(a)  The  high  incidence  of  disease  which  would  facilitate  efficient  recruitment 
of  patients. 
(b)  The  rapid  diagnosis  and  progression  of  the  disease  which  would  allow 
examination  of  what  happened  to  the  patients  after  diagnosis  and  treatment. 
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The  setting 
This  project  was  undertaken  in  the  Northern  sector  of  Glasgow.  This  area  of 
Glasgow  was  chosen  because  of  local  interest,  facilities  and  a  sufficient 
number  of  patients  that  would  allow  recruitment  of  an  appropriate  sample  for 
the  study.  In  addition,  there  is  a  clear  contrast  of  social  structure  within  the 
population.  That  structure  reflects  a  range  of  socio-economic  deprivation.  On 
the  basis  of  these  considerations,  Stobhill  Hospital  Trust,  a  large  teaching  and 
District  General  Hospital,  was  chosen  as  an  ideal  setting  for  this  study.  It  has: 
an  active  Department  of  Respiratory  Medicine,  good  relationships  with 
General  Practitioners  (GPs)  in  the  area,  has  been  and  is  presently  involved  in 
other  collaborative  projects. 
The  study 
There  have  been  many  published  studies  (about  170  reviews,  papers, 
abstracts,  and  reports)  on  quality  of  life  in  lung  cancer  patients  since  1970. 
This  project  is  an  advance  on  these  because  it  comprises  the  following  eight 
criteria  that  have  not  been  brought  together  in  other  studies. 
The  eight  criteria  not  previously  brought  together: 
1.  Quality  of  life  as  the  main  outcome  measure. 
2.  An  epidemiological  population-based  study  rather  than  a  clinical  study. 
3.  A  prospective  case-control  study. 
4.  At  the  baseline  interview  both  patients  and  interviewer  being  blind  to  the 
final  diagnosis. 
5.  A  detailed  investigation  of  socio-economic  status  of  patients. 
6.  Assessment  made  using  an  interviewer-administered  approach. 
7.  Data  obtained  either  at  patients'  home  or  in  the  clinic. 
8.  Patients'  attitudes  toward  the  study  examined. 
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These  are  all  important  issues  both  from  a  methodological  point  of  view  and 
as  far  as  quality  of  life  studies  are  concerned. 
The  thesis 
It  consists  of  eight  chapters.  In  the  first  chapter  the  study  background  is 
presented  in  addition  to  a  description  of  lung  cancer  and  its  management.  The 
next  two  chapters  are  a  review  of  literature.  While  Chapter  two  reviews  the 
issue  of  quality  of  life  in  cancer  patients  in  general,  chapter  three  more 
specifically  looks  at  studies  of  quality  of  life  in  patients  with  lung  cancer.  In 
this  chapter  a  comprehensive  review  of  literature  from  1970  (when  the  first 
study  of  quality  of  life  in  lung  cancer  patients  was  published)  to  the  end  of 
1995  is  provided.  Aims  and  objectives  are  listed  in  chapter  four.  The 
methodology  is  presented  in  chapter  five.  In  this  chapter  the  unique  design  of 
the  study  is  explained.  In  addition,  the  instruments  used  to  measure  quality  of 
life  and  study  limitations  are  described.  Chapter  six  presents  the  results.  There 
are  two  main  groups  of  results:  the  first,  measuring  quality  of  life  in  lung 
cancer  patients  and  controls  including  comparing  these  outcomes  based  on 
their  socio-economic  characteristics  and  secondly,  the  initial  quality  of  life  in 
lung  cancer  patients  compared  with  their  follow-up  quality  of  life  measures.  In 
chapter  seven  the  study  findings  are  discussed.  Finally,  in  chapter  eight 
conclusions,  and  recommendations  are  presented. 
It  is  hoped  that  this  project  would  provide  an  insight  into  quality  of  life  in 
patients  with  lung  cancer  and  identify  areas  for  future  improvement  in  lung 
cancer  care. 
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Summary 
Lung  cancer  is  one  of  the  most  fatal  malignancies  world-wide.  To  provide  an 
introduction  for  this  project,  this  chapter  describes  lung  cancer,  its  treatment 
and  symptoms.  There  are  different  types  of  lung  cancers  and  they  require 
different  management  policies.  The  survival  outcome  of  treatment  for  lung 
cancer  is  poor  and  most  patients  die  within  one  year  of  diagnosis  with  a 
median  survival  of  less  than  six  months.  The  disease  and  its  treatment  have 
severe  effects  on  the  physical  and  psychosocial  well-being  of  the  patients. 
There  are  several  risk  factors  for  developing  lung  cancer.  Of  these,  smoking 
accounts  for  most  cases  of  lung  cancer.  A  section  on  aetiology  of  lung  cancer 
and  socio-economic  deprivation  is  provided  to  explain  why  people  in  lower 
social  classes  develop  more  lung  cancer  as  compared  to  affluent.  The 
magnitude  of  the  problem  is  demonstrated  by  lung  cancer  statistics  from 
Scotland,  the  setting  for  this  study.  There  were  two  preliminary  investigations 
in  conducting  this  research,  experiences  from  a  study  on  cancer 
communication,  and  a  study  on  quality  of  life  in  patients  with  ovarian  cancer; 
these  are  described.  This  chapter  however,  summarises  the  situation  which  a 
patient  with  diagnosis  of  lung  cancer  is  likely  to  face,  a  situation  which 
suggests  that  "quality  of  life"  is  one  of  the  most  relevant  and  important 
outcomes  in  lung  cancer  care. 
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Introduction 
Cancer  is  a  generic  term  applied  to  a  variety  of  different  diseases  that  have  in 
common  a  deformity  of  cell  development,  leading  to  unregulated  proliferation 
of  cell  growth  that  in  turn  results  in  invasion  and  metastases.  The  primary  site 
and  cell  type  of  a  cancer  dictates  many  of  its  features  including  rate  of 
development,  response  to  cancer  therapies,  common  sites  of  metastatic  spread 
of  the  disease,  symptoms,  and  consequent  quality  of  life. 
Studying  outcome  in  lung  cancer  care  requires  a  primary  knowledge  of  the 
disease  and  its  management.  Similarly,  studying  quality  of  life  needs  initial 
information  about  the  disease  and  the  ways  that  its  treatment  is  managed. 
Thus,  to  provide  an  introduction  to  this  study  and  demonstrate  the  complex 
situation  that  patients  with  diagnosis  of  lung  cancer  and  their  clinicians  are 
likely  to  face,  this  chapter  gives  a  brief  description  of  the  disease  and  its 
management. 
The  situation  for  lung  cancer  patients  is  different  from  those  which  patients 
with  other  cancer  types  are  may  possibly  confront  (Gregor  and  Macbeth, 
1995).  First,  most  lung  cancer  patients  come  from  lower  socio-economic 
backgrounds.  This  is,  therefore,  against  the  formation  of  patient-led  political 
pressure  groups  that  have,  made  so  much  political  headway  in  treatment  of 
other  cancers.  Thus,  one  may  argue  that  a  patient  with  a  diagnosis  of  lung 
cancer  and  with  an  underprivileged  life,  might  suffer  from  even  much  poorer 
quality  of  life  in  the  future. 
Secondly,  despite  advances  in  the  treatment  of  other  cancers,  the  treatment  of 
lung  cancer  remains  unsatisfactory  and  the  outcome  survival  of  the  treatment 
for  this  cancer  is  short.  This  by  itself  raises  the  question  of  cost-benefit  issues, 
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cost  in  terms  of  resources  used  and  social  costs  and  benefit  in  terms  of  health 
gain  and  the  quality  of  life.  For  example,  despite  aggressive  treatments  for 
lung  cancer,  the  survival  benefit  is  sometimes  a  matter  of  living  for  a  few 
extra  weeks  with  major  adverse  side-effects.  In  such  a  situation  therefore,  the 
question  for  example,  is:  does  staging  make  any  differences  in  the  outcome 
with  outcome  measured  both  in  terms  of  survival  and  quality  of  life? 
Thirdly,  more  than  half  the  patients  with  lung  cancer  are  never  seen  by  an 
oncologist  and  also  lung  cancer  specialisation  within  oncology  is  uncommon. 
This  in  turn  may  cause  several  problems  including  "nihilistic  attitudes" 
towards  treatment  of  lung  cancer  patients. 
This  chapter  provides  introductory  information  and  basic  facts  about  lung 
cancer  that  was  necessary  for  the  investigator,  and  that  would  perhaps  be 
necessary  for  the  readers  of  this  thesis  in  order  to  appreciate  the  problem. 
1.  Global  overview 
"...  a  disease  which,  I  am  satisfied,  is  more  common  than  it  is  supposed  to  be  by  the 
profession,  and  which,  unless  a  careful  examination  be  made,  both  of  the  history  of  the 
case,  and  of  the  physical  signs  attending  it,  is  very  apt  to  be  mistaken  for  some  other 
complaint.  " 
Kilgour  A.  (1850) 
[cited  in:  Thatcher  and  Spiro  (1994)  New  Perspectives  in  Lung  Cancer] 
Lung  cancer  is  the  most  common  cancer  of  men  and  the  fifth  most  frequent 
cancer  of  women  world-wide  (Parkin  et  al.,  1993).  It  is  a  complex 
environmental  disease  involving  the  accumulation  of  several  risk  factors 
(Economou  et  al.,  1994).  The  study  of  the  epidemiology  of  lung  cancer  has 
been  one  of  the  rewarding  aspects  of  medical  research  in  the  past  50  years  and 
it  has  already  taught  us  enough  to  ensure  that  lung  cancer  can  be  considered  to 
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be  the  most  common  form  of  fatal  yet  preventable  cancer  throughout  the 
world  (Doll,  1994). 
A  world-wide  lung  cancer  epidemic  has  occurred  during  the  20th  century. 
Parkin  et  al.  (1993)  estimated  that  lung  cancer  was  the  most  common  cancer 
in  the  world  in  1985,  with  896,000  new  cases,  or  11.8%  of  the  total,  about 
61%  of  which  occur  in  developed  countries.  They  '  calculated  that  this  is  a 
large  increase  (36%)  since  the  1980  estimate. 
The  highest  incidence  rates  of  lung  cancer  currently  observed  in  men  are'  in 
the  Maori  population  of  New  Zealand  (119.1  per  100,1000),  and  several  black 
populations  of  the  United  States  including  New  Orleans  (115.9),  San 
Francisco  Bay  area  (107.4),  Detroit  (107.2),  and  Alameda  county  (106.9).  The 
incidence  rate  in  the  West  of  Scotland  remains  very  high  (97.2).  The  lowest 
incidence  rates  in  men  at  the  present  time  are  reported  from  Indian,  African 
and  South  American  populations  ranging  from  13.5  to  'I  per  100,1000 
respectively.  In  women,  the  highest  incidence  rate  is  found  in  the  Maori 
population  (62.2),  Canada  (51.8)  and  among  black  and  white  populations  of 
the  United  States  (36.5  and  37.9).  The  lowest  rates  occur  in  similar 
populations  to  those  in  men  (Parkin  et  al.,  1992). 
Although  the  incidence  of  lung  cancer  is  presently  declining  among  middle- 
aged  men  in  some  countries,  it  is  increasing  among  women  in  many  developed 
countries  (Gillis  et  al.,  1992).  For  example,  in  the  United  Kingdom  the  Chief 
Medical  Officer  of  the  Department  of  Health  reported  that  in  England  and 
Wales  over  the  period  of  1979-1990  age-adjusted  rates  of  lung  cancer 
decreased  for  males  but  for  females  increased.  This  report  did  not  indicate  the 
figures  (Department  of  Health,  1995).  Data  from  United  States  indicate  that 
from  1973-1977  to  1983-1987,  the  age-adjusted  rates  of  lung  cancer  increased 
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by  30%,  with  the  gain  markedly  greater  in  women  (70%)  than  in  men  (17%) 
(Travis  et  al.,  1995). 
The  rise  of  smoking  in  developing  nations  will  inevitably  be  followed  by 
spread  of  the  lung  cancer  epidemic.  Epidemiological  research  has 
convincingly  established  that  cigarette  smoking  is  a  cause  of  lung  cancer 
(early  studies  such  as:  Wynder  and  Graham,  1950;  Levin  et  al.,  1950;  Doll  and 
Hill,  1950;  1952),  accounting  for  the  majority  of  lung  cancer  cases  in  most 
countries.  The  international  variation  in  incidence  rates  of  lung  cancer  is  well 
explained  by  different  current  and  past  exposures  to  the  main  cause  of  lung 
cancer-  cigarette  smoking  (Tomatis  et  al.,  1990). 
Overall  risk  of  lung  cancer  for  smokers  depends  on  several  factors  including 
age  at  starting,  number  of  cigarettes  smoked,  the  products  smoked  and 
inhaling  pattern.  Other  causes  of  lung  cancer  include  exposure  to  occupational 
agents,  environmental  tobacco  smoke  (ETS),  residential  exposure  to  radon, 
radiation,  diet,  and  alcohol  consumption  (Tomatis  et  al.,  1990;  Samet,  1993; 
1994;  Kabat,  1993). 
Discussions  about  risk  factors  for  developing  lung  cancer  still  continue  to  be 
topical  in  biomedical  literature.  For  instance,  in  a  recent  study  Gross  (1995) 
after  reviewing  32  studies  world-wide  (29  case-control  and  3  cohort  studies) 
involving  exposed  and  unexposed  male  and  female  smokers  concluded  that  a 
causal  relationship  between  ETS  and  lung  cancer  is  currently  not  supported  by 
the  data.  In  response,  Leeuwen  (1995)  argued  that  epidemiological  studies, 
provide  strong  evidence  for  a  causal  association  between  ETS  and  lung  cancer 
risk. 
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However,  since  smoking  is  the  main  cause  of  lung  cancer,  it  is  argued  that 
over  90%  of  lung  cancer  may  be  avoided  simply  through  avoidance  of 
cigarette  smoking.  There  is  a  world-wide  epidemic  of  smoking  among  young 
people,  which  will  be  translated  into  increasing  rates  of  lung  cancer  cases  in 
the  coming  decades.  (Boyle  and  Maisonneuve,  1995). 
2.  Diagnosis  of  lung  cancer 
A  chest  X-ray  is  the  initial  test  to  establish  diagnosis  of  lung  cancer. 
Following  abnormal  X-ray,  a  pathological  diagnosis  is  required.  Sometimes 
this  is  established  from  sputum  cytology.  More  clinicians  prefer  to  have  the 
greater  accuracy  and  confidence  by  examining  a  piece  of  the  tumour  itself  (a 
biopsy).  This  can  be  done  by  biopsy  of  an  abnormal  lymph  gland  (usually  at 
the  root  of  the  neck)  or  a  piece  of  the  pleural  lining  of  the  chest  (if  there  was 
pleural  effusion,  fluid  between  the  lung  and  chest  wall).  More.  often, 
bronchoscopic  biopsy  is  needed.  This  test  allows  the  doctor  to  look  into  the 
airways  and  the  lungs.  By  this  test  it  is  also  possible  to  take  a  small  piece  of 
tissue  for  examination.  However,  if  it  is  not  possible  to  make  a  diagnosis  by 
these  tests,  an  exploratory  operation  (thoractomy)  can  be  done  to  examine  the 
lungs  (Williams,  1992;  Hancock  and  Coleman,  1996). 
3.  Screening  for  lung  cancer 
Two  techniques  were  used  for  detecting  lung  cancer:  the  chest  X-ray  and 
sputum  cytology.  The  intention  is  that  the  patients  found  on  screening,  will 
have  a  better  chance  of  cure.  Studies  have*  shown  that  the  benefit  achievable 
by  screening  is  limited  both  by  the  sensitivity  of  currently  used  methods  for 
early  lung  cancer  detection  and  by  the  cure  probability  associated  with 
treatment  of  those  patients  who  were  found  by  screening  techniques 
(Flehinger  et  al.,  1994).  Thus,  population-based  screening  or  large-scale 
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screening  for  those  who  are  in  risk  of  developing  lung  cancer,  has  not  been 
recommended. 
4.  Types  of  lung  cancer 
Lung  cancer  is  not  one  disease  and  there  are  several  types  of  cancers  that  can 
develop  in  the  lungs.  Lung  cancers  have  been  divided  into  two  major  groups; 
small  cell  and  non-small  cell  lung  cancer.  Table  1.1  presents  the  main  types  of 
lung  cancer  in  a  typical  population. 
Small  cell  lung  cancer  is  a  unique  form  of  lung  cancer  characterised  by  rapid 
growth  and  dissemination  at  diagnosis  (Hinson  and  Perry,  1993).  Non-small 
cell  lung  cancer  is  the  most  common  type  of  the  disease  and  consists  of  three 
major  histologic  types:  squamous  cell  carcinoma,  adenocarcinoma,  and  large 
cell  carcinoma. 
Table  1.1  Main  types  of  lung  cancer 
Type  Estimated  incidence 
Small  cell  lung  cancer  (oat-cell)  25 
Non-small  cell  lung  cancer 
(squamous,  adeno,  and  large  cell 
carcinoma) 
Mesothelioma 
74  (34,25,15) 
i 
Source:  adapted  from  Williams  (1992) 
There  was  a  long-standing  belief  that  squamous  and  oat-cell  carcinoma  were 
smoking  associated,  but  that  adenocarcinoma  was  not.  It  now  appears  that 
adenocarcinoma  and  bronchioloalveolar  carcinoma  (a  special  type  of 
adenocarcinoma)  are  both  associated  with  smoking  (Petersen,  1994). 
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5.  Staging  of  disease 
There  are  separate  staging  systems  for  small-cell  and  non-small  cell  lung 
cancer.  The  staging  system  of  small  cell  lung  cancer  is  very  simple  (Table 
1.2). 
Table  1.2  Staging  system  for  small  cell  lung  cancer 
Limited  disease 
The  tumour  is  confined  to  one  side  of  the  chest  and  to  the  draining  lymph  nodes  on  that 
side. 
Extensive  disease 
The  tumour  is  spread  beyond  the  chest  including  distant  lymph  nodes,  bone,  liver,  bone 
marrow,  brain,  etc. 
Source:  adapted  from  Williams  (1992) 
In  non-small  cell  lung  cancer  the  staging  system  is  more  complex  and  is  based 
on  tumour  size,  lymph  nodes  and  metastases  (TNM)  system.  The  various  T, 
N,  M  categories  are  organised  into  stage  groupings:  stage  I,  II,  IIIa  111b,  and 
IV  (Table  1.3) 
While  in  small  cell  lung  cancer  the  distinction  between  limited  and  extensive 
disease  is  more  important  in  understanding  patient's  attitude  towards 
treatment,  in  non-small  cell  lung  cancer  staging  is  part  of  the  treatment 
procedure  and  the  importance  of  such  staging  system  is  in  selecting  those 
patients  who  will  benefit  from  an  operation. 
Table  1.3  Simplified  staging  system  for  non-small  cell  lung  cancer 
Stage  Description 
Limited  disease  Stage  I  Tumour  size  less  than  3  cm,  no  spread 
to  lymph  nodes,  no  metastasis. 
Stage  II  Tumour  size  more  than  3  cm,  spread  to 
the  first  group  of  lymph  nodes,  no 
metastasis. 
Extensive  disease  Stage  Ma,  Stag  IIIb  Locally  advanced,  tumour  with  any 
size  spread  to  other  respiratory  organs, 
no  distant  metastasis. 
Stage  IV  Advanced,  tumour  with  any  size, 
distant  metastasis  found. 
Source:  adapted  from  Mountain  (1986) 
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6.  Treatment  of  lung  cancer 
Treatment  of  lung  cancer  continues  to  be  one  of  the  greatest  challenges  in 
oncology  today.  In  the  following  sections  a  brief  description  of  different 
treatment  policies  in  management  of  lung  cancer  is  presented. 
6.1.  Small  cell  lung  cancer 
6.1.1.  Surgery 
Most  patients  are  not  candidates  for  curative  surgical  resection  due  to  their 
tumour  extent  or  coexistent  disease  (Ginsberg,  1989).  Therefore,  surgery  is 
usually  considered  only,  an  as  addition  to  chemotherapy  in  small  cell  lung 
cancer. 
6.1.2.  Radiotherapy 
Small  cell  lung  cancer  is  quite  sensitive  to  radiation  therapy  and  historically  it 
was  managed  with  radiotherapy  (McLennan  and  Roder,  1989).  The  results  of 
radiation  when  used  as  the  main  treatment  for  small  cell  lung  cancer,  have 
proved  to  be  similar  to  surgery.  However,  chemotherapy  was  subsequently 
introduced  as  an  adjunct  to  radiotherapy,  and  is  now  routinely  administered  to 
patients  with  limited  disease  (Pignon  et  al.,  1992).  Radiotherapy  does  not 
appear  to  have  any  benefit  in  patients  with  extensive  disease  except  for 
symptom  palliation. 
6.1.3.  Chemotherapy 
Although  small  cell  lung  cancer  remains  largely  incurable,  considerable 
progress  has  been  made  over  the  past  20  years  in  the  development  of 
combination  chemotherapy  regimens  that  significantly  improve  patient 
survival  and  quality  of  life.  The  chemotherapy  of  small  cell  lung  cancer 
includes  many  active  single  and  combinations  agents.  In  limited  disease  it  is 
not  uncommon  to  see  response  rates  of  greater  than  80  per  cent  to 
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combination  chemotherapy,  and  even  in  extensive  disease,  response  rates  of 
over  50  per  cent  can  be  achieved  (Natale,  1995). 
For  patients  with  limited  disease  the  current  standard  of  care  is  chemotherapy 
plus  thoracic  radiation  therapy.  Patients  with  extensive  disease  initially 
receive  combination  chemotherapy.  Radiation  therapy  is  not  used  for  most 
patients  with  extensive  disease,  since  their  disease  has  spread  to  distant  parts 
of  the  body. 
It  is  argued  that  ultimately  to  provide  the  maximum  palliative  benefit  for 
patients  with  extensive  small  cell  lung  cancer,  the  therapeutic  benefit  must  be 
balanced  against  the  costs  (physical,  psychological,  and  financial)  of  treatment 
(Loehrer,  1995). 
6.2.  Non-small  cell  lung  cancer 
6.2.1.  Surgery 
In  case  of  stage  I  and  II  non-small'  cell  lung  cancer  surgical  resection  is 
considered  to  be  the  treatment  of  choice,  but  the  problem  is  that  two  thirds  of 
the  patients  present  with  a  late  stage  of  the  disease  and  therefore  are  not 
suitable  for  surgery.  After  surgery,  long  term  survival  is  seen  in  approximately 
70  per  cent  of  patients  with  stage  I  and  in  40  to  50  per  cent  of  patients  with 
stage  II  disease  (Friedland  and  Comis,  1995). 
6.2.2.  Radiotherapy 
For  inoperable  non-small  cell  lung  cancer,  radiotherapy  used  to  be  the 
standard  treatment  in  most  institutions  (Palmer  et  al.,  1990).  Effective 
radiotherapy  of  locally  advanced  non-small  cell  lung  cancer  remains  a 
challenge.  Distant  relapse  is  the  main  cause  of  failure  of  radiotherapy  to 
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control  disease  (Koukourakis  et  al.,  1995).  Radiotherapy  has  a  major  role  in 
patients  with  non-small  cell  lung  cancer  for  the  palliation  of  symptoms. 
6.2.3.  Chemotherapy 
Chemotherapy,  sometimes  combined  with  radiotherapy,  can  be  administered 
before  surgery  (neoadjuvant  chemotherapy)  or  after  surgery  with  or  without 
radiotherapy  (adjuvant  chemotherapy).  The  role  of  neoadjuvant  and  adjuvant 
chemotherapy  in  non-small  cell  lung  cancer  remains  undetermined,  although 
there  are  some  encouraging  results  (Milroy  and  Macbeth,  1995).  ', 
Previously  there  was  considerable  pessimism  about  the  role  of  chemotherapy 
in  the  treatment  of  non-small  cell  lung  cancer,  but  a  recent  meta-analysis  of 
the  52  randomised  clinical  trials  concluded  that  chemotherapy  may  have  a  role 
in  treating  this  disease  (Stewart  and  Pignon,  1995).  Meta-analysis  suggests 
that  modem  combination  chemotherapy  regimens  may  provide  absolute 
benefits  of  about  5  per  cent  with  surgical  treatment,  2  per  cent  with  radical 
radiotherapy,  and  10  per  cent  from  supportive  care-all  at  five  years. 
Comparing  modem  combination  chemotherapy  with  single  agent 
chemotherapy,  again  the  literature  suggests  that  combination  chemotherapy 
does  improve  the  probability  of  survival  of  patients  with  non-small  cell  lung 
cancer  (Marino  et  al.,  1995). 
Therefore,  it  is  argued  that  non-small  cell  lung  cancer  can  no  longer  be 
regarded  as  resistant  to  chemotherapy  and  that  chemotherapy  can  produce  a 
small  but  modest  survival  benefit  (Thatcher  et  al.,  1995). 
6.2.4.  Supportive  care 
This  refers  to  no  active  treatment  policy  and  sometimes  is  called  "Best 
supportive  care".  The  best  supportive  care  is  usually  used  for  symptom  relief 
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and  includes  one  or  more  analgesic  treatment,  palliative  radiotherapy  and 
psychological  support.  Patients  with  poor  performance  status  or  elderly 
patients  in  advanced  stage  of  disease  are  the  most  appropriate  candidates  for 
supportive  care. 
The  results  of  a  recent  meta-analysis,  which  also  included  a  review  of 
individual  patient  data,  comparing  chemotherapy  versus  supportive  care  in 
advanced  non-small  cell  lung  cancer  suggests  that  chemotherapy  is  superior  to 
supportive  care.  However,  the  authors  conclude  that  the  results  have  to  be 
considered  in  the  light  of  their  actual  clinical  relevance  and  of  the  balance 
between  quality  of  life,  toxicity  and  costs  of  chemotherapy  and  best 
supportive  care  (Marino  et  al.,  1994) 
7.  Symptoms  of  lung  cancer 
There  are  two  major  categories  of  symptoms:  disease-  and  treatment-related 
symptoms.  Often,  it  is  difficult  to  differentiate  between  these  two,  but 
generally  speaking,  disease-related  symptoms  are  those  that  patients  report  at 
the  time  of  diagnosis  of  the  disease  and  treatment-related  symptoms  (side- 
effects)  are  those  appearing  after  receiving  treatment. 
7.1.  Disease-related  symptoms 
The  most  common  symptoms  for  lung  cancer  patients  are:  cough,  coughing  up 
blood  '  (haemoptysis),  breathlessness  (dyspnoea),  chest  discomfort  and  pain, 
chest  infection  and  obstruction,  hoarseness,  swelling  of  the  neck  or  face 
caused  by  pressure  on  large  veins  in  the  chest,  symptoms  caused  by  tumour  in 
the  brain  or  tumour  pressing  on  a  nerve.  Mures  et  al.  (1993)  studied  symptoms 
in  a  group  of  non-small  cell  patients  and  observed  that  patients  at  presentation 
reported  the  following  symptoms  (Table  1.4).  They  graded  symptoms  as 
severe,  moderate,  and  mild. 
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However,  patients  with  metastatic  disease,  for  example  with  brain  or  spinal 
cord  metastases,  may  suffer  from  additional  symptoms.  Common  symptoms 
are:  severe  headache,  nausea  and  vomiting,  weakness  of  parts  of  the  body 
usually  both  legs,  disturbances  in  balance  and  of  vision,  and  change  in  mood. 
Table  1.4  Some  common  symptoms  at  presentation 
Symptoms  All  grades 
No.  (%) 
Severe 
No.  "/. 
Moderate 
No.  (%) 
Mild 
No.  "/. 
Cough  228(79)  12(4)  101  (35)  116(40) 
Haemoptysis  101  (35)  4  (1)  30(10)  67  (23) 
Breathlessness  216  (75)  23  (8)  95  (33)  98  (34) 
Chest  pain  107  (37)  9  (3)  40(14)  58  (20) 
Hoarseness  32  (11)  6  (2)  6  (2)  20  (7) 
Anorexia  130  (45)  10  (3)  47  (16)  73  (25) 
Malaise  136(47)  6(2)  43(15)  87(30) 
Source:  adapted  from  Mures  et  at.  (1993) 
7.2.  Treatment-related  symptoms  (side-effects) 
7.2.1.  Potential  complications  of  surgery 
Despite  careful  selection  of  patients  for  surgery  on  the  lungs,  a  very  small 
proportion  die  soon  after  operation  and  this  is  usually  due  to  heart  problems  in 
older  patients.  The  potential  complications  of  surgery  include  excessive 
bleeding,  change  in  heart  rhythm,  persistent  leakage  of  air  into  the  chest, 
collapse  or  infection  in  the  other  lung,  and  infection  in  the  chest  between  the 
lung  and  the  chest  wall. 
7.2.2.  Side-effects  of  radiotherapy 
Common  side-effects  include  cough  caused  by  the  inflammation  of  the  lung, 
pain  on  swallowing,  tiredness,  nausea  and  loss  of  appetite,  sleepiness  and  loss 
of  concentration  and  memory,  reddening  and  soreness  of  the  skin. 
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7.2.3.  Side-effects  of  chemotherapy 
Common  side-effects  include  tiredness,  loss  of  appetite  (anorexia),  hair  loss, 
feeling  sick,  vomiting,  constipation,  diarrhoea,  sore  mouth  or  tongue,  tingling 
hands  or  feet,  anaemia,  and  susceptibility  to  infection. 
In  a  typical  sample  (100  patients)  of  the  general  lung  cancer  population 
receiving  different  treatment  regimens,  Krech  et  al.  (1992)  found  that  the  most 
common  and  severe  symptoms  were  pain  (86),  dyspnoea  (70)  and  anorexia 
(68).  There  were  no  difference  between  males  and  females.  The  following 
common  symptoms  are  reported  (Table  1.5). 
However,  apart  from  physical  symptoms,  psychological  morbidity  has  often 
been  reported  after  diagnosis  of  cancer.  This  is  an  additional  symptom  which 
may  reinforce  physical  morbidity  as  well  as  affecting  their  family  and  social 
life.  These  will  be  discussed  in  more  detail  in  chapter  3. 
Table  1.5  Some  common  treatment-related  symptoms  in  lung  cancer  patients 
Symptom  All  grades 
No.  % 
Severe 
No.  % 
Moderate 
No.  % 
Mild 
No.  % 
No  rating 
No.  % 
Pain  86  32  38  16  0 
Dyspnoea  70  12  35  17  6 
Anorexia  68  13  33  16  6 
Constipation  52  9  26  12  5 
Fatigue  52  6  29  11  6 
Cough  47  0  17  26  4 
Weakness  47  8  27  6  6 
Sleep  problem  43  2  24  16  1 
Weight  loss  39  39  0  0  0 
Depression  34  7  18  5  4 
Anxiety  27  1  17  8  1 
Source:  adapted  from  Krech  et  al.  (1992) 
39 Study  background 
8.  Lung  cancer  in  Scotland 
"This  is  the  only  case  of  cancer  of  the  lung  which  I  have  ever  met  with;  so  I  presume  the 
disease  rarely  attacks  this  organ  in  Scotland". 
Bennett  J.  H.  (1849,  in  Edinburgh) 
[cited  in:  Thatcher  and  Spiro  (1994)  New  Perspectives  in  Lung  Cancer] 
Now  lung  cancer  is  the  most  common  cancer  both  in  men  and  females  in 
Scotland.  In  1980  lung  cancer  ranked  first  in  males  and  third  in  females.  From 
1981  to  1990  the  incidence  of  lung  cancer  declined  by  15.9%  in  men  and 
increased  by  25.5%  in  females.  This  has  resulted  in  lung  cancer  becoming  the 
second  most  common  cancer  in  Scottish  females  in  1990  (Sharp  et  al.,  1993). 
This  may  be  partly  explained  by  the  changes  in  smoking  habit  among  males 
and  females  in  Scotland.  Smoking  has  declined  in  recent  years  amongst  men, 
and  there  is  evidence  that  morbidity  rates  for  lung  cancer  have  fallen  in 
Scottish  men  under  50  years.  In  women,  where  the  numbers  smoking  are 
increasing,  the  lung  cancer  rates  are  also  increasing  (Gillis,  1987,  Gillis  et  al, 
1992). 
Within  Scotland,  the  West  of  Scotland  has  an  even  higher  rate  as  compared  to 
the  Scottish  average.  The  West  of  Scotland  is  among  countries  with  the 
highest  recorded  incidence  rate  of  lung  cancer  in  the  world;  with  incidence  of 
97.2  per  100,000  for  males  and  33.6  per  100,1000  for  females  (Parkin  et  al., 
1992).  Greater  Glasgow  has  more  than  30%  higher  incidence  than  the  Scottish 
average  (Sharp  et  al.,  1993).  With  a  population  of  1,000,000;  each  year  there 
are  more  than  1000  new  case  in  Greater  Glasgow.  More  importantly,  since 
1990  the  age  standardised  incidence  of  lung  cancer  in  females  in  Glasgow  has 
overtaken  that  of  breast  cancer  (Gillis  et  al.,  1992). 
The  most  recent  figures  available  indicate  that  33%  of  adult  males  (over  16 
years)  and  35%  of  adult  females  are  smokers  (Scottish  Health  Statistics, 
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1992).  In  young  adults  (16-24  years)  the  corresponding  figures  are  28%  for 
males  and  38%  for  females.  The  level  of  smoking  in  Scottish  males  has 
steadily  declined  since  1972  but  in  females  there  was  an  increase  between 
1984  and  1988  (Scottish  Forum  for  Public  Health  Medicine,  1994). 
Gillis  and  his  colleagues  (1988a;  1988b)  in  their  two  most  cited  works  showed 
that  the  risk  of  lung  cancer  did  not  increase  significantly  with  increasing 
amounts  of  tobacco  exposure  above  an  average  consumption  of  20  cigarettes 
per  day.  They  argued  that: 
"...  it  is  not  just  the  West  of  Scotland  smoker  who  is  at  an  increased  level  of 
risk  compared  with  his  equal  smoking  counterpart  elsewhere  but  also  the  West 
of  Scotland  non-smoker  who  may  also  experience  a  higher  than  expected  lung 
cancer  risk.  " 
These  findings  however,  led  the  authors  to  investigate  other  possible  risk 
factors  including  environmental  tobacco  smoke  (Hole  et  al.,  1989), 
occupational  exposure  (de  vos  Irvine  et  al.,  1993),  and  socio-economic 
depri  vation  (Hart  et  al.,  1996).  These  will  be  described  in  the  following 
section. 
It  has  been  reported  that  the  five  year  relative  survival  rate  for  males  is  6.6% 
and  for  females  the  figure  is  6.4%.  In  1994  there  were  4,237  deaths  from  lung 
cancer  in  Scotland  (Registrar  General  for  Scotland,  1995). 
9.  Lung  cancer  and  socio-economic  deprivation 
It  is  often  found  that  lung  cancer  is  inversely  related  to  socio-economic  status 
of  individuals  (Baquet  et  al.,  1991).  Socio-economic  deprivation  is  usually 
regarded  as  an  indicator  for  lifestyles  such  as  smoking,  and  exposures  to 
41 Study  background 
occupational  carcinogens  that  have  been  recognised  as  possible  risk  factors  for 
lung  cancer  (Firth  et  al.,  1993).  There  is  evidence  that  differences  in  smoking 
partially  are  responsible  for  the  difference  in  lung  cancer  risk  (Levi  et  al., 
1988).  In  most  divided  societies  smoking  has  been  found  to  be  more  prevalent 
among  lower  social  classes  (Rosen  et  al.,  1990)  and  therefore  they  are  more 
likely  to  have  lung  cancer  as  compared  to  the  more  affluent. 
Although  not  a  direct  cause,  it  is  argued  that  in  aetiology  of  lung  cancer 
poverty  plays  a  role.  For  example,  it  has  been  suggested  that  unemployed  men 
and  their  families  have  increased  mortality  experience,  particularly  from 
suicide  and  lung  cancer  (Wilson  and  Walker,  1993).  In  the  United  States  of 
America  data  from  the  Western  Collaborative  Group  Study,  a  prospective 
cohort  study  with  a  22-year  follow-up,  showed  that  after  adjustment  for  other 
risk  factors,  having  lower  income  did  increase  the  relative  risk  for  lung  cancer 
mortality  (Bucher  and  Raglend,  1995). 
Austoker  et  al.  (1994)  argued  that  smoking  is  undoubtedly  associated  with  the 
problems  of  poverty,  unemployment,  and  other  kinds  of  socio-economic 
deprivation.  They  pointed  out  that  in  the  United  Kingdom  men  and  women  in 
social  class  V  are  nearly  four  times  more  likely  to  be  smokers  than  are  those  in 
social  class  I.  Working  class  men  are  three  times  more  likely  to  die  of  lung 
cancer  than  are  those  in  middle  class  occupations.  Among  females,  death  rates 
from  lung  cancer  increased  in  social  class  IV  and  V  and  decreased  in  social 
class  I  and  II. 
A  Danish  study  found  substantial  social  inequalities  in  the  risk  of  lung  cancer. 
They  found  that  the  people  in  lower  social  classes  had  a  higher  risk  for  lung 
cancer  even  after  adjustments  were  made  for  form  of  smoking,  amount 
smoked,  whether  inhalation  took  place,  number  of  pack-years  and  age.  In 
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contrast  to  the  findings  from  other  studies,  the  effect  of  these  adjustments  was 
small.  They,  therefore,  concluded  that  these  inequalities  in  lung  cancer  risk  in 
Denmark  are  only  to  a  minor  degree  explained  by  social  class  differences  in 
tobacco  smoking  (Hein  et  al.,  1992). 
A  recent  prospective  cohort  study  of  58,279  men  from  Netherlands  concluded 
that  there  is  an  inverse  association  between  highest  level  of  education  and 
lung  cancer  even  after  adjustment  for  all  other  possible  socio-economic 
related  risk  factors  including  age,  smoking  habit,  dietary  intake  of  vitamin  C, 
beta-carotene  and  retinol.  They  also  found  that  lower  white  collar  workers  had 
a  significant  lower  lung  cancer  risk  as  compared  to  the  blue  collar  workers 
that  could  partially  be  explained  by  their  smoking  habits  (Loon  et  al.,  1995). 
Similar  findings  were  previously  reported  from  Italy  where  in  a  case-control 
study  it  was  observed  that  the  men  in  the  lowest  level  of  education  had 
increased  risk  of  lung  cancer,  but  not  females.  There  was  also  an  inverse 
association  between  risk-  for  lung  cancer  and  housing  tenure  for  both  sexes 
(Faggiano  et  al.,  1994). 
There  is  a  strong  deprivation  gradient  in  the  incidence  of  lung  cancer  in 
Scotland,  with  some  80%  higher  incidence  in  the  most  deprived  areas  (Sharp 
et  al.,  1993).  Studies  have  shown  that  in  1980-1982  the  standardised  mortality 
rate  of  carcinoma  of  the  lung  and  bronchus  for  patients  with  most  deprived 
backgrounds  was  120%  greater  than  that  for  affluent  patients  but  was  170% 
greater  by  1990-1992  (McLoone  and  Boddy,  1994).  This  may  be  attributed  to 
several  factors  including  smoking  habit  in  lower  social  class  and  exposure  to 
occupational  hazards.  Studies  of  incidence  of  mesothelioma  and  asbestos 
related  lung  cancer  in  Glasgow  and  the  West  of  Scotland  clearly  suggest  that 
part  of  the  excess  of  lung  cancer  in  these  groups  of  people  may  be  explained 
by  occupational  exposure  to  asbestos  (Gillis  et  al.,  1990;  de  vos  Irvine  et  al., 
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1993).  Other  studies  from  Scotland  found  a  less  clear  pattern  of  association 
between  lung  cancer  and  social  class  (Williams  and  Lloyd,  1991).  They  only 
observed  a  negative  correlation  in  social  class  II  and  a  positive  correlation  in 
social  class  V.  This  finding  could  not  be  generalised  since  the  method  of 
statistical  analysis  was  based  on  the  percentages  of  the  districts'  populations 
with  each  group  of  social  class  not  based  on  each  individual  characteristics. 
A  recent  study  by  the  West  of  Scotland  Cancer  Surveillance  Unit  (Hart  et  al., 
1996),  comparing  three  prospective  cohort  studies  in  the  UK  including  a  male 
cohort  population  from  the  Renfrew/Paisley  general  population  study  (a 
typical  population  of  the  West  of  Scotland)  found  that  there  is  a  difference  in 
cancer  risk  between  social  classes  in  addition  to  the  effect  of  smoking.  Social 
class  was  measured  by  the  Registrar  General's  classification  based  on 
occupation.  They  concluded  that  this  may  help  to  explain  why  the  West  of 
Scotland,  an  area  of  high  socio-economic  deprivation  and  levels  of  smoking, 
has  such  high  lung  cancer  mortality. 
To  sum  up  it  is  clear  that  socio-economic  status  as  measured  by  educational 
level,  occupational  social  class,  house  ownership,  and  level  of  income  all  play 
important  roles  in  the  aetiology  of  lung  cancer. 
10.  Preliminary  investigations 
To  set  the  stage  for  the  main  study  of  quality  of  life  in  patients  with  lung 
cancer  two  practical  investigations  were  conducted.  The  first  was  a  study  of  a 
cancer  support  group,  Tak  Tent,  and  the  second  involved  a  preliminary 
investigation  to  set  up  a  study  of  quality  of  life  in  ovarian  cancer  patients.  The 
objectives  were: 
1.  To  understand  issues  in  communication  with  cancer  patients  in  general. 
II.  To  develop  the  study  protocol 
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III.  To  test  the  study-specific  questionnaire 
In  the  following  sections  brief  description  are  presented. 
10.1.  Communication  with  cancer  patients:  Tak  Tent  study 
To  have  a  better  understanding  of  cancer  patients,  and  to  practice  interviewing 
skills,  it  was  decided  to  participate  in  a  cancer  support  group  known  as  "Tak 
Tent"-Old  Scots  for  "Take  Care"  (Appendix  I).  Permission  was  asked  from 
the  Tak  Tent  Executive  Committee  and  on  several  occasions  the  researcher 
took  part  in  activities  of  the  six  branches  of  Tak  Tent  in  the  West  of  Scotland. 
Following  visits  to,  and  conversations  with,  patients  and  their  relatives  a 
descriptive  study  was  carried  out  by  means  of  a  structured  interview.  Patients 
and  their  families  were  asked  about  their  demographic  and  socio-economic 
status,  support  they  were  receiving,  their  concerns  and  problems,  and  their 
general  health  status  and  global  quality  of  life. 
The  study  had  several  results: 
I.  It  was  shown  that  interviewing  cancer  patients  was  feasible  and  that  they 
were  pleased  to  talk  about  their  concerns  and  quality  of  life  issues. 
II.  A  purposed-designed  questionnaire  was  tested  and  it  was  found  that  the 
questionnaire  could  be  used  in  the  main  project. 
III.  A  paper  for  publication  was  prepared. 
Full  details  of  the  study  can  be  found  in  Appendix  II. 
10.2.  Quality  of  life  in  patients  with  ovarian  cancer 
The  West  of  Scotland  Cancer  Surveillance  Unit  originated  and  carried  out  a 
series  of  investigations  on  variation  in  the  care  of  ovarian  cancer  in  the  West 
of  Scotland  and  demonstrated  significant  differences  in  outcome  of  therapy 
between  hospitals  inside  and  outside  Glasgow  (Gillis,  1991).  Their  recent 
study  showed  that  improvement  in  survival  is  significantly  associated  with 
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multi-disciplinary  therapy  and  optimal  treatment  (Junor  et  -al.,  1994).  Thus, 
based  on  these  clear-cut  findings,  the  researcher  was  interested  in  a 
fundamental  question:  does  optimal  treatment  result  in  better  quality  of  life? 
This  was  the  subject  of  the  research  proposal  submitted  to  the  Department  of 
Public  Health,  University  of  Glasgow. 
To  set  up  the  study,  several  visits,  including  meetings  with  a  leading 
gynaecologist  in  Glasgow,  were  held.  These  provided  an  opportunity  to 
discuss  the  proposed  project  and  to  evaluate  the  practicality  of  the  research. 
After  careful  consideration  it  was  realised  that  it  would  be  difficult  to  conduct 
this  research  study.  First,  because  of  time  constraint,  since  during  one  year  it 
would  only  be  possible  to  collect  or  interview  a  very  small  number  of  the 
patients  even  in  the  whole  of  Glasgow  because  the  incidence  of  the  disease  is 
very  low.  Secondly,  it  was  unrealistic  to  assume  that  the  researcher  alone 
could  catch  all  possible  cases  in  Glasgow  during  a  particular  period. 
Therefore,  because  of  insufficient  numbers  of  patients  for  the  study  and  time 
constraint,  this  led  to  the  submission  of  a  new  proposal  on  quality  of  life  in 
lung  cancer  patients. 
Several  lessons  were  learned.  First,  all  experiences  gained  during  the  setting 
up  of  the  ovarian  cancer  study  were  applied  to  the  present  study.  Secondly,  a 
comprehensive  literature  review  on  quality  of  life  in  ovarian  cancer  was 
carried  out.  This,  by  itself  led  to  interesting  results: 
I.  A  recommendation  for  an  international  study  on  quality  of  life  in  ovarian 
cancer  patients  was  made. 
II.  It  was  learned  that  relying  solely  on  standard  measures  of  quality  of  life  is 
not  enough.  Based  on  this  understanding  it  was  decided  when  studying  quality 
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of  life  in  lung  cancer  patients,  that  socio-economic  status  of  patients  be  taken 
into  account. 
III.  The  main  study  protocol  had  been  developed. 
IV.  A  similar  method  of  literature  search  was  used  in  the  lung  cancer  study. 
V.  The  review  has  been  published  (Montazeri  et  al.,  1996a). 
11.  Conclusion 
Against  these  backgrounds  the  study  set  out  to  investigate  quality  of  life  in 
patients  with  lung  cancer  with  the  hope  that  the  results  would  contribute  to 
existing  knowledge  in  lung  cancer  care. 
This  chapter  summarises  the  situation  which  a  patient  with  a  diagnosis  of  lung 
cancer  is  likely  to  face.  A  situation  which  will  change  the  patient's  and  his  or 
her  family's  life.  The  effects  of  disease  and  its  treatment,  the  short  survival 
time,  and  the  psychological  morbidity  all  suggest  that  there  is  nothing  more 
important  than  the  "quality  of  life"  in  lung  cancer  patients,  although 
improving  survival  should  not  be  neglected.  The  question  is-  at  what  price? 
This  is  why  it  is  argued  that  "quality  of  life"  in  oncology  is  essential.  In  the 
following  two  chapters  the  literature  on  "quality  of  life"  in  cancer  patients  in 
general  and  in  lung  cancer  patients  in  particular  will  be  reviewed  to  give  a 
better  perspective  on  the  subject. 
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Summary 
This  chapter  examines  some  of  the  fundamental  issues  in  health  related  quality 
of  life  measurement  with  particular  attention  being  given  to  assessment  of 
quality  of  life  in  patients  with  cancer,  thus  helping  to  focus  the  direction  and 
methodological  rigour  required  in  future  investigations.  Three  relevant  topics 
are  discussed  to  illustrate  the  importance  of  quality  of  life  measures  in  cancer 
therapy.  A  perspective  on  the  meaning  of  "outcome"  and  "quality  of  life"  is 
presented  to  demonstrate  the  controversies  that  exist  in  the  field.  Some 
experiences  from  the  treatment  of  cancer  are  discussed,  relevant  literature  is 
reviewed  and  new  directions  in  measuring  quality  of  life  are  highlighted.  It  is 
argued  that  in  a  chronic  condition,  adding  life  to  years  instead  of  years  to  life 
is  an  important  task.  Adding  years  to  life  may  prolong  survival,  but  whether 
this  is  to  the  benefit  of  patients  is  debatable.  Considering  patients'  views  may 
improve  the  quality  of  care  and  at  the  same  time,  reduce  the  psychological 
distress  and  physical  discomfort  in  patients  with  cancer.  It  is  concluded  that 
quality  of  life  measures  have  considerable  potential  in  this  challenging  issue. 
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Introduction 
The  issues  of  measuring  health  are  always  surrounded  by  a  number  of 
uncertainties,  strengths  and  weaknesses.  Four  distinctive  components  or 
approaches  related  to  the  measurement  of  health  and  outcome  can  be 
identified:  quantity  of  life,  health  related  quality  of  life,  satisfaction  with  care, 
and  process  based  outcome  measures  (Long  et  al.,  1993).  Studies  in  the 
outcome  of  clinical  treatment  have  concentrated  increasingly  on  subjective 
health-related  measures.  There  is,  however,  a  long  standing  debate  on  the 
topic-  sometimes  called  "unresolved  issues"  (Patrick  and  Bergner,  1990).  This 
chapter  attempts  to  examine  general  aspects  of  quality  of  life  measurement 
and  in  particular,  as  it  relates  to  oncology.  Since  quality  of  life  can  be  viewed 
primarily  as  an  outcome  measure,  issues  relating  to  "outcome"  are  described 
in  order  to  demonstrate  the  place  and  role  of  perceived  health  assessment  in 
the  health  care  system.  Difficulties  in  measuring  health  status  are  also 
discussed. 
1.  Outcome:  measuring  health,  "hard"  and  "soft"  data 
There  is  no  single  definition  for  outcome,  but  perhaps  Donabedian's  (1985)  is 
the  most  familiar  one.  He  defines  outcome  as  "those  changes  either  favourable 
or  adverse  in  the  actual  or  potential  health  status  of  persons,  groups  or 
communities  that  can  be  attributed  to  prior  or  concurrent  care".  But  as 
Gulliford  (1992)  notes: 
health  care  is  only  one  of  the  factors  which  determines  the 
outcome  of  disease.  Age,  gender,  ethnicity,  psychological  factors,  the  social 
and  physical  environment,  and  the  nature  of  underlying  and  associated 
conditions  also  combine  to  influence  the  prognosis.  A  clear  distinction  should 
therefore  be  maintained  between  the  general  term  "outcome"  and  the  specific 
term  "healthcare  outcome". 
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Alternatively  in  examining  measured  "outcomes"  the  factors  which  might 
have  contributed  to  the  "outcome"  should  be  ascertained  and  identified. 
There  is  also  concern  about  the  distinction  between  the  notions,  "impact"  and 
"outcome".  The  former  can  be  taken  to  refer  to  short  term,  while  the  latter 
refers  to  long  term  consequences  of  health  care  interventions  (McCallum, 
1993).  Metcalfe  (1990)  defines  outcome  as  the  output  of  medical  intervention, 
and  he  argues  that  outcome  cannot  be  measured  unless  the  medical 
intervention  is  correctly  explained  so  that  the  end  point  can  be  judged. 
In  fact,  the  term  "outcome"  means  different  things  to  different  people. 
Clinicians  are  concerned  with  the  results  of  their  practice;  patients  seek  relief 
and  satisfaction;  carers  have  an  interest  in  improving  services;  managers  are 
concerned  with  resource  utilisation  to  provide  a  more  effective  and  efficient 
service;  and  there  is  a  concern  that  patients  should  be  treated  as  individuals 
and  given  choice,  respect  and  dignity  (Austin  and  Clark,  1993).  It  is  suggested 
that  in  assessing  medical  outcomes  five  key  aspects  should  be  considered. 
These  include  the  facts  that:  outcomes  are  multidimensional;  most  outcomes 
are  qualitative;  assessment  of  outcomes  will  be  affected  by  timing;  subgroups 
of  disease  may  have  differing  outcomes;  and  outcomes  may  not  be  attributable 
to  specific  treatments  (Orchard,  1994). 
However,  a  number  of  systematic  ways  exist  to  measure  health  care  outcomes. 
In  some  ways  "hard"  data  such  as  morbidity  and  mortality  statistics  are 
outcomes,  but  these  are  not  always  enough  (Spitzer  et  al.,  1981)  or  relevant 
(Ebrahim,  1990).  First,  they  have  their  own  limitations  in  the  context  of 
completeness  and  validity  and  secondly,  for  chronic  illnesses  such  as 
malignancy,  they  may  not  be  very  useful  measurements.  It  is  understood  that 
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for  cancers  "in  which  treatment  has  improved  mortality,  statistics  must  be 
interpreted  with  care"  (Coggon  and  Inskip,  1994). 
As  Bardsley  and  Coles  (1992)  pointed  out  in  the  case  of  chronic  conditions,  it 
is  necessary  that  outcomes  be  considered  as  changes  in  the  patient's  health 
status  whether  improvement  or  deterioration.  "  When  the  aim  of  clinical 
treatment  is  to  control  disease  or  its  progression  and  associated  symptoms, 
outcome  should  be  expanded  "from  objective  evidence  of  the  effect  of  disease 
and  treatment  to  the  subjective  or  personal  perception  of  patients"  (Warner 
and  Williams,  1987).  In  other  words,  outcome  measures  in  chronic  situations 
must  also  rely  on  other  sources  of  information,  namely  "soft"  data. 
Information  which  is  more  cognitive,  perceptual,  or,  filtered  by  human 
judgement  is  likely  to  be  considered  soft  (Read,  1993).  In  this  respect,  there 
are  several  other  reasons  to  judge  outcomes  based  on  "soft"  data.  These  are: 
objective  standards  of  assessment  with  cut-off  points  indicating  desirable 
outcomes  are  limited,  objectively  defined  disease  is  not  always  a  causal 
association  with  subjectively  experienced  illness,  and  finally  certain  forms  of 
objectively  defined  disease  may  be  so  prevalent  that  they  are  rarely  viewed  as 
illness  by  people  who  are  experiencing  them  (Jenkinson,  1994a).  Therefore, 
outcome  measures,  for  example,  may  rely  on  'individuals'  judgements, 
whether  patients'  or  clinicians'  views  (Donovan  et  al.,  1993).  In  oncology  (and 
other  chronic  diseases)  this  judgement  is  seen  as  lying  beyond  the  scope  of 
survival  and  traditional  measurements  (Ware,  1984)  and  usually  refers  to 
terms  such  as  quality  of  life  (Najman  and  Levine,  1981)  or  more  accurately, 
health  related  quality  of  life,  or  health  status  measures. 
2.  Quality  of  life:  meaning  and  purposes 
Although  the  concern  over  health  related  quality  of  life  is  relatively  recent 
(Olweny,  1993)  quoting  Heroditus-  450  BC-,  Rosser  (1993)  believes  that  the 
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issue  had  been  investigated  in  early  medical  care.  in  Egypt.  As  she  explains, 
"in  the  second  millennium  the  tombs  in  the  valley  of  the  kings  and  those  of 
nobles  at  Thebes  showed  an  anticipation  that  the  quality  of  life  after  death 
would  be  desirable"!  More  generally,  McEwen  (1993)  argues  that  the  efforts 
to  measure  health  began  in  the  1930s  when  Stouman  and  Falk  (1936) 
introduced  the  concept  of  health  indicators,  but  that  it  was  in  the  1970s  that 
the  explosion  of  interest  began. 
The  history  of  quality  of  life  measures  in  cancer  generally,  goes  back  to  the 
use  of  Karnofsky's  Index  in  the  1940s  as  a  key  measure  of  performance  status 
(Spitzer,  1986).  However,  as  Strain  (1990)  points  out  quality  of  life  had  its 
earlier  roots  in  the  political  and  social  arena  rather  than  the  medical  one. 
Psychologists,  and  sociologists  carried  out  most  of  the  early  empirical  social 
research  on  quality  of  life  studies  with  an  intention  to  estimate  well  being, 
satisfaction  or  happiness  (Bowling,  1995a).  It  is  argued  that  the  "social 
indicators  movement"  of  the  1960s  and  1970s  actually  initiated  quality  of  life 
studies  before  current  research  interest  on  the  subject  emerged  (Andersen  et 
al.,  1994).  In  this  instance,  it  is  believed  that  Breslow  (1972)  and  some  other 
social  scientists  conceptualised  quality  of  life  research,  adopting  the  World 
Health  Organisation  definition  of  health  focusing  on  physical,  mental  and 
social  well-being.  According  to  such  a  view,  quality  of  life  encompasses  all 
aspects  of  life  including  literacy,  leisure  activities,  housing,  employment,  the 
physical  environment,  etc.  (e.  g.  Campbell  et  al.,  1976).  Thus,  it  is  not  far  from 
reality  to  say  that  measuring  quality  of  life  is  an  emerging  science  in  health 
and  medicine. 
Quality  of  life  can  be  defined  in  two  ways:  conceptual  and  operational. 
Conceptually,  it  refers  to  well-being,  quality  of  survival,  human  values  and  the 
satisfaction  of  needs  (van  Knippenberg  et  al.,  1988).  It  has  also  been  described 
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as  the  "complete  life".  Calman  (1987)  refers  to  Oliver  Wendell  Holmes  (1860) 
and  quotes: 
The  longer  I  live  the  more`  I  am  satisfied  of  two  things.  First 
that  the  truest  lives  are  those  that  are  cut  rose-diamond  fashion,  with  many 
facets.  Second  that  society  is  always  trying  in  some  way  or  another  to  grind  us 
down  to  a  single  flat  surface. 
Fallowfield  (1990)  states  that  "quality  of  life  is  not  a  unitary  concept,  but 
rather  a  complex  amalgam  of  satisfactory  functioning  in  essentially  four  core 
or  primary  domains";  these  are:  psychological,  social,  occupational,  and 
physical.  She  argues  that  this  was  recognised  by  Herophilus  in  300  BC: 
To  lose  one's  health  renders  science  null,  art  inglorious, 
strength  effortless,  wealth  useless  and  eloquence  powerless.  (Quoted  by  Sextus 
Empricus  in  Adversus  Ethicus,  XL50.  ) 
Operationally,  quality  of  life  refers  to  patients'  evaluation  of  their  own  life  as 
compared  to  what  they  expect  to  be  possible  or  ideal  (Cella  and  Tulsky, 
1990).  It  can  also  be  seen  as  a  measurement  of  difference  between  the  hopes 
and  expectations  of  the  individuals  (Calman,  1984).  Quality  of  life  sometimes 
has  been  explained  in  a  form  of  formula:  QL  =  NE  x  (H+S)  where  NE  is  the 
patient's  natural  endowment,  and  H  and  S  are  the  efforts  made  on  behalf  of 
patient  by  his  or  her  family,  and  society  (de  Haes  and  van  Knippenberg, 
1985).  It  is  argued  that  many  people  talk  about  quality  of  life,  but  nobody 
knows  precisely  what  it  is  or  what  to  do  about  it  (Campbell  et  al.,  1988). 
Being  abstract  as  it  is,  Aaronson  et  al.  (1988)  'suggest  that  quality  of  life 
should  be  defined  and  broken  into  its  components,  but  they  did  not  attempt  to 
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demonstrate  how  to  achieve  a  unique  agreement  about  its  component  parts. 
This  is  the  focus  of  the  following  section. 
It  seems  that  to  overcome  the  problem  of  definition,  specially  on  operational 
grounds,  it  should  be  understood  that  quality  of  life  as  a  global  term  is  usually 
not  relevant  and  can  not  be  used.  But  as  far  as  health  is  concerned  it  should  be 
regarded  as  perceived  health  and  a  self-rated  measure,  and  therefore  it  should 
be  lay-defined.  However,  there  are  considerable  variations  in  the  purposes  of 
quality  of  life  studies.  Table  2.1  illustrates  some  suggested  areas. 
Table  2.1.  Examples  of  variations  in  purposes  of  quality  of  life  studies 
Katz's  (1987)  suggested  list  Application  of  quality  of  Three  general  reasons  for 
life  measures  by  measuring  quality  of  life  in 
Fitzpatrick  et  al.  (1992)  patients  with  cancer  by 
Cella  et  al.  (1993) 
To  measure  well-being  Screening  and  monitoring  of  Assessment  of  rehabilitation 
psychosocial  problems  needs 
To  improve  treatment  and  care  for  Perceived  health  investigation  As  an  end  point  of  health  care 
chronic  illnesses  outcome 
To  provide  data  for  policy-making 
and  planning 
To  provide  information  about  risk 
factors 
To  develop  new  and  cost-effective 
methods  of  health  care 
Medical  audit 
Evaluation  of  health  services 
Cost-utility  analyses 
Clinical  i 
As  predictor  of  response  to 
future  treatment 
There  are  two  main  gaps  in  quality  of  life  measures,  whatever  the  purposes 
are.  First,  the  comparison  between  studies  with  different  objectives  are 
difficult  (Gelber  et  al.,  1993)  and  sometimes  impossible  (Fallowfield,  1993; 
1994).  This  is  due  to  several  facts  including:  variations  in  methodology, 
sampling  procedures,  and  instruments  used.  Secondly,  there  is  a  gap  between 
the  expectation  of  patients  from  such  studies  and  researchers'  achievement. 
Patients  are  concerned  about  their  immediate  needs  of  relief  from  symptoms 
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whereas  psychologists,  sociologists,  clinicians  and  other  contributors  to 
quality  of  life  studies  concentrate  on  their  study  objectives.  In  a  study  on 
quality  of  life  in  lung  cancer  patients,  Bernhard  et  al.  (1995)  reported  that  "  an 
unexpected  and  more  difficult  'problem.  was  that  some  patients  thought  that 
their  individual  response  would  be  the  basis  for  further  treatment  decisions 
and  a  worse  level  of  self-estimation  was  to  be  avoided".  These  may  therefore, 
not  only  influence  quality  of  life  studies  in  the  context  of  external  validity  but 
also  in  reliability. 
3.  Quality  of  life:  Controversies 
There  are  several  useful  reviews  of  quality  of  life  measures  (e.  g.  Fallowfield 
1990;  Bowling,  1991;  Wilkin  et  al.,  1992;  Walker  and  Rosser,  1993;  Patrick 
and  Errickson,  1993;  Jenkinson,  1994a;  Bowling,  1995a)  and  these  provide  an 
excellent  insight  into  the  issue.  Considerable  literature  also  exist  in  the  area  of 
cancer  therapy  (e.  g.,  Clark  and  Fallowfield,  1986;  Aaronson  and  Beckmann 
1987;  Donovan  et  al.,  1989;  Osoba,  1991;  Selby,  1993).  Full  discussion  of  all 
these  works  is  beyond  the  scope  of  this  chapter,  but  some  of  the  key  issues 
have  been  selected. 
3.1.  The  use  of  objective  health  measures 
Although  quality  of  life  measures  are  today  more  acceptable  than  at  their 
earlier  stages,  Donovan  et  al.  (1993)  in  their  paper  "assessing  the  need  for 
health  measures",  heavily  criticised  the  use  of  subjective  health-related 
measures.  They  argued  that  "it  is  not  clear  what  would  be  gained  from  the 
health  status  questionnaire  material  that  might  not  be  found  more 
economically  from  routinely  available  statistics".  They  concentrated  on  the 
Nottingham  Health  Profile  (NHP)  as  an  example  and  pointed  out  that  these 
measures  do  not  "allow  people  to  express  what  they  really  feel".  They 
observed  that  several  people  with  serious  disease  assigned  themselves  as 
56 Measuring  quality  of  life 
being  relatively  healthy  because  their  symptoms  had  become  part  of  their 
normal  life.  However,  they  pointed  out  that  the  extent  to  which  these  measures 
would  in  practice  modify  the  interpretation  of  conventional  measures  of  health 
need  are  not  clear,  although  some  assessment  of  perceived  health  might  in 
principle  be  desirable. 
Their  discussion  is  limited.  First,  they  de-emphasise  the  fact  that  people's 
feelings  are  subject  to  changes  overtime.  If  therefore,  there  are  differences 
between  data  obtained  by  a  questionnaire  at  a  particular  time  and  an  interview 
sometime  later,  this  could  be  true  for  any  subsequent  new  interviews  as  well. 
People's  views  may  change  with  time.  Although  interview  is  a  better  way  of 
providing  in-depth  information,  this  is,  not  a  sound  basis  for  judging  the 
measurement  of  people's  perceived  health  status  as  worthless.  Secondly,  it  is 
not  clear  what  the  outcome  for  chronic  diseases  should  be-  a  situation  in 
which  the  power  of  medicine  to  cure  is  limited  and  the  main  objectives  of 
health  care  are  relief  of  symptoms  and/or  reduction  of  side  effects  of 
treatments.  Thirdly,  it  is  not  a  systematic  approach  to  extract  data  from  tape 
and  come  to  a  general  conclusion  about  health  measures  or  even  about  that 
particular  instrument.  There  is  supporting  evidence  for  the  applications  of 
these  measures  in  well  designed  studies  (e.  g.,  Kind  and  Gudex,  1994;  Visser 
et  al.,  1994;  Westlake  and  George,  1994),  although  the  limitation  of  the  NHP 
is  recognised  both  by  its  own  pioneers  (McEwen,  1993)  and  others  (Kind  and 
Carr-Hill,  1987).  In  a  recent  paper  there  is  a  critical  review  of  international 
assessments  of  health-related  quality  of  life  including  the  NHP.  The  authors 
stated  that  "the  NHP  has  performed  well  in  the  role  for  which  it  was 
developed:  to  measure  distress  in  functional  status  and  estimate  major  needs 
" 
for  health  services  in  populations  from  major  disabling  health  conditions" 
(Anderson  et  al.,  1993). 
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3.2.  Definitions  of  quality  of  life 
Quality  of  life  is  not  well  defined.  The  literature  reveals  that  much  effort  has 
been  made  to  define  quality  of  life,  but  there  is  no  "common  rules  and 
language"  (Aaronson,  1990)  to  bring  into  agreement  all  contributors  to  the 
quality  of  life  studies. 
However,  there  should  be  at  least  a  clear  distinction  between  conceptual  and 
operational  definitions,  and  secondly,  different  approaches  to  quality  of  life 
assessment  should  be  recognised.  Fries  and  Spitz  (1990)  pointed  out  that  in 
clinical  studies  quality  of  life  does  not  mean  happiness,  satisfaction,  living 
standards,  climate  or  environment,  but  rather  it  can  be  defined  as  those 
dimensions  of  life  that  might  be  influenced  positively  or  negatively  in  clinical 
studies  and  in  the  clinical  situation.  Five  basic  approaches  to  definition  of 
quality  of  life  have  been  recognised  (Schipper  et  al.,  1990).  These  are: 
(i)  The  psychological  approach  and  this  refers  to  the  fact  that  measuring 
quality  of  life  means  distinction  between  illness  and  disease  as  perceived  by 
patients  (Kleinman,  1986). 
(ii)  The  time  trade-off  or  utility  concept  which  refers  to  the  desirability  or 
preference  that  individuals  -exhibit  fora  particular  condition,  for  example 
preferring  quality  of  life  instead  of  survival  or  vice  versa  (Torrance,  1987). 
(iii)  Ware's  concept  of  quality  of  life  which  emphasis  five  concepts  as  minimal 
standards  for  the  content  validity  of  health  measures:  physical  health,  mental 
health,  general  health  perceptions,  social  functioning,  and  role  functioning 
(Ware,  1984;  1987). 
(iv)  The  reintegration  to  normal  living  concept  which  has  been  defined  as  "the 
reorganisation  of  physical,  psychological,  and  social  characteristics  of  an 
individual  into  a  harmonious  whole  so  that  one  can  resume  well-adjusted 
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living  after  an  incapacitating  illness  or  trauma"  (Wood-Dauphinee  and 
Williams,  1987). 
(v)  Calman's  Gap  Theory  which  defines  quality  of  life  as  a  measurement  of 
difference  between  the  hopes  and  expectations  of  individuals  (Calman,  1984). 
It  appears  that  these  are  all  different,  but  at  the  same  time,  the  same.  In  other 
words,  all  are  discussing  a  subjective  impression  perceived  by  the  patients  or  a 
normal  population  about  their  own  health  status,  but  with  different  names  and 
different  usage.  Thus,  expending  much  more  time  on  definition  is  no  longer  a 
beneficial  practice. 
3.3.  Differing  approaches 
A  decade  ago  quality  of  life  was  "a  glimmer  in  the  eye  of  a  small  number  of 
psychologists  and  sociologists",  but  the  issue  "  at  best  rarely  entered  the 
clinician's  mind.  At  worst  it  was  an  anathema"  (Schipper,  1990).  It  is  argued 
that  there  are  two  different  approaches  to  quality  of  life  measures:  a  pragmatic 
clinical  point  of  view,  and  the  methodologist's  point  of  view  (Greer,  1987). 
The  former  refers  to  clinicians  who  believe  in  simple  instruments  of  direct  use 
in  their  speciality.  The  latter  refers  to  those  who  are  more  concerned  with 
methodological  aspects  of  quality  of  life  instruments.  These  are  reliability, 
validity  and  responsiveness,  namely  psychometric  properties  of  quality  of  life 
measures  (Hays  et  al.,  1993). 
However,  it  is  recommended  that  "the  gap  between  these  two  points  of  view 
must  be  closed  if  we  are  to  create  a  sound  methodology  of  quality  of  life 
evaluation  which  will  be  both  useful  and  used  in  the  clinical  realm".  Similarly, 
Tchekmedyian  and  Cella  (1990)  highlighted  that  there  is  a  gap  in  information 
and  communication  between  social  scientists  and  clinicians  and  that  this  gap 
should  be  filled.  In  other  words,  social  scientists  should  realise  that  in  a 
practical  setting,  for  example  in  a  clinic  or  in  a  clinical  trial,  it  is  very  difficult 
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to  consider  all  methodological  aspects,  and  in  contrast,  clinicians  require  to 
accept  that  any  instrument  for  measuring  quality  of  life  should  be  valid  and 
reliable.  Such  considerations  by  both  sides,  however,  may  make  the  issue 
easier  and  reduce  conflicts. 
3.4.  Use  of  general  or  specific  measures 
There  are  several  names  for  different  classifications  of  health  measures, 
although  some  of  these  categories  are  the  same.  Two  basic  types  of 
instruments  have  been  identified:  disease  specific  and  generic  (Fletcher  et  al., 
1992).  The  former  refers  to  the  measures  which  are  used  for  one  disease  or 
narrow  range  of  illnesses  while  the  latter  refers  to  those  which  can  be  used  for 
a'  wide  range  of  purposes.  Donovan  et  al.  (1993)  identify  health  status 
instruments  as  falling  into  seven  basic  categories:  general  health  measures, 
measures  of  physical  function,  pain  measures,  social  health  measures, 
psychological  measures,  quality  of  life  measures,  and  specific  disease 
measures.  As  it  is  clear,  there  is  no  need  for  such  a  classification,  because 
many  of  these  instruments  fall  into  the  same  category. 
In  cancer  literature,  these  categories  are  mostly  described  in  two  ways.  In  their 
review  van  Kinppenberg  and  de  Haes  (1988)  distinguished  three  types  of 
instruments:  ad  hoc  instruments  constructed  for  a  specific  'study,  general 
instruments,  and  instruments  specifically  designed  for  measuring  quality  of 
life  of  patients  with  cancer.  Aaronson  (1989)  describes  four  categories: 
generic,  disease-specific,  ad  hoc,  and  disease-cluster  that  "have  a  somewhat 
narrower  focus,  while  still  maintaining  a  generic  element". 
Advantages  and  disadvantages  of  these  measures  are  discussed  in  the 
literature.  There  is  "a  spectrum  of  opinions  from  those  who  discourage  generic 
measures  preferring  diagnostic-  or  individual-specific  measures  through  to 
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those  still  look  for  a  single  index  for  use  at  the  top  level  of  government 
decision  making"  (Rosser,  1993).  It  is  argued  that  "generic  measures  should 
not  be  expected  to  completely  capture  the  particular  effects  of  disease  or 
treatment"  (Ware,  1987).  In  contrast,  it  is  suggested  that,  because  generic 
measures  contain  many  health  related  dimensions,  these  are  more  likely  to 
detect  unexpected  effects  (Fletcher  et  al.,  1992).  It  is  argued  that  generic 
measures  make  the  comparison  between  studies  possible,  while  specific 
approaches  have  the  advantage  of  detecting  specific  disease  related  quality  of 
life  problems. 
However,  there  are  no  simple  answers  to  the  question,  rather  it  depends  on 
which  dimension  of  quality  of  life  is  under  study,  for  which  type  of  people  it 
is  used  e.  g.  ill  or  general  population,  and  to  what  type  of  disease  it  is  going  to 
be  applied. 
Several  instruments  have  been  used  for  the  measurement  of  quality  of  life  of 
cancer  patients.  Maguire  and  Selby  (1989)  reviewed  all  available  measures 
with  regard  to  their  clinical  application,  ease  of  administration,  scoring,  and 
reliability  and  validity  (20  instruments).  They  concluded  that  the  "best-  bet" 
instrument  is  the  Rotterdam  Symptom  Checklist.  Sometime  later  Selby  (1993) 
concluded  that  no  single  measurement  method  for  quality  of  life  in  cancer 
patients  is  yet  satisfactory.  In  examining  item  content  of  these  measures,  it 
appears  that  many  concepts  measured  are  generic  rather  than  cancer-specific. 
A  recent  review  of  measures  widely  used  in  oncology  (10  instruments) 
addressed  the  problem  (Cella,  1995a)  showing  that  there  is  little  attention  to 
underlying  factors  which  contribute  to  the  quality  of  life  in  cancer  patients 
such  as  social  and  family  life.  Since  patients  with  cancer  need  more  support, 
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for  example,  the  issues  of  family  and  caregivers  become  very  vital  to  patients' 
daily  life. 
Progress  has  been  made  in  synthesising  a  single  modular  assessment  strategy 
which  provides  a  combination  of  general  and  disease-specific  measures.  The 
European  Organisation  for  Research  and  Treatment  of  Cancer  questionnaire 
(EORTC  Quality  of  Life  Questionnaire)  is  a  product  of  such  an  approach 
(Aaronson,  1989)  and  the  final  stages  of  development  and  validation  of  their 
instrument  was  recently  reported  (Aaronson  et  al.,  1993).  Similarly,  Fletcher 
et  al.  (1992)  argued  that  "a  common  recommendation  is  to  include  both 
disease  specific  and  generic  measures  in  a  study".  In  addition,  it  seems  that  in 
each  study  it  would  be  beneficial  to  consider  a  set  of  study  specific  questions 
to  cover  all  quality  of  life  related  problems  of  the  subjects  under  study. 
It  is  difficult  to  indicate  the  best  available  instrument,  but  to  meet  the  major 
principles  that  quality  of  life  measures  require,  the  EORTC  QLQ-C30  (cancer 
core  questionnaire)  seems  to  be  one  of  the  best  developed  measures  across 
different  European  and  North  American  languages  and  cultures  (Cella, 
1995a).  In  a  comprehensive  review  of  more  than  30  instruments  used  in 
oncology  settings  Bowling  (1995a)  concludes  that  the  best  developed  measure 
for  use  with  cancer  patients  is  currently  the  EORTC  QLQ. 
However,  an  ideal  selection  depends  on  the  objectives  of  the  study  and  the 
current  emphasis  is  on  supplementation  with  other  measures.  For  example,  the 
EORTC,  now  has  developed  a  modular  supplement  (QLQ-LC13)  to  the  core 
questionnaire  (QLQ-C30)  for  use  in  lung  cancer  clinical  trials  (Bergman  et  al., 
1994).  Another  example  'of  such  a  development  is  the  Functional  Assessment 
of  Cancer  Therapy-Lung  quality  of  life  questionnaire  (FACT-L).  The  FACT- 
L  has  been  developed  after  the  FACT-G  (general  cancer  core  questionnaire, 
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34-item  version  2)  and  its  reliability  and  validity  have  recently  been  published 
(Cella  et  al.,  1995).  Yet,  a  major  question  remains:  to  what  extent  does  the 
initial  quality  of  life  and  socio-economic  status  of  patients  contribute  to  their 
recent  quality  of  life? 
3.5.  Major  dimensions  to  be  included 
From  the  literature  review  it  appears  that  a  quality  of  life  instrument  should  at 
least  contain  four  areas  as  important  dimensions:  physical,  psychological, 
social,  and  performance.  It  is  argued  that  physical  function,  mood,  symptoms 
and  social  support  are  the  key  predictors  of  the  assessment  of  the  quality  of 
life  and  should  be  monitored  from  diagnosis,  through  treatment  to  terminal 
illness  (Mor,  1987).  Although  quality  of  life  measures  only  include  a  few 
items  related  to  the  social  aspect  of  quality  of  life,  many  researchers  emphasis 
that  social  well-being  should  be  considered  as  an  important  part  of  these 
instruments.  In  their  review  de  Haes  and  van  Knippenberg  (1985)  suggest  that 
social  aspects  of  quality  of  life  "may  account  for  some  of  the  unexplained 
variance  in  the  indicators  of  well-being". 
However,  there  have  been  different  ideas  about  major  dimensions  to  be 
included  in  a  quality  of  life  measure.  Some  argue  a  minimum  of  four 
components  should  be  contained  in  a  quality  of  life  instrument:  physical 
functional  status,  disease  symptoms  and  treatment  side-effects,  psychological 
status,  and  social  functioning  (Aaronson,  1990).  After  consideration  of  30 
different  categories  for  component  parts  of  quality  measures  applied  by 
various  authors,  Cella  and  Tulsky  (1990)  distinguished  ten  dimensions: 
physical  concern  (symptoms;  pain),  functional  ability  (activity),  family  well- 
being,  emotional  well-being,  spirituality,  treatment  satisfaction  (including 
financial  concerns),  future  orientation  (planning;  hope),  sexuality/intimacy 
(including  body  image),  social  functioning,  and  occupational  functioning. 
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This  problem  (including  different  items  and  domains  by  different  researchers) 
may  explain  why  there  are  so  many  instruments.  Some  of  these  are  not  truly 
quality  of  life  measures  (e.  g.  Karnofsky  Performance  Status),  some  are 
generic  measures  (e.  g.  Sickness  Impact  Profile)  and  a  few  are  cancer-specific 
(e.  g.  Functional  Living  Index-Cancer).  In  addition,  including  several 
dimensions  in  an  instrument  may  cause  other  problems  such  as  administrative 
difficulties  and  an  excessive  burden  on  patients.  Different  people,  perceive 
quality  of  life  differently.  For  example,  in  a  study  on  quality  of  life  in  lung 
cancer  patients  including  a  sample  of  patients  with  chronic  respiratory  disease 
it  was  found  that  patients  defined  quality  of  life  as  "good  health"  (42%), 
"enjoyment  of  life"  (25%),  "good  family  life"  (24%),  "happiness"  (21%), 
"ability  to  do  what  one  wants  to  do/work"  (16%),  "financial  security  "  (16%), 
"good  social  life/leisure  activities"  (13%),  and  "living  longer"  (5%) 
(Montazeri  et  al.,  1996b).  There  is  no  way  to  include  all  these  dimensions  in 
an  instrument.  Again,  it  is  very  unlikely  to  find  an  instrument  which  covers  all 
these  items. 
On  the  other  hand,  the  development  of  new  instruments  is  not  a  solution  to  the 
limitations  of  existing  quality  of  life  measures.  Simply,  to  create  a  new 
specific  measure  will  result  in  subsequent  similar  criticisms  of  not  meeting 
another  defined  need.  Sometimes  behind  the  development  of  these  new 
instruments  there  is  a  lack  of  logical  reasoning  and  theoretical  justification. 
The  establishment  of  any  new  measurement  requires  to  be  justified.  It  may  be 
preferable  to  use  existing  measures  and  improve  their  application  to  reduce 
confusion  in  the  field. 
3.6.  Who  should  measure 
The  next  question  is,  who  should  measure  quality  of  life,  patients  or 
clinicians?  It  has  been  suggested  that  there  are  three  possible  options  for 
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measuring  quality  of  life:  measurement  by  outside  observer,  by  the  patient, 
and  by  measuring  objective  parameters  e.  g.  physiological  ones  (van 
Knippenberg  and  de  Haes,  1988).  All  are  different  however,  and  all  require 
different  approaches  and  measuring  instruments.  Several  studies  have  shown 
that  assessment  of  quality  of  life  by  doctors  and  nurses  correlated  poorly  with 
those  rated  by  the  patients  themselves  (Slevin  et  at.,  1988). 
In  contrast,  in  a  study  of  quality  of  life  measurement  in  breast  cancer  patients, 
Bell  et  al.  (1985),  using  a  physician  as  an  independent  observer,  reported  that 
in  general  there  is  good  agreement  between  'patients  self-rating  and 
independent  observer  assessment  of  quality  of  life.  Hunt  and  McKenna  (1992) 
pointed  out  that  "since  quality  of  life  is  assumed  to  encompass  psycho-social 
elements  which  are  not  normally  accessible  to  doctors,  it  is  possible  to  argue 
that  the  patient  is  the  best  judge  of  quality  of  life  and  that  it  is  the  patient's 
self-report  which  should  carry  most  weight". 
However,  in  palliative  care,  in  which  sometimes  the  patients  may  not  be  able 
to  speak  for  themselves,  proxy  rating  (observer  rating  on  behalf  of  the  patient) 
must  be  considered.  This  also  is  crucial  in  assessing  quality  of  life  in 
cognitively  impaired  individuals  (Cella,  1995b).  Since  the  proxy  assessments 
reflect  the  caregivers'  concerns  (family  or  health  professionals)  rather  than  the 
patients'  feelings,  then,  the  challenge  is  how  reliable  are  these  measures? 
Finally,  sometimes  clinicians  are  rather  reluctant  to  judge  outcomes  based  on 
quality  of  life  measures.  Thus,  it  is  difficult  to  ask  them  to  measure  patients' 
quality  of  life  as  outside  observer.  This  is  due  to  several  reasons  (Feld,  1995; 
Montazeri  et  al.,  1996c): 
1.  The  benefits  of  these  measures  are  not  clear  relative  to  standard  endpoints. 
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2.  In  a  busy  clinic  it  is  not  possible  or  it  is  very  difficult  to  administer  these 
measures.  In  other  words,  in  a  clinical  setting  measuring  quality  of  life  is  not 
the  first  priority. 
3.  Some  clinicians  are  concerned  about  burden  on  patients  in  such 
assessments. 
4.  There  are  some  uncertainties  about  how  to  measure  quality  of  life  and  how 
to  analyse  the  information  obtained  and  how  to  interpret  them.  This  is  true 
even  for  some  researchers,  especially  those  who  are  dealing  with  analysing 
these  data.  Difficulties  in  analysing  quality  of  life  data  include  the 
multidimensional  nature  of  data,  attrition,  and  missing  information  (Hopwood 
et  al.,  1994). 
However,  difficulties  which  arise  from  theoretical  concepts  through  to 
operational  practices  all  demonstrate  the  limitations  rather  than  possibilities. 
For  example,  since  each  individual  has  his  or  her  own  values  and  norms  even 
within  a  study  it  is  difficult  to  compare  quality  of  life  scores  among  study 
subjects;  or  from  a  more  radical  point  of  view  it  is  difficult  to  judge  on  quality 
of  life  scores  of  the  same  individual  through  time  in  the  same  study.  Jenkinson 
(1994b)  argued  that,  to  date,  the  benefits  of  including  health  status  measures 
routinely  in  clinical  practice  are  far  from  conclusive. 
Criticism  about  quality  of  life  measures  continues,  since  it  is  argued  that  these 
measures  are  subjected  to  measurement  of  many  variables  which  are  often 
neglected.  This  means  that  quality  of  life  does  not,  to  some  extent,  reflect  a 
sound  scientific  approach  where  the  basis  of  any  measurement  is  the 
perception  of  individuals  which  changes  over  time  either  due  to  change  in 
their  own  values  or  because  they  are  human  beings.  In  addition,  experiences 
of  illness  change  because  people  learn,  adjust,  or  accommodate  over  the 
course  of  illness  (Liang  et  al.,  1990). 
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In  contrast,  it  is  argued  that  despite  so  many  shortcomings  in  measuring 
quality  of  life;  it  can  do  more  good  than  harm  if  the  basic  principles  are 
considered.  Measuring  quality  of  life  may  help  to  build  up  a  more  realistic 
picture  of  patients'  feelings,  and  their  needs.  In  the  following  -section 
experiences  from  the  treatment  of  cancer  may  help  to  justify  the  application  of 
these  measures. 
4.  Experiences  from  the  treatment  of  cancer 
In  assessing  the  outcome  of  clinical  treatment  it  is  important  to  identify 
whether  treatment  results  in  a  better  quality  of  life-  if  not  a  longer  life  (Katz, 
1987).  It  is  argued  that  if  the  patient  would  not  be  able  to  enjoy  his  or  her  own 
time,  survival  for  a  few  extra  months  is  meaningless.  This  will  only  cause  the 
patient  to  suffer  more.  A  patient  with  cancer  experiences  a  "living-dying" 
situation  and  this  is  "the  intolerable  incompatibility  of  life  and  death"  (Muzzin 
et  al.,  1994).  For  example,  30-40%  of  patients  with  cancer  "experience 
periods  of  depression  or  anxiety  or  both"  (Higginson,  1993),  and 
psychosexual  morbidity  is  one  of  the  most,  important  problems  in  women  with 
gynaeocologic  malignancies  (Crowther  et  al.,  1994). 
Three  reasons  have  been  mentioned  to  justify  considering  quality  of  life  as  an 
important  part  of  cancer  treatment  (Slevin,  1992).  First,  a  patient  with  cancer 
has  no  control  over  his  or  her  disease.  Secondly,  the  cause  of  illness  cannot  be 
explained.  The  explanation  can  only  create  confusion  and  sometimes  there  is 
no  answer  even  for  experts.  Thirdly,  patients  are  often  told  "there  is  nothing 
we  can  do  for  you". 
it  is  therefore  not  surprisingly  that  patients  with  cancer  often 
feel  more  miserable  and  despondent  than  patients  with  other  potentially  fatal 
illnesses  and  that  quality  of  life  is  a  much  bigger  issue  in  cancer  than  it  is  in 
other  equally  life  threatening  disease. 
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In  addition,  others  observed  that  in  cancer  therapy  it  is  difficult  to  describe 
whether  a  patient  has  benefited  overall  from  a  treatment  or  not  (Rees,  1991), 
because  the  side-effects  of  treatment  have  also  a  major  contribution  to  the 
quality  of  life.  Surgery  can  seriously  damage  a  patient's  body,  radiotherapy 
may  cause  physical  and  emotional  discomfort,  and  chemotherapy  can  often  be 
toxic  (de  Haes  and  van  Knippenberg,  1985).  Quality  of  life  studies,  however, 
have  several  advantages  in  cancer  treatment.  A  few  examples  are  given  to 
demonstrate  why  measuring  quality  of  life  is  so  important. 
4.1.  Quality  of  life  and  survival 
Quality  of  life  measures  can  be  used  as  an  end  point  in  clinical  trials  to 
compare  different  treatments,  to  measure  outcome  of  health  care  or  as  a 
predictor  of  survival  (Weeks,  1992).  Quality  of  life  studies  may  influence 
decisions  about  the  effectiveness  of  therapies,  enhance  supportive  care,  and 
identify  the  patient's  reaction  towards  treatment. 
In  a  prospective  clinical  trial  of  different  treatment  protocols  for  advanced 
breast  cancer,  Coates  et  al.  (1992)  found  that  there  is  a  significant  association 
between  scores  obtained  from  quality  of  life  measures  and  changes  in  scores 
on  survival  duration.  To  explore  the  relationship  between  quality  of  life  and 
subsequent  survival,  studying  lung  cancer  patients  it  was  found  that 
nonmedical  factors  such  as  quality  of  life  assessment  and  marital  status  play  a 
role  in  survival  and  that  they  should  be  evaluated  and  described  as  potential 
predictors  of  survival  in  cancer  patients  in  clinical  trials  (Ganz  et  al.,  1991). 
In  addition,  survival  is  not  patients'  only  consideration  towards  treatment.  In  a 
study  of  attitudes  towards  the  quantity  and  quality  of  life  in  a  group  of  healthy 
volunteers,  presented  with  hypothetical  options  for  treatment  of  advanced 
laryngeal  cancer,  it  was  found  that  20  per  cent  of  volunteers  preferred  to  trade 
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off  their  life  expectancy  so  that  they  can  retain  speech  (McNeil  et  al.,  1981). 
This  is  true  even  in  trade  off  between  two  different  treatments.  When  survival 
for  two  different  regimens  are  the  same,  it  will  be  useful  to  judge  outcomes 
based  on  the  quality  of  life  which  is  perceived  by  the  patients.  If  survival  for 
one  treatment  is  better,  but  the  quality  of  life  is  decreased,  the  patient  may 
contribute  to  the  process  of  decision-making.  In  this  situation  offering  a 
choice  of  treatment,  when  it  is  possible,  may  help  to  overcome  some  problems 
related  to  the  treatment.  It  is,  argued  that  patients  with  cancer  in  choosing 
between  two  treatments,  when  disease  is  likely  to  be  cured,  may  be  willing  to 
accept  a  treatment  that  effects  their  quality  of  life  in  a  negative  way;  but  if  the 
chance  of  survival  is  small,  then  the  quality  of  life  becomes  the  main  concern 
(Slevin  et  al.,  1990;  Kiebert  et  al.,  1994). 
The  literature  suggests  that  several  contextual  factors  may  affect  the  patients' 
choices  between  survival  and  quality  of  life;  for  example  age,  sex,  marital  and 
domestic  status  of  the  patients,  and  probability  of  survival  (Coates  et  al.,  1983; 
O'Conner,  1989).  To  explore  the  issue  further,  in  a  study  by  Kiebert  et  al. 
(1994)  it  was  found  that  having  a  partner,  having  children,  the  nature  of  side 
effects  of  treatment,  and  baseline 
.  quality  of  life  were  all  of  considerable 
importance  in  choosing  between  quality  of  life  and  survival.  This  is  why  it  has 
been  argued  that  survival  and  quality  of  life  are  not  competing  predictors  of 
outcome  measures,  but  rather  complement  each  other  in  decision  making.  The 
initiative  to  combine  length  of  survival  and  quality  of  life  into  a  single  end 
point  to  provide  quality-adjusted  life  years  is  an  example  (Olschewski  et  al., 
1994). 
Quality-adjusted  life  years  (QALYs)  measure  the  health  gain  which  combine 
the  survival  time  and  quality  of  life.  Quality  of  life  is  usually  measured  on  a 
scale  from  zero  (death)  to  one  (full  health).  Thus,  to  calculate  QALYs,  first 
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the  change  in  both  survival  and  quality  of  life  from  a  particular  treatment 
should  be  estimated,  then  QALYs  can  be  calculated  as:  change  in  survival 
multiplied  by  change  in  quality  of  life  (Petrou  and  Renton,  1993).  The  two 
proposed  applications  for  QALYs  are  as  a  measure  to  be  used  in  the  allocation 
of  resources  and  second  as  a  measure  to  determine  which  individuals  should 
receive  the  available  treatment  (Goodinson  and  Singleton  1989).  On  this  basis 
the  use  of  QALYs  has  been  criticised  in  many  ways.  For  example,  it  is  argued 
that  QALY-based  analysis  will  tend  to  discriminate  against  elderly  people  and 
those  with  shorter  life  expectancies  because  greater  QALY  benefits  can  be 
obtained  by  treating  younger  patients  and  those  with  longer  survival 
(Spiegelhalter  et  al.  1992;  Selai  and  Rosser  1993). 
A  more  acceptable  model  of  such  an  approach  is  Time  Without  Symptoms 
and  Toxicity  (TWIST).  This  model  of  quality-adjusted  survival  analyses  the 
length  of  survival  without  symptoms  of  disease  and  toxicity  of  treatment  can 
be  used  as  an  outcome  to  describe  patient's  quality  of  life  (Gelber  et  al., 
1986). 
4.2.  Contribution  to  development  of  cancer  treatment 
There  is  an  extensive  body  of  literature  on  the  role  of  quality  of  life  studies  in 
clinical  trials  and  development  of  cancer  treatment. 
Barofsky  and  Sugarbaker  (1990)  demonstrated  that  quality  of  life  assessment 
can  lead  to  improved  cancer  treatment  in  two  ways:  when  it  is  an  integral  part 
of  the  treatment  development  process  (single  step),  and  when  it  contributes  to 
improvement  through  a  multistep  procedure. 
To  explain  these  two  procedures  they  discuss  the  development  of  soft  tissue 
sarcoma  and  breast  cancer  treatment.  For  example  in  the  case  of  the  extremity 
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soft-tissue  sarcoma  it  was  found  that  the  limb-sparing  surgery  procedure  did 
not  produce  better  quality  of  life  than  amputation.  Then,  other  studies 
modified  the  limb-sparing  surgery  and  radiotherapy  that  patients  received. 
Subsequently,  new  evidence  shows  that  compared  with  the  previous  method, 
the  modified  procedure  can  lead  to  a  better  quality  of  life.  At  last,  the 
modified  limb-sparing  method  was  confirmed  and  accepted  as  the  new 
protocol. 
4.3.  Identification  of  psychological  needs 
Modem  therapies  in  medicine  have  become  increasingly  effectual  and,  at  the 
same  time,  more  likely  to  produce  harmful  side  effects  (Greer,  1984).  Thus, 
with  regard  to  the  psychological  morbidity  associated  with  cancer  medicine,  it 
is  recommended  that  clinical  trials  should  contain  measures  of  psychological 
adjustment  to  enable  clinicians  to  base  their  decisions  not  only  on  survival  but 
also  on  the  quality  of  that  survival. 
In  this  instance,  studies  of  quality  of  life  measurements  in  breast  cancer 
provide  an  interesting  experience.  While  it  was  thought  that  lumpectomy 
would  reduce  psychological  morbidity  in  women  who  underwent  breast 
conservation  it  was  found  that  there  are  no  significant  differences  in  the 
incidence  of  anxiety  and  depression  between  women  who  underwent 
mastectomy  and  those  who  have  had  breast  conservation  (Fallowfield  et  al., 
1986;  1990).  Morris  and  Ingham  (1988)  showed  that  choice  of  surgery 
treatment,  independent  of  the  type  of  operation,  is  attributed  to  better 
psychological  outcomes.  This  finding,  however,  was  not  supported  by  a  recent 
study  on  which  patients  with  stage  I  or  II  breast  cancer  were  offered  choice  of 
surgery.  The  patients  were  followed  up  for  3  years  after  their  treatment  and 
the  results  showed  that  there  is  no  evidence  to  support  the  notion  that  choice 
prevents  psychological  morbidity  (Fallowfield  et  al.,  1994). 
71 Measuring  quality  of  life 
It  is,  however,  suggested  that  quality  of  life  of  patients  with  breast  cancer  may 
be  improved  by  a  good  communication  style  (Fallowfield,  1993).  A 
prospective  randomised  trial  indicated  that  adjuvant  psychological  therapy  can 
lead  to  a  reduction  in  psychological  distress  (Greer  et  al.,  1992).  This  adjuvant 
psychological  therapy  is  a  "cognitive  behavioural  treatment  programme"  in  six 
sessions,  focusing  on  an  individual's  personal  strengths  to  overcome 
psychological  morbidity  related  to  cancer  (Greer  et  al.,  1991). 
4.4.  Quality  of  life  and  alternative  therapy 
Use  of  alternative  therapy  or  complementary  medicine  for  the  treatment  of 
cancer  has  increased  in  recent  years  (Hauser,  1993).  It  is  argued  that  these 
therapies  may  lead  to  a  better  quality  of  life.  A  study  on  survival  of  patients 
with  breast  cancer  attending  the  Bristol  Cancer  Help  Centre  (BCHC),  offering 
alternative  treatment,  showed  that  "patients  choosing  to  attend  the  BCHC  do 
not  gain  any  substantial  benefit.  Whether  quality  of  life  is  enhanced  is  yet  to 
be  answered"  (Bagenal  et  al.,  1990),  although  subsequent  debate  revealed  that 
this  study  suffered  from  design  flaws,  since  patients  attending  BCHC  had 
more  advanced  disease  (Morris  et  al.,  1992). 
Another  study  on  survival  and  quality  of  life  among  a  group  of  patients  with 
cancer  receiving  unproven  cancer  therapy  as  compared  with  a  group  of 
patients  receiving  conventional  treatment  showed  no  difference  between  the 
two  patient  groups  in  length  of  survival.  On  the  other  hand,  the  same  study 
shows  that  quality  of  life  is  better  among  conventionally  treated  patients 
(Cassileth  et  al.,  1991). 
Recently  the  BMJ  (Downer  et  al.,  1994)  reported  a  study  on  use  of 
complementary  therapies  by  cancer  patients  receiving  conventional  treatment. 
Overall,  a  high  proportion  (82%)  of  those  using  complementary  treatments 
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along  side  the  conventional  therapies  indicated  that  they  are  either  satisfied  or 
very  satisfied.  They  specified  that  the  benefits  are  both  physical  and 
psychological.  The  psychological  benefits,  included  feeling  more  optimistic 
and  hopeful  about  the  future.  This  indicates  that  patients  with  cancer  need 
more  support  and  help  which  may  make  life  more  meaningful  to  people  with 
an  incurable  disease  (Taylor,  1993). 
4.5.  Obtaining  additional  information 
A  critical  review  on  quality  of  life  in  patients  with  ovarian  cancer  shows  that 
there  is  much  to  learn  from  such  studies  (Montazeri  et  al.,  1996a).  For 
example,  studies  have  shown  that  psychological  factors,  experience  of  pain, 
gastrointestinal  symptoms  and  experience  of  fatigue  and  malaise  all  contribute 
to  quality  of  life  of  patients  with  ovarian  cancer  (de  Haes  et  al.,  1990).  Thus, 
measuring  quality  of  life  in  this  way  may  help  to  identify  people  in  need  and 
provide  interventions  required,  especially  psychological  support  to  enhance 
the  quality  of  life  in  these  groups  of  patients  who  are  affected  by  life 
threatening  disease. 
However,  interpretation  of  results  concerning  studies  of  quality  of  life  is  not 
an  easy  task.  van  Knippenberg  et  al.  (1992)  reported  on  a  study  of  quality  of 
life  in  patients  with  resected  oesophageal  '  cancer  and  showed  that  quality  of 
life  of  surgically  treated  patients  can  be  assessed  in  two  opposite  ways- 
depending  on  the  indicator  chosen:  from  a  medical  point  of  view  patients  were 
considered  to  have  been  adequately  treated,  but  when  other  variables  such  as 
physical  symptoms  and  the  effect  on  activity  level  are  taken  into  account 
quality  of  life  had  deteriorated. 
Furthermore,  social  and  cultural  contexts  also  affect  one's  perceptions  of 
health  and  illness.  Thus,  patients'  feelings  and  problem  contexts  are  also 
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essential  in  understanding  health  status  and  quality  of  life  (Albrecht,  1994; 
Fitzpatrick,  1994). 
5.  New  directions 
Several  lessons  have  been  learned  from  measuring  quality  of  life  in  oncology. 
These  include:  quality  of  life  is  multidimensional;  observers  are  poor  judges 
of  how  patients  feel  about  their  quality  of  life;  symptoms  are  associated  with 
quantifiable  disruptions  in  quality  of  life;  and  pre-treatment  quality  of  life  may 
be  predictive  of  on-treatment  quality  of  life  and  survival  (Osoba,  1994).  Yet, 
several  challenges  remain.  One  such  challenge  is  how  should  the  values  and 
preferences  of  patients  be  integrated  into  quality  of  life  measures? 
It  is  argued  that  since  quality  of  life  is  a  uniquely  personal  perception,  most 
measurements  of  quality  of  life  in  the  medical  literature  seem  to  aim  at  the 
wrong  target.  Reviewing  75  randomly  selected  original  quality  of  life  articles, 
Gill  and  Feinstein  (1994)  observed  that  in  87%  of  the  articles,  patients  were 
allowed  to  respond  only  to  a  list  of  items  previously  selected  by  experts  and 
were  not  invited  to  add  any  individual  responses.  This  is  a  serious  problem 
which  questions  the  face  validity  of  these  instruments. 
Recently,  there  have  been  interesting  attempts  to  identify  the  components  of 
quality  of  life  as  perceived  by  individuals.  Two  examples  of  these  are  the 
Schedule  for  the  Evaluation  of  Individual  Quality  of  Life  (SEIQoL),  and  the 
Patient  Generated  Index  (PGI). 
The  SEIQoL  was  developed  using  the  judgement  analysis  technique  in  a  semi- 
structured  interview  form  and  provides  a  list  of,.  five  areas  that  individuals 
judge  to  be  the  most  important  to  their  quality  of  life.  It  also  indicates  the 
relative  weights  of  importance  attached  to  the  components  of  quality  of  life 
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nominated  by  the  individuals  (McGee  et  al.,  1991;  O'Boyle  et  al.,  1992; 
O'Boyle,  1992). 
The  PGI  was  developed  using  the  priority  evaluator  method  (to  take  account 
of  the  preferences)  and  designed  as  a  self-completed  questionnaire.  It  is  very 
similar  to  the  SEIQoL  and  allows  patients  to  define  quality  of  life  and  to  value 
the  relative  importance  of  improvement  in  their  chosen  areas  of  life  (Ruta  and 
Garratt,  1994;  Ruta  et  al.,  1994).  A  similar  method  was  used  by  Guyatt  et  al. 
(1987)  when  they  developed  a  questionnaire  that  asks  patients  to  specify  the 
five  most  important  areas  of  their  lives  affected  by  their  condition,  or  to 
choose  the  five  most  important  from  a  list  of  20  items. 
Using  the  SEIQoL,  in  a  limited  sample  of  healthy  individuals  (42)  it  was 
found  that  a  variety  of  areas  of  life  were  nominated  as  being  important  to  their 
overall  quality  of  life.  Considerable  variability  was  also  found  in  the  relative 
importance  attached  by  participants  to  the  various  aspects  of  their  quality  of 
life.  For  example,  those  who  nominated  health  as  an  'important  factor, 
weighted  health  varying  from  3  to  59  out  of  a  possible  100  score.  A  similar 
study  with  a  sample  of  40  patients  indicated  that  leisure,  family  and  work 
were  significantly  more  important  components  of  quality  of  life  for  the 
patients  than  for  the  healthy  comparison  sample,  while  fewer  patients  referred 
to  health  than  did  members  of  the  healthy  group  (McGee  et  al.,  1991). 
Although  this  method  has  been  reported  to  be  valid,  the  bias  of  introducing 
life  domains  by  showcards  to  those  who  have  no  idea  about  nominated  areas, 
remains  to  be  resolved. 
Two  recent  publications  by  Farquhar  (1995)  and  Bowling  (1995b)  are  the 
most  advanced  in  these  series  of  investigations.  'While  the  former  aimed  to 
identify  lay  definitions  of  quality  of  life  among  people  aged  65  and  over  living 
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in  three  different  areas  (204  subjects),  the  latter  aimed  to  provide  population 
norms  on  the  dimensions  of  life  that  people  perceive  to  be  important  in 
relation  to  their  quality  of  life  based  on  a  large  sample  (2033)  of  the  general 
public.  The  former  study  (Farquhar,  1995)  using  a  set  of  simple  questions 
highlights  how  quality  of  life  varies  among  different  age  groups  of  the  elderly 
population  living  in  different  geographical  areas.  The  study  conclusions  also 
indicate  that  social  contacts  appear  to  be  as  valued  as  health  status.  The  latter 
study  (Bowling,  1995)  which  used  a  method  very  similar  to  the  SEIQoL  found 
that  relationship  with  family  or  relatives,  the  respondents'  own  health,  the 
health  of  someone  close,  and  finances  (good  or  bad)  were  the  most  important 
things  in  respondents'  lives. 
However,  considering  the  patient's  viewpoint,  validity  of  quality  of  life 
measures  must  become  the  central  measure  of  efficacy  for  a  quality  of  life 
instrument.  To  achieve  this  research  into  the  best  ways  of  measuring  and 
assessing  quality  of  life  must  continue  to  seek  individual  values  and 
preferences.  These  methods  now  are  being  applied  in  assessment  of  quality  of 
life  in  cancer  patients.  Examples  of  such  instruments  are  the  Functional 
Assessment  of  Cancer  Therapy,  FACT  (Cella  et  al.,  1995),  the  Subjective 
Quality  of  Life  Profile,  SQLP  (Dazord,  1995),  and  an  Italian  instrument  the 
GIVP-  individual  ranking  of  values  and  preferences  (Belli  et  al.,  1996). 
5.  Conclusion 
Since  health  and  illness  are  not  confined  to  a  biomedical  model  of  well  being, 
quality  of  life  is  a  potential  perspective  of  individuals'  judgement  about  their 
own  values  and  expectations.  The  recent  definition  by  the  WHO  Quality  of 
Life  Group  confirms  this  where  they  state  that  quality  of  life  is  "an 
individual's  perception  of  his/her  position  in  life  in  the  context  of  the  culture 
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and  value  systems  in  which  he/she  lives,  and  in  relation  to  his/her  goals, 
expectations,  standards,  and  concerns"  (WHOQOL  Group,  1994). 
There  are  several  practical  and  acceptable  measures,  to  all  sides  (clinicians, 
patients,  social  scientists,  psychologists),  and  these  should  be  used. 
Methodological  limitations"  are  no  longer  an  excuse  for  not  measuring  quality 
of  life.  We  cannot  wait  for  a  "gold  standard".  As  Ganz  (1994)  reminds  us, 
"although  quality  of  life  was  once  described  as  being  subjective, 
unmeasureable,  and  poorly  defined,  this  is  no  longer  the  case". 
Cancer  has  become  a  new  public  health  priority  (BMJ,  1994)  and  the 
information  which  is  available  from  quality  of  life  studies  may  have  a  central 
role  in  providing  additional  data  for  the  development  of  cancer  control  and  its 
treatments.  The  autonomy  of  patients  is  one  of  the  main  features  of  these  types 
of  assessment  that  may  contribute  to  their  participation  in  informed  decision- 
making  (Payen,  1992). 
Patients  with  cancer  need  cure,  prolongation  of  survival,  and  improvement  of 
quality  of  life.  These  may  not  be  achievable  unless  we  provide  a  good 
partnership  between  social  sciences,  medical  science,  complementary  health 
care,  and  faith  (Morris  et  al.,  1992). 
Quality  of  life  measures  may  help  in  adding  life  to  years  instead  of  years  to 
life.  Adding  years  to  life  may  prolong  survival  time,  but  it  should  not  be  the 
cause  of  suffering,  deterioration  in  health  status,  and  the  quality  of  life  of 
patients  with  cancer.  Cancer  patients  may  refuse  further  treatment,  not 
because  they  want  to  die,  but  because  treatment  leads  to  a  life  not  worth 
living,  a  situation  which  would  result  in  a  health  status  worse  than  death 
(Kiebert  et  al.,  1994). 
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Experiences  from  the  treatment  of  cancer  indicate  that  quality  of  life  measures 
could  be  used  in  different  ways.  For  example,  these  measures  may  be  used  to 
assess  the  overall  outcome  of  a  particular  regimen  or  procedure,  to  compare 
different  treatments,  to  predict  survival,  to  examine  health  care  outcome,  and 
to  use  these  measures  as  screening  tools  to  identify  patients'  particular  needs 
in  the  context  of  their  social  and  cultural  status. 
Patients  with  cancer  need,  more  than  any  thing,  hope  (Slevin,  1992;  Downer 
et  at.,  1994)  and  quality  of  life  studies  may  bring  this  to  them  by  considering 
their  own  views  and  preferences.  That  is  the  way  forward:  adding  life  to  years 
to  make  patients'  life,  even  short,  happy  and  enjoyable. 
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Summary 
, 
A  review  of  the  literature  was  carried  out  covering  the  last  25  years  (1970- 
1995)  by  searching  through  the  MEDLINE  and  manually.  The  review  consists 
of  two  companion  parts.  The  first  includes  studies  of  quality  of  life  in  lung 
cancer  patients  in  general,  while  the  second  part  is  restricted  to  defined 
samples  of  small  and  non-small  cell  lung  cancer  patients.  Excluding  non- 
English  and  review  papers,  in  total  150  citations  were  identified  and  all  have 
been  reviewed.  Over  fifty  instruments  were  used  to  measure  quality  of  life  in 
lung  cancer  studies.  Of  these,  the  European  Organisation  of  Research  and 
Treatment  of  Cancer  Quality  of  Life  Lung  Cancer  Questionnaire  (EORTC 
QLQ-LC13)  in  conjunction  with  the  core  cancer  questionnaire  (QLQ-C30) 
was  found  to  be  the  best  developed  instrument,  although  there  were  two  other 
lung  cancer  specific,  measures  with  good  reliability  and  validity.  Several 
topics  in  this  chapter  have  been  highlighted  including  the  importance  of 
regularly  measuring  quality  of  life  in  lung  cancer  patients.  Progress  and 
achievements  in  areas  such  as  performance  status  as  a  proxy  of  quality  of  life 
measure,  psychological  morbidity  and  symptom  distress  as  predictive  factors 
of  quality  of  survival,  and  communication  problems  in  quality  of  life  studies 
of  lung  cancer  patients  have  been  emphasised  and  their  implications  in  lung 
cancer  care  discussed.  It  is  argued  that  palliation  of  symptoms,  psychosocial 
interventions,  and  understanding  patients'  feelings  and  concerns  all  contribute 
to  improving  quality  of  life  in  lung  cancer 
-patients. 
It  is  concluded  that  the 
future  challenge  in  treatment  of  lung  cancer  lies  not  only  in  improving  the 
survival,  but  mainly  the  patients'  quality  of  life  regardless  of  cell  type. 
Clinical  trial  and  epidemiological  population-based  outcome  studies  are 
recommended  to  provide  this  and  to  allow  a  better  understanding  of  the 
contribution  of  the  socio-economic  characteristics  of  the  patients  to  their  pre- 
and  post-treatment  quality  of  life. 
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Introduction 
For  the  purpose  of  this  study,  this  chapter  reviews  the  literature  on  quality  of 
life  studies  in  lung  cancer  patients  and  gives  an  insight  into  the  improvement 
achieved  and  highlights  the  problems  and  deficiencies.  In  the  following 
sections  two  topics  will  be  covered;  firstly  studies  on  quality  of  life  in  patients 
with  lung  cancer  covering  more  general  aspects  and  secondly,  studies  of  small 
and  non-small  cell  lung  cancer  including  more  specific  issues.  This  distinction 
was  made  due  to  the  fact  that  in  the  former  studies  either  the  cell  type  was  not 
identified  or  different  histologic  types  were  included  in  the  studies  whereas  in 
the  latter  studies  only  small  cell  lung  cancer  or  non-small  cell  lung  cancer 
patients  were  included  in  the  studies. 
There  are  several  papers  on  the  subject.  Of  these,  most  are  commentaries,  one 
is  a  symposium  agenda,  one  is  a  report,  and  one  is  a  paper  that  examines 
different  ways  of  analysing  the  quality  of  life  data.  The  remaining  papers  are 
reviews.  Table  3.1  gives  a  summary  of  all  these  papers.  The  review  papers 
mainly  focus  on  two  issues:  review  of  instruments  used  and,  the  effect  of 
disease  and  its  treatment  on  quality  of  life  of  lung  cancer  patients.  All  papers 
suggest  that  assessment  of  quality  of  life  should  be  included  in  evaluating 
treatment  outcomes.  Of  these,  only  two  papers  include  a  summary  of  quality 
of  life  studies  in  lung  cancer  patients  (Bergman,  1992;  Bergman  and 
Aaronson,  1995).  Some  of  these  review  papers  have  a  narrow  focus  on 
clinical  trials  and  none  were  carried  out  in  a  systematic  way.  The  method  of 
review  and  the  criteria  for  including  papers  are  not  identified.  In  addition, 
these  reviews  did  not  include  all  published  papers  at  the  time  they  were 
carried  out. 
Two  methods  of  investigations  were  carried  out:  MEDLINE  search,  and  a 
manual  search.  The  year  1970  was  chosen  because  the  first  study  of  quality  of 
81 Lung  cancer  and  quality  of  life 
life  in  patients  with  lung  cancer  was  published  in  1970.  For  MEDLINE  search 
the  key  words  "quality  of  life"  and  "lung  cancer"  were  used.  This  provided  the 
initial  database  for  the  review.  The  initial  search  was  carried  out  in  1994  and 
up-dated  twice  in  1995  and  once  at  the  end  of  January  1996. 
In  the  second  procedure,  using  the  initial  database,  the  papers  cited  in  the 
literature  were  examined  for  possible  additional  existing  papers.  There  were 
no  specific  criteria  for  inclusion  of  papers  in  the  review,  but  they  were 
excluded  if  the  language  was  not  English.  A  similar  method  of  investigation 
was  used  in  reviewing  quality  of  life  in  patients  with  ovarian  cancer 
(Montazeri  et  al.,  1996a). 
A  total  of  150  citations  were  identified  and  reviewed.  Of  these,  67  citations 
were  not  restricted  to  specific  cell  type  of  lung  cancer,  but  the  remaining  were 
restricted  to  define  samples  of  small  and  non-small  cell  lung  cancer  patients. 
Thus,  the  review  consists  of  two  parts. 
1.  Quality  of  life  in  lung  cancer  patients  in  general 
Excluding  non-English  and  review  papers  a  total  of  67  citations  were 
identified,  47  citations  on  quality  of  life  in  lung  cancer  patients  in  general 
(Table  3.2),  and  20  citations  on  quality  of  life  in  cancer  patients  including  that 
of  lung  (Table  3.3).  Out  of  67  citations,  18  were  in  abstract  form  (Tables  3.2 
and  3.3)  and  there  were  studies  which  appeared  both  in  an  abstract  form  and 
in  a  complete  publication  form.  This  means  that  some  studies  were  counted 
twice  (once  in  an  abstract  form  and  once  in  form  of  a  complete  publication). 
In  addition  there  were  identical  studies  from  the  same  author(s)  that  had  been 
published  at  different  stages  of  the  studies  or  with  different  findings.  These 
were  also  counted  as  many  times  as  they  appeared  in  the  literature.  In  fact, 
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there  were  51  studies  with  67  citations  (35  lung  cancer  studies  and  16 
including  samples  of  lung  cancer  patients). 
However,  out  of  67  citations,  16  citations  (in  fact,  14  actual  studies)  were 
validation  studies  and  one  was  a  feasibility  study  (Tables  3.2  and  3.3).  The 
rest  were  studies  with  different  objectives  including  investigations  of  quality 
of  life  in  lung  cancer  clinical  trials,  descriptive  studies  measuring  clinical 
outcomes,  and  supportive  care. 
1.1.  Instruments 
Over  50  instruments  were  used  to  measure  quality  of  life  or  some  dimensions 
of  life  quality  in  patients  with  lung  cancer.  Some  of  these  instruments  were 
used  rarely,  some  were  used  only  for  validation  purposes,  and  some  were  not 
true  quality  of  life  measures.  The  European  Organisation  for  Research  and 
Treatment  of  Cancer  Quality  of  Life  Questionnaire  (EORTC  QLQ  C-36  or  C- 
30),  the  Rotterdam  Symptom  Checklist  (RSCL),  the  Hospital  Anxiety  and 
Depression  Scale  (HADS),  the  Functional  Living  Index-Cancer  (FLI-C),  and 
the  Daily  Diary  Card  (DDC)  were  among  the  most  popular  instruments  used 
and  their  applications  in  studies  of  quality  of  life  is  well  documented. 
The  Daily  Diary  Card  (DDC)  is  one  of  the  widely  used  instruments  in  the  UK 
context.  The  instrument  was  developed  by  the  Medical  Research  Council 
(MRC)  Lung  Cancer  Working  Party  and  has  been  used  in  many  randomised 
trials.  Although  its  sensitivity  is  well  documented,  it  has  been  criticised 
because  compliance  with  DDC  is low,  and  it  has  a  limited  focus  on  treatment 
related  side-effects. 
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There  were  three  site-specific  (lung  cancer)  measures:  the  Lung  Cancer 
Symptom  Scale  (LCSS),  the  Functional  Assessment  of  Cancer  Therapy-Lung 
(FACT-L),  and  the  EORTC  QLQ  LC-13. 
The  LCSS  focuses  on  the  physical  and  functional  dimensions  of  quality  of  life 
measuring  major  lung  cancer  symptoms  and  their  effect  on  activity  status.  It 
consists  of  two  instruments;  one  for  patients  and  one  for  health  professionals 
as  observers.  The  patient  scale  consist  of  nine  items:  six  measuring  major 
symptoms  for  lung  cancer  (loss  of  appetite,  fatigue,  cough,  dyspnoea, 
haemoptysis,  and  pain)  and  three  summation  items  related  to  total 
symptomatic  distress,  activity  status,  and  overall  quality  of  life  all  using  visual 
analogue  scale.  The  observer  scale  is  a  5-point  ordinal  level  scale  similar  in 
content  to  the  patient  scale  measuring  the  intensity  of  six  major  lung  cancer 
symptoms. 
The  LCSS  is  a  very  limited  measure  of  quality  of  life  because  it  does  not 
contain  many  of  the  important  components  of  the  quality  of  life  and  in 
addition,  in  its  introductory  statement  contains  the  word  "lung  cancer"  which 
might  be  seen  as  a  limiting  factor. 
The  FACT-L  (version  3)  is  a  44-item  self-reported  instrument  and  consists  of 
two  parts.  Part  one  is  a  34-item  measure  of  general  health  related  quality  of 
life  (FACT-G)  covering  five  dimensions;  physical,  social  and  family, 
emotional,  and  functional  well-being  and  relationship  with  doctor.  Part  two 
(Lung  Cancer  Subscale,  LCS)  is  a  10-item  measure  of  quality  of  life  with 
emphasis  on  lung  cancer  symptoms. 
The  problem  with  the  FACT-  L  is  that  it  mostly  covers  lung  cancer  related 
and  not  the  treatment-related  symptoms.  The  most  important  feature  of  the 
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FACT-L  is due  to  the  fact  that  it  measures  the  relative  weight  of  importance 
attached  to  the  components  of  quality  of  life. 
However,  both  the  LCSS  and  the  FACT-L  have  been  validated  and  show  a 
high  level  of  reliability  and  validity  including  good  internal  consistency, 
content  validity,  and  responsiveness  (Hollen  et  al.,  1993a;  Cella  et  al.,  1995). 
A  full  description  about  the  EORTC  QLQ-C-36,  QLQ-C30,  and  QLQ-LC13 
can  be  found  in  chapter  five  section  3.2  and  3.3.  Table  3.4  summarises  the 
instruments  cited  in  quality  of  life  studies  in  lung  cancer  patients. 
However,  these  are  the  most  useful  instruments  and  can  provide  information 
additional  to  the  clinical  data.  With  such  a,  relatively  good  number  of 
measures  it  appears  that  there  is  no  excuse  for  not  measuring  quality  of  life  in 
lung  cancer  patients.  Such  information  has  an  important  role  in  clinical 
decision  making  and  ensuring  effective  care  for  lung  cancer  patients. 
1.2.  General  findings 
1.2.1.  Performance  status 
The  frequent  use  of  performance  status  as  a  proxy  of  quality  of  life  is  not 
uncommon.  In  lung  cancer  patients  it  is  an  important  prognostic  factor  and 
predictor  of  survival  (Buccheri  and  Ferrigno,  1994a).  The  history  of  quality  of 
life  studies  in  lung  cancer  patients  goes  back  to  1970  when  the  first  paper  was 
published  by  Carlens  et  al.  (1970)  using  the  "vitagram  index".  It  consisted  of 
two  dimensions:  x-axis  (survival)  and  y-axis  (every  month  of  survival  as 
judged  on  a  scale  of  performance  status  ranging  from  -20  to  20).  They  found 
that  patients  undergoing  radical  operations  had  a  substantially  better  survival 
and  performance  status.  Subsequent  studies  confirmed  that  performance  status 
is  a  good  predictor  of  quality  of  life  or  there  is  a  significant  correlation 
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between  performance  status  and  psychological,  physical  and  symptomatic 
distress  (Nou  and  Aberg,  1980;  Eguchi  et  al.,  1992;  Aaronson  et  al.,  1993; 
Buccheri  et  al.,  1995).  Although  the  use  of  performance  status  has  been 
controversial,  correlation  between  performance  status  and  global  quality  of 
life  is  well  established  (Osoba  et  al.,  1994a;  1994b).  It  has  also  been  shown 
that  the  number  and  severity  of  symptoms  increases  with  worsening 
performance  status  (Hopwood  and  Stephens,  1995).  In  addition  it  has  been 
suggested  that  psychiatric  disorder  in  lung  cancer  patients  is  significantly 
associated  with  poorer  performance  status  (Cody  et  al.,  1993).  Schag  et  al. 
(1994)  studied  57  lung  cancer  disease  free  survivors  and  reported  that  the 
Karnofsky  Performance  Scale  (KPS)  was  the  best  predictor  of  quality  of  life. 
In  contrast,  studying  139  lung  cancer  patients  receiving  palliative  treatment, 
quality  of  life  was  found  to  be  a  much  broader  concept  than  the  KPS  and  there 
was  a  weak  association  between  the  KPS  and  the  quality  of  life  as  measured 
by  the  European  Organisation  of  Research  and  Treatment  of  Cancer  quality  of 
life  questionnaire  (EORTC  QLQ-C30)  (Schaafsma  and  Osoba,  1994). 
Contradictory  to  these  findings,  Osoba  et  al  (1994b)  found  that  performance 
status  as  measured  by  the  ECOG  (European  Cooperative  Oncology  Group) 
performance  status  strongly  correlated  with  several  domains  of  quality  of  life 
as  measured  by  the  EORTC  QLQ-C30. 
However,  although  performance  status  is  not  a  true  measure  for  quality  of  life 
and  there  is  inconsistency  in  findings,  it  should  be  seen  as  an  important 
predictor  of  survival  and  quality  of  life.  This  implies  that  physicians, 
especially  oncologists,  should  record  the  performance  status  of  the  lung 
cancer  patients  in  the  case  notes.  They  can  use  either  the  KPS  or  the  ECOG 
performance  status.  Although.  the  ECOG  is  superior  to  the  KPS,  both  are 
valid,  easy  to  score  and  take  a,  few  seconds  to  rate  (Buccheri  and  Ferrigno, 
1994b).  As  Osoba  (1994)  pointed  out  multidimensional  instruments  provide 
86 Lung  cancer  and  quality  of  life 
much  more  information  about  quality  of  life  than  do  unidimensional 
instruments.  Therefore,  a  distinction  should  be  made  between  the 
comprehensive  measurement  of  quality  of  life  and  the  measures  that  only  have 
one  or  two  components. 
1.2.2.  Quality  of  life  as  a  prognostic  factor 
One  of  the  most  interesting  findings  in  quality  of  life  studies  of  lung  cancer 
patients  is  that  initial  quality  of  life  was  found  to  be  the  strongest  prognostic 
factor  for  survival.  This  was  confirmed  by  studies  carried  out  by  Ruckdeschel 
and  Piantodosi  (1989;  1991;  1994)  and  Ganz  et  al.  (1991).  Using  the 
Functional  Living  Index-Cancer  (FLI-C),  it  was  found  that  FLI-C  score  was 
an  independent  predictor  of  survival  even  after  correcting  for  initial 
performance  status,  weight  loss,  stage  of  disease,  number  of  metastatic  sites, 
and  type  of  treatment. 
These  findings  have  shown  that  non-medical  factors  such  as  quality  of  life 
assessment  play  an  important  role  in  predicting  survival  and  they  should  be 
evaluated.  For  example,  Buccheri  et  al.  (1995)  in  a  study  of  128  lung  cancer 
patients  using  the  Therapy  Impact  Questionnaire  (TIQ)  found  that  in  addition 
to  the  stage  of  disease  some  aspect  of  quality  of  life  such  as  difficulty  at  work 
and  doing  household  jobs  are  prognostic  factors  of  improved  survival. 
1.2.3.  Psychosocial  issues 
It  has  been  shown  that  a  diagnosis  of  lung  cancer  by  itself  is  a  cause  of 
depression.  An  early  study  of  134  lung  cancer  patients  and  controls 
(consisting  of  chest  disease,  patients  with  hernia  and  healthy  population),  it 
was  found  that  depression  was  higher  in  lung  cancer  patients  than  controls 
even  before  the  diagnosis  was  confirmed.  A  past  history  of  psychiatric  illness 
and  the  presence  of  metastatic  disease  were  the  most  significant  correlates  of 
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depression  (Hughes,  1985a).  The  follow-up  study  of  a  sub-group  of  the  same 
lung  cancer  patients  (50  patients)  showed  that  depression  was  associated  with 
severe  physical  disability  and  the  anticipation  of  a  fatal  outcome  (Hughes, 
1985b).  Therefore,  regardless  of  tumour  type,  there  is  a  significant  correlation 
between  psychological  disorder  and  physical  symptoms  (Goldberg  et  at., 
1984)  which  leads  to  a  lower  quality  of  life  in  lung  cancer  patients.  Similarly 
in  a  study  of  136  lung  cancer  patients  it  has  been  suggested  that  a  diagnosis  of 
lung  cancer  is  associated  with  considerable  psychiatric  morbidity. 
Furthermore,  initial  psychiatric  illness  was  a  predictor  of  psychiatric  disorder 
at  follow-up  and  significantly  associated  with  physical  symptoms,  pain,  past 
psychiatric  history,  and  female  gender  (Cody  et  al.,  1993). 
These,  however,  confirm  that  there  is  a  need  for  more  comprehensive 
interventions  including  psychosocial  support.  For  example,  in  a  study  of  87 
lung  cancer  patients,  it  was  found  that  there  were  significant  associations 
between  overall  quality  of  life  and  four  factors  including  health,  socio- 
economic,  psychospiritual  and  family  criteria.  The  personal  and  contextual 
factors  together  accounted  for  30%  of  the  variance  in  quality  of  life  of  the 
patients  under  the  study  (Hinds,  1990).  A  study  of  50  lung  cancer  patients 
indicated  that  they  described  their  leisure  as  the  domain  where  they  are  the 
most  dissatisfied  (Dazord,  1995). 
These  clearly  suggest  that  standard  clinical  quality  of  life  measures  are  very 
limited  in  nature.  It  is  necessary  to  consider  a  broader  concept  of  quality  of 
life  and  to  include  areas  of  life  which  are  important  to  patients,  such  as  family 
or  social  life. 
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1.2.4.  Symptom  distress 
There  in  no  doubt  that  lung  cancer  and  its  treatment  affects  patients'  physical 
ability  and  consequently  causes  several  physical  and,  as  discussed  earlier, 
psychosocial  problems.  Hopwood  and  Stephens  (1995)  argued  that  it  is 
important  to  have  a  better  understanding  of  the  symptoms  lung  cancer  patients 
suffer  from  to  provide  an  effective  treatment.  In  this  respect,  they  studied  650 
lung  cancer  patients  using  the  Rotterdam  Symptom  Checklist  (RSCL)  and 
found  that  the  most  frequently  reported  symptoms  at  presentation  included 
tiredness,  lack  of  appetite,  worry,  anxiety,  cough,  and  shortness  of  breath. 
Early  studies  of  quality  of  life  in  cancer  patients  receiving  chemotherapy  have 
shown  that  lung  cancer  patients  experienced  more  problems  with  vomiting, 
sleeping,  loss  of  weight,  and  anxiety  over  treatment  than  other  cancer  patients 
(Coates  et  al.,  1983a).  It  has  been  reported  that  the  most  troublesome 
symptoms  in  patients  receiving  chemotherapy  were  anorexia,  alopecia,  pain, 
and  constipation  (Ahmedzai  et  al.,  1984).  Similarly  it  was  found  that  after 
radiotherapy  distress  as  measured  by  the  Symptom  Distress  Scale  (SDS),  was 
the  most  important  predictor  of  survival  after  adjusting  for  age,  functional 
status,  and  patient's  personality  (Kukull  et  al.,  1986).  The  same  finding  was 
reported  in  a  study  of  434  cancer  patients  including  82  lung  cancer  patients 
where  higher  distress  was  found  in  lung  cancer  patients  and  this  was  a 
significant  predictor  of  survival  (Degner  and  Sloan,  1995).  Interviewing  30 
lung  cancer  patients,  Benedict  (1989)  reported  that  15  patients  suffered  from 
the  disease  process  by  itself  producing  disability,  pain,  anxiety,  changed  daily 
activities,  weakness  and  fatigue  which  were  the  causes  of  greatest  suffering. 
In  a  study  of  61  lung  cancer  patients  receiving  palliative  radiotherapy  it  was 
reported  that  males  and  females  experienced  treatment  related  symptoms 
equally  including  chest  pain,  rigor,  fever,  sweat,  and  difficulties  in  normal 
activity  (Omand  and  Meredith,  1994).  On  the  other  hand,  it  has  been  shown 
that  there  is  significant  link  between  symptoms  and  loss  of  physical 
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functioning  (Ballatori  et  al.,  1993).  It  was  found  that  there  was  a  significant 
association  between  symptom  distress  '  and  disruption  in  quality  of  life  in 
females  (Sarna,  1993a;  1993b;  1994).  In  a  validation  study  of  a  quality  of  life 
instrument  it  was  demonstrated  that  there  was  a  high  correlation  between 
quality  of  life  and  nausea  and  vomiting,  but  low  correlation  concerning  hair 
loss  and  lack  of  appetite  (Kaasa  et  al.,  1988a). 
Thus,  assessment  of  a  wider  range  of  symptoms  both  before  and  after 
treatment  may  help  clinicians  to  increase  their  knowledge  of  patients'  feelings 
and  concerns  and  justify  any  further  decisions,  especially  when  the  intention  is 
palliation  and  there  is  no  survival  benefit. 
1.3.  Communication 
Communication  problems  between  patients  and  their  physicians  and  their 
contribution  to  the  quality  of  life  in  lung  cancer  patients  have  been 
investigated  by  several  researchers.  Early  studies  on  the  subject  showed  that 
psychological  adjustment  in  lung  cancer  patients  might  be  improved  if 
patients  were  given  opportunities  to  ask  questions  about  their  disease  and 
participate  in  decisions  about  treatment  (Hughes,  1985b).  Berglund  and 
Sjoden  (1987)  noticed  that  communication  problems  with  medical  staff  were 
strongly  associated  with  anxiety  and  with  anticipatory  nausea  and  vomiting. 
Studying  94  lung  cancer  patients,  74%  wanted  to  be  told  about  their  diagnosis. 
On  the  other  hand,  in  those  who  did  not  want  to  know  about  the  disease,  their 
quality  of  life  was  found  to  have  deteriorated  as  measured  by  psychological, 
social  and  financial  factors  (Sakai  et  al.,  1994a). 
However,  these  indicate  firstly  the  importance  of  the  communication  issues, 
and  secondly  that  studying  quality  of  life  requires  a  straightforward 
communication  with  patients  themselves.  Relying  on  other  sources  of 
90 Lung  cancer  and  quality  of  life 
information  such  as  relatives  or  physicians,  may  not  reflect  the  exact  nature  of 
the  patients'  feelings  and  concerns.  Interviewing  40  lung  cancer  patients  and 
their  relatives  showed  that  relatives  rated  symptoms  higher  and  mood  lower 
than  patients  (Ahmedzai  et  al.,  1988a).  Significant  differences  were  found 
between  71  lung  cancer  patients,  their  relatives  and  physicians.  Physicians 
were  more  optimistic,  relatives  were  more  pessimistic.  Physicians  were  most 
reliable  at  rating  treatment  tolerance  by  patients  (Buccheri  et  al.,  1992;  1993). 
Two  British  randomised  clinical  trials,  revealed  high  levels  of  agreement 
between  clinicians  and  patients  in  reporting  symptoms,  but  increasing 
disagreement  with  increasing  severity  of  symptoms.  They  also  found  that 
physicians  underestimated  the  level  of  severity  of  the  patient's  symptoms 
(Stephens,  1994). 
2.  Quality  of  life  in  patients  with  small  and  non-small  lung  cancer 
In  the  following  sections  the  literature  on  quality  of  life  in  patients  with  firstly 
small  and  secondly  non-small  cell  lung  cancer  is  considered.  This  is  the  first 
systematic  review  on  the  subject,  since  previously  there  have  only  been  two 
commentaries  on  the  subject  (Feld,  1987;  Fayers,  1992).  The  method  of 
investigation  has  already  been  described  in  the  introduction  to  this  chapter. 
Excluding  non-English  and  review  papers,  83  citations  were  identified.  Of 
these,  41  were  on  quality  of  life  in  patients  with  small  cell  lung  cancer  (Table 
3.5),  and  42  studies  of  non-small  cell  lung  cancer  (Table  3.6).  Out  of  83 
citations,  30  were  abstracts  (Tables  3.5,  and  3.6),  three  validation  studies 
(Aaronson  et  al.,  1987;  Hurny  et  al.,  1988;  Hollen  et  al.,  1994a),  and  two 
feasibility  investigations  (Hurry  et  al.,  1992;  Monars  et  al.,  1985).  Most 
studies  were  clinical  trials  with  survival  time  and  quality  of  life  as  end  points. 
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2.1.  Small  cell  lung  cancer 
Combination  chemotherapy  with  or  without  radiotherapy  is  the  treatment  of 
choice  in  small  cell  lung  cancer.  Thus,  most  studies,  both  randomised  trials 
and  descriptive  ones  evaluated  chemotherapy  and  its  effects  on  quality  of  life. 
In  reviewing  quality  of  life  studies  in  patients  with  small  cell  lung  cancer  the 
following  results  could  be  identified. 
2.1.1.  Tumour  response 
Not  surprisingly  early  studies  of  quality  of  life  showed  that  patients  with  good 
performance  status  and  who  responded  to  chemotherapy  had  a  better  quality 
of  life  (Lau,  1988;  Flechtner  et  al.,  1988).  In  a  study  of  321  patients  with  small 
cell  lung  cancer  (of  those  195  patients  were  entered  into  the  quality  of  life 
study)  quality  of  life  was  found  to  be  dependent  on  tumour  stage  and  tumour 
response  (Wolf  et  al.,  1991).  Using  the  Sickness  Impact  Profile  (SIP)  in 
measuring  quality  of  life  in  62  patients,  Bergman  et  al.  (1991)  found  that 
tumour  response  correlated  with  SIP  summary  scores  and  anxiety.  The  same 
authors  with  the  same  patients  using  the  European  Organisation  of  Research 
and  Treatment  of  Cancer  quality  of  life  questionnaire  (EORTC  QLQ-C36) 
reported  that  there  were  good  correlation  between  changes  of  the  QLQ-C36 
scores  over  a  given  time  period  and  clinical  variables  as  measured  by  tumour 
response  and  performance  status  (Bergman  et  al.,  1992). 
These  findings,  however  indicate  that  early  detection  of  lung  cancer  is  an 
important  issue.  Detection  of  disease  at  an  early  stage  would  allow  better 
management  and  thus  increase  the  chance  of  cure.  Benefit  achievable  by 
screening  is  limited  (Flehinger  and  Melamed,  1994).  Early  detection  mainly 
depends  on  referrals  by  General  Practitioners  (GPs).  Figures  from  the 
Yorkshire  Cancer  Registry  (England)  1988-91  showed  that  the  median  delay 
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was  12  days  (range  6-20)  between  referral  and  first  hospital  visit  and  22  days 
(range  11-40)  between  this  hospital  visit  and  the  start  of  treatment  (Muers, 
1994). 
2.1.2.  Intensive  versus  less  intensive  therapy 
The  challenge  to  improve  survival  and  quality  of  life  led  some  investigators  to 
study  different  ways  of  managing  small  cell  lung  cancer.  Most  studies  have 
shown  that  conventional  (scheduled,  planned)  policies,  although  intensive,  are 
providing  a  better  quality  of  life  (less  nausea  and  pain,  better  sleep,  mood  and 
general  well-being)  than  less  intensive  (experimental,  as  required,  unplanned) 
regimens  (Geddes  et  al.,  1988;  Spiro  et  al.,  1988;  Earl  et  al.,  1991). 
Comparing  standard  chemotherapy  with  a  palliative  regimen,  Wolf  et  al. 
(1994)  studied  221  patients  and  found  no  significant  difference  in  survival 
between  these  two  regimens.  However,  patients  receiving  the  standard 
regimen  had  a  better  tumour  response  and  improvement  of  quality  of  life  than 
patients  receiving  palliative  treatment,  but  the  former  group  had  more  severe 
side  effects.  In  a  similar  study  (standard  versus  palliative  chemotherapy)  a 
significantly  better  survival  was  observed  in  patients  receiving  standard 
treatment,  despite  its  greater  toxicity.  Assessment  of  quality  of  life  using  the 
EORTC  42-item  QLQ,  demonstrated  no  significant  difference  in  most  areas 
measured.  Less  mucositis  and  alopecia  were  reported  by  the  patients  receiving 
palliative  treatment  while  patients  in  the  standard  group  had  better  values  for 
sleep  disturbance,  fatigue,  and  psychological  distress  (Joss  et  al.,  1995a).  It  is 
argued  that  regular  chemotherapy,  although  producing  unpleasant  side  effects, 
also  could  be  palliative  and  may  control  the  effects  of  the  progression  of 
cancer  (Fayers,  1992).  Several  studies  have  shown  that  different  management 
policies  resulted  in  no  major  survival  benefit.  Studying  early  versus  late 
alternating  chemotherapy  in  a  group  of  127  patients  showed  that  there  was  no 
significant  survival  difference  between  treatment  groups,  but  patients 
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receiving  early  alternating  chemotherapy  had  a  better  quality  of  life  as 
measured  by  the  EORTC  QLQ  questionnaire  (Joss  et  al.,  1995b). 
On  the  other  hand  some  studies  suggested  that  the  less  intensive  the  treatment, 
the  better  the  quality  of  life.  The  result  of  a  recent  randomised  trial  comparing 
conventional  versus  intensive  chemotherapy  showed  a  better  quality  of  life  in 
favour  of  conventional  chemotherapy  (Gower  et  al.,  1994;  1995).  In  a 
randomised  trial  of  12  (maintenance)  versus  6  (no  maintenance)  courses  of 
chemotherapy  with  addition  of  radiotherapy  in  both  regimens  it  was  shown 
that  there  were  no  significant  differences  in  survival.  Both  assessments  of  the 
quality  of  life  as  measured  by  patients  using  the  Daily  Diary  Card  (DDC)  and 
as  measured  by  physicians  indicated  a  better  quality  of  life  in  favour  of  6 
courses  of  treatment  (Bleehen  et  al.,  1989a).  However  it  was  reported  that  no 
maintenance  chemotherapy  patients  experienced  a  gradually  deteriorating 
quality  of  life  as  compared  to  the  more  severe  effects  in  the  maintenance 
group  (Hopwood,  1991  a).  Using  the  same  method  of  measurement  Geddes  et 
al.  (Geddes  et  al.,  1990)  in  a  study  of  8  versus  4  courses  of  chemotherapy 
reported  that  there  was  no  significant  survival  difference  between  these  two 
regimens.  The  study  results  indicated  that  each  successive  cycle  of 
chemotherapy  had  a  negative  impact  on  the  patients'  quality  of  life,  especially 
in  patients  receiving  8  courses  of  chemotherapy.  In  a  series  of  randomised 
trials  comparing  alternating  versus  response-dependent  chemotherapy,  carbo- 
versus  cis-platinum,  and  treatment  for  extensive  versus  limited  disease,  it  was 
noticed  that  intensive  treatment  of  more  than  4  cycles  resulted  in  an  overall 
marked  negative  effect  on  patients'  quality  of  life  (Flechtner  et  al.,  1993). 
Although  these  findings  are  not  consistent,  the  results  suggest  that  when  there 
is  no  clinical  benefit,  for  example  in  survival  time  or  tumour  response, 
perceptions  and  attitudes  of  patients  toward  different  treatment  policies  could 
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provide  additional  information.  Therefore,  measuring  quality  of  life  becomes 
essential  and  it  seems  that  it  is  the  most  reasonable  way  of  judging  the  clinical 
outcomes.  As  Hopwood  and  Cull  (1994)  remind  us  there  is  no  guarantee  that 
adding  quality  of  life  measures  makes  the  choice  of  treatment  policy  easier, 
but  it  does  serve  to  clarify  the  potential  trade-offs  that  need  to  be  discussed 
with  patients.  There  is  evidence  that  physical  functioning,  treatment  side- 
effects,  disease-related  symptoms,  psychological  distress,  fatigue  and  malaise 
are  the  most  relevant  aspect  of  quality  of  life  in  patients  receiving 
chemotherapy  (Bernhard  et  al.,  1988).  Furthermore,  fatigue  and  malaise  were 
found  to  be  global  indicators  of  quality  of  life  (Hurry  et  al.,  1993).  Using  such 
findings  may  provide  a  better  understanding  of  clinical  achievements.  It  is 
argued  that  it  is  important  to  ascertain  what  patients  feel  about  the  trade-offs 
between  improved  quality  of  life  and  toxicity  where  there  is  a  significant 
potential  for  long-term  side  effects  that  may  result  in  less  than  an  optimum 
quality  of  life  (Osoba,  1994). 
2.1.3.  Radiotherapy 
Little  is  know  about  the  effect  of  radiotherapy  on  patients'  quality  of  life.  The 
International  Association  for  the  Study  of  Lung  Cancer  (IASLC)  workshop  on 
quality  of  life  reported  that  local  radiation  in  addition  to  chemotherapy  in 
small  cell  lung  cancer  showed  a  significant  advantage  in  median  and  long 
term  survival.  Randomised  trials  of  prophylactic  cranial  irradiation  (PCI)  have 
failed  to  demonstrate  survival  advantage  (Abratt,  1994).  Recent  meta  analysis 
of  thoracic  radiotherapy  for  small  cell  lung  cancer  has  also  confirmed  the  view 
that  radiotherapy  can  have  survival  benefits  (Pignon  et  al.,  1992). 
Studying  53  patients  receiving  therapeutic  or  elective  brain  irradiation,  it  was 
found  that  patients  receiving  elective  irradiation  had  both  better  survival  and 
quality  of  life  as  measured  by  Karnofsky  Performance  Status  (Rosenman  and 
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Noah,  1982).  The  role  of  chemotherapy  in  addition  to  radiotherapy  has  been 
studied  and  it  was  shown  that  patients  receiving  immediate  chemotherapy  plus 
radiotherapy  had  better  survival  as  compared  to  groups  of  patients  who 
received  palliative  treatment.  In  terms  of  quality  of  life  physicians  reported  a 
better  "condition"  in  favour  of  immediate  chemotherapy  plus  radiotherapy, 
but  patients  reported  a  better  quality  of  life  in  favour  of  palliative  treatment. 
Both  groups  reported  the  same  "overall  condition"  and  anxiety  (Bleehen  et  al., 
1989b).  Recently  Cull  et  al.  (1994)  have  reported  the  results  of  a  retrospective 
study  on  52  patients  who  had  received  PCI.  They  observed  that  anxiety  and 
depression  in  these  patients  were  lower  than  patients  recently  receiving  active 
treatment.  However,  it  was  found  that  a  high  proportion  of  patients  still 
experienced  treatment-related  symptoms,  but  not  functional  impairment. 
These  studies  highlight  the  palliative  effect  of  the  radiotherapy  in  the 
management  of  small  cell  lung  cancer.  Radiotherapy  is  a  common  treatment, 
but  there  are  few  studies  that  investigate  the  quality  of  life  in  patients 
receiving  radiation  treatment.  The  need  to  conduct  such  studies  is  essential. 
2.2.  Non-small  cell  lung  cancer 
There  are  various  policies  in  the  management  of  non-small  cell  lung  cancer 
and  aspects  of  the  treatment  related  to  quality  of  life  outcome  are  discussed. 
2.2.1.  Chemotherapy 
As  Thatcher  et  at.  (1995)  pointed  out  non-small  cell  lung  cancer  can  no  longer 
be  regarded  as  resistant  to  chemotherapy.  Early  studies  of  quality  of  life  in 
patients  receiving  chemotherapy  suggested  that  treatment-related  toxicity  and 
the  deterioration  of  patient's  well-being  offset  any  potential  survival 
advantage  for  the  majority  of  the  patients  (Bakker  et  al.,  1986).  In  a  more 
systematic  assessment  of  quality  of  life,  change  in  quality  of  life  scores  as 
96 Lung  cancer  and  quality  of  life 
measured  by  Functional  Living  Index-Cancer  (FLI-C),  correlated  with 
performance  status  change  and  weight  loss,  but  not  with  treatment  regimen, 
side-effects  of  treatment  or  change  of  pain  (Finkelstein  et  at.,  1988). 
Consequent  studies  pointed  out  that  after  chemotherapy  patients  had  marked 
relief  of  symptoms  (Moreno  et  al.,  1988;  Fernandez  et  al.,  1988).  Recent 
studies,  however  have  shown  that  improved  or  stable  quality  of  life  mainly 
depends  on  tumour  response.  For  example,  Pujo  et  al.  (1994)  in  a  study  of  54 
patients  found  a  stable  quality  of  life  in  responders  as  compared  to  those  who 
had  not  responded  to  treatment.  Another  explanation  is  that  baseline  quality  of 
life  not  only  predicts  the  likelihood  of  response  and  survival,  but  also  has 
greater  impact  than  most  known  prognostic  factors  (treatment  types, 
performance  status,  gender,  and  age).  tralla  et  al.  (1995)  in  a  multi-centre 
randomised  trial  of  a  combination  chemotherapy  regimen  studied  673  patients 
using  the  Lung  Cancer  Symptom  Scale  (LCSS)  and  found  that  baseline 
quality  of  life  was  the  best  predictor  of  both  response  to  the  treatment  and 
survival.  Using  the  same  instrument  (LCSS),  Hollen  et  at.  (Hollen  et  al., 
1994b)  found  that  physical  and  functional  dimensions  were  the  most 
important  predictors  of  quality  of  life  in  patients  receiving  chemotherapy. 
2.2.2.  Chemotherapy  and  best  supportive  care 
Comparing  chemotherapy  versus  supportive  care  alone  Buccheri  et  al.  (1989) 
studied  74  patients  and  found  that  there  was  no  significant  difference  in 
depression  and  performance  status  between  treatment  arms.  As  expected, 
while  a  better  treatment  tolerance  was  reported  in  favour  of  supportive  care,  a 
better  physical  status  has  been  found  in  favour  of  the  chemotherapy  group.  In 
another  study,  by  Ganz  et  al.  (1986;  1989)  due  to  poor  compliance  with 
quality  of  life  assessment  it  was  impossible  to  examine  differences  between 
treatment  arms  (supportive  care  versus  supportive  care  plus  chemotherapy). 
However,  they  found  that  there  was  a  positive  correlation  between  quality  of 
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life  scores  as  measured  by  the  Functional  Living  Index-Cancer  (FLI-C)  and 
performance  status  as  measured  by  the  KPS.  In  a  retrospective  study  in  which 
patients  had  received  chemotherapy  or  supportive  care,  it  was  found  that 
chemotherapy  produced  a  temporary  benefit  in  quality  of  life  as  measured  by 
improvement  in  performance  status  (Weeks  et  al.,  1989). 
In  terms  of  quality  of  life  there  is  no  single  answer  to  the  question,  as  to 
whether  the  best  supportive  care  or  chemotherapy  could  produce  a  better 
quality  of  life,  but  there  is  evidence  that  chemotherapy  is  less  expensive  than 
supportive  care.  This  is  due  to  the  fact  that  chemotherapy  produces  tumour 
control,  requires  shorter  hospital  stay,  and  thus  is  less  expensive 
(Jaakkimainen  et  al.,  1990). 
2.2.3.  Radiotherapy 
The  value  of  radiotherapy  in  controlling  specific  cancer  related  symptoms  is 
undisputed  and  can  be  achieved  with  unsophisticated  and  undemanding 
schedules  (Gregor,  1995).  Yet,  more  research  is  needed  in  order  to  answer  the 
critical  issues  of  role  of  radiotherapy  in  the  treatment  of  non-small  cell  lung 
cancer  (Damstrup  and  Poulsen,  1994).  As  far  as  quality  of  life  studies  are 
concerned  there  are  several  studies  to  help  answer  some  of  these  issues.  Kaasa 
et  al.  (1988b;  1988c)  randomised  95  patients  to  receive  either  radiotherapy  or 
chemotherapy.  They  found  significant  differences  in  psychosocial  well-being 
and  global  quality  of  life  in  favour  of  radiotherapy.  There  were  no  significant 
group  differences  in  physical  functioning  and  daily  activities.  A  British  study 
has  shown  that  conventional  and  experimental  radiotherapy  policies  are  the 
same  both  in  survival  time  and  quality  of  life.  The  study  suggested  that 
dysphagia  and  reduction  in  physical  activities  were  the  most  important  side- 
effects  of  the  radiotherapy  (Bleehen  et  al.,  1991).  Considering  these  side 
effects  which  affects  the  patients'  quality  of  life,  consequent  studies  indicated 
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that  there  were  no  survival  benefits  with  multi  or  even  2  fractions  as  compared 
with  single  fraction  radiotherapy.  The  quality  of  life  assessment  as  measured 
by  the  Daily  Diary  Card  (DDC),  the  Hospital  Anxiety  and  Depression  Scale 
(HADS)  and  the  Rotterdam  Symptom  Checklist  (RSCL)  showed  that  disease- 
related  symptoms  improved,  anxiety  improved,  depression  was  unchanged 
and  there  was  less  dysphagia  in  favour  of  single  fraction  (Hopwood  1991b; 
Bleehen  et  al.,  1992).  In  their  recent  study  comparing  short  versus  aggressive 
radiotherapy,  they  found  that  survival  improved  slightly  in  favour  of  the 
aggressive  regimen,  but  in  other  respects  (palliation  of  main  symptoms, 
adverse  effects,  response,  appearance  of  metastases)  the  two  regimens  were 
very  similar  (Hopwood  and  Stephens  1994c). 
2.2.4.  Adjuvant  chemotherapy  with  radiotherapy 
A  recent  meta  analysis  of  randomised  trials  of  combined  chemotherapy  and 
radiotherapy  in  non-small  cell  lung  cancer  concluded  that  cisplatin-based 
chemotherapy  and  radiotherapy  are  superior  to  the  other  regimens,  but  these 
results  must  be  considered  in  the  light  of  the  balance  between  quality  of  life, 
toxicity,  and  costs  of  chemotherapy  (Marino  et  al.,  1955).  There  are  a  few 
studies  that  examine  the  quality  of  life.  Early  studies  used  the  KPS  as  the 
proxy  of  quality  of  life  and  had  shown  different  results.  Arcangeli  et  al.  (1985) 
reported  that  chemotherapy  plus  radiotherapy  improved  patients'  performance 
status  markedly,  while  Minet  et  al.  (1987)  in  a  randomised  trial  comparing 
radiotherapy  alone  versus  radiotherapy  along  with  chemotherapy  found  that 
there  was  no  significant  difference  between  treatment  arms  in  both  survival 
and  quality  of  life.  In  a  study  where  patients  were  randomised  to  receive  either 
radiotherapy  alone,  radiotherapy  plus  chemotherapy  or  palliative  treatment, 
the  results  suggested  that  the  patients  who  received  radiotherapy  or 
radiotherapy  plus  chemotherapy  had  fewer  physical  and  psychological 
99 Lung  cancer  and  quality  of  life 
problems  as  compared  with  those  who  received  palliative  treatment 
(Ahmedzai  et  al.,  1988b). 
2.2.5.  Surgery 
Surgery  is  the  treatment  of  choice  for  stage  I  and  II  non-small  cell  lung 
cancer.  The  only  study  that  has  been  reported  so  far  is  the  one  that  carried  out 
by  Dales  et  al.  (1993;  1994).  They  studied  117  patients,  92  patients  with  and 
25  patients  without  a  confirmed  post-operative  diagnosis  of  lung  cancer.  They 
found  that  pre-operatively,  the  prevalence  of  dyspnoea  was  4  times  higher  in 
the  cancer  group,  but  other  global  quality  of  life  indicators  were  similar. 
Dyspnoea  worsened  in  both  groups  at  1  and  3  months  post-operatively. 
Quality  of  life  deteriorated  post-operatively  in  those  with  cancer  and  returned 
to  pre-operative  levels  at  6-9  months,  but  showed  no  deterioration  post- 
operatively  in  those  without  cancer  even  at  1  and  3  months.  They  concluded 
that  surgery  resulted  in  deterioration  in  the  quality  of  life  during  the  first  3 
months  post-operatively  in  those  with  final  diagnosis  of  cancer,  but 
improvement  back  to  baseline  can  be  expected  thereafter. 
3.  Discussion  and  conclusions 
Survival  in  lung  cancer  patients  is  poor  and  has  improved  little  over  time. 
Despite  the  increasing  research,  there  remains  among  many  physicians  a  high 
degree  of  pessimism  about  the  gains  made  in  clinical  care  (Aisner  and  Belani, 
1993),  especially  when  one  considers  the  side-effects  of  treatments  and  the 
costs  involved.  On  the  other  hand  there  are  those  who  believe  that  using  both 
traditional  outcomes  (survival,  and  tumour  response)  and  patient-based  quality 
of  life  assessment  may  offer  a  more  comprehensive  approach  to  evaluating  the 
relative  risks  and  benefits  associated  with  treatment  (Bergman  and  Aaronson, 
1995).  It  is  argued  that  if  there  is  no  gain  in  survival  time  from  clinical 
investigations,  there  are  several  other  ways  to  improve  health  care  delivery  for 
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lung  cancer  patients  and  add  quality  to  their  life.  Strategies  for  supportive  care 
or  inclusion  of  quality  of  life  measures  as  an  endpoint  in  clinical  practice  are  a 
few  examples  of  such  proposals. 
The  review  highlights  both  the  progress  and  the  shortcomings  of  the  research 
activities  on  the  subject.  Despite  25  years  of  investigations  and  existence  of 
nearly  150  papers  and  reviews,  discrepancies  are  obvious.  Many  studies  are 
built  on  common  sense  conclusions.  For  example,  in  a  study  of  455  patients  it 
was  found  that  performance  status  and  extent  of  disease  had  a  significant 
association  with  reported  distress  as  measured  by  Profile  of  Mood  States 
(POMS).  The  study  concluded  that  the  extent  of  disease  can  be  seen  as  a  risk 
factor  for  distress  (Cella  et  al.,  1987).  When  there  is  no  insight  into  the 
patients'  daily  experiences  nor  to  their  living  conditions,  little  is  gained  from 
studying  such  limited  aspects  of  quality  of  life.  In  addition,  as  shown  in 
Tables  3.2,3.3,3.5,  and  3.6  many  researchers  included  a  restricted  sample  of 
patients  in  their  studies.  In  these  studies,  mostly,  there  is  generally  no 
explanation  of  why  the  other  patients  were  not  included.  It  is  not  possible  to 
be  sure  that  these  investigations  are  unbiased.  Again,  as  these  tables  show, 
studies  have  used  ad  hoc  instruments  to  measure  quality  of  life  and  the 
findings  in  such  assessments  should  be  interpreted  with  caution.  However,  the 
achievements  of  researchers  in  this  field  should  not  be  underestimated, 
especially  the  efforts  of  the  clinicians  and  the  oncologists  who  enthusiastically 
conducted  the  research.  ' 
Although  clinical  findings  in  these  studies  are  important  and  have  been 
discussed,  the  emphasis  of  this  review  was  on  general  aspects  of  the  findings 
concerning  the  quality  of  life.  These  findings  constitute  a  crucial  role  in  the 
treatment  of  lung  cancer  patients  and  reflect  a  wide  spectrum  of  issues  which 
should  be  integrated  into  clinical  practice. 
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Several  topics  in  this  chapter  have  been  highlighted.  First,  that  quality  of  life 
assessment  can  be  a  prognostic  factor  and  predictor  of  survival.  Secondly,  the 
need  for  psychosocial  interventions  in  treatment  of  lung  cancer  patients  has 
been  emphasised.  Since  most  lung  cancer  patients  live  for  a  short  time,  the 
need  for  palliation  of  symptoms  is  the  first  priority.  Data  from  clinical  studies 
of  lung  cancer  clearly  indicate  that,  for  example,  out  of  100  lung  cancer 
patients,  86  suffer  from  pain,  70  have  dyspnoea,  and  68  have  anorexia  (Krech 
et  al.,  1992).  These  findings  suggest  that  to  improve  the  quality  of  life  in  lung 
cancer  patients,  resources  should  be  directed  to  palliative  care  and  this  has 
implications  for  lung  cancer  care  purchasers. 
As  discussed  earlier  several  recent  meta-analyses  have  shown  promising 
clinical  achievements  in  the  management  of  small  and  non-small  cell  lung 
cancer  (e.  g.  Damstrup  and  Poulsen,  1994;  Marino  et  al.,  1995;  Stewart  and 
Pignon,  1955).  These  findings  suggest  that  for  patients  with  advanced  and 
metastatic  small  and  non-small  cell  lung  cancer  survival  alone  should  not  be 
considered  as  the  only  outcome,  rather  the  best  way  forward  is  through  further 
clinical  trials  looking  at  new  drug  schedules  and  using  as  end  points  cost 
effectiveness  and  validated  quality  of  life  measures  (Smith,  1994). 
The  problem  is  that  in  these  meta-analyses  it  is  not  possible  to  study  quality  of 
life.  Thus,  individual  clinical  trials  need  to  address  quality  of  life  in  an  agreed 
manner  and  find  out  whether  the  progress  in  survival  could  lead  to  better 
quality  of  life  or  not?  In  addition  to  the  clinical  trials  it  is  worthwhile  to 
conduct  population-based  outcome  studies  to  have  a  better  understanding  of 
patients'  pre-  and  post-treatment  quality  of  life.  In  such  evaluations  patients' 
socio-economic  characteristics  may  play  an  important  role.  Variation  in 
quality  of  life  among  patients  with  small  and  non-small  cell  lung  cancer  may 
be  explained  by  other  factors  such  as  patients'  socio-economic  background 
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rather  than  just  disease-  or  treatment-related  side  effects.  Since  little  is  known 
about  the  role  of  these  factors,  further  investigation  in  this  area  is 
recommended. 
The  psychological  symptoms  after  diagnosis  of  lung  cancer  should  not  be 
underestimated.  Patients  may  not  want  to  show  their  distress,  but  the  reality  is 
that  these  people  are  suffering  from  a  lot  of  pain  and  physical  and 
psychological  symptoms  including  anxiety  and  depression.  It  is  argued  that 
many  cancer  patients  will  not  disclose  emotional  distress  unless  specifically 
questioned  in  a  systematic  way  or  given  an  opportunity  to  describe  their 
feelings.  Thus,  it  is  reasonable  to  recommend  that  in  future  all  clinical 
investigations  should  include  measures  of  psychological  adjustment  before 
and  after  treatment  (Greer,  1984).  Recent  evidence  has  shown  that  the 
clinicians  underestimate  the  distress  in  their  patients  (Ford  et  al.,  1994).  There 
is  need  to  assess  these  symptoms  carefully  and  necessary  actions  such  as 
psychosocial  interventions  betaken.  Such  interventions  should  not  be  seen  as 
an  optional  extra  but  as  an  integral  part  of  every  patient's  management  plan 
(Fallowfield,  1995). 
In  addition  'creation  of  a  supportive  environment  may  help  patients  overcome 
their  problems.  Relatives,  clinicians,  social  work  departments,  and  cancer 
support  groups  all  have  an  important  role  to  play  in  this  matter.  Of  these  the 
role  of  clinicians  in  recognising  these  symptoms  and  referring  patients  to 
appropriate  care  is  very  crucial.  This  can  be  achieved  by  simple  measures  of 
quality  of  life,  for  example  the  Hospital  Anxiety  and  Depression  Scale 
(HADS)  which  is  a  good  screening  tool  to  identify  patients  in  need. 
While  there  are  still  deficiencies  in  both  quality  of  life  measurement  and 
research  design,  this  review  clearly  shows  that  during  the  last  25  years  there 
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have  been  promising  developments  in  '  many  areas  of  quality  of  life  related 
research.  For  example,  there  now  are  several  valid  instruments  to  measure 
quality  of  life,  quality  of  life  is  increasingly  becoming  integrated  as  part  of 
clinical  trials,  and  that  quality  of  life  by  itself  is  becoming  an  issue  of  interest 
both  for  patients  and  clinicians.  Patients  themselves  have  expressed  a  wish  for 
more  emphasis  on  research  into  quality  of  life  issues  (Goodare  and  Smith, 
1995).  In  contrast,  the  explosion  of  so  many  new  instruments  without  critical 
appraisal,  poor  presentation  of  their  data  in  published  papers,  complex 
statistical  analyses,  and  lack  of  guidelines  all  can  be  seen  as  major  causes  of 
confusion.  However,  these  recent  developments  should  not  prevent  clinicians 
and  oncologists  from  using  the  new  instruments  provided  that  they  have 
evaluated  them  critically. 
The  most  difficult  problem  in  studies  of  quality  of  life  come  from  the  many 
methodological  issues  such,  as  data  collection,  analysis  and  barriers  to  the 
interpretation  of  the  results.  Since  these  could  be  counter  productive,  there  is 
an  urgent  need  to  provide  simple  and  constructive  guidelines  to  help 
researchers  andclinicians  in  administering  these  measures. 
The  role  of  family,  relatives,  social  life,  economic,  and  leisure  time  received 
less  attention  in  quality  of,  life  investigations.  Focusing  only  on  disease-  or 
treatment-related  symptoms  makes  quality  of  life  studies  very  limited.  There 
is  an  urgent  need  to  investigate  these  issues  more  comprehensively,  since  lung 
cancer  patients  have  indicated  that  family  or  leisure  times  are  as  important  as 
their  health. 
Patients  are  the  best  source  of  information  for  any  assessment  of  quality  of  life 
except  in  a  terminal  situation.  Clinicians  should  take  advantage  of  this,  since 
most  patients  seem  to  want  to  please  their  doctors.  A  study  of  cancer  patients 
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receiving  radiotherapy  showed  that  verbal  communication  especially  from  the 
physicians  was  the  most  popular  choice  for  receiving  information  before 
treatment  (Hinds  et  al.,  1995).  This,  however  means  that  communication 
between  clinicians  and  patients  needs  to  be  improved  (Montazeri  et  al., 
1996c).  Understanding  lung  cancer  patients'  feelings  and  concerns  may  help  to 
improve  the  quality  of  care  and  the  quality  of  life.  There  is  evidence  that 
patients  do  not  necessarily  share  clinicians'  priorities  or  place  the  same 
emphasis  on  different  types  of  morbidity  (Turner  et  al.,  1996). 
In  conclusion,  while  research  into  quality  of  life  has  made  substantial  progress 
in  a  relatively  short  period  of  time,  there  is  an  urgent  need  to  include  a  broader 
concept  of  quality  of  life  in  future  studies  despite  the  methodological 
difficulties.  At  present  comprehensive  lung  cancer  care  requires  a  cyclical 
process  that  includes  prevention,  early  detection,  specific  therapy, 
improvement  in  survival  and  supportive  care  strategies.  In  future  the  real 
challenge  in  the  management  of  lung  cancer  lies  in  improving  quality  of  life. 
4.  Summary  Tables 
Six  summary  tables  are  provided: 
1.  Review  papers  of  quality  of  life  studies  in  patients  with  lung  cancer. 
2.  Quality  of  life  studies  in  patients  with  lung  cancer  (in  general). 
3.  Quality  of  life  studies  in  patients  with  cancer  including  lung  cancer. 
4.  Quality  of  life  measures  used  in  lung  cancer  studies. 
5.  Quality  of  life  studies  in  patients  with  small  cell  lung  cancer. 
6.  Quality  of  life  studies  in  patients  with  non-small  cell  lung  cancer. 
To  use  tables  the  following  notes  should  be  considered. 
(i)  Those  indicated  with  asterisk  are  abstracts. 
(ii)  The  full  name  of  measures  are  presented  in  Table  3.4. 
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(iii)  In  Tables  3.2,3.5,  and  3.6  numbers  in  the  parentheses  are  actual  samples 
that  participated  in  quality  of  life  assessments.  In  Table  3.3  numbers  in  the 
parentheses  are  the  numbers  of  lung  cancer  patients  in  each  study. 
(iv)  Abbreviations  are  listed  below: 
QL  =  quality  of  life,  LC  =  lung  cancer,  SCLC  =  small  cell  lung  cancer, 
NSCLC  =  non-small  cell  lung  cancer,  Pt(s)  =  patient(s),  Phyns  =  physicians, 
PS  =  performance  status,  CT  =  chemotherapy,  RT  =  radiotherapy,  PT  = 
palliative  treatment,  SC  =  supportive  care. 
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V--4 Table  3.4  Quality  of  life  measures  used  in  lung  cancer  studies 
Instruments  Items  Dimensions 
1.  Performance  status 
Vitagram  index  2  axis  Quality  of  survival  regarding  the  performance  status 
Karnofsky  Performance  Scale  (KPS)  11  Performance  status 
Eastern  Co-operative  Oncology  Group  5  Performance  status 
Performance  Scale  (ECOG) 
World  Health  Organisation  (WHO)  Performance  5  Performance  status 
Scale 
2.  Functional  status 
Rand  Physical  Functioning  Scale  (PES)  10  Functional  status  (self-care,  mobility,  physical 
activity 
Enforced  Social  Dependency  Scale  (ESDS)  10 
3.  Generic  measures 
Sickness  Impact  Profile  (SIP)  136 
Medical  Outcome  Study-Short  Form  20  (MOS-  20 
SF  20) 
Medical  Outcome  Study-Short  Form  36  (MOS-  36 
SF  36) 
General  Health  Rating  Index  (GHRI)  22 
Subjective  Quality  of  Life  Profile  (SQLP)  33 
Ferrans  and  Powers  Quality  of  Life  Index  Cancer  46 
(FPQLIC) 
Linear  Analogue  Self  assessment  Scale  (LASA) 
4.  Psychological 
Mental  Adjustment  to  Cancer  Scale  (MACS) 
General  Health  Questionnaire  (GHQ) 
Leeds  General  Scales  for  Anxiety  and  Depressio 
(LGSAD) 
Profile  of  Mood  States  (POMS) 
Brief  Profile  of  Mood  States  (B-POMS) 
Mood  Adjective  Checklist  (Bf-S  well  being 
scale) 
Hospital  Anxiety  and  Depression  scale  (HADS) 
Beck  Depression  Inventory  (BDI) 
Psychosocial  Adjustment  to  Illness  Scale  (PAIS) 
Symptom  Checklist-90  (SCL-90) 
Personality  Factor  Questionnaire  (PFQ) 
Eysenck  Personality  Questionnaire  (EPQ) 
Yatabe-Guilford  questionnaire  (YGQ) 
Cancer  Locus  of  Control  (CLC) 
Inventory  of  Current  Concerns  (ICC) 
Awareness  of  Illness  Scale  (AIS) 
Functional  status  (personal  and  social  competence 
etc.  ) 
Physical  and  psychological  status,  sleep  and  rest, 
work,  home  management,  recreation  and  pastimes. 
Physical  and  social  functioning,  role  limitations, 
mental  health,  energy,  pain,  general  health 
perception 
Physical  and  social  functioning,  role  limitations, 
mental  health,  energy,  pain,  general  health 
perception 
Health  perception 
Functional  life,  social  life,  material  life,  spiritual  life, 
unforeseen  domains,  global  assessment 
Physical  and  functional  ability,  family  well-being, 
spirituality,  future  orientation,  sexuality,  social  and 
occupational  functioning 
General  well-being 
30  Psychosocial  assessment 
?  Anxiety  and  depression 
65  Tension,  depression,  anger,  vigour,  fatigue, 
confusion 
?  Psychosocial  well  being 
28  Anxiety,  depression 
14'  Anxiety,  depression 
21  Cognitive  Symptoms  of  depression 
46  Psychosocial  adjustment  to  illness  (seven  domains) 
90  Nine  sub-scales:  depression,  anxiety,  somatisation, 
obsessive-compulsive,  interpersonal  sensitivity, 
hostility,  phobic  anxiety,  paranoid  ideation  and 
psychotics 
?  Personality  assessment 
39  Patients'  personalities 
72  Current  concerns  under  seven  psychosocial 
categories 
18  How  patients  referred  to  their  condition,  their  death 
and  how  describe  their  future  and  purpose  of  their 
treatments 
Minnesota  Multiphasic  Personality  Inventory  556  Ten  major  dimensions  of  emotional  distress  and 
(MMPI)  personality  disturbance 
State  Trait  Anxiety  Inventory  (STAI)  40  Trait  anxiety,  and  state  anxiety 
5.  Pain  and  symptoms 
McGill  Pain  Questionnaire  (MPQ)  78  Pain  frequency,  intensity  and  severity 
116 Table  3.4  continued 
Short  Form  McGill  Pain  Questionnaire  15  As  above 
(SM-MPQ) 
Symptom  Distress  Scale  (SDS)  13  Cancer  symptoms  (appetite,  nausea,  sleep, 
Brief  Symptom  Inventory  (BSI) 
6.  Dyspnoea 
Clinical  Dyspnoea  Index  (CDI) 
Respiratory  Status  (RS) 
Pneumoconiosis  Research  Unit  Index  (PRU) 
American  Thoracic  Society  Questionnaire  (ATS) 
7.  Social  functioning 
Duke-University  North  Carolina  Social  Support 
Scale 
Short  Form  Marlowe-Crowne  Social  Desirability 
Scale  (M-CSDS) 
8.  cancer-specific 
Spitzer  Quality  of  Life  Index  (QL-I) 
Daily  Diary  Card  (DDC) 
elimination,  pain,  fatigue,  breathing,  cough,  outlook, 
appearance,  concentration) 
53  Psychological  symptoms  and  symptomatic  distress 
?  Perceived  dyspnoea  (functional  impairment  at  work 
or  home) 
5  Respiratory  status 
7  Perceived  dyspnoea 
29  Measuring  pulmonary  disease 
Social  support 
10 
Functional  Living  Index-Cancer  (FLI-C)  22 
Rotterdam  Symptom  Checklist  (RSCL)  38 
Cancer  Inventory  of  Problem  Situations  (CIPS)  131 
Cancer  Rehabilitation  Evaluation  System  139 
(CARES),  early  version  called  CIPS 
Cancer  Rehabilitation  Evaluation  System-Short  59 
Form  (CARES-SF) 
Time  Without  Symptoms  and  Toxicity  (TWiST)  - 
European  Organisation  for  Research  and  36 
Treatment  of  Cancer  Quality  of  Life 
Questionnaire  (EORTC  QOL-C36) 
European  Organisation  for  Research  and  30 
Treatment  of  Cancer  Quality  of  Life 
Questionnaire  (EORTC  QOL-C30) 
Therapy  Impact  Questionnaire  (TIQ)  11(36) 
Quality  of  Life  Radiation  Therapy  Instrument  24 
(QOL-RTI) 
9.  site-specific 
Social  desirability 
Activity,  daily  living,  health,  support,  outlook 
Overall  condition,  physical  activity,  vomiting,  mood, 
anxiety 
Physical  symptoms,  mood,  physical  activity,  work, 
social  interaction.  It  is  a  VAS 
Physical,  psychological  and  functional  status 
Problem-oriented  statements  caused  by  cancer 
disease 
Physical  psychological,  occupational,  and  sexual 
functioning,  marital  and  medical  interaction,  family 
and  social  life, 
Physical,  psychological  and  sexual  functioning, 
medical  and  marital  interaction 
Quality-adjusted  survival 
Functioning  (physical,  role,  emotional,  social), 
cancer  symptoms,  financial  impact,  physical 
symptoms,  overall 
health  and  quality  of  life 
Functioning  (physical,  role,  cognitive,  emotional, 
social),  global  health  and  quality  of  life,  dyspnoca, 
appetite  loss,  sleep  disturbance,  constipation, 
diarrhoea,  perceived  financial  impact  of  the  disease 
and  treatment 
Psychological  and  functional  status,  social 
interaction,  disease-  and  treatment-related  symptoms 
(main  instrument  including  physical  symptoms  and 
total  of  36  items) 
Functional  status,  emotional  status,  family  and 
socio-economic  status,  general  quality  of  life 
European  Organisation  for  Research  and  44(13)  EORTC  core  questionnaire  plus  Lung  cancer  related 
Treatment  of  Cancer  Lung  Cancer  Quality  of  Lif  symptoms  and  treatment  side-effects  (30  core  items 
Questionnaire  (EORTC  QOL-LC13)  + 
13-item  lung  cancer  specific) 
Lung  Cancer  Symptom  Scale  (LCSS)  15  Lung  cancer  related  symptoms  (patient-  and 
observer-rated) 
Functional  Assessment  of  Cancer  Therapy-Lung  44(10)  Physical  well-being,  social/family  well-being, 
(FACT-L)  relationship  with  doctor,  emotional  well-being, 
functional 
well-being,  lung  cancer  symptoms  (34  items  general 
and  10  specific) 
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AIMS  AND  OBJECTIVES Aims  and  objectives 
1.  Aims 
1.  To  understand  the  contribution  of  quality  of  life  to  lung  cancer  care. 
2.  To  understand  to  what  extent  the  socio-economic  characteristics  of  lung 
cancer  patients  contribute  to  the  outcome  of  their  clinical  management  with 
outcome  measured  in  terms  of  quality  of  life. 
2.  Objectives 
1.  To  determine  the  social  characteristics  of  patients  with  lung  cancer  and 
chronic  respiratory  disease  in  a  geographically  defined  area. 
2.  To  measure  and  compare  quality  of  life  in  patients  with  lung  cancer  and 
chronic  respiratory  disease. 
3.  To  examine  the  relative  contribution  of  the  socio-economic  characteristics 
of  patients  to  variation  in  their  baseline  quality  of  life. 
4.  To  compare  quality  of  life  of  patients  in  different  settings  these  are:  at  home 
and  in  the  clinic. 
5.  To  compare  baseline  quality  of  life  in  patients  who  knew  their  cancer 
diagnosis  and  those  who  did  not  know  their  diagnosis. 
6.  To  investigate  the  relationship  between  baseline  quality  of  life  and  survival. 
7.  To  compare  quality  of  life  in  lung  cancer  patients  before  and  after  diagnosis 
and  treatment. 
8.  To  determine  what  predicts  global  quality  of  life  at  follow-up  assessments. 
9.  To  investigate  how  patients  reacted  to  the  study. 
10.  To  study  patients'  perceptions  of  quality  of  life. 
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3.  Hypotheses 
1.  There  is  no  difference  between  the  socio-economic  characteristics  of  lung 
cancer  cases  and  chronic  respiratory  disease  controls. 
2.  There  is  no  difference  between  the  social  networks  and  social  support 
systems  of  patients  with  lung  cancer  and  patients  with  chronic  respiratory 
disease. 
3.  There  is  no  difference  between  the  baseline  quality  of  life  of  patients  with 
lung  cancer  and  patients  with  chronic  respiratory  disease. 
4.  Socio-economic  status  and  social  support  system  variables  do  not  contribute 
to  the  patients'  quality  of  life. 
5.  Interview  setting  would  not  affect  the  outcome  as  measured  in  terms  of 
quality  of  life. 
6.  Knowledge  of  having  lung  cancer  diagnosis  would  not  affect  the  outcome  as 
measured  in  terms  of  quality  of  life. 
7.  The  baseline  quality  of  life  is  not  a  predictor  of  survival  time. 
8.  Treatment  will  not  improve  quality  of  life  in  patients  with  lung  cancer  as 
compared  to  their  baseline  assessments. 
9.  Patients  would  prefer  to  fill  in  a  questionnaire  in  the  clinic  rather  than  being 
interviewed  at  home. 
10.  Patients  perceive  quality  of  life  in  a  similar  way  to  health  professionals. 
These  all  were  tested  and  the  results  are  presented  in  chapter  6. 
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Summary 
A  prospective  study  was  conducted  to  measure  quality  of  life  in  patients  with 
lung  cancer.  Data  were  collected  during  one  complete  calendar  year-from  Ist 
January  to  the  31st  of  December  1995  with  the  intention  to  interview  all 
patients  attending  the  chest  clinic  in  Stobhill  Hospital  in  the  northern  sector  of 
Glasgow.  Interviews  were  carried  out  at  patients'  homes  or  in  the  clinic  both 
before  and  after  treatment.  Permission  was  obtained  from  the  hospital  ethical 
committee,  general  practitioners  (GPs),  clinicians,  -  and  the  patients 
themselves.  Quality  of  life  was  assessed  at  baseline  and  three  months  later 
using  three  standard  questionnaires  (the  Nottingham  Health  profile,  the 
EORTC  quality  of  life  core  questionnaire,  and  the  EORTC  lung  cancer 
questionnaire).  In  addition  there  was  a  study  specific  questionnaire  to  collect 
data  on  the  socio-demographic  status  of  the  study  subjects.  Baseline 
assessments  were  scheduled  after  referral  by  GPs  and  before  the  diagnosis  was 
made  by  the  consultant  in  respiratory  medicine.  At  this  stage  for  each 
suspected  case,  one  patient  with  chronic  respiratory  disease  was  interviewed 
as  a  control.  The  researcher  was  blind  to  this  selection,  the  nature  of  the 
L 
disease  and  diagnosis.  At  the  time  of  the  baseline  interview  patients  did  not 
know  their  confirmed  diagnosis.  All  lung  cancer  patients  were  informed  at  a 
return  appointment  when  the  clinical  tests  were  complete.  Follow-up 
assessments  were  scheduled  for  those  with  a  confirmed  diagnosis  of  lung 
cancer  three  months  later. 
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Introduction 
To  achieve  the  aims  and  objectives  of  the  study,  a  prospective  double  blind 
case-control  study  was  designed.  In  the  following  sections  the  method  of 
investigation  and  the  materials  used  are  described. 
1.  Setting 
1.1.  Stobhill  Hospital  catchment  area 
The  study  was  carried  out  in  the  Northern  sector  of  Glasgow.  Since  one  of  the 
most  important  objectives  of  the  study  was  to  investigate  the  relationship 
between  patients'  socio-economic  status  and  quality  of  life,  it  was  thought  that 
the  area  was  an  ideal  setting.  There  is  a  clear  contrast  of  social  structure 
within  the  population  in  this  area  reflecting  a  range  of  deprivation  categories 
from  the  least  to  the  most  deprived  areas,  and  this  would  allow  for  a 
comparison  of  quality  of  life  in  different  social  groups.  Thus,  Stobhill 
Hospital  NHS  Trust,  a  large  teaching  and  District  General  Hospital,  serving 
the  population  of  the  Northern  sector  of  Glasgow  was  chosen  for  the  study. 
The  catchment  area  of  Stobhill  Hospital  is  shown  in  the  following  map.  The 
map  is  divided  into  postcode  sectors.  These  postcode  sectors  were  in  part, 
used  to  indicate  patients'  socio-economic  status  as  described  by  Carstairs  and 
Morris  (1991).  Using  area-based  analysis,  and  studying  similar  methods  in  the 
UK  (  for  example  the  Jarman  score  (1983)  which  calculates  "underprivileged 
area  scores"  in  England  and  Wales),  a  Deprivation  Category  was  established 
for  each  postcode  sector  in  Scotland.  These  categories  range  from  1  (affluent) 
to  7  (deprived).  Deprivation  Category,  takes  four  variables  into  account: 
overcrowding,  male  employment,  social  class,  and  car  ownership.  Glasgow  is 
fortunate  to  contain  precise  match  of  Deprivation  Category  and  social  class. 
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The  catchment  area  is  classified  into  two  main  divisions  by  the  Stobhill  Trust: 
"official"  (the  northern  sector  of  Glasgow),  and  "unofficial"  (a  few  fund 
holding  general  practitioners  send  their  patients  to  Stobhill  from  these  areas, 
see  the  map). 
However,  as  mentioned  above,  the  Stobhill  catchment  area  contains  a  sharp 
contrast  of  social  structure  as  indicated  by  postcode  sectors.  The  composition 
of  the  area  can  be  summarised  as  follow: 
-  Postcode  sectors  indicating  Deprivation  Category  1  and  2  (affluent)  19%, 
-  Postcode  sectors  indicating  Deprivation  Category  3,4,  and  5  (middle)  29%, 
and 
-  Postcode  sectors  indicating  Deprivation  Category  6  and  7  (deprived)  52%. 
This  structure  is  very  similar  to  the  distribution  of  Deprivation  Category  in 
Glasgow,  but  is  fundamentally  different  from  that  of  Scotland  (Table  5.1) 
Table  5.1  Population  living  at  differing  levels  of  Deprivation:  Stobhill 
catchment  area,  Greater  Glasgow,  Scotland,  and  England  and  Wales 
Deprivation  Category  Stobhill  Greater  Glasgow'  Scotland'  England  & 
catchment  area'  Wales' 
Affluent  (1&2)  19  18  20  52 
Middle  (3,4&5)  29  32  62  44 
Deprived  (6&7)  52  50  18  4 
+  Source:  1991  census;  "  Source:  Carstairs  and  Moms  (1991) 
To  give  an  example  of  variation  in  people's  living  conditions,  comparative 
statistics  for  postcode  sectors  from  Stobhill  catchment  area  are  presented  in 
Table  5.2. 
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Table  5.2  Census  1991  statistics  for  selected  postcode  sectors  from  Stobhill 
catchment  area 
Postcode  sector  Deprivation 
Category 
%  Home 
ownership 
%  Car 
ownership 
%  Population  with  I 
term  illness 
%  Males 
unemployed 
G64  3  1  95  85  8  5 
G65  8  2  77  79  7  6 
G641  3  75  70  9  8 
G65  7  4  50  62  12  12 
G66  2  5  34  46  17  15 
G20  0  6  25  31  23  27 
G213  7  18  25  27  32 
Greater  Glasgow  -  44  43  18  20 
1.2.  Department  of  Respiratory  Medicine 
Stobhill  Hospital  has  an  active  Department  of  Respiratory  Medicine  which 
deals  with  all  respiratory  patients  and  there  are  no  other  chest  specialists  in 
this  Hospital.  The  Department  has  six  out-patient  and  one  shared  clinic  every 
week  run  by  two  chest  physicians  and  six  registrars.  There  is  the  "Oncology 
Clinic"  in  which  an  additional  oncologist  participates  (from  the  Beatson 
Oncology  Centre)  with  one  of  the  chest  physicians  for  patients  who  are 
diagnosed  as  having  lung  cancer.  There  are  also  two  "broncoscopy"  clinics  for 
examination  of  patients  suspected  of  lung  cancer.  The  Department  has  an  in- 
patient  ward  for  all  respiratory  patients  including  lung  cancer  patients 
connected  to  a  "Day  Unit"  for  management  of  patients  who  are  receiving  out- 
patient  chemotherapy.  Patients  who  need  radiotherapy  and  surgery  are 
referred  to  other  hospitals,  but  after  or  during  their  additional  care  all  return  to 
the  "Oncology  Clinic"  in  Stobhill  Hospital  for  further  management. 
For  the  purpose  of  this  study  the  researcher  was  present  at  each  clinic  from 
Monday  to  Friday  over  the  whole  study  period.  The  procedures  for  selection 
of  patients  and  study  design  are  described  in  the  following  sections. 
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2.  Design 
This  was  a  prospective  study  carried  out  to  measure  quality  of  life  in  patients 
with  lung  cancer  attending  the  chest  clinic  in  the  Stobhill  Hospital. 
The  research  proposal  was  submitted  to  the  Hospital  Ethical  Committee  on 
November  1994  and  was  approved.  Prior  to  data  collection  a  letter  was  sent  to 
all  General  Practitioners  (GPs)  using  Stobhill  Hospital  for  chest  diseases, 
signed  by  one  of  the  chest  consultants  on  behalf  of  the  Department  of 
Respiratory  Medicine.  One-hundred  and  sixty-seven  (167)  GPs  were  mailed 
with  the  study  protocol  and  a  copy  of  the  instruments  asking  permission  for 
their  potential  patients  to  participate  in  the  study  (Appendix  III).  The 
recruitment  of  patients  was  then  planned  for  one  complete  calendar  year-from 
the  first  January  1995  to  the  end  of  December  1995.  This  period  was  chosen 
because  there  is  a  peak  time  for  referrals  (usually  March,  and  November,  see 
Table  5.3).  The  intention  was  to  assess  quality  of  life  at  baseline  and  three 
months  later. 
Table  5.3  New  referrals  to  the  Department  of  Respiratory  Medicine  - 
Stobhill  Hospital,  1995 
Month  New  referrals  Month  New  referrals  Month  New  referrals  Month  New  referrals 
an.  70  Apr.  27  Jut.  48  Oct.  64 
Feb.  51  May  71  Aug.  64  Nov,  111 
mar.  81  Jüi. 
_ 
63  St  p.  24  Dec.  52 
Tutul  number  of  new  referrals  to  the  Department  of  Respirator  y  Medicine:  -26 
Source:  Medical  Records,  Stobhill  Hospital  (personal  communication) 
I.  Baseline  assessment 
Figure  5.1  shows  a  schematic  view  of  the  study  design.  Baseline  assessment 
was  scheduled  after  referral  by  GPs  and  before  diagnosis  was  made  by 
consultants.  Patients  were  first  referred  to  the  study  coordinator.  The  study 
coordinator  was  a  member  of  the  research  staff  at  Stobhill  Hospital  and  for 
two  reasons  she  was  asked  to  co-operate:  to  keep  the  researcher  blind  to  the 
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selection  of  patients  and  secondly,  to  ask  GPs'  and  patients'  permissions  for 
the  researcher  to  interview  patients  (Appendix  N).  At  this  stage  for  each 
suspected  case,  one  patient  with  chronic  respiratory  disease  was  interviewed 
as  a  control.  The  researcher  was  thus  blind  to  the  diagnosis.  At  the  time  of  the 
baseline  interview  patients  did  not  know  their  confirmed  diagnosis.  All  lung 
cancer  patients  were  informed  of  their  diagnosis  at  a  return  appointment  when 
the  clinical  tests  were  completed. 
However,  at  baseline  it  was  not  always  possible  to  carry  out  interviews  blind. 
This  was  due  to  several  practical  reasons:  it  was  not  always  feasible  for  the 
clinicians  to  introduce  patients  for  interview  before  confirmed  diagnosis; 
some  patients  were  referred  internally  rather  than  by  GPs  and  some  patients 
were  referred  with  short  notice.  Thus,  to  enter  all  cases  to  be  included  in  the 
study  on  some  occasions  baseline  assessments  were  scheduled  after  diagnosis 
but  before  the  start  of  treatment.  This  means  that  at  baseline  assessment  there 
were  two  groups  of  lung  cancer  patients:  those  who  did  not  know  the 
diagnosis,  and  those  who  knew  about  their  disease.  These  later  patients  knew 
that  they  had  lung  cancer  when  they  were  entered  into  the  study.  However, 
this  allowed  the  study  to  examine  an  additional  question:  does  it  matter  if 
patients  know  their  diagnosis  at  baseline  assessment  of  quality  of  life? 
2.2.  Follow-up  assessment 
This  was  scheduled  for  those  with  a  confirmed  diagnosis  of  lung  cancer  at 
three  months  later,  that  is,  after  the  completion  of  their  initial  management. 
This  timing  was  based  on  the  fact  that  the  initial  management  (surgery, 
chemotherapy,  or  radiotherapy)  takes  at  least  three  months  to  be  completed. 
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3.  Patients 
In  1995  there  were  726  new  patients  referred  to  the  Department  of  Respiratory 
Medicine  of  Stobhill  Hospital  (see  Table  5.3).  Out  of  these,  samples  of  cases 
and  controls  were  selected. 
3.1.  Cases 
All  suspected  primary  lung  cancer  cases  regardless  of  their  sex,  age, 
performance  status,  histologic  type  and  stage  of  disease  were  entered  into  the 
study.  The  only  criterion  of  exclusion  was  if  patients  were  referred  prior  to  the 
start  of  the  study,  that  is  patients  who  were  referred  in  1994.  Based  on 
information  from  the  West  of  Scotland  Cancer  Surveillance  Unit  in  1994  there 
were  169  lung  cancer  patients  registered  from  Stobhill  Hospital.  The  data  for 
1994  gives  an  initial  impression  of  the  study  subjects  (Table  5.4). 
Table  5.4  Lung  cancer  cases  registered  from  Stobhill  Hospital-  1994 
Characteristics  No.  "/. 
Gender 
Male  108  64 
Female  61  36 
Age  Group 
41-54  17  10 
55-64  47  28 
65-74  62  36 
75-84  35  21 
85+  8  5 
Deprivation  Category 
Affluent  22  13 
Middle  41  24 
Deprived  106  63 
Total  169  100 
Source:  West  of  Scotland  Cancer  Surveillance  Unit 
3.2.  Controls 
In  this  study  to  be  scientifically  valid  it  had  been  decided  to  match  each  lung 
cancer  patients  with  one  chronic  respiratory  disease  control.  The  controls  were 
selected  if  they  presented  with  acute  symptoms  very  similar  to  lung  cancer 
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patients.  To  avoid  any  selection  biases  there  were  no  matching  for  sex,  age, 
performance  status  or  other  socio-demographic  variables  in  the  study. 
4.  Materials 
Assessment  of  quality  of  life  requires  valid,  reliable,  and  responsive 
instruments.  To  assess  quality  of  life  and  social  characteristics  in  lung  cancer 
patients  three  main  standard  measures  plus  a  study  specific  questionnaire  were 
used.  The  selection  of  these  measures  was  based  on  three  main  factors:  their 
validity,  recommendations  from  previous  research,  and  the  study  objectives. 
Another  consideration  in  such  selection  was  related  to  the  fact  that  these 
instruments  do  not  contain  any  words  indicating  "cancer".  In  this  project  this 
was  an  important  factor,  since  at  baseline  assessment  the  study  design 
required  that  patients  do  not  know  they  were  suspected  of  having  lung  cancer. 
In  addition,  from  the  study  objectives  there  was  a  need  to  have  a  detailed 
assessment  of  social  characteristics  of  patients.  Thus,  a  study  specific 
questionnaire  was  constructed.  The  inclusion  of  items  were  based  on  several 
factors  including  study  objectives,  pre-validated  items  from  previous  research 
works,  and  the  pilot  study.  In  the  following  sections  each  of  these  instruments 
is  discussed. 
4.1.  Nottingham  Health  Profile  (NHP) 
This  is  a  general  health  questionnaire  and  is  used  widely  both  within  the  UK 
and  in  other  countries  with  a  number  of  validated  versions  for  countries 
including  Sweden,  Spain,  France  and  Italy.  The  NHP  is  accepted  as  one  of  the 
recognised  instruments  associated  with  the  extensive  interest  in  quality  of  life. 
The  main  feature  of  the  instrument  is  that  it  was  developed  through 
participation  of  members  of  the  public.  Thus,  it  is  highly  acceptable  to 
respondents.  Since  the  NHP  does  not  ask  directly  if  people  have  a  health 
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problem,  it  is  more  likely  to  pick  up  people  who  are  ill  or  at  risk  but  who  do 
not  perceive  their  problems  as  being  related  to  health.  In  addition,  the  measure 
is  easy  to  complete  and  score,  it  has  a  very  simple  response  format,  and  it 
takes  a  short  time  to  complete  (McEwen,  1993).  The  reliability  and  validity  of 
the  NHP  are  well  established  in  a  wide  range  of  studies  from  individual 
clinical  interviews  to  large  scale  postal  surveys  (McDowell  and  Newell,  1987; 
Bowling,  1991). 
Specifically  relating  to  this  study,  it  has  been  suggested  that  while  the  NHP 
can  be  used  in  clinical  trials  for  selected  groups  of  patients,  it  is  also  a 
valuable  measure  in  other  clinical  settings  such  as  outcome  studies  in  health  of 
chronically  ill  patients,  as  an  adjunct  to  the  clinical  interview,  and  in 
evaluating  clinical  intervention  (McEwen  and  McKenna,  1996). 
The  NHP  has  also  been  used  in  an  oncology  setting  measuring  perceived 
health  status  in  four  groups  of  cancer  patients  including  lung  cancer  patients. 
There  appeared  to  be  a  positive  relation  between  score  at  diagnosis  and  the 
end  of  therapy  with  those  patients  having  more  difficulties  showing  little 
improvement  after  treatment  (cited  in  Hunt  et  al.,  1993). 
The  NHP  consists  of  two  parts.  Part  I  includes  38  items  covering  six  areas: 
sleep  (5  items),  physical  mobility  (8  items),  energy  (3  items),  pain  (8  items), 
emotional  reactions  (9  items),  and  social  isolation  (5  items).  Respondents  are 
asked  to  answer  "Yes"  or  "No"  to  problems  identified  "in  general  at  the 
present  time".  "Yes"  answers  carry  one  and  "No"  answers  carry  zero  score. 
Each  item  on  Part  I  has  a  weight.  Therefore,  the  initial  scores  can  be 
computed  to  obtain  a  weighted  score  for  each  area.  The  total  score  for  each 
dimension  (area)  on  Part  I  ranges  from  zero  (no  problem)  to  100  (all  problems 
are  affirmed).  Part  II  of  the  NIP  consists  of  seven  items  relating  to  paid 
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employment,  looking  after  the  home,  social  life,  family  relation,  sex  life, 
hobbies  and  interests,  and  holidays.  Items  are  scored  one  for  affirmative  and 
zero  for  a  negative.  Since  in  this  study  some  of  the  items  on  Part  II  were  not 
applicable  to  all  respondents  in  this  study  e.  g.  work  and  sex  life,  as 
recommended  by  its  authors,  it  was  not  used  (Appendix  V). 
However,  there  have  been  some  criticisms  on  the  use  of  NHP,  for  example, 
suggesting  that  the  items  do  not  reflect  the  extent  of  severity  of  the  problems 
(Kind  and  Carr-Hill,  1987;  Jenkinson,  1994a).  The  severity  of  problems  on 
the  NHP  means  that  some  individuals  with  illness  may  not  show  up  on  the 
NHP.  Although  this  also  has  been  highlighted  by  the  authors  of  the  NHP 
themselves,  it  is  argued  that  is  not  unusual  for  researchers  to  claim  that  the 
NHP  lacks  sensitivity  in  studies  where  it  was  not  an  appropriate  measure  or 
where  the  sample  size  were  inadequate  (McEwen  and  McKenna,  1996). 
Fallowfield  (1990)  argues  that  one  of  difficulties  with  using  the  NHP  as  a 
quality  of  life  measure  is  the  problem  that  it  only  looks  at  negative  aspects  of 
health,  although  very  few  statements  cover  positive  health.  However,  in 
overall  evaluation,  she  states  that  this  well-researched  instrument  it  worth 
considering  as  a  quality  of  life  measure  in  view  of  its  acceptability,  cheapness 
and  easy  scoring. 
In  conclusion,  since  all  measures  have  their  own  limitations,  the  NHP  is  one 
of  the  best  developed  general  health  measures  for  administration,  especially  in 
the  UK  context.  As  it  was  discussed  in  Chapter  One  its  international  use  also 
confirms  such  a  conclusion. 
The  NHP  is  copyrighted  to  the  authors.  Permission  to  use  the  NHP  was 
obtained  from  Professor  James  McEwen. 
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4.2.  European  Organisation  fro  Research  and  Cancer  Treatment  Quality 
of  Life  Questionnaire  (EORTC  QLQ-C30) 
The  first  generation  of  the  EORTC  QLQ  was  developed  in  1987.  This  was  a 
36-item  questionnaire  (EORTC  QLQ-C36)  designed  to  be  cancer-specific, 
multidimensional,  easy  to  complete,  and  applicable  across  a  range  of  cultural 
settings.  The  QLQ-C36  was  tested  in  an  international  field  study  in  a  sample 
of  lung  cancer  patients  (n  =  537)  drawn  from  15  countries  including  most 
Western  European  countries,  Australia,  Canada,  and  Japan.  Following  this,  a 
revision  was  carried  out  and  there  were  minor  changes  in  the  wording  of 
items,  a  few  noninformative  items  were  discarded,  and  due  to  inadequate 
reliability  of  the  eight-item  emotional  functioning  subscale  it  was  substantially 
reviewed  (Aaronson  et  al.,  1991). 
T  'able  5.5  Content  of  QLQ-C36  and  OLO-C30 
Dimensions  QLQ-C36  QLQ-C30 
Functional  scale, 
Physical  7  5 
Role  2  2 
Emotional  8  4 
Cognitive  1  2 
Social  2  2 
Global  quality  of  life  2  2 
Symptom  scales 
Fatigue  5  3 
Nausea  and  vomiting  2  2 
Pain  1  2 
Dyspnoea  1  1 
Sleep  disturbance  1  1 
Appetite  loss  1  1 
Constipation  1  1 
Diarrhea  1  1 
Financial  impact  1  1 
Total  36  30 
Source:  adapted  from  (Aaronson  et  al.,  1996) 
The  second  generation  questionnaire,  is  known  as  the  EORTC  QLQ-C30. 
Table  5.5  demonstrates  its  differences  from  the  QLQ-C36.  It  is  a  30-item 
questionnaire  and  consists  of  five  functional  scales  (physical,  role,  cognitive, 
emotional),  three  symptoms  scales  (fatigue,  pain,  and  nausea  and  vomiting) 
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and  a  global  health  and  quality  of  life  scale.  The  remaining  single  items  (six 
items)  assess  additional  symptoms  commonly  reported  by  cancer  patients 
including:  dyspnoea,  lack  of  appetite,  sleep  problem,  constipation,  and 
diarrhoea,  as  well  as  the  perceived  financial  difficulties  of  the  disease  and 
treatment  (Appendix  VI). 
The  items  on  physical  functioning  have  a  dichotomous  responses  (yes  or  no). 
The  sections  on  symptoms,  anxiety,  depression,  and  limitations  have  a  4-point 
response  choices  ranging  from  1  (not  at  all)  to  4  (very  much).  The  global 
questions  on  general  health  and  quality  of  life  are  a  7-point  visual  analogue 
scale  ranging  from  1  (very  poor)  to  7  (excellent).  Apart  from  the  physical 
functioning  all  items  employ  a  1-week  time  frame. 
The  EORTC  QLQ-C30  has  been  validated  in  an  international  (Western 
Europe,  North  America,  Australia,  and  Japan)  field  study  of  lung  cancer 
patients  and  it  was  found  to  be  a  reliable  and  valid  measure  of  the  quality  of 
life  of  cancer  patients  (Aaronson  et  al.,  1993).  In  a  recent  study  of  quality  of 
life  in  a  group  of  cancer  patients  including  a  sample  of  lung  cancer  patients 
receiving  radiotherapy  it  was  found  that  the  EORTC  QLQ-C30  not  only  is  a 
valid  instrument  in  measuring  quality  of  life  in  a  cancer  population  in  general, 
but  also  in  patients  with  advanced  disease  (Kaasa  et  al.,  1995).  It  is  argued 
that  the  best  developed  quality  of  life  measure  for  use  with  cancer  patients  is 
currently  the  EORTC  QLQ-C30  (Bowling,  1995a),  although  it  has  been 
criticised  as  being  too  narrow  in  its  focus  with  regard  to  ignoring  much  of  the 
impact  of  cancer  on  social  life  (Siegrist  and  Junge,  1990).  Currently  the 
following  proposed  refinements  are  under  test:  an  alternative  role  functioning 
scale  which  will  include  not  only  work  and  household  jobs  but  also  hobbies 
and  leisure  time  activities  and  wider  range  of  response  categories;  a  revised 
physical  functioning  scale  that  employs  four-point  rather  than  dichotomous 
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response  choice;  and  a  revised  overall  health  status/quality  of  life  aspects  of 
health  (Aaronson  et  al.,  1996). 
4.3.  EORTC  QLQ  Lung  Cancer  Questionnaire  (The  EORTC  QLQ- 
LC13) 
This  is  a  tumour-specific  questionnaire  supplementary  to  the  EORTC  quality 
of  life  cancer  questionnaire. 
The  EORTC  QLQ-LC13  is  a  13-item  measure  of  -  lung-cancer  related 
symptoms  and  treatment  side-effects  including:  coughing  (1  item), 
haemoptysis  (1  item)  , 
dyspnoea  (3  items),  sour  mouth  or  tongue  (1  item), 
trouble  swallowing  (1  item),  tingling  hands  and  feet  (1  item),  hair  loss  (1 
item),  experience  of  pain  (3  items),  and  pain  medication  (2  items).  With  the 
exception  of  the  first  item  on  pain  medication,  which  has  dichotomous 
response  categories  (yes  or  no),  all  items  are  scored  on  a  4-point  categorical 
scale  ranging  from  1  (not  at  all)  to  4  (very  much).  All  items  employ  a  1-week 
time  frame  (Appendix  VI). 
A  recent  publication  by  the  EORTC  Study  Group  on  Quality  of  Life 
concluded  that  the  results  from  international  field  testing,  yielding  a  data  base 
with  over  700  lung  cancer  patients,  lend  support  to  the  EORTC  QLQ-LC13  as 
a  clinically  valid  and  useful  tool  for  assessing  disease-  and  treatment-specific 
symptoms  in  lung  cancer  patients,  when  combined  with  the  EORTC  core 
quality  of  life  questionnaire.  All  symptom  and  toxicity  scores  changed 
significantly  over  time,  with  disease  symptoms  declining  and  treatment 
toxicities  increasing  during  the  treatment  period.  In  a  few  cases,  however,  the 
questionnaire  module  could  benefit  from  further  refinements.  In  addition,  its 
performance  over  a  longer  period  of  time  still  needs  to  be  investigated 
(Bergman  et  al.,  1994). 
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The  use  of  both  EORTC  QLQ-C30  and  QLQ-LC13  are  subjected  to 
copyright.  The  permission  to  use  these  instruments  was  provided  by  a  written 
agreement  from  the  EORTC  Data  Centre  (Appendix  VII). 
4.4.  Study  specific  questionnaires 
4.4.1.  Socio-demographic  questionnaire 
Different  patients  vary  in  their  initial  quality  of  life.  Thus,  relying  solely  on 
standard  measures  of  health-related  quality  of  life  may  not  reflect  the  role  of 
other  variables  which  could  be  considered  as  possible  confounders.  For 
example,  variables  such  as  socio-economic  status  of  patients  or  their  family 
structure  and  social  networks  may  account  for  great  deal  of  variances  in 
patients'  quality  of  life.  In  this  respect  one  may  argue  that  patients'  scores  on 
one  standard  measure  not  only  depend  on  disease-  and  treatment-  related 
parameters  but  could  also  be  affected  by  several  other  factors,  namely 
patients'  socio-economic  background  or  lifestyle.  Therefore,  to  adjust  findings 
from  standard  measures  of  quality  of  life  used  in  this  study  against  patients' 
background,  a  proposed-questionnaire  was  constructed  to  provide  this 
information.  The  variables  were  governed  by  a  combination  of  previous 
research  findings  (Pill  et  al.,  1995;  Oostrom  et  al.,  1995;  Osler,  1995),  the 
pilot  study  (see  chapter  one),  and  the  desire  to  take  advantage  from  face-to 
face  interviewing  the  patients.  In  the  following  section  these  variables  are 
described. 
(a)  Socio-demographic  status:  gender,  age,  martial  status,  and  education  level. 
Gender,  martial  status,  and  education  level  were  categorical  and  age  was 
recorded  as  a  continuous  variable. 
Variables  were  categorised  as  follows: 
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-  Educational  level:  no  school  leaving  certificate  (those  who  left  school  at  age 
14  or  15  which  is  very  common  for  elderly  people),  school  certificate,  college, 
diploma,  or  university  qualification. 
-  Marital  status:  married,  widowed,  separated,  divorced,  and  single. 
(b)  Family  structure:  number  of  people  in  household,  and  number  of  children. 
All  variables  were  numerical. 
(c)  Social  network:  visit  frequency  from  children  who  had  left  home,  visit 
frequency  with  other  members  of  family  and  relatives,  visit  or  contact 
frequency  with  neighbours.  All  variables  were  rated  on  a  categorical  basis. 
-  Visit  frequency  was  categorised  as  follows: 
Always  (every  day),  almost  always  (2  or  3  times  per  week),  sometimes  (1  to  3 
times  per  month),  almost  never  (once  a  year),  never  (none). 
(d)  Social  support:  support  and  help  received  from  children,  family  and 
relatives,  and  neighbours.  This  included  any  form  of  support  such  as  financial, 
transport  to  shopping  centres,  or  hospital,  emotional  support,  shopping, 
cooking,  cleaning,  etc. 
-  Support  was  categorised  as  follows: 
always,  almost  always,  sometimes,  almost  never,  never. 
(e)  Socio-economic  status:  employment  status,  home  ownership,  type  of 
accommodation,  persons  per  room,  and  car  ownership. 
Variables  was  categorised  as  follows: 
-  Employment  status:  employed,  unemployed,  housewife,  and  retired. 
-  Home  ownership:  owned,  rented  from  private  sector,  rented  from  council  or 
housing  association. 
-  Type  of  accommodation:  based  on  Scottish  Housing  Survey  (1991),  type  of 
accommodation  defined  as  flat,  semidetached,  4  in  a  block,  and  terraced 
house,  detached  house,  bungalow. 
-  Persons  per  room:  number  of  rooms  available  divided  by  number  of  people 
at  household.  This  was  a  numerical  variable. 
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-  Car  ownership:  having  car,  no  car. 
(f)  Deprivation  Category:  was  measured  by  Carstairs  and  Morris  (1991) 
Deprivation  Category  index  (Depcat)  as  described  in  this  chapter  section  1.1. 
It  was  used  as  an  additional  indicator  of  socio-economic  deprivation  of  the 
respondents. 
(g)  Access  to  hospital:  home  distance  from  Stobhill  Hospital,  how  transport  to 
hospital  is  arranged. 
The  variables  were  rated  as  follows: 
-  Home  distance  from  Stobhill  Hospital  were  recorded  in  miles.  These  were 
numerical  variables. 
-  Transport  to  hospital  was  categorised  as  follows:  private  car  (own  or 
relatives'  car),  public  transport,  walking,  and  hospital  ambulance. 
(h)  Comorbidity:  this  was  investigated  by  asking  patients  whether  they  were 
admitted  to  hospital  during  the  last  year  prior  to  their  recent  illnesses 
(Appendix  VIII). 
4.4.2.  Acceptability  questionnaire 
This  was  a  12-item  short  questionnaire  to  examine  how  the  study  population 
reacted  to  the  study  (Appendix  IX).  It  included  items  on:  easiness  of 
understanding  the  questionnaires,  relevance  of  the  questions  to  the  patients, 
preferences  on  how  the  patients  would  like  to  be  assessed  (that  is,  whether 
they  prefer  to  be  interviewed  or  to  fill  in  a  questionnaire  by  themselves), 
feelings  about  interview,  and  the  preference  on  setting  (that  is,  whether  they 
prefer  to  be  interviewed  at  home  or  in  the  clinic).  These  are  important 
questions  since  many  clinicians  argue  that  assessing  patients  through 
interview  is  too  upsetting  particularly  if  it  is  conducted  in  the  home 
environment  (Montazeri  et  al.,  1996c). 
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4.4.3.  Quality  of  life:  patients'  perceptions 
There  were  two  open-ended  questions  to  find  out  what  quality  of  life  means  to 
the  patients.  Patients  were  asked  what  quality  of  life  is.  They  did  not  receive 
any  special  instruction  and  were  given  freedom  to  mention  as  many  areas  or 
factors  as  they  wanted.  They  were  then  asked  what  a  good  quality  of  life  is  for 
them  and  to  rank  nominated  factors  in  order  of  importance. 
4.5.  Additional  study  measures 
4.5.1.  Clinical  variables 
These  were  extracted  from  case  notes  and  only  recorded  for  lung  cancer 
patients  not  controls.  These  included: 
-  Histologic  types  of  the  disease:  small  cell  lung  cancer,  non-small  cell  lung 
cancer,  and  unspecified  or  others  such  as  mesothelioma  (pleura). 
-  Stage  of  the  disease:  limited  to  chest,  and  extensive  (metastatic  disease 
identified  outside  chest) 
-  Weight  loss:  significant  weight  loss,  weight  steady,  possible  weight  loss,  no 
comments  in  case  notes 
Types  of  treatment  received:  surgery,  chemotherapy,  radiotherapy  or no  active 
treatment  policy  (best  supportive  care). 
4.5.2.  ECOG  Performance  Scale 
This  is  an  observer  rating  of  physical  ability  developed  by  the  Eastern 
Cooperative  Oncology  Group-ECOG  (Zubrod  et  al.,  1960).  It  is  a  5-grade 
scale  ranging  from  zero  to  4.  Zero  indicates  that  patient  is  able  to  carry  out  all 
normal  activities  and  4  represents  that  the  patient  is  completely  disabled 
(Table  5.6). 
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5.6  ECOG  Performance  Status  Scale 
Score  Definition 
0  Able  to  carry  out  normal  activities  without  restriction 
1  Restricted  in  physically  strenuous  activity  but  ambulatory  and  able  to  carry  out  light 
work 
2  Ambulatory  and  capable  of  all  self-care  but  unable  to  carry  out  any  work;  up  and  about 
more  than  50%  of  waking  hours 
3  Capable  of  only  limited  self-care;  confined  to  bed  or  chair  more  than  50%  of  waking 
hours 
4  Completely  disabled,  cannot  carry  on  self-care;  totally  confined  to  bed  or  chair 
5.  Data  collection 
After  approval  from  Stobhill  Hospital  Ethical  Committee  and  GPs' 
preliminary  agreements,  data  collection  began  on  Ist  January  1995.  Baseline 
assessment  was  finished  by  the  end  of  December  1995  and  the  follow-up 
interviews  ended  by  the  10th  of  April  1996.  In  this  section  the  ways  in  which 
data  were  collected  and  interviews  were  carried  out  are  described. 
5.1.  Baseline  data  collection 
After  GP  referral  and  selection  of  patient  by  the  chest  consultant  (either 
suspected  lung  cancer  cases  or  chronic  respiratory  controls),  they  were 
referred  to  the  study  coordinator.  Permission  was  first  obtained  from  the 
patient's  GP,  and  if  there  was  no  objection  the  patient  was  contacted  to  ask  his 
or  her  permission  and  to  arrange  a  convenient  time  for  interview.  At  this 
stage,  the  patient  was  introduced  to  the  researcher. 
Interviews  were  carried  out  either  in  the  clinic  or at  the  patients'  homes.  There 
were  two  chest  consultants.  One  of  the  consultants  asked  that  his  patients 
should  only  be  interviewed  in  the  clinic.  The  other  consultant  agreed  for  his 
patients  to  be  interviewed  either  at  home  or  in  the  clinic. 
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Home  interviews  usually  were  arranged  before  the  patient  was  seen  by  the 
consultant,  whereas  in  the  clinic  interviews  took  place  after  the  patient  had 
seen  the  consultant  in  a  separate  room.  The  procedure  of  data  collection  at 
baseline  is  shown  in  Figure  5.2. 
5.3.  Follow-up  data  collection 
For  follow-up  interviews  the  patient's  GP  was  first  contacted  to  ask  his  or  her 
permission  and  confirm  that  the  patient  was  still  alive  and  under  the  GP's 
care.  Subsequently,  a  letter  was  sent  to  each  lung  cancer  patient  signed  by  one 
of  the  chest  consultants  (controls  were  not  followed-up).  They  were  asked  if 
they  were  willing  to  be  interviewed  for  the  second  time.  There  was  a 
telephone  number  for  patients  to  call  the  study  coordinator  and  indicate  if  they 
do  not  wish  to  participate  in  the  follow-up  interview  (Appendix  X).  If  there 
was  no  reply,  that  was  taken  as  a  sign  of  the  patient's  agreement.  Then,  the 
patient  was  contacted  and  a  convenient  time  was  arranged  for  interview  either 
at  home  or  in  the  clinic.  If  a  patient  did  not  have  a  telephone  number  or  his  or 
her  name  was  not  listed  in  the  telephone  directory,  a  letter  was  sent  by  the 
researcher  asking  the  patient  to  contact  the  researcher  and  indicate  a 
convenient  time  for  interview  (Appendix  XI).  The  procedure  of  data 
collection  at  follow-up  is  shown  in  Figure  5.2. 
5.3.  Interviewer-administered  approach 
Data  were  collected  via  a  series  of  interviewer-administered  approach. 
Although  the  NIHP,  the  EORTC  QLQ-C30,  and  the  EORTC  QLQ  LC13  are 
designed  as  a  self-administered  questionnaire,  the  literature  indicates  that  they 
can  be  administered  in  interview  form  as  well.  In  the  case  of  the  NIHP,  the 
user's  manual  indicates  that  the  questionnaire  can  be  used  as  part  of  an 
interview  (taunt  et  al.,  1993).  For  the  EORTC  questionnaires  the  authors 
reported  that  the  mode  of  administration  does  not  influence  the  patients' 
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responses  (Aaronson  et  al.,  1993).  Thus,  in  this  study  these  questionnaires 
were  administered  in  interview  form. 
This  method  of  data  collection  was  used  because  one  way  of  collecting  high- 
quality  data  in  quality  of  life  studies  is  by  interview  (Cella,  1995a).  It  is 
argued  that  an  interview  is  a  more  sensitive  way  of  collecting  accurate  quality 
of  life  data  as  opposed  to  data  collection  by  a  self-administered  questionnaire 
(Anderson  et  al.,  1986).  Relying  solely  on  self-reporting  questionnaires  to 
assess  quality  of  life  can  result  in  many  problems  such  as  missing  data  and 
inconsistent  responses  (Cella,  1995b).  In  addition,  it  is  argued  that  self- 
administered  instruments  may  cause  some  cognitive  problems.  In  a  study  of 
quality  of  life  in  lung  cancer  patients,  it  was  reported  that  elderly  patients 
often  had  difficulties  in  understanding  the  different  response  formats.  Patients 
with  lower  educational  status  also  were  sometimes  afraid  to  make  mistakes 
while  filling  in  the  questionnaire  (Bernhard  et  al.,  1995). 
5.4.  Time  spent  interviewing  and  traveling 
The  home  interviews  were  not  restricted  to  particular  days  or  times  and  took 
place  throughout  the  week,  including  evenings  and  weekends  based  on  the 
patients'  preferences.  For  each  home  interview  the  researcher  traveled  by 
means  of  a  private  car  or  bus  and  usually  took  two  to  three  hours  to  conduct 
an  interview.  As  described  earlier,  clinic  interviews  took  place  from  Monday 
to  Friday  within  the  working  hours.  In  the  clinic,  based  on  the  patient's 
situation  (consultant  examination,  medical  tests,  etc.  )  the  researcher  usually 
waited  for  one  to  two  hours  to  carry  out  the  interview.  To  set  up  the  study  and 
collect  data  about  1460  trips  to  Stobhill  Hospital  or  patients'  homes  were 
made,  in  total  near  10,000  miles  of  travelling. 
Each  trip  defined  as  a  journey  from  the  Department  of  Public  Health  University  Glasgow  or  the 
Ruchill  Hospital  (the  researcher's  base)  to  Stobhill  Hospital,  and  patients'  homes,  and  the  return 
journey  also  was  counted  as  one  trip. 
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5.5.  Other  sources  of  identification  of  cases 
In  the  baseline  interviews  in  addition  to  GP  referrals,  other  sources  of 
identification  of  possible  cases  were  considered.  These  included:  the 
"bronchoscopy"  diary  list,  "pathology"  results,  internal  referrals  (referrals  by 
other  consultants  in  Stobhill  Hospital  to  chest  physicians  where  it  was 
possible),  the  in-patient  list  in  the  Respiratory  Medicine  ward,  and  the 
Oncology  Clinic. 
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6.  Analysis 
Data  were  analysed  using  the  Statistical  Package  for  Social  Sciences  (SPSS) 
for  Windows  (Norusis,  1993).  It  was  realised  that  for  some  response 
categories  the  numbers  and  frequencies  were  rather  small,  thus  to  be  able  to 
carry  out  tests  of  significance,  some  categorical  variables  were  re-coded.  The 
procedure  of  re-coding  was  as  follows. 
6.1  Coding 
1.  Education  level:  "no  school  leaving  certificate"  and  "school  certificate" 
were  classified  as  "primary  education",  and  "college,  diploma,  or  university 
qualifications"  were  classified  as  "higher  education". 
2.  Marital  status:  "widowed",  "separated",  and  "divorced"  were  classified 
under  one  category,  and  the  other  response  categories  remain  as  their  original 
coding. 
3.  Deprivation  Category  (Depcat):  deprivation  categories  1  and  2  defined  as 
"affluent",  categories  3,4,  and  5  defined  as  "middle",  and  categories  6,  and  7 
as  "deprived". 
4.  Variables  on  social  network  and  social  support:  "always"  and  "almost 
always"  were  classified  under  one  category.  The  same  order  was  applied  to 
"almost  never"  and  "never"  categories.  "Sometimes"  was  used  as  its  original 
coding. 
5.  Home  ownership:  "private  rented",  "rented  from  Council  or  Hosing 
Association"  all  were  classified  as  "rented",  and  "owner  occupied"  coded  as 
its  original  category. 
6.  Number  of  children:  number  of  children  were  classified  into  three 
categories:  those  with  "0-2"  children,  those  with  "3-5"  children,  and  those  "6- 
8"  children. 
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7.  Finally,  according  to  the  manual  of  the  NHP  and  the  EORTC 
questionnaires,  patients'  responses  to  these  questionnaires  were  converted  to  a 
numerical  basis  to  provide  sub-scales  as  defined  in  this  chapter  ranging  from 
zero  (0)  to  100.  (Appendix  XII  and  Appendix  XIII) 
6.2  Presentation  of  data  and  statistical  tests 
6.2.1  Categorical  data  and  Chi-square  test 
For  categorical  data,  numbers  and  percentages  of  responses  for  each  response 
category  of  each  variable  were  used.  These  were  followed  by  Chi-square  test 
where  it  was  necessary  to  investigate  associations  or  differences  between 
different  variables. 
6.2.2  Numeric  data  and  non  parametric  tests 
For  numerical  data,  means  and  standard  deviations  (SD)  were  used  as 
summary  statistics  followed  by  non-parametric  tests  for  comparison. 
Parametric  tests  such  as  t-test  were  not  used  because  parametric  tests  are 
based  on  the  assumption  that  data  are  normally  distributed  (Bland,  1987). 
Since  in  this  study  the  distribution  of  numeric  data  were  rather  skewed,  non- 
parametric  tests,  where  the  analysis  are  based  on  free  distribution,  were  used 
(Everitt,  1995).  The  following  tests  were  performed  for  the  analysis. 
1.  Mann-Whitney  U  test  (also  known  as  Wilcoxon-Mann-Whitney  test  or 
Wilcoxon  Rank  Sum  test):  is  a  distribution-free  method  used  as  an  alternative 
to  the  t-test  assessing  whether  there  was  a  significant  difference  between 
scores  of  two  independent  samples  (groups).  The  test  does  not  use  the  actual 
values  of  the  observations,  but  replaces  them  with  ranks.  The  hypothesis  is 
that  the  mean  ranks  are  equal  in  two  groups.  If  the  mean  ranks  are  equal,  the 
groups  are  similar.  In  contrast,  if  the  mean  rank  is  substantially  higher  in  one 
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group  than  the  other,  the  difference  is  considered  to  be  significant  (Everitt, 
1995). 
2.  Kruskal-Wallis  test:  this  is  a  distribution-free  method  used  as  an  alternative 
to  the  "one  way  analysis  of  variance"  (ANOVA)  assessing  whether  there  were 
significant  differences  between  scores  of  more  than  two  independent  samples. 
The  test  does  not  use  the  actual  values  of  the  observations,  but  replaces  them 
with  ranks  (Everitt,  1995). 
3.  Wilcoxon  Matched-Pairs  Signed-Rank  test:  this  is  a  distribution-free 
method  used  as  an  alternative  to  the  paired  t-test  assessing  whether  there  was 
a  significant  difference  between  scores  of  two  dependent  samples.  The  test 
does  not  use  the  actual  values  of  the  observations,  but  replaces  them  with 
ranks  (Everitt,  1995). 
6.2.3  Logistic  regression  analysis 
A  logistic  regression  analysis  was  performed  to  assess  the  relationship 
between  outcome  variables  (dependent  variables)  and  independent  factors. 
The  test  predicts  whether  an  event  will  or  will  not  occur,  as  well  as  identifying 
the  variables  useful  in  making  the  prediction  (Norusis,  1994). 
To  carry  out  the  analysis,  the  dependent  variables  (outcomes)  can  only  have 
two  values  (binary),  but  the  independent  variables  may  be  numerical, 
categorical,  ordered,  etc.  For  example,  to  predict  which  variables 
(independent  factors)  predict  patients'  "global  quality  of  life"  (outcome 
variable),  first  patients  should  be  classified  in  two  groups.  Those  say  with 
"very  poor  or  poor"  quality  of  life  in  one  group,  and  those  with  "good  or  very 
good"  quality  of  life  in  the  second  group.  Then,  input  variables  (independent 
factors)  such  as  age,  sex,  social  background,  diagnosis,  etc.  may  be  used  to 
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investigate  which  of  these  variables  best  predict  the  outcome,  here  the  "global 
quality  of  life".  The  analysis  indicates  which  variables  significantly  contribute 
to  the  outcome. 
6.2.4.  Cox  regression  analysis 
The  analysis  was  performed  to  investigate  the  relationship  between  survival 
and  the  baseline  quality  of  life.  In  this  analysis  the  survival  is  the  dependent 
variable  and  other  variable(s)  both  numerical  or  categorical  could  be  used  as 
independent  or  predictor  factor(s).  The  Cox  regression  coefficient  indicates 
the  relative  risk  between  each  independent  variable  and  the  outcome  variable 
(survival),  adjusted  for  the  effect  of  the  independent  variable(s).  Cox 
regression  is  also  called  proportional  hazard  model  indicating  that  the 
relationship  between  survival  and  hazard  is  proportional.  Thus,  the  analysis 
not  only  indicates  the  probability  of  survival,  but  also  shows  the  probability  of 
an  event  occurring,  for  example  dying  (Dawson-Saunders  and  Trapp  1994; 
Norusis,  1994). 
In  this  study  the  analysis  was  performed  to  investigate  whether  the  baseline 
quality  of  life  as  measured  by  the  NHP  and  the  EORTC  QLQ-C30  was  a 
predictor  of  survival  or  not.  In  doing  so,  the  survival  was  calculated  and 
examined  against  patients'  baseline  aggregate  scores  on  the  NHP,  and  the 
EORTC-QLQ-C30. 
6.2.5.  Content  analysis 
This  was  performed  to  analyse  qualitative  data  obtained  from  the  open-ended 
questions  used  in  the  "acceptability  questionnaire"  and  questions  on 
perception  of  the  patients  about  quality  of  life  as  described  in  this  chapter  in 
sections  4.4.2  and  4.4.3. 
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To  carry  out  the  content  analysis,  first  all  responses  were  extracted  from  the 
questionnaires.  Secondly,  to  designate  the  units  to  be  coded,  the  "theme"  of 
each  response  was  characterised  by  placing  it  in  a  given  category  and  then 
Chi-square  test  was  performed  (Holsti,  1969). 
6.3.  Sample  size  and  the  power  of  the  study 
This  was  a  prospective  study,  therefore  it  was  not  realistic  to  calculate  sample 
size  and  the  power  of  the  study  beforehand.  However,  based  on  the  existing 
data  already  presented  in  this  chapter  (Tables  5.3  and  5.4),  it  was  thought  that 
for  principal  comparison  between  cases  and  controls  at  least  a  sample  of  200 
patients  (100  cases  and  100  controls)  was  necessary.  A  study  of  this  size  has  a 
power  of  90%  to  detect  a  difference  of  20%  between  cases  and  controls  at  5% 
significance  level  (Machin  and  Campbell,  1987).  The  actual  sample  obtained 
in  this  study  was  238  (129  cases  and  109  controls).  This  is  fully  presented  in 
the  result  section. 
7.  Limitations  and  difficulties 
Although  the  study  was  designed  carefully  to  avoid  any  pitfalls,  there  were 
both  limitations  and  difficulties  in  the  research  methodology. 
7.1.  Study  design 
The  initial  design  of  the  study  was  to  interview  cases  before  diagnosis,  but 
when  the  study  started  it  was  realised  that  this  was  not  always  possible. 
Therefore,  the  cases  were  interviewed  either  before  confirmed  diagnosis 
(intended  design)  or  after  confirmed  diagnosis  but  before  the  start  of  treatment 
(alternated  design).  As  mentioned  earlier  there  were  several  practical 
limitations  to  the  intended  design.  The  most  important  consideration  was  to 
enter  all  cases  with  a  confirmed  diagnosis  into  the  study  in  order  to  have  a  big 
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enough  sample  size.  However,  this  allowed  the  study  to  examine  an  extra 
question,  already  described  in  section  2.1. 
7.2.  Follow-up  of  controls 
Controls  were  not  followed-up  after  their  baseline  interviews.  Since  this  was  a 
case-control  study,  it  would  have  been  better  to  have  follow-up  interviews  for 
the  controls  as  well,  but  time  constraints  and  scarce  resources  did  not  allow 
this. 
7.3.  Interview  settings 
In  the  baseline  interviews  the  primary  intention  was  to  visit  patients  either  at 
their  home  or  in  the  clinic.  While  most  cases  were  interviewed  in  the  clinic, 
most  controls  were  interviewed  at  home.  This  meant  that  access  to  the  cases' 
home  environment  was  limited,  and  there  was  not  enough  data  to  compare 
cases  and  controls  in  this  important  aspect.  This  problem  occurred  for  two 
main  reasons:  suspected  cases  were  usually  referred  with  short  notice,  and 
after  referral,  hospital  appointments  given  very  quickly.  Thus,  there  was  not 
enough  time  to  arrange  a  home  visit.  In  addition,  as  indicated  before,  one  of 
the  chest  consultants  did  not  agree  to  the  researcher  carrying  out  the  baseline 
interview  at  his  patients'  home.  However  this  problem,  to  some  extent,  was 
solved  since  in  the  follow-up  interviews,  most  patients  were  interviewed  at 
their  home. 
7.4.  Blindness 
Considering  the  above  mentioned  problem,  there  was  a  subjective  impression 
that  short  notice  referrals  or  those  who  received  a  quick  hospital  appointment, 
were  suspected  lung  cancer  cases.  Although  this  was  not  always  the  case,  the 
researcher  had  a  feeling  that  in  some  instances  he  was  not  absolutely  blind. 
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7.5.  Sample 
Comparing  the  number  of  cases  to  controls,  the  number  of  controls  were  less 
than  cases.  This  was  not  identical  to  the  study  design.  Since  the  selection  of 
cases  and  controls  was  based  on  the  decision  of  clinicians,  a  possible 
explanation  is  that  there  were  not  enough  controls  to  match  with  suspected 
cases.  This  will  be  presented  fully  in  the  result  section. 
7.6.  Missing  cases 
There  were  some  cases  missing-The  reasons  and  the  full  picture  of  this  will 
be  presented  in  the  result  section.  In  summary,  this  was  due  to  several  factors: 
patients  were  referred  through  the  internal  referral  system,  not  by  GPs; 
sometimes  the  principal  consultants  were  not  in  the  clinic  and  therefore 
relying  on  junior  doctors  led  to  some  cases  being  missed;  on  rare  occasions 
the  researcher  was  not  in  the  clinic;  and  there  was  less  than  the  expected 
number  of  cases  from  one  of  the  chest  clinicians. 
7.7.  Difficulties 
The  most  difficult  aspect  of  this  study  arose  from  interviewing  patients  at 
home  or  in  the  clinic.  The  advantages  and  disadvantages  of  interviewing 
patients  at  home  or  in  the  clinic  are  presented  here. 
The  advantages  of  home  interviews  can  be  summarised  as  follows:  (i)  the 
interview  had  been  arranged,  therefore  patients  were  expecting  the  researcher, 
(ii)  there  was  enough  time  to  carry  out  the  interview,  (iii)  direct  inspection  of 
the  home  environment  as  part  of  research  project  was  possible,  (iv)  patients 
felt  the  home  interview  was  more  conversational,  (v)  it  was  possible  to 
arrange  the  interview  for  any  time  of  the  day  and  it  was  not  restricted  to  the 
time  of  clinics,  (vi)  it  was  possible  to  interview  patients  before  they  were  seen 
by  consultants,  while  in  the'  clinic  it  was  usually  not  practical  to  interview 
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patients  beforehand.  The  disadvantages  of  home  interviews  were:  (i)  getting 
permission  was  difficult  and  required  several  procedures  including  permission 
from  GPs,  patients,  and  sometimes  their  relatives,  (ii)  each  interview  took  a 
long  time  including  travelling  time,  and  (iii)  it  was  costly. 
Interviewing  a  patient  in  the  clinic  had  advantages  and  disadvantages.  The 
advantages  included:  (i)  the  recruitment  of  patients  was  much  easier  than 
interviewing  patients  at  home,  which  required  further  attempts  to  get 
permission  from  GPs  and  patients  themselves,  (ii)  the  patient  saw  the 
interviewer  (researcher)  as  part  of  the  clinical  team  and  therefore  felt  more  at 
ease,  (iii)  it  saved  time  and  reduced  cost,  and  (iv)  reduced  the  risk  of  refusal. 
The  disadvantages  of  interviewing  patients  at  the  clinic  were:  (i)  clinics  were 
usually  busy  and  thus,  there  was  a  risk  of  interference  with  clinical  teams,  (ii) 
patients  had  already  waited  for  a  long  time  to  see  clinicians,  therefore  the 
researcher  was  more  under  ethical  pressure  in  the  clinic,  (iii)  sometimes  it 
created  extra  anxiety  in  patients,  wondering  what  was  the  purpose  of  the 
interview  despite  a  clear  explanation  at  the  beginning  of  the  each  interview. 
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Introduction 
Based  on  the  study  objectives  the  presentation  of  findings  will  follow  in  five 
distinct  parts:  study  population,  baseline  and  follow-up  assessments,  the 
evaluation  of  study  acceptability,  and  finally  patients'  perceptions  of  quality 
of  life. 
1.  Study  population 
Figure  6.1  is  a  schematic  presentation  of  the  patients  recruited  to  the  study. 
The  study  population  consisted  of  273  patients.  Two  hundred  and  forty-two 
interviews  of  patients  were  completed.  Four  lung  cancer  patients  were 
excluded  from  the  study.  These  4  cases  were  excluded  because  they  were 
referred  and  diagnosed  in  1994  while  the  criteria  for  inclusion  of  the  patients 
in  the  study  was  that  they  should  have  been  referred  and  diagnosed  in  1995. 
Thus,  overall,  data  obtained  from  238  patients  were  analysed.  Of  these,  129 
patients  had  a  confirmed  diagnosis  of  lung  cancer  and  109  were  chronic 
respiratory  disease  controls.  However,  the  number  of  controls  were  less  than 
cases.  This  was  due  to  the  selection  of  cases  and  controls  not  being  under  the 
researcher's  direct  control,  and  because  the  study  design  made  the  researcher 
blind  to  the  diagnosis.  He  was  thus,  not  able  to  inform  clinicians  about  the 
numbers  of  cases  and  controls  recruited  to  the  study.  Finally,  the  clinicians' 
outpatient  department  was  very  busy  and  in  practice  it  was  not  possible  for 
them  to  choose  exactly  one  control  per  each  case.  " 
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Figure  6.1  A  schematic  presentation  of  study  samples 
Original  sample* 
Cases  Controls 
t6A  109 
issed  Excluded 
J'ntervieweci 
Interviewed 
(18)  (13)  r.  - 
(133) 
w.  , 
(109) 
-4  excluded) 
Study  population 
*  From  local  General  Practitioners  and  West  of  Scotland  Cancer  Surveillance  unit. 
The  response  rate  was  89%  (238  of  273)  and  there  were  no  refusals,  but  there 
were  two  other  groups  of  cases:  first,  those  who  were  excluded  from  the  study 
before  baseline  interviews  (13  patients-the  first  group),  and  second,  those  who 
were  missed  during  the  study  period  (18  patients-the  second  group).  The  main 
difference  between  these  two  groups  lies  on  the  fact  that  the  patients  in  the 
first  group  were  "  caught  by  'the`  researcher,  while  the  patients  in  the  second 
group  were  not  known  to  the  researcher  until  their  names  were  identified  from 
the  cancer  registry  database: 
k-  -' 
Since  from  the  methodological  'stand-point  'this  is  an  important  issue,  for  the 
first  group,  the  characteristics  and  the  reasons  why  they  were  excluded  are 
given  in  Table  6.1.  For  the  second  group  (missing  cases),  this  was  extracted  at 
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the  end  of  April  1996  based  on  data  provided  from  the  West  of  Scotland 
Cancer  Surveillance  Unit.  This  was  done  by  providing  a  list  of  cases  who 
were  registered  from  Stobhill  Hospital  in  1995  and  then,  the  list  was  checked 
against  the  list  of  cases  who  participated  in  the  study.  The  characteristics  of 
these  missing  cases,  and  reasons  why  they  were  missed  out  are  also  given  in 
Table  6.1. 
Table  6.1  Excluded  and  missing  cases 
Excluded  cases  (n  -  13)  Missing  cases  (n  -I 
No.  No. 
Sex 
male  8  13 
female  5  5 
Lung  cancer  diagnosis 
non-small  6  4 
small  cell  0  4 
unspecified  4  10 
not  available  3  0 
Reasons  why  patients  were  excluded  or 
missed 
Identified  after  the  treatment  5  0 
Internal  referral  0  3 
Emergency  admission  1  9 
Not  well  enough  to  be  interviewed  4  0 
Died  before  baseline  interview  2  0 
Mental  illness  1  0 
Clinicians  did  not  introduce  the  patients  to  0  6 
the  researcher  to  be  interviewed 
1.1.  Socio-demographic  characteristics 
The  socio-demographic  characteristics  of  the  study  population  are  shown  in 
Table  6.2.  There  were  no  significant  differences  between  cases  and  controls, 
except  for  age  (p  =  0.02)  and  comorbidity  (p  =  0.02).  The  controls  tended  to 
be  slightly  younger  than  cases  and  had  more  comorbidity. 
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Out  of  238  patients,  134  (56%)  were  males  and  104  (44%)  females.  Overall, 
the  majority  of  cases  and  controls  were  in  their  60s  (mean  age  66.1  years,  sd  = 
9.8),  married  (56%),  retired  (56%),  with  a  low  level  of  education  (95%),  most 
from  deprived  areas  (60%),  and  living  in  rented  houses  (66%).  Classifications 
of  patients'  characteristics  are  fully  described  in  the  methods  section. 
Table  6.2  Socio-demographic  characteristics  of  study  population 
Cases 
(n  =  129) 
No.  % 
Controls 
(0-109) 
N0.  % 
Total 
(a-239) 
No.  % 
P 
Sex 
male  77(60)  57(52)  134(56) 
female  52  (40)  52  (48)  104(44) 
0.3 
Age 
mean  (SD)  67.5  (9.1)  64.6  (10.4)  66.1(9.8) 
range  40-87  38-83  38-87 
'  0.02 
Marital  status 
married  77(60)  56(51)  133(56) 
single  7  (5)  10  (9)  17  (7) 
widowed/divorced/separated  45(35)  43(40)  88(37) 
0.3 
Educational  level 
primary  122  (95)  104  (95)  226(95) 
higher  7  (5)  5  (5)  12  (5) 
0.8 
Employment  status 
employed  17(13)  17(16)  34(14) 
unemployed  8  (6)  14(13)  22  (9) 
housewife  24(19)  26(24)  50(21) 
retired  80(62)  52(48)  132  (56) 
0.1 
Deprivation  category 
affluent  23(18)  17(16)  40(17) 
middle  32(25)  22  (20)  54  (23) 
deprived  74(57)  70(64)  144(60) 
0.6 
Comorbidity 
yes  18(14)  28(26)  46(19) 
no  111(86)  81(74)  192  (81) 
'  0.02 
House  ownership 
owned  48  (37)  33  (30)  81(34) 
rented  81(63)  76(70)  157(66) 
0.3 
Car  ownership 
yes  37(29)  25(23)  62(26) 
no  92  (71)  84(77)  176(70) 
0.3 
Significant  at  5%  level. 
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Table  6.3  shows  the  patients'  social  network  and  social  support  systems  as 
indicated  by  frequency  of  visits  from  their  children,  families,  support  offered 
by  their  children,  families,  contact  with  neighbours,  and  support  received  from 
them.  There  were  no  significant  differences  for  all  the  variables  measured 
between  cases  and  controls,  except  for  support  received  from  their  children  (p 
=  0.007).  The  controls  reported  that  they  received  less  support  from  their 
children  as  compared  to  the  cases. 
I 
Overall,  the  majority  of  patients  (n  =  128,54%)  indicated  that  their  children 
were  visiting  them  "always/almost  always",  while  a  high  proportion  (n  =  102, 
43%)  reported  that  they  were  not  visited  by  their  relatives  at  all.  When 
patients  were  asked  "how  often  do  you  contact  your  neighbours?  ",  the 
majority  (n  =  123,52%)  again  stated  "almost  never/never". 
I 
Results 
The  pattern  of  responses  to  the  variable  on  support  from  children,  relatives, 
and  neighbours  was  even  worse.  The  majority  (n  =  122,52%)  stated  that  they 
did  not  receive  any  support  from  their  children.  Also  most  patients  reported 
that  they  did  not  receive  any  support  from  their  relatives  (n  =  187,79%)  and 
form  their  neighbours  (n  =172,72%). 
f"ý  ýý 
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Table  6.3  Patients'  social  network  and  social  support 
Cases  Controls  Total  p 
(n  =129)  (n  s  109)  (n  -  238) 
No.  ("/.  )  No.  (%)  No.  ("/.  ) 
Children's  visit 
always/almost  always  71(55)  57  (52)  128  (54) 
sometimes  26(20)  16(15)  42  (18) 
almost  never/never  32(25)  36  (33)  68  (28) 
Relatives'  visit 
always/almost  always  49(38)  38  (35)  87(37) 
sometimes  26(20)  23  (21)  49(20) 
almost  never/never  54  (42)  48  (44)  102(43) 
Contact  with  neighbours 
always/almost  always  45  (35) 
, 
35(32)  80  (33) 
sometimes  22(17)  13(12)  35(15) 
almost  never/never  62  (48)  61(56)  123  (52) 
Receiving  support  from  children 
always/almost  always  63  (49)  33  (30)  96  (40) 
sometimes  7  (5)  13  (12)  20  (8) 
almost  never/never  59  (46)  63  (58)  122  (52) 
Receiving  support  from  relatives 
always/almost  always  20(16)  11(10)  31(13) 
sometimes  10  (8)  10  (9)'  20  (8) 
almost  never/never  99  (76)  88  (81)  187  (79) 
Receiving  support  from  neighbours 
always/almost  always  23  (18)  18  (17)  41  (17) 
sometimes  13(10)  12(11)  25  (11) 
almost  never/never  93  (72)  79  (72)  172  (72) 
0.3 
0.9 
0.4 
0.007'1 
0.45 
0.95 
1.3.  Housing,  and  family  structure 
Dwelling  types  and  the  patients'  home  distance  from  the  Stobhill  Hospital 
were  investigated.  There  were  no  significant  differences  between  cases  and 
controls.  These  are  shown  in  Table  6.4. 
Accommodation  was  defined  as  in  the  Scottish  Housing  Survey  (1991) 
classification.  It  was  found  that  97  patients  (41%)  lived  in  a  "flat",  61  (25%) 
0  Significant  at  5%  level. 
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in  "semi-detached"  houses,  33'(14%)  in  "4  in  a  block"  houses,  and  the 
remaining  47  (20%)  in  "terrace  house/house/others".  The  mean  distance  from 
patients'  homes  to  Stobhill  Hospital  was  4.2  miles  (SD  =  3.5).  Only  a  small 
number  of  patients  (n  =  38,16%)  used  the  hospital  ambulance,  whereas  111 
patients  (47%)  stated  that  they  used  their  own  or  their  relatives'  car  to  travel 
to  hospital  for  their  first  visit  to  the  hospital  outpatient  clinic.  The  remaining 
89  patients  (37%)  reported  that  they  used  public  transport.  There  was 
significant  difference  between  cases  and  controls  (p  =  0.002)  indicating  that 
controls  used  more  public  transport  and  less  private  car  and  hospital 
ambulance  as  compared  to  the  cases. 
The  mean  of  "overcrowding",  as  measured  by  the  ratio  of  people  in  the 
household  to  the  number  of  available  rooms,  was  0.63  (SD  =  0.27)  person  per 
room.  One  hundred  and  thirty-five  patients  (57%)  had  0-2  children,  91  (38%) 
3-5,  and  the  remaining  12  patients  (5%)  had  6-8  children. 
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Table  6.4  Patients'  housing  and  family  structure 
Cases 
_(n 
-  129) 
No.  "/. 
Controls 
(n  -  109) 
No.  % 
Total 
(n  -  238) 
No.  "/. 
P 
Types  of  dwelling 
flat  53  (41)  44  (40)  97(41) 
semidetached  35  (27)  26  (24)  61(25) 
4  in  a  block  17  (13)  16  (15)  33(14) 
terrace  house/house/others  24  (19)  23  (21)  47(20) 
0.9 
Home  distance  from  Stobhill  Hospital 
mean  (SD)  4.3  (3.5)  4.1  (3.4)  4.2  (3.5) 
range  0.25-15  0.25-25  0.25-25 
0.7 
Means  of  travelling  to  Stobhill  Hospital 
private  car  (own  or  relatives'  car)  69  (54)  42(38)  111(47) 
public  transport/by  walking  35  (27)  54  (50)  89(37) 
hospital  transport  25(19)  13(12)  38(16) 
0.002 
Travelling  problem 
yes  13  (10)  15  (14)  28(12) 
no  116(90)  94(86)  210  (88) 
0.4 
Problems  (n  =  28) 
long  walk/health  8(62)  11(73)  19  (68) 
time/travel  fair  5  (38)  4  (27)  9  (32) 
0.7 
Number  of  children 
0-2  69  (54)  66  (60)  135  (57) 
3-5  53  (41)  38  (35)  91(38) 
6-8  7  (5)  5  (5)  12  (5) 
0.6 
Number  of  people  in  the  household 
one  41(32)  45(41)  86(36) 
two  65(51)  38(35)  103  (43) 
three  16(12)  16(17)  34(14) 
four/five  7  (5)  8  (7)  15  (7) 
0.1 
Overcrowding  (persons  per  room) 
mean  (SD)  0.64  (0.26)  0.62  (0.28)  0.63  (027) 
range  0.25-1.33  0.13-1.33  0.13-133 
0.7 
0  Significant  at  5%  level. 
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1.4.  Patients'  characteristics,  local  and  national  figures 
In  Table  6.5  the  study  population's  characteristics  with  reference  to  some 
national  and  local  figures  are  given. 
In  general,  there  were  a  reasonable  agreement  between  the  characteristics  of 
the  study  population  with  that  of  local  and  national  statistics.  However,  car 
ownership  and  employment  status  in  study  population  were  very  different 
from  reference  figures.  Since  a  high  proportion  of  the  study  population  was  a 
group  of  retired  elderly  patients,  this  was  not  unexpected.  " 
Table  6.5  Patients'  characteristics  compared  with  available  local  and 
national  figures  (all  figures  are  percentages) 
Study  population 
n=238 
Northern  sector  of 
Glasgow 
n-169016 
Greater  Glasgow  He 
Board 
ne916600 
Scotland 
a-  5,132,400 
Sex 
male  56  48  48  48 
female  44  52  52  52 
Deprivation  Category 
affluent  17  19  18  20 
middle  23  29  32  62 
deprived  60  52  50  18 
House  ownership 
owner  occupied  34  46  45  33 
rented  66  54  55  67 
Types  of  dwelling 
flat  41  50  51  36 
semidetached  25  14  12  20 
4  in  a  block  14  14  12  27 
detached/others  20  ""  22  24  17 
Car  ownership  29  46  42  57 
Unemployment  9  20  20  13 
Overcrowding 
mean  (sd)  0.63  (0.27)  n/a  n/a  0.25  (0.11) 
0  Considering  that  only  56  patients  (23%)  of  all  study  sample  were  able  to  work  (see  table 
6.2),  then  the  real  figure  for  unemployment  is  22  out  of  56  which  is  39%.  This  is  much  higher 
than  the  unemployment  rate  in  the  northern  sector  of  Glasgow  or  Greater  Glasgow. 
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2.  Baseline  assessments 
The  baseline  assessments  were  made  either  at  first  presentation  to  the 
consultants  in  the  outpatient  clinic  or  after  referral  by  the  General 
Practitioners  (GPs)  and  before  consultant  visit  at  patient's  home.  Quality  of 
life  was  measured  by  the  Nottingham  Health  Profile  (NHP),  and  the  European 
Organisation  for  Research  and  Treatment  of  Cancer,  Core  Quality  of  Life 
Questionnaire  (EORTC  QLQ-C30)  and  its  supplementary  Lung  Cancer 
Questionnaire  (EORTC  QLQ-LC13). 
2.1  The  Nottingham  Health  Profile  (NHP) 
Table  6.6  presents  results  obtained  from  the  analysis  of  the  baseline 
assessment  of  the  NHP-Part  I  for  the  cases  and  controls.  The  higher  values 
indicate  more  perceived  health  problems.  There  were  no  significant 
differences  between  cases  and  controls  in  all  areas  measured,  these  were, 
energy,  pain,  emotional  reactions,  sleep  difficulties,  social  isolation  and 
physical  mobility.  However,  in  some  areas  the  mean  scores  of  controls  were 
higher  than  cases  indicating  that  they  had  more  perceived  problems.  These 
were:  energy  (45.1  vs.  42.7),  and  social  isolation  (15.6  vs.  12.6).  In  contrast, 
the  cases  had  more  perceived  problems  than  controls  in  pain  (mean  score  24.5 
vs.  19.5),  and  physical  mobility  (32.2  vs.  29.3).  The  differences  between  mean 
scores  on  emotional  reactions  and  sleep  were  very  small:  25.8  in  cases  vs.  25.4 
in  controls  (for  emotional  reactions),  and  39  in  controls  vs.  38.3  in  cases  (for 
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sleep).  The  mean  scores  on  the  NHP,  by  cases  and  controls  are  shown 
graphically  in  Figure  6.2. 
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Table  6.6  Baseline  scores  on  NHP-Part  I  by  cases  and  controls  (the  higher 
values  indicate  more  perceived  health  problems,  min.:  0,  max.:  100) 
Cases 
(n  =  129) 
Mean  (SD) 
Controls 
(n  =  109) 
Mean  SD 
P4 
Energy  42.7  (41.6)  45.1  (39.9)  0.6 
Pain  24.5  (29.2)  19.5  (26.7)  0.1 
Emotional  reactions  25.8  (24.2)  25.4  (23.9)  0.9 
Sleep  38.3  (32.5)  39.0  (31.6)  Ox 
Social  isolation  12.6  (22.0)  15.6  (22.2)  0.2 
Physical  mobility  32.2  (28.0)  29.3  (27.3)  0.8 
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En  =  Energy,  Pa=Pain,  Em=Emotional  reactions,  SI=Sleep, 
So=Social  isolation,  Pm=Physical  mobility 
I   Cases  ®  Controls 
2-tailed  probability  based  on  Mann-Whitney  U  test. 
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Figure  6.2  NHP-Part  I  by  Cases  and  Controls Results 
2.2  The  European  Organisation  for  Research  and  Treatment  of  Cancer 
Quality  of  Life  Questionnaires  (EORTC  QLQ-C30  and  QLQ-LC13) 
2.2.1.  Functioning  and  global  quality  of  life 
Table  6.7  presents  the  results  obtained  from  the  EORTC  QLQ-C30  by  cases 
and  controls.  This  table  includes  scores  on  5  functioning  scales  (physical,  role, 
emotional,  social,  cognitive)'  and  the  global  quality  of  life.  The  higher  values 
indicate  higher  level  of  functioning  and  a  better  global  quality  of  life. 
There  were  no  significant  differences  between  cases  and  controls.  However, 
the  cases  had  higher  mean  scores  than  the  controls  in  emotional  functioning 
(78.4  vs.  75.9),  cognitive  functioning  (85.5  vs.  82.9),  and  global  quality  of  life 
(49.8  vs.  47.6).  On  the  other  hand,  the  controls  had  higher  mean  score  than  the 
cases  in  role  functioning  (63.7  vs.  58.9).  The  mean  scores  on  physical  and 
social  functioning  were  also  slightly  better  in  controls  (62.6  vs.  61.9  and  87.5 
vs.  87  respectively).  The  graphical  presentation  of  the  mean  scores  is  shown  in 
Figure  6.3. 
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Table  6.7  Baseline  functioning  and  global  quality  of  life  scores  on  EORTC 
QLQ-C30  by  cases  and  controls  (the  higher  values  indicate  a  higher  level  of 
functioning  and  quality  of  life,  min.:  0  and  max.:  100) 
Physical  functioning 
Role  functioning 
Emotional  functioning 
Social  functioning 
Cognitive  functioning 
Global  quality  of  life 
Cases 
(n  =  129) 
Controls 
(n  =  109) 
p 
Mean  (SD)  Mean  (SD) 
61.9  (27.6)  62.6(26  1)  1U 
58.9  (37.2)  63.7  (33.9)  0.4 
78.4  (21.5)  75.9  (23.2)  0.5 
87.0  (23.2)  87.5  (22.4)  1.0 
85.5  (20.9)  82.9  (24  2)  11.  (1 
49.8  (23.1)  47,6  (24  7)  ºl  5 
Figure  6.3  EORTC  QLQ-C30  by  Cases  and 
Controls 
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PF=Physical,  RF=Role,  EF=Emotional,  SF=Social,  and 
CF=Cognitive  functioning,  QL=Global  health  and  quality  of  life 
I   Cases  ®  Controls 
2-tailed  probability  based  on  Mann-Whitney  U  test. 
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2.2.2.  Main  symptoms 
Tables  6.8  presents  the  mean  scores  of  main  symptoms  on  the  EORTC  QLQ- 
30  and  QLQ-LC13.  The  higher  values  indicate  a  greater  degree  of  symptoms. 
There  were  no  significant  differences  between  cases  and  controls  except  in 
pain  (p  =  0.04)  and  loss  of  appetite  (p  =  0.00  1).  The  cases  reported 
significantly  more  problems  in  these  symptoms.  Although  not  significant,  the 
mean  scores  of  the  cases  also  were  higher  than  the  controls  for  the  following 
symptoms:  pain  in  shoulder  (27.4  vs.  20.2),  sleep  difficulties  (30.7  vs.  27.2), 
fatigue  (37.3  vs.  34.6).  In  contrast,  the  mean  scores  of  the  controls  were  higher 
for  cough  (51.7  vs.  -  46.8),  dyspnoea  (43  vs.  37.7),  and  haemoptysis  (10.1  vs. 
8.6). 
Table  6.8  Baseline  scores  of  main  symptoms  on  EORTC  QLQ-C30  and  QLQ-LC13 
by  cases  and  controls  (the  higher  values  indicate  a  greater  degree  of  symptoms, 
min:  0  and  max.:  100), 
Cases 
*(n  -129) 
Mean  (SD) 
Controls 
(n  -109) 
Mean  (SD) 
P+ 
Cough  46.8  (32.7)  51.7  (34.1)  0.2 
Haemoptysis  10.1(23.4)  8.6  (22.4)  0.3 
Dyspnoea  37.7  (27.4)  43.0  (29.3)  0.2 
Pain  27.1(28.7)  19.7  (25.3)  0.04' 
Pain  in  chest  21.7  (28.8)  21.1  (28.9)  0.8 
Pain  in  shoulder  27.4  (34.7)  20.2  (28.3)  0.2 
Pain  elsewhere  24.8  (33.4)  24.8  (31.2)  0.8 
Sleep  difficulties  30.7  (37.2)  27.2  (35.2)  0.5 
Fatigue  37.3  (29.2)  34.6  (29.3)  0.5 
Appetite  loss  34.4  (34.3)  21.1(30.1)  0.001' 
2-tailed  probability  based  on  Mann-Whitney  U  test. 
"  Significant  at  5%  level. 
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2.3.  Baseline  quality  of  life  and  socio-economic  deprivation 
The  relationship  between  baseline  quality  of  life  and  socio-economic 
deprivation,  as  measured  by  the  Carstairs  and  Morris  (1991)  Deprivation 
Category  was  investigated.  Since  there  were  no  significant  differences  in 
mean  scores  between  cases  and  controls,  the  following  are  results  from  pooled 
data.  In  fact,  when  the  same  analysis  was  performed  separately  for  lung  cancer 
patients  and  the  controls  the  findings  were  similar  to  the  findings  from  pooled 
data.  Thus,  to  avoid  repetition,  only  the  pooled  results  are  reported  here. 
2.3.1.  The  NHP  by  Deprivation  Category 
Table  6.9  presents  baseline  scores  of  all  patients  on  the  NHP-Part  I  by 
Deprivation  Category  (Carstaris  and  Morris,  1991),  namely:  affluent,  middle, 
and  deprived.  The  "one  way  analysis  of  variance"  (ANOVA)  was  carried  out 
to  investigate  whether  there  were  statistically  significant  differences  among 
mean  scores  of  these  three  groups  on  the  NHP-Part  I  or  not.  Except  for  mean 
scores  on  pain  (p  =  0.03)  and  physical  mobility  (p  =  0.03)  which  indicated  a 
significant  difference  among  three  groups,  the  other  mean  scores  were  not 
significantly  different.  However,  there  was  a  clear  pattern  of  differences  in 
mean  scores  among  these  three  groups  indicating  that  people  of  lower  socio- 
economic  status  had  more  perceived  health  problems  compared  to  the  more 
affluent  group.  Only  in  one  measure  (sleep)  did  the  middle  group  of  patients 
have  more  perceived  problems  than  the  affluent  and  the  deprived  groups. 
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Figure  6.4  presents  the  mean  scores  on  the  NHP-Part.  I  by  Deprivation 
Category. 
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Table  6.9  Patients'  baseline  scores  on  NHP-Part  I  by  Deprivation  Category 
(the  higher  values  indicate  more  perceived  health  problems,  min:  0  and 
max.:  100) 
Affluent 
(n  =  40) 
Mean  (SD) 
Middle 
(n  =  54) 
Mean  (SD) 
Deprived 
(n  =  144) 
Mean  (SD) 
P4 
Energy  33.5  (39.4)  39.0  (422)  4S.  5  (4O.  2)  0,07 
Pain  16.4  (25.0)  17.9  (26.4)  25.5  (29.4)  O_0 
Emotional  reactions  23.4  (25.1)  22.7  (21.9)  27.3  (24.4)  tº  1 
Sleep  30.0  (27.3)  44.0  (30.4)  39.0(33.5)  O. 
Social  isolation  11.6  (23.1)  11.7  (20.5)  15.5  (22.4)  0.2 
Physical  mobility  22.9  (26.3)  25.2  (25.3)  313.4  (28.4)  tº.  Ot' 
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En  =  Energy,  Pa=Pain,  Em=Emotional  reactions,  SI=Sleep, 
So=Social  isolation,  Pm=Physical  mobility 
I   Dprived  ®  Middle  Q  Affluent 
Probability  based  on  Kruskal-Wallis  one  way  analysis  of  variance  corrected  for  tics. 
Significant  at  50%  level. 
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Figure  6.4  NHP-Part  I  by  Deprivation  Category Results 
2.3.2.  The  EORTC  by  Deprivation  Category 
1.  The  mean  scores  of  patients'  functioning  and  global  quality  of  life  on  the 
EORTC  QLQ-C30  by  Deprivation  Category  are  shown  in  Table  6.10. 
Performing  the  -  ANOVA,  there  were  significant  differences  among  affluent, 
middle,  and  deprived  groups  in  physical  functioning  (p  =  0.002),  and  role 
functioning  (p  =  0.02)  indicating  that  the  patients  of  lower  socio-economic 
status  had  a  lower  level  of  functioning.  In  other  measures  the  differences  were 
not  statistically  significant. 
There  was  a  clear  trend  of  differences  among  these  groups  indicating  that  the 
patients  in  the  deprived  group  had  lower  scores  tlian  the  other  groups.  Only  in 
one  measure  (social  functioning),  did  patients  in  the  middle  group  have  a 
better  mean  score  than  affluent  and  deprived  groups.  The  results  are  presented 
graphically  in  Figure  6.5. 
ý_ 
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Table  6.10  Patients'  baseline  functioning  and  global  quality  of  life  scores  on 
EORTC  QLQ-C30  by  Deprivation  Category  (the  higher  values  indicate  a 
higher  level  of  functioning  and  quality  of  life,  min:  0  and  max.:  100) 
Affluent 
(n  =  40) 
Mean  (SD) 
Middle 
(n  =  S4) 
Mean  (SD) 
Deprived 
(n  =  144) 
Mean  (SD) 
P 
Physical  functioning  73.0  (25.4)  66.7  (24.9)  57.5  (27.0)  0.002' 
Role  functioning  71.3  (33.8)  66.7  (37.6)  56  3049)  O  u?  * 
Emotional  functioning  80.4  (22.1)  77.6  (20.5)  7i,  3(23  I)  05 
Social  functioning  84.9  (23.4)  89.5  (20.3)  87.1)  (23.7)  ()  S 
Cognitive  functioning  87.9  (20.7)  82.1  (23.8)  84.1  (22.3)  0.3 
Global  quality  of  life  52.7  (25.2)  50.8  (23.9)  47.  O  (23.4)  0.2 
Figure  6.5  EORTC  QLQ-C30  by  Deprivation 
Category 
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PF=Physical,  RF=Role,  EF=Emotional,  SF=Social,  and 
CF=Cognitive  functioning,  QL=Global  health  and  quality  of  life 
1Q  Affluent  ®  Middle     Deprived 
"  Probability  based  on  Kruskal-Wallis  one  way  analysis  of  variance  corrected  for  ties. 
Significant  at  5%  level. 
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2.  Table'6.11  presents  the  mean  scores  of  patients'  symptoms  on  the  EORTC 
QLQ-C30  and  the  QLQ-LC  13  by  `  Depcat.  Performing  the  ANOVA,  there 
were  no  significantdifferences*among  affluent,  middle,  and  deprived  groups, 
except  for  dyspnoea  (p  ='0.01)  indicating  that`  patients  ý'of  lower  socio- 
economic  status  had  a  significantly  greater  degree  of  dyspnoea  as  compared  to 
the  other  groups. 
However  there  were  marked  differences  among  these  groups  in  the  following 
symptoms:  cough,  haemoptysis,  pain,  pain  in  chest,  and  fatigue  indicating  that 
patients  in  the  deprived  group  had  more  symptoms.  In  contrast,  patients  in  the 
affluent  group  had  more  problems  with:  pain  in  shoulder,  and  pain  in  other  parts 
of  their  bodies.  On  two  measures,  patients  in  the  middle  group  had  scored  higher: 
sleep,  and  loss  of  appetite.  I 
Table  6.11  Patients'  baseline  scores  of  main  symptoms  on  EORTC  QLQ-C30  and 
LC-13  by  Deprivation  Category  (the  higher  values  indicate  a  greater  degree  of 
symptoms,  min:  0,  and  max.:  100 
Affluent 
(n  °  40) 
Mean  (SD) 
Middle 
(n  =  54) 
Mean  (SD) 
Deprived 
(a-144) 
Mean  (SD) 
P' 
Cough  44.2  (31.5)  47.3  (34.6)  50.9  (33.4)  0.5 
Haemoptysis  6.7  (17.2)  9.3  (22.8)  10.2  (24.4)  0.8 
Dyspnoea  "32.9  (31.8)  34.0  (26.0)  44.4  (27.5)  0.010 
Pain  23.3  (26.6)  21.9  (26.5)  24.5  (28.1)  0.8 
Pain  chest  14.2  (23.7)  17.9  (28.0)  24.8  (30.0)  0.06 
Pain  in  shoulder  25.0  (35.2)  24.7  (31.2)  23.6  (31.8)  0.9 
Pain  elsewhere  30.0  (32.7)  24.1(33.3)  23.6  (32.0)  0.4 
Sleep  difficulties 
, 
25.0  (33.5)  34.5  (36.6)  28.2  (36.8)  0.4 
Fatigue  34.4  (32.6)  32.1(27.4)  38.0  (28.9)  0.4 
A  tite  loss  27.5  29.1  29.6  33.4  28.0(34.7)  0.8 
'  Probability  based  on  Kruskal-Wallis  one  way  analysis  of  variance  corrected  for  ties. 
Significant  at  5%  level. 
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2.4.  Pain  medication 
When,  based  on  the  EORTC  QLQ-C30,  patients  were  asked  "Did  you  take 
any  medicine  for  pain",  124  patients  (52%)  responded  "yes".  There  was  no 
significant  difference  between  cases  and  controls  (p  =  0.08).  Of  these,  17 
patients  (14%)  stated  that  pain  medication  did  not  help  them  at  all,  53  (42%) 
reported  that  it  did  help  a  little,  48  (39%)  indicated  that  it  did  help  quite  a  bit, 
and  6  patients  (5%)  said  that  it  did  help  very  much.  Again,  there  was  no 
significant  difference  between  cases  and  controls  (p  =  0.09). 
2.5.  Prediction  of  baseline  quality  of  life 
It  was  hypothesised  that  patients'  baseline  quality  of  life  as  measured  by  the 
standard  instruments  (the  NHP,  and  the  EORTC  questionnaires)  may  be  the 
result  of  patients'  socio-economic  status  or  their  social  support  systems  rather 
than  the  effect  of  their  diseases  or  health  status  alone.  Thus,  to  examine  such 
an  hypothesis,  some  relevant  subscales  of  the  NHP  Part-I  and  the  EORTC 
QLQ-C30  were  selected  as  outcome  measures,  and  the  socio-economic  and 
support  variables  (such  as  family  support)  and  some  other  psycho-social 
indicators  as  predictor  variables.  The  selection  of  these  subscales  was  due  to 
the  fact  that  it  was  thought  these  variables  might  explain  how  patients'  socio- 
economic  status  and  social  support  system  contribute  to  their  quality  of  life.  A 
logistic  regression  analysis,  as  described  in  the  methods  section,  was  carried 
out  to  investigate  this  relationship. 
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2.5.1.  Emotional  problems 
Based  on  patients'  scores  for  emotional  reactions  on  the  NHP,  they  were 
divided  into  two  groups,  those  with  no  emotional  problems  and  those  with 
emotional  problems.  It  was  found  that  several  variables  had  significant  value 
in  predicting  emotional  problems.  These  were:  marital  status  (being  single,  p 
=  0.002),  family  support  (those  who  did  not  receiving  any  support,  p=0.03). 
In  addition,  the  analysis  indicated  that  energy  (p  =  0.002),  sleep  (p  =  0.003), 
social  isolation  (p  =  0.0003)  and  global  quality  of  life  (p  =  0.01)  were  all 
predictors  of  emotional  problems.  Figure  6.6  shows  a  simplified  print  out  of 
the  logistic  regression  an  alysis. 
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Figure  6.6  Logistic  regression  analysis-Baseline  emotional  reactions 
Number  of  cases  included  in  the  analysis:  238 
Parameter  coding  (categorical  data) 
Value  Freq  Coding 
(1)  (2) 
NEIGHBOUR  SUPPORT 
never/almost  never  1  172  1.000 
. 
000 
sometimes  2  25 
. 
000  1.000 
almost  always/always  3  41 
. 
000 
.  000 
FAMILY  SUPPORT 
never/almost  never  1  187  1.000 
.  000 
sometimes  2  20 
. 
000  1.000 
almost  always/always  3  31 
. 
000 
. 
000 
CHILDREN  SUPPORT 
never/almost  never  1  122  1.000 
.  000 
sometimes  2  20 
. 
000  1.000 
almost  always/always  3  96 
. 
000 
.  000 
MARITAL  STATUS 
married  1  133 
. 
000 
.  000 
single  2  17  1.000 
. 
000 
widowed/separated/divorced  3  88 
. 
000  1.000 
DEPRIVATION  CATEGORY 
affluent  1  40  .  000 
.  000 
middle  2  54  1.000 
.  000 
deprived  3  144  .  000  1.000 
CASE 
case  1  129  1.000 
control  2  109 
. 
000 
SEX 
male  1  134  .  000 
female  2  104  1.000 
Dependent  Variable..  Baseline  Emotional  Reactions 
*  Constant  is  included  in  the  model. 
Beginning  Block  Number  1.  Method:  Enter 
Variable(s)  Entered  on  Step  Number 
1..  AGE  Age 
SEX  sex 
MARITAL  Marital  status 
DEPCAT  Deprivation  Category 
CASE  Case  or  control 
CHILHEL  Support  receiving  from  children 
FAMILYH  Support  receiving  from  family 
NEIGHBH  Support  receiving  from  neighbours 
TEN1  Total  energy-baseline 
TP1  Total  pain-baseline 
TPM1  Total  physical  mobility-baseline 
TSL1  Total  sleep-baseline 
TSO1  Total  social  isolation-baseline 
XQL1  Global  quality  of  life-baseline 
-----------------------  Variables  in  the  Equation  ------------------------- 
Variable  B  S.  E.  Wald  df  Sig  R  Exp(B) 
AGE  .  0133  .  0245  .  2959  1 
.  5865 
.  0000  1.0134 
SEX(1)  -.  2387  .  5149  .  2149  1  .  6429 
.  0000  .  7876 
MARITAL  10.0246  2 
.  0067  .  1537 
MARITAL(1)  -3.4208  1.1153  9.4065  1 
.  0022  -.  1705  .  0327 
MARITAL(2)  -1.1271  .  6247  3.2552  1  .  0712  -.  0702  .  3240 
DEPCAT  .  5901  2  .  7445 
.  0000 
DEPCAT(1)  -.  0875  .  6922  .  0160  1  .  8995 
.  0000  .  9163 
DEPCAT(2)  .  3209  .  5967  .  2893  1  .  5907 
.  0000  1.3784 
CASE(1)  .  2687  .  4851  .  3068  1 
.  5797  .  0000  1.3082 
CHILHEL  2.2999  2  .  3167  .  0000 
CHILHEL(l)  -.  5651  .  5098  1.2287  1  .  2677  .  0000  .  5683 
CHILHEL(2)  .  6410  .  9372  .  4678  1 
.  4940  .  0000  1.8983 
FAMILYH  5.9877  2 
.  0501  .  0883 
FAMILYH(1)  -1.7498  .  8075  4.6959  1  .  0302  -.  1028  .  1738 
FAMILYH(2)  -.  1685  1.1680  .  0208  1  .  8853  .  0000  .  8450 
NEIGHBH  3.4896  2  .  1747  .  0000 
NEIGHBH(1)  1.3212  .  7733  2.9187  1  .  0876  .  0600  3.7479 
NEIGHBH(2)  .  3327  1.0416  .  1020  1  .  7494  .  0000  1.3947 
TEN1  .  0392  .  0129  9.2192  1  .  0024  .  1683  1.0400 
TP1  -.  0034  .  0182  .  0348  1  .  8519  .  0000  .  9966 
TPM1  -.  0048  .  0162  .  0886  1  .  7659  .  0000 
.  9952 
TSL1  .  0301  .  0101  8.8731  1  .  0029  .  1642  1.0306 
TS01  .  1807  .  0500  13.0677  1  .  0003  .  2084  1.1981 
XQL1  -.  0352  .  0145  5.9274  1  .  0149  -.  1241 
.  9654 
Constant  1.2048  2.0516  .  3449  1  .  5570 
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2.5.2  Social  isolation  t 
The  same  analysis  was  carried  out  to  find  out  which  variables  best  predicted 
social  isolation.  It  was  found  that  gender  (being  female,  p=0.01),  marital 
status  (being  single,  p=0.02;  being  widowed/separated/divorced,  p=0.004), 
family  visit  (those  who  were  not  visiting  their  relatives,  p=0.02),  emotional 
problems  (p  =  0.0000),  energy  (p  =  0.008),  pain  (p  =  0.004),  physical  mobility 
(p  =  0.01)  all  were  predictors  of  social  isolation.  The  other  variables  such  as 
children's  visits,  contact  with  neighbours,  and  Deprivation  Category  were  not 
significant  predictors.  A  simplified  print  out  of  the  logistic  regression  analysis 
is  shown  in  Figure  6.7. 
2.5.3.  Global  quality  of  life 
Global  quality  of  life  as  measured  by  the  EORTC  QLQ-C30  was  best 
predicted  by  the  following  variables:  age  (p  =  0.02),  Depcat  (deprived  group, 
p=0.04),  employment  status  (being  unemployed,  p=0.04;  being  retired,  p= 
0.02),  The  other  socio-economic  variables  were  not  significant  predictors. 
Figure  6.8  presents  a  simplified  print  out  of  the  logistic  regression  analysis. 
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Figure  6.7  Logistic  regression  analysis-Baseline  social  isolation 
Number  of  cases  included  in  the  analysis:  238 
Parameter  coding  (categorical  data) 
Value  Freq  Coding 
(1)  (2) 
NEIGHBOUR  CONTACT 
never/almost  never  1  123  1.000 
.  000 
sometimes  2  35  .  000  1.000 
almost  always/always  3  80 
.  000  .  000 
FAMILY  VISIT 
never/almost  never  1  102  1.000 
.  000 
sometimes  2  49  .  000  1.000 
almost  always/always  3  87 
.  000 
.  000 
CHILDREN  VISIT 
never/almost  never  1.00  68  1.000 
.  000 
sometimes  2.00  42  .  000  1.000 
almost  always/always  3.00  128 
.  000  .  000 
MARITAL  STATUS 
married  1  133 
.  000 
.  000 
single  2  17  1.000 
.  000 
widowed/separated/divorced  3  88 
.  000  1.000 
DEPRIVATION  CATEGORY 
affluent  1  40  .  000 
.  000 
middle  2  54  1.000 
.  000 
deprived  3  144 
.  000  1.000 
CASE 
case  1  129  1.000 
control  2  109 
.  000 
SEX  'I 
male  1  134 
.  000 
female  2  104  1.000 
Dsp.  ndont  Variable..  Basslira.  Social  I  solation 
*  Constant  is  included  in  the  model. 
Beginning  Block  Number  1.  Method:  Ente  r 
Variable(s)  Entered  on  Step  Number 
1..  AGE  Age 
SEX  sex 
MARITAL  Marital  status 
DEPCAT  Deprivation  Category 
CASE  Case  or  control 
CHILVI  Children  visit 
FAMILYV  Family  visit 
NEIGHBV  Neighbour  contact 
TEM1  Total  emotional  reac  tions-baseline 
TEN1  Total  energy-baseline 
TP1  Total  pain-baseline 
TPM1  Total  physical  mobil  ity-baseline 
TSL1  Total  sleep-baseline 
XQL1  Global  quality  of  li  fe  scale-baseline 
----------------  -------  Variables  i  n  the  Equation  -  -------  --------  --------  Variable  B  S.  E.  Wald  df  Sig  R  Exp(B) 
AGE  -.  0015  .  0212  .  0049  1 
.  9443  .  0000  .  9985 
SEX(1)  -1.0482  .  4186  6.2700  1  .  0123  -.  1163  .  3506 
MARITAL  10.4696  2  .  0053  .  1432 
MARITAL(1)  2.1028  .  8884  5.6028  1  .  0179 
.  1068  8.1891 
MARITAL(2)  1.3432  .  4653  8.3317  1  .  0039  .  1416  3.8312 
DEPCAT  .  5065  2 
.  7763  .  0000 
DEPCAT(1)  .  4735  .  6920  .  4682  1  .  4938  .  0000  1.6056 
DEPCAT(2)  .  2164  .  6077  .  1269  1  .  7217  .  0000  1.2417 
CASE(1)  -.  7410  .  3997  3.4370  1 
.  0638  -.  0675  .  4766 
CHILVI  1.8167  2  .  4032  .  0000 
CHILVI(1)  .  1584  .  5232  .  0917  1 
.  7621  .  0000  1.1716 
CHILVI(2)  -.  6891  .  5715  1.4539  1  .  2279 
.  0000  .  5020 
FAMILYV  5.5996  2  .  0608  .  0712 
FAMILYV(1)  1.0653  .  4506  5.5881  1 
.  0181  .  1066  2.9017 
FAMILYV(2)  .  5914  .  5703  1.0752  1  .  2998  .  0000  1.8065 
NEIGHBV  .  5552  2  .  7576  .  0000 
NEIGHBV(1)  -.  0044  .  4565  .  0001  1  .  9923  .  0000  .  9956 
NEIGHBV(2)  .  4154  .  6206  .  4482  1  .  5032  .  0000  1.5150 
TEM1  .  0779  .  0130  35.9003  1  .  0000 
.  3277  1.0810 
TEN1  -.  0213  .  0081  6.9888  1 
.  0082  -.  1257  .  9789 
TP1  .  0255  .  0088  8.3125  1  .  0039  .  1414  1.0258 
TPM1  .  0279  .  0111  6.3401  1  .  0118  .  1173  1.0283 
TSL1  -.  0107  .  0072  2.1925  1  .  1387  -.  0247  .  9894 
XQL1  -.  0228  .  0120  3.6053  1  .  0576  -.  0713 
.  9175 
Constant  -2.2027  1.7471  1.5895  1  .  2074 
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Figure  6.8  Logistic  regression  analysis-Baseline  Global  quality  of  Life 
Number  of  cases  included  in  the  analysis:  238 
Parameter  coding  (categorical  data) 
Value  Freq,  Coding 
(1)  (2)  (3) 
EMPLOYMENT  STATUS 
employed  1  34 
. 
000 
. 
000 
. 
000 
unemployed  2  22  1.000 
. 
000 
.  000 
housewife  3  50 
.  000  1.000 
.  000 
retired  4  132 
.  000 
. 
000  1.000 
DEPRIVATION  CATEGORY 
affluent  1  40 
.  000  .  000 
middle  2  54  1.000 
.  000 
deprived  3  144 
.  000  1.000 
MARITAL  STATUS 
married  1  133 
. 
000 
. 
000 
single  2  17  1.000 
. 
000 
widowed/separated/divorced  3  88 
.  000  1.000 
CASE 
case  1  129  1.000 
control  2  109 
.  000 
SEX 
male  1  134  .  000 
female  2  104  1.000 
Dependent  Variable..  Baseline  Global  Quality  of  Life 
*  Constant  is  included  in  the  model. 
Beginning  Block  Number  1.  Method:  Enter 
Variable(s)  Entered  on  Step  Number 
1..  AGE  Age 
SEX  sex 
MARITAL-  Marital  status 
DEPCAT  Deprivation  Category 
EMPLOY  Employment  status 
CASE  Case  or  control 
-----------------------  Variables  in  the  Equation  ------------------------- 
Variable  .BS. 
E.  Wald  df  Sig  R  Exp(B) 
AGE  -.  0457  . 
0189  5.8116  1 
. 
0159  -.  1087 
. 
9553 
SEX(1)  -.  0527  . 
3601 
. 
0214  1 
. 
8836 
. 
0000 
.  9487 
MARITAL  1.6614  2 
.  4358 
. 
0000 
MARITAL(1)  -.  6919  .  5814  1.4163  1  .  2340  .  0000  .  5006 
MARITAL(2)  .  0714  .  3230  .  0489  1  .  8250  .  0000  1.0740 
-DEPCAT  5.8225  2  .  0544  .  0752 
DEPCAT(1)  .  2842  .  4787  .  3523  1  .  5528  .  0000  1.3286 
DEPCAT(2)  .  8712  .  4210  4.2828  1  .  0385  .  0841  2.3898 
EMPLOY  6.6020  3  .  0857  .  0432 
EMPLOY(1)  1.2862  .  6217  4.2800  1  .  0386  .  0841  3.6190 
EMPLOY(2)  .  8495  .  5741  2.1894  1  .  1390  .  0242  2.3385 
EMPLOY(3)  1.1978  .  5090  5.5370  1  .  0186  .  1047  3.3129 
CASE(1)  .  1245  .  2845  .  1915  1  .  6616  .  0000  1.1326 
Constant  1.0522  1.1762  .  8003  1  .  3710 
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2.6.  Does  the  interview  setting  matter? 
Out  of  238  baseline  interviews  with  patients,  60  interviews  (25%)  took  place 
at  patients'  homes  and  178  (75%)  in  the  clinic.  To  examine  whether  this  had 
any  effects  on.  outcomes,  a  comparison  was  made  between  baseline  scores 
obtained  at  home  and  in  the  clinic. 
Although  there  were  some  differences  between  scores  obtained  at  home  and  in 
the  clinic,  these  were  not  significant  except  for  emotional  reactions  (p  =  0.04) 
indicating  that  those  who  were  interviewed  at  home  reported  more  emotional 
problems. 
Both  on  the  NHP,  and  the  EORTC  questionnaires  the  patients  at  home 
reported  more  problems  than  those  interviewed  in  the  clinic.  In  some  areas 
either  there  were  no  differences  (pain  from  the  NHP),  or  the  differences  were 
in  opposite  directions  (pain,  and  pain  in  shoulder  from  the  EORTC 
questionnaire  were  reported  more  in  the  clinic  as  compared  to  the  home 
interview). 
Tables  6.12,6.13,  and  6.14  present  the  data  obtained  from  the  whole  study 
samples,  both  cancer  patients  and  the  chronic  respiratory  disease  controls.  As 
described  the  results  suggest  that  patients  in  the  clinic  perceived  themselves  to 
be  healthier  than  those  who  were  interviewed  at  home.  When  the  analysis  was 
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restricted  only  to  cancer  patients  in  the  study,  the  results  were  the  same  (to 
avoid  repetition,  the  data  are  not  shown). 
Table  6.12  Patients'  baseline  scores  on  NHP-Part  I  by  interview  settings  (the 
higher  values  indicate  more  perceived  health  problems,  min:  0,  max.:  100) 
Home 
(n  -  60) 
Mean  (SD) 
Clinic 
(n  -  178) 
Mean  (SD) 
P' 
Energy  52.8  (40.3)  40.7  (40.7)  0.05 
Pain  22.3  (25.7)  22.2  (29.1)  0.6 
Emotional  reactions  31.1(26.1)  23.8  (23.0)  0.040 
Sleep  37.7  (35.3)  38.9  (30.9)  0.5 
Social  isolation  16.6  (23.2)  13.1  (21.7)  0.2 
Physical  mobility  33.0  (27.7)  28.6  (27.6)  03 
Table  6.13  Patients'  baseline  functioning  and  global  quality  of  life  scores  on 
EORTC  QLQ-C30  by  interview  settings  (the  higher  values  indicate  a  higher 
level  of  functioning  and  quality  of  life,  min.:  0  and  max.:  100) 
Home 
(n  m  60) 
Mean  (SD) 
Clinic 
(n  -178) 
Mean.  (SD) 
P' 
Physical  functioning  60.3  (25.9)  62.8  (27.2)  0.4 
Role  functioning  58.3  (34.6)  62.1  (36.2)  0.4 
Emotional  functioning  73.9  (25.0)  78.4  (21.3)  0.4 
Social  functioning  86.4  (24.8)  87.5  (22.2)  0.8 
Cognitive  functioning  80.3  (24.5)  85.7  (21.6)  0.1 
Global  quality  of  life  45.3  (25.0)  50.0  (233)  0.2 
2-tailed  probability  based  on  Mann-Whitney  U  test. 
*  Significant  at  5%  level. 
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Table  6.14  Patients'  baseline  scores  of  main  symptoms  on  EORTC  QLQ- 
C30  and  QLQ-LC13  by  interview  settings  (the  higher  values  indicate  a 
greater  degree  of  symptoms,  min:  0  and  max.:  100) 
Home 
(n  -'  60) 
Mean  (SD) 
Clinic 
(n  -  178) 
Mean.  (SD) 
P' 
Cough  52.8  (35.9)  47.8  (32.4)  0.3 
Haemoptysis  12.2  (28.8)  8.4  (20.6)  0.7 
Dyspnoea  45.7  (29.8)  38.2  (27.7)  0.09 
Pain  21.7  (25.5)  24.4  (28.0)  0.7 
Pain  in  chest  25.0  (27.2)  20.2  (29.3)  0.1 
Pain  in  shoulder  20.6  (28.2)  25.3  (333)  0.5 
Pain  elsewhere  26.7  (32.9)  24.2  (32.2)  0.6 
Sleep  difficulties  28.9  (37.6)  29.2  (35.9)  0.8 
Fatigue  37.6  (29.8)  35.5  (29.1)  0.6 
Appetite  loss  29.4  (30.7)  27.9  (34.4)  0.5 
2.7.  Does  knowing  diagnosis  matter? 
At  baseline  interviews  most  lung  cancer  patients  and  the  researcher  were  blind 
to  the  final  diagnosis.  However,  in  some  instances  the  assessments  (30 
interviews)  were  made  after  the  diagnosis  and  before  the  start  of  the  treatment. 
Thus,  this  group  of  patients  were  interviewed  while  they  knew  their  diagnosis. 
To  investigate  whether  this  would  affect  the  patients'  perception  of  their  own 
quality  of  life,  a  comparison  was  made  between  scores  of  the  patients  who  did 
not  know  their  diagnosis  (n  =  99,77%)  and  those  who  knew  their  cancer 
diagnosis  (n  =  30,23%).  There  was  no  significant  sex  difference  between 
these  two  groups,  while  the  age  difference  between  them  was  significant 
2-tailed  probability  based  on  Mann-Whitney  U  test. 
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indicating  that  those  who  knew  their  diagnosis  were  younger  than  those  who 
did  not  (p  =  0.04).  The  mean  age  of  those  who  knew  their  diagnosis  was  64.5 
years  (SD  =  8.7),  whereas  the  mean  age  of  those  who  did  not  was  68.4  years 
(SD  =  9.0). 
Tables  6.15,6.16,  and  6.17  present  mean  scores  of  the  cancer  patients  who 
knew  their  diagnosis  and  those  did  not  know.  Although  there  were  some 
differences  between  those  who  knew  their  diagnosis  and  those  who  did  not, 
there  were  no  significant  differences  between  these  two  groups  of  patients  nor 
did  any  consistent  pattern  emerge. 
Patients  who  did  not  know  their  cancer  diagnosis  reported  more  problems  for 
some  'measures,  while  in  some  others  the  patients  who  knew  their  diagnosis 
had  more  problems.  For  example,  on  the  NHP,  patients  who  knew  their 
diagnosis  reported  more  problems  with  regard  to  energy,  and  physical 
mobility,  whereas  patients  who  did  not  know  their  diagnosis  reported  more 
problems  with  pain,  sleep,  and  social  isolation.  The  emotional  reaction  for 
both  groups  were  the  same.  On  the  other  hand,  on  the  EORTC  QLQ-C30, 
patients  who  knew  their  diagnosis  reported  a  better  global  quality  of  life  as 
compared  to  those  who  did  not  know  their  cancer  diagnosis. 
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Table  6.15  Baseline  scores  on  NHP-Part  I  by  patients  who  knew  their  cancer 
diagnosis  and  those  who  did,  not  know  (the  higher  values  indicate  more 
perceived  health  problems,  -  min:  0,  max.:  100) 
Knew 
(n=30) 
Mean  (SD) 
Did  not  know 
(o=99) 
Mean  (SD) 
P+ 
Energy  49.1  (40.3)  40.8  (42.0)  0.3 
Pain  18.6  (25.4)  26.3  930.2)  0.2 
Emotional  reactions  26.2  (23.0)  25.6  (24.6)  0.8 
Sleep  33.7  (31.0)  39.7  (32.9)  0.5 
Social  isolation  11.9  (19.5)  12.9  (22.8)  1.0 
Physical  mobility  38.5  (29.5)  27.7  (27.2)  0.07 
Table  6.16  Baseline  functioning  and  global  quality  of  life  scores  on  EORTC 
QLQ-C30  by  patients  who  knew  their  cancer  diagnosis  and  those  who  did 
not  (the  higher  values  indicate  a  higher  level  of  functioning  and  quality  of 
life,  min.:  0  and  max.:  100) 
Knew 
(n  =  30) 
Mean  (SD) 
Did  not  know 
(0=") 
Mean.  (SD) 
P' 
Physical  functioning  54.0  (28.8)  64.2  (26.8)  0.1 
Role  functioning  48.3  (38.2)  62.1  (36.5)  0.08 
Emotional  functioning  79.4  (21.0)  78.1  (21.8)  0.7 
Social  functioning  85.0  (27.5)  87.5  (22.0)  1.0 
Cognitive  functioning  87.2  (20.8)  85.0  (21.0)  0.4 
Global  quality  of  life  51.7  (25.2)  49.2  (22.5)  0.9 
`  2-tailed  probability  based  on  Mann-Whitney  U  test. 
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Table  6.17  Baseline  scores  of  main  symptoms  on  EORTC  QLQ-C30  and 
QLQ-LC13  by  patients  who  knew  their  cancer  diagnosis  and  those  who  did 
not  know  (the  higher  values  indicate  a  greater  degree  of  symptoms,  min:  0 
and  max.:  100) 
Knew 
(n  -  30) 
Mean  (SD) 
Did  not  know 
(n  -  99) 
Mean.  (SD) 
P+ 
Cough  46.7  (32.3)  46.8  (33.0)  1 
Haemoptysis  10.0  (23.4)  10.1  (23.5)  1 
Dyspnoea  39.7  (28.8)  37.0  (27.1)  0.7 
Pain  20.6  (26.5)  29.1(29.2)  0.2 
Pain  in  chest  20.0  (27.1)  22.2  (29.4)  .  0.8 
Pain  in  shoulder  18.9  (32.4)  30.0  (35.2)  0.1 
Pain  elsewhere  31.1(37.1)  22.9  (32.2)  0.2 
Sleep  difficulties  17.8  (32.4)  34.7  (37.8)  0.02* 
Fatigue  37.0  (25.2)  37.4  (30.5)  0.8 
Appetite  loss  41.1(32.4)  32.3  (34.8)  0.1 
,. 
2-tailed  probability  based  on  Mann-Whitney  U  test. 
Significant  at  5%  level. 
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3.  Follow-up  assessments 
All  lung  cancer  patients  were  followed-up  after  the  completion  of  their  initial 
management.  The  follow-up  assessments  were  scheduled  for  three  months 
after  the'  baseline  interviews.  At  the  time  of  follow-up,  out  of  129  lung  cancer 
patients,  33  (25%)  were  dead,  8  (6%)  refused  to  take  part  in  the  study  for  the 
second  time,  6  (5%)  were  terminally  ill  and  it  was  not  appropriate  to  interview 
these  patients,  and  82  (64%)  were  interviewed.  Considering  that  at  follow-up 
stage  90  patients  were  alive  and  suitable  for  interview,  the  response  rate  was 
91%.  The  mean  follow-up  time  was  98  days  (SD  =  11.1).  In  the  following 
sections  the  analysis  will  be  restricted  to  the  82  patients  who  were  alive  and 
where  it  was  possible  to  compare  their  present  situations  with  their  previous 
Status. 
Furthermore,  4  hospital  case  records  were  missing  at  the'time  of  analysis  and 
therefore,  when  the  analysis  depended  on  the  clinical  characteristics  of  the 
patients  the  number  of  patients  in  the  follow-up  group  was  81,  those  who  had 
died  31,  the  refusal  group  7,  and  the  terminally  ill  patients  6.  Figure  6.9  is  a 
schematic  view  of  the  study  population  at  the  follow-up  stage. 
The  characteristics  of  patients  are  given  in  Table  6.18.  Due  to  the  small 
sample  sizes  it  was  not  appropriate  to  carry  out  tests  of  significance. 
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Finally,  it  is  worth  noting  that  from  82  follow-up  interviews  50  interviews 
(63%)  took  place  at  patients'  home  and  the  remaining  30  interviews  (37%) 
conducted  in  the  clinic.  In  this  respect,  comparing  these  figures  with  the 
baseline,  it  is  clear  that  at  follow-up  there  were  more  home  interviews  (63% 
vs.  25%). 
Figure  6.9  A  schematic  view  of  the  study  population  at  follow-up  stage 
Lung  cancer  patients  at 
baseline  interviews:  129 
Follow-up: 
after  3  months 
Followed-up:  82  Died:  33  11  Refused:  8 
case  records  case  records  case  records 
available  for  81  available  for  31  available  for  7 
scLc  17  503 
NSCLC  44  14  61 
Unspecified  1.  I 
20  12  1  f-1  2 
Terminally  ill:  6 
case  records 
available  for  6 
Key:  SCLC  =  small  cell  lung  cancer;  NSCLC=  non-small  cell  lung  cancer, 
Unspecified  =  clinically  diagnosed  lung  cancer  patients 
197 Results 
Table  6.18  Lung  cancer  patients'  demographic  and  clinical  characteristics 
Baseline 
n=129 
NO.  (%) 
Followed-up 
(n  -8 
No.  ("/.  ) 
Died 
n=33 
No.  (%) 
Refused 
n-8 
No.  (%) 
Terminally  III 
n- 
NO. 
Set 
male  77(60)  48  (58)  22  (67)  4  (50)  3  (50) 
female  52  (40)  34(42)  11(33)  4  (50)  3  (50) 
Age 
mean  (sd)  67.5  (9.1)  66.2  (8.6)  70.0  (9.9)  73.1  (7.1)  63.5  (7.5) 
Deprivation  category 
affluent  23  (18)  16  (20)  5  (15)  2  (25)  00(00) 
middle  32(25)  19  (23)  9  (27)  2(25)  2  (33) 
deprived  74  (57)  47  (57)  19(58)  4  (50)  4  (67) 
Diagnosis 
non-small  cell  67(52)  44  (54)  14  (43)  6(75)  3  (50) 
small  cell  23  (18)  17  (21)  5  (15)  00  (00)  1(17) 
unspecified'  35  (27)  20  (24)  12(36)  1  (13)  2  (33) 
not  available  "  4  (3)  1  (1)  2  (6)  1(13)  00(00) 
Extent  of  disease 
limited  101(78) 
. 
70(85)  20  (61)  7  (88)  4  (67) 
extensive  24  (19)  11(14)  11(33)  00(00)  2  (33) 
not  available"  4  (3)  1  (1)  2  (7)  1(12)  00  (00) 
Initial  treatment 
chemotherapy  32(25)  25  (31)  6(18)  00(00)  1(17) 
radiotherapy  39  (30)  29  (35)  6(18)  2  (25)  2  (33) 
surgery  6  (5)  6  (7)  00(00)-  00(00)  00  (00) 
supportive  care  48  (37)  21(26)  19  (58)  5  (63)  3  (50) 
not  available"  4  (3)  1  (1)  2  (6)  1  (13)  00  (00) 
Baseline  performance  status 
(ECOG  Scale) 
0  (normal  activity)  29  (23)  21(26)  4  (12)  2(25)  2  (33) 
1  (symptoms)  60(47)  42  (51)  12(36)  4(50)  2(33) 
2  (sometimes  in  bed)  25  (19)  13  (16)  10(30)  1(13)  1(17) 
3  (need  to  be  in  bed)  15  (11)  6  (7)  7(21)  1(13)  1(17) 
4  (confined  to  bed)  00  00  00  00  00 
Weight  loss 
significant  weight  loss  51(40)  '33  (40)  15  (45)  00(00)  3  (50) 
weight  steady  40(31)  26(32)  7(21)  5  (62)  2  (33) 
possible  weight  loss  12  (9)  7  (9)  4  (12)  1(13)  00(00) 
no  comment  22(17)  15(18)  5(15)  1(13)  1(17) 
not  available  "  4  (3)  1  (1)  2  (6)  1(13)  00  (00) 
Unspecified  cases  were  those  for  whom  diagnosis  was  not  based  on  pathology  reports  and 
they  were  clinically  diagnosed  lung  cancer  patients. 
$0  Not  available  refers  to  those  for  whom  case  notes  were  not  available. 
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3.1.  Baseline  quality  of  life  as  indicator  of  length  of  survival 
3.1.1.  Descriptive  analysis 
There  were  4  groups  of  lung  cancer  patients:  those  who  were  alive  and 
participated  in  the  study  for  the  second  time,  those  who  were  alive  and  refused 
to  participate  in  the  study,  those  who  were  terminally  ill,  *  and  those  who  were 
dead.  Examining  these  4  groups  of  patients'  baseline  quality  of  life,  "it  was 
found  that  baseline  quality  of  life  was'a'  good  indicator  of  patients'  length  of 
survival.  In  other  words,  when  at  follow-up  stage,  lung  cancer  patients' 
baseline  scores  were  reviewed,  it  was  found  that  their  scores  at  baseline  were 
good  pointers  in  indicating  that  what  might  happen  to  the  patients  in  the  future 
Table  6.19  presents  lung  cancer  patients'  baseline  perceived  health  status 
(NHP)  in  the  four  groups.  Except  for  social  isolation,  all  other  measures  were 
.  significantly  different  indicating  that  those  who  were  dead  or  were  in  terminal 
stage  had  lower  quality  of  life  at  baseline  assessments. 
Patients'  baseline  functioning  and  global  quality  of  life  scores  on  the  EORTC 
QLQ-C30  are  shown  in  Table  6.20.  On  three  measures  (physical,  role  and 
cognitive  functioning)  there  were  significant  differences  among  these  4 
groups  of  patients  indicating  that  those  who  had  died  or  were  terminally  ill  by 
the  follow-up  stage  had  lower  levels  of  functioning  at  their  baseline  as 
compared  to  those  who  were  alive.  On  the  remaining  measures  (emotional  and 
Patients  who  were  confined  to  bed  and  in  fact,  they  were  in  the  last  stages  of  their  lives.  It 
was  impossible  to  interview  these  patients  at  the  time  of  follow-up  as  they  died  soon  after. 
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social  functioning  and  global  quality  of  life),  although  not  significant,  the 
differences  were  in  the  same  directions. 
Table  6.19  Lung  cancer  patients'  baseline  scores  on  NHP-Part  I  (higher 
values  indicate  more  perceived  health  problems,  min.:  0,  max.:  100) 
Refused 
(n  a  8) 
Mean  (SD) 
Followed-up 
(n  =  82) 
Mean  (SD) 
Died 
(n  -  33) 
Mean  (SD) 
Terminally  III 
(n  -  6) 
Mean  (SD) 
P` 
Energy  32.9  (38.9)  33.6  (37.5)  63.4  (44.5)  66.7  (41.4)  0.007' 
Pain  7.3  (17.3)  21.1  (27.7)  30.9  (29.0)  59.3  (35.5)  0.005' 
Emotional  reactions  20.6  (16.8)  22.6  (23.9)  30.4  (22.3)  51.0  (32.0)  0.04' 
Sleep  32.6  (24.6)  35.8  (32.0)  37.7  (30.7)  83.3  (31.2)  0.02' 
Social  isolation  2.5  (7.1)  12.1  (22.8)  13.5  (19.3)  28.9  (31.8)  0.1 
Physical  mobility  22.4  (26.9)  23.8  (25.2)  46.2  (26.9)  40.9  (40.1)  0.001' 
Table  6.20  Lung  cancer  patients'  baseline  functioning  and  global  quality  of 
life  scores  on  EORTC  QLQ-C30  (higher  values  indicate  a  higher  level  of 
functioning  and  quality  of  life,  min.:  0,  max.:  100) 
Refused  Followed-up  Died  Terminally  ill 
(n  =  8)  (n=82),  (n  =  33)  (a  =  6) 
Mean  (SD)  Mean  (SD)  Mean  (SD)  Mean  (SD) 
Physical  functioning  67.5  (26.0)  67.1  (25.0)  47.9  (28.7)  60.0  (35.8)  0.01 
Role  functioning  62.5  (44.3)  64.6  (34.7)  42.4  (35.6)  66.7  (51.6)  0.03' 
Emotional  functioning  75.0  (25.2)  79.0  (22.3)  80.1(17.8)  66.6  (26.9)  0.6 
Social  functioning  95.8  (11.8)  86.2  (24.5)  85.4  (23.5)  94.4  (13.6)  0.5 
Cognitive  functioning  91.7  (17.8)  86.2  (20.8)  87.9  (15.7)  55.6  (31.0)  0.04' 
Global  quality  of  life  51.0  (15.1)  53.8  (22.3)  41.2  (24.7)  41.7  (21.7)  0.08 
Probability  based  on  Kruskal-Wallis  one  way  analysis  of  variance  corrected  for  ties. 
Significant  at  5%  level. 
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3.1.2.  Cox  regression  analysis 
To  confirm  the  above  mentioned  results;  the  Cox's  regression  analysis  was 
carried  out.  This  analysis  allowed  the  investigation  of  relationship  between 
patients'  baseline  quality  of  life  and  survival.  The  survival  time  for  each 
patient  was  calculated  from  the  baseline  interview  to  the  follow-up  interview. 
If  a  patient  was  dead  at  follow-up  stage,  his  or  her  'survival  time  was 
calculated  from  the  baseline  interview  to  -death.  '  The  dates  of  death  were 
worked  out  from  medical  records  and  death  certificates'  (from  the  West  of 
Scotland  Cancer  Surveillance  Unit).  As  described  in  the  methodology,  in  the 
Cox's  regression  analysis  survival  was  the  dependent  variable  and  quality  of 
life  scores  as  measured  by  the'  NHP  and  the  EORTC  QLQ-C30  were 
independent  variables  (predictors). 
The  mean  survival  time  (from  the  baseline  to  the  follow-up  interview)  for 
survivors  was  98  days  (SD  ='I  I-  1),  while  for  patients  who  died  (from  '  the 
baseline  interview  to  death)  was  47  days  (SD  =18.7). 
Figure  6.10  presents  a  summary  of  the  analysis  based  on  the  aggregate  scores 
of  each  patients  on  the  NIP  as  a  general  health  measure.  The  plot  represents 
survival  function  showing  the  probability  of  surviving.  Patients  based  on  their 
aggregate  scores  on  the  NUP  were  categorised  into  two  groups:  those  with 
scores  below  the  mean  (good  general  health)  and  those  above  (poor  general 
health).  Based  on  the  analysis,  patients'  baseline  scores  on  the  NHP  was  a 
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significant  predictor  of  survival  (p  =  0.003)  and  the  probability  of  dying  for 
those  with  poor  general  health  was  3  times  higher  as  compared  to  those  with  a 
good  general  heath  status  [Exp  (B)/Expected  regression  coefficient  =  3.0].  * 
The  same  analysis  with  the  same  procedure  was  carried  out  for  the 
relationship  between  patients'  baseline  functioning  scores  (physical,  role, 
emotional,  social  and  cognitive  as  measured  by  the  EORTC  QLQ-C30)  and 
survival.  The  analysis  is  shown  in  Figure  6.11.  It  was  found  that  the  baseline 
functioning  was  a  significant  predictor  of  survival  (p  =  0.03).  The  plot 
presents  survival  function  as  described  earlier.  The  probability  of  dying  for 
those  with  low  level  of  functioning  was  2  times  higher  as  compared  to  those 
with  high  level  of  functioning  at  baseline  assessment  [Exp  (B)  =  2.2]. 
Again,  the  relationship  between  baseline  global  quality  of  life  as  measured  by 
the  EORTC  QLQ-C30  and  the  survival  was  investigated.  The  result  is  shown 
in  Figure  6.12.  It  was  found  that  baseline  global  quality  of  life  was  a 
significant  predictor  of  survival  (p  =  0.03). 
, 
The  hazard  function  as  indicated 
by  the  Expected  (B)  was  2.2,  indicating  that  those  with  lower  global  quality  of 
Exp  (B)  is  the  hazard  function,  or  death  rate  at  time  t.  It  indicates  how  likely  it  is  for  a  case 
to  experience  an  event,  given  that  it  has  survived  to  that  time.  The  hazard  function  is  not  a 
probability  but  a  death  rate  per  unit  of  time,  so  it  needs  not  to  be  less  than  1.  Thus,  Exp  (B) 
for  continous  variables  shows  the  percentage  change  in  the  hazard  rate  for  a  unit  increase  in 
the  covariate.  For  a  dichotomous  variable,  such  as  sex  or  extent  of  disease,  when  two 
sequential  numbers  are  used  for  coding  and  the  larger  of  the  two  indicates  presence  of  the 
characteristics,  the  Exp  (B)  is  the  ratio  of  the  estimated  hazard  for  a  case  with  the 
characteristic  to  that  for  a  case  without  the  characteristics.  This  is  often  called  the  relative  risk 
associated  with  the  variable  (Norusis,  1994). 
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life  2  times  were  more  likely  to  die  as  compared  to  those  'who  had  a  better 
global  quality  of  life. 
3.1.3.  Split  between  Survivors  and  non-survivors  at  follow-up 
When  the  above  analysis  was  restricted  only  to  survivors  at  follow-up  (n  = 
82),  there  was  no  significant  difference  between  those  initially  with  high  level 
of  functioning,  global  quality  of  life,  and  a  better  general  health  status  and 
those  with  low  level  x  on  these  three  measures.  This  was  observed  with  non- 
survivors  as  well  when  the  analysis  was  restricted'  to  those  who  were  dead  at 
follow-up  (n  =  33). 
However  these  findings  also  indicated  that  at  the  time  of  second  interview 
there  was  no  evidence  of  selection  bias  in  interviewing  patients  with  a  better 
quality  of  life  later  than  patients  with  a  lower  quality  of  life. 
3.1.4.  Cox  regression  analysis  forward  selection  of  variables 
In  order  to  allow  for  adjustment  of  known  prognostic  factors,  that  is  age,  sex, 
performance  status,  weight  loss,  and  extent  of  disease,  and  also  baseline 
general  health  status,  and  functioning,  the  Cox's  regression  analysis  was 
repeated  by  selecting  the  `forward  conditional'  model.  Based  on  this  selection, 
variables  are  considered  one  at  time  for  entry  in  the  model.  The  results 
indicated  that  the  baseline  global  quality  of  life  subscale  as  measured  by  the 
EORTC  QLQ-C30  was  the  strongest  significant  predictor  of  length  of  survival 
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(age  p=0.0035,  extent  of  disease  ;p=0.0034,  global  quality  of  life  p= 
ar 
0.0029),  while  sex,  weight  loss,  performance  status,  the  NHP  and  functioning 
(as  measured  by  the  EORTC  QLQ-C30)  were  not.  The  following  table  shows 
the  significant  levels  for  each  variable  at  the  start  and  the  final  stage  of  the 
analysis.  The  table  clearly  suggests  that  there  were  strong  interactions 
between  extent  of  disease,  performance,  status,  baseline  functioning  and 
general  health  status.  It  also  indicates  that  although  performance  status  was 
significant  at  start,  age  and  extent  of  disease  strongly  interacted  with  it  to 
make  it  non-significant  at  the  end  Unlike  performance  status,  due  to  the 
interactions  between  age  and  extent  of  disease  and  baseline  global  quality  of 
life,  global  quality  of  life  by  its  own  became  the  most  significant  predictor  of 
survival. 
Variables  Significant  level  at  start  Significant  level  at  final  stage 
Age 
Sex 
ECOG  Performance  status 
Extent  of  disease 
Weight  loss 
Baseline  general  health  status  (NHP) 
Baseline  functioning 
(EORTC  QLQ-C30) 
Global  quality  of  life 
0.03 
0.54 
0.006* 
0.003* 
0.56 
0.006" 
0.0250 
0.009' 
0.55 
0.16 
0.0034* 
0.68 
0.16 
0.56 
0.0029- 
However,  it  is  interesting  to  know  that  the  extent  of  disease  had  an  adjusted 
relative  risk  of  3.1,  and  global  quality  of  life  an  adjusted  relative  risk  of  3.2 
(even  higher  than  its  unadjusted  relative  risk  of  2.2,  see  above  section  3.1.2). 
For  the  continuous  variable  (age),  the  hazard  ratio  showed  increase  of  8%  for 
each  year.  This  means  that  with  an  increase  of  1  year  in  the  patients'  age,  the 
rate  of  death  will  increase  by  8%. 
0  Significant  at  5%  level. 
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Figure  6.10  Cox  regression  analysis-Survival  by  baseline  general  health 
status  as  measured  by  the  NHP 
Indicator  Parameter  Coding 
Value  Freq  (1) 
NHP  General  health 
good  73  .  000 
poor  56  1.000 
129  Cases  available  for  the  analysis 
Dependent  Variable:  SURVIVAL  Survival  time  since  baseline  interview  (days) 
Died  Alive 
33  96  (74.4%) 
Beginning  Block  Number  1.  Method:  Enter 
Variable(s)  Entered  at  Step  Number  1.. 
NHP  Baseline  General  health 
-----------  Variables  in  the  Equation 
Variable  B  S.  E.  Wald  df  Sig  R  Exp(B) 
NHP  1.1037  . 
3696  8.9181  1 
. 
0028 
.  1490  3.0152 
1.1 
1.0 
Good  general  health 
Survival  By  NHP 
r  general  health 
-ZU  U 
Survival  time  (days) 
'-k 
20  40  60 
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Figure  6.11  Cox  regression  'analysis-Survival  function  by  baseline 
functioning  as  measured  by  the  EORTC  QLQ-C30 
Indicator  Parameter  Coding 
Value  Freq  (1) 
FUNCT  Functioning 
high  level  72 
. 
000 
low  level  57  1.000 
129  Cases  available  for  the  analysis 
Dependent  Variable:  SURVIVAL  Survival  time  since  baseline  interview  (days) 
Died  Alive 
33  96  (74.4%) 
Beginning  Block  Number  1.  Method:  Enter 
Variable(s)  Entered  at  Step  Number  1.. 
FUNCT  Baseline  Functioning 
Variables  in  the  Equation  ---------------- 
Variable  B  S.  E.  Wald  df  Sig  R  Exp(B) 
FUNCT 
,  . 
7666  .  3564  4.6249  1  .  0315 
.  0918  2.1524 
Survival  By  Functioning  (EORTC  QOL-C30) 
1 
1 
. 
.1 
.0 
.9  High  functioning 
.8 
Low  functioning 
.7 
-1U  U  1U  40  60  80 
Survival  time  (days) 
100 
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Figure  6.12  Cox  regression  analysis-Survival  function  by  baseline  global 
quality  of  life  as  measured  by  the  EORTC  QOL-C30 
Indicator  Parameter  Coding 
Value  Freq  (1) 
QOL  Global  quality  of  life 
high  level  76  . 
000 
low  level  53  1.000 
129  Cases  available  for  the  analysis 
Dependent  Variable:  SURVIVAL  Survival  time  since  baseline  interview  (days) 
Died  Alive 
33  96  (74.4°x6) 
Beginning  Block  Number  1.  Method:  Enter 
Variable(s)  Entered  at  Step  Number  1.. 
QOL  Baseline  Global  quality  of  life 
----  Variables  in  the  Equation 
Variable  B  S.  E.  Wald  df  Sig  R  Exp(B) 
QOL  .  7813  .  3524  4.9156  1 
. 
0266 
.  0967  2.1843 
Survival  By  Global  QOL  (EQRTC  QOL-C3n) 
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3.2  Comparing  baseline  with  follow-up  assessments 
Data  obtained  from  the  82  patients  at  baseline  and  follow-up  stage  were 
compared  to  examine  what  happened  to  the  patients  after  diagnosis  and 
completion  of  the  initial  treatment.  The  Wilcoxon  Matched-Pairs  Signed 
Ranks  Test  were  carried  out  to  achieve  this.  In  the  following  sections  these  are 
presented.  '  11 
3.2.1  General  health 
Table  6.21  presents  patients'  baseline  and  follow-up  scores  on  the  N  UP. 
Except  for  slight  improvement  with  sleep  difficulties  (35.8  at  baseline  vs.  34 
at  follow-up),  on  all  other  measures  patients  reported  that  their  perceived 
health  problems  increased.  Notably  deterioration  in  energy,  "  social  isolation 
and  physical  mobility  at  follow-up  as  compared  to  baseline  assessments  were 
highly  significant  (energy  p=0.0004,  social  isolation  p=0.02,  and  physical 
mobility  p=0.0008). 
3.2.2  Functioning  and  global  quality  of  life 
Baseline  and  follow-up  assessments  of  the  patients'  functioning  and  global 
quality  of  life  as  measured  by  the  EORTC  QLQ-C30  are  shown  in  Table  6.22. 
In  all  areas  the  patients'  functioning  and  global  quality  of  life  decreased. 
These  reductions  in  patients'  physical,  role  and  cognitive  functioning  were 
highly  significant  (p  =  0.0003,0.0004,  and  0.04  respectively),  while  on  other 
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measures  (including  emotional  and  social  functioning  and  global  quality  of 
life),  they  were  not. 
3.2.3  Symptoms 
The,  only  significant  improvement  after  treatment  was  seen  in  patients' 
coughing  (p  =  0.006).  Although  not  significant,  there  were  also  some 
improvement  in  haemoptysis,  pain  in  shoulder,  sleep  difficulties,  and 
diarrhoea.  Three  measures  did  not  change:  dyspnoea,  pain,  and  pain  in  other 
Y'  t 
sites  of,  the  bodies.  In  all  other  symptoms,  patients'  scores  increased, 
indicating  that  their  quality  of  life  had  deteriorated.  Of  these,  4  measures  had 
significant  increases  as  compared  to  baseline  assessments:  fatigue  (p  =  0.02), 
hair  loss  (p  =  0.0000),  constipation  (p  =  0.007),  and  sore  mouth  (p  =  0.0004) 
indicating  side-effects  of  the  treatment  on  patients'  quality  of  life.  These  are 
shown  in  Table  6.23.. 
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Table  6.21  Lung  cancer  patients'  baseline  and  follow-up  scores  on  NHP- 
Part  I  (the  higher  values  indicate  more  perceived  health  problems,  min.:  0, 
max.:  100) 
Baseline 
(n  -  82) 
Mean  (SD) 
Follow-up 
(n  -  82) 
Mean  (SD) 
P` 
Energy  33.9  (37.5)  51.1  (38.6)  0.0004" 
Pain  21.1(27.7)  25.4  (27.2)  0.2 
Emotional  reactions  22.6  (23.9)  28.9  (29.2)  0.06 
Sleep  35.8  (32.0)  34.0  (31.2)  0.7 
Social  isolation  12.1  (22.8)  18.9  (26.3)  0.02' 
Physical  mobility  23.8  (25.2)  34.7  (27.2)  0.0008' 
Table  6.22  Lung  cancer  patients'  baseline  and  follow-up  functioning  and 
global  quality  of  life  scores  on  EORTC  QLQ-C30  (the  higher  values  indicate 
a  higher  level  of  functioning  and  quality  of  life,  min.:  0,  max.:  100) 
Baseline 
(o  -  82) 
Mean  (SD) 
Follow-up 
(o  °  82) 
Mean  (SD) 
P` 
Physical  functioning  67.1(25.0)  55.9  (24.9)  0.0003* 
Role  functioning  64.3  (34.9)  46.3  (30.2)  0.0004' 
Emotional  functioning  79.0  (22.2)  75.8  (22.1)  0.3 
Social  functioning  86.2  (24.5)  82.1  (22.9)  0.06 
Cognitive  functioning  86.2  (20.8)  80.7  (24.1)  0.04' 
Global  quality  of  life  53.8  (22.3)  51.8  (25.6)  0.6 
Probability  based  on  Wilcoxon  matched-pairs  signed-ranks  test. 
Significant  at  5%  level. 
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Table  6.23  Lung  cancer  patients'  baseline  and  follow-up  symptoms  scores  on 
EORTC  QLQ-C30  and  QLQ-LC13  (the  higher  values  indicate  a  greater 
degree  of  symptoms,  min.:  0,  max.:  100) 
Baseline 
(o  °  82) 
Mean  (SD) 
Follow-up 
(n  °  82) 
Mean  (SD) 
Cough  50.0  (31.5)  37.8  (30.0)  0.006 
Haemoptysis  10.6(23.4)  4.1  (15.2).  0.05 
Dyspnoea  35.8  (26.9)  35.8  (27.5)  0.9 
Pain  24.2  (24.9)  24.4  (28.5)  0.8 
Pain  in  chest  22.0  (28.3)  24.4  (31,9)  0.7 
Pain  in  shoulder  26.0  (33.5)  18.7  (27.8)  0.05 
Pain  elsewhere  19.9  (29.1)  20.3  (29.5)  1 
Sleep  difficulties  29.7  (36.3)  24.8  (32.6)  0.3 
Fatigue  33.1  (28.2)  40.0  (27.0)  0.02' 
Appetite  loss  30.9  (33.4)  32.1(33.3)  0.7 
Hair  loss  0.8  (5.2)  23.2  (38.4)  0.0000 
Nausea  and  vomiting  7.7  (16.0)  12.2  (20.5)  0.08 
Constipation  15.9  (28.8)  28.9  (36.2)  0.007' 
Diarrhoea  7.3  (18.9)  4.1(13.2)  02 
Peripheral  neuropathy  12.2  (28.0)  17.5  (26.3)  0.1 
Sore  mouth  0.8  (5.2)  13.0  (27.6)  0.0004' 
Trouble  swallowing  7.3  (19.6)  12.6  (24.4)  0.1 
Financial  difficulties  7.7  (19.8)  8.9  (24.0)  0.6 
Probability  based  on  Wilcoxon  matched-pairs  signed-ranks  test. 
Significant  at  5%  level. 
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3.3  Quality  of  life  and  different  types  of  treatments 
At  follow-up  stage  82  patients  were  interviewed.  Of  these,  one  patient's  case 
record  was  not  available.  Thus,  data  obtained  from  81  patients  at  baseline  and 
follow-up  assessments  were  analysed  to  investigate  the  outcomes  based  on  the 
different  types  of  initial  treatments  that  patients  received.  These  are: 
chemotherapy,  radiotherapy,  surgery,  and  best  supportive  care.  Twenty  five 
patients  were  initially  treated  with  chemotherapy,  29  radiotherapy,  6  surgery, 
and  21  supportive  care.  It  is  worth  noting  that  some  patients  also  received 
other  adjuvant  treatments  in  addition  to  their  initial  management,  but  the 
following  analyses  are  based  on  patients'  initial  management. 
3.3.1  General  health 
Table  6.24  shows  patients'  scores  on  the  NHP  by  treatment  types.  Not  only 
were  there  no  improvements,  but  almost  on  all  measures,  patients  reported 
more  perceived  problems  after  their  treatments.  Chemotherapy  caused 
significant  problems  relating  to  social  isolation  (p  =  0.02),  radiotherapy  in 
energy  (p  =  0.02)  and  -  emotional  reactions  (p  =  0.04),  surgery  in  physical 
mobility  (p  =  0.03),  and  supportive  care,  in  energy  (p  =  0.02).  Only  slight 
improvement  can  be  seen  in  patients  sleep  scores  where  they  had  received 
radiotherapy  and  surgery. 
ýt,  .,: 
212 Results 
3.3.2  Functioning  and  global  quality  of  life 
Except  emotional  functioning  which  improved  slightly  in  those  who  received 
chemotherapy,  surgery  and  best  supportive  care,  almost  all  other  scores  have 
decreased  indicating  that  patients'  functioning  and  global  quality  of  life  had 
deteriorated.  Those  who  received  chemotherapy  and  radiotherapy  reported 
significant  deterioration  in  physical  functioning  (p  =  0.01  and  p=0.007 
respectively).  The  patients'  functioning  and  global  quality  of  life  scores  as 
measured  by  the  EORTC  QLQ-C30  are  shown  in  Table  6.25. 
3.3.3  Symptoms 
Table  6.26  presents  patients'  scores  on  the  EORTC  QLQ-C30  and  QLQ-LC13 
before  and  after  treatment.  It  shows  that  patients'  scores  on  cough  and 
haemoptysis  reduced  after  they  had  received  treatment  indicating  that  patients 
had  some  symptom  relief.  This  is  true  for  other  symptoms  such  as  dyspnoea, 
pain,  pain  in  chest,  pain  in  shoulder,  and  sleep  difficulties,  although  there 
were  some  variations  between  different  treatment  regimens  especially  in  those 
who  had  received  supportive  care  or  radiotherapy  where  some  of  these 
symptoms  not  only  did  not  reduce,  but  increased. 
In  contrast  to  symptom  relief,  there  were  increases  in  side-effects  of  treatment 
including  nausea  and  vomiting,  hair  loss,  constipation,  peripheral  neuropathy, 
sore  mouth,  and  trouble  swallowing  depending  on  the  treatment  types.  For 
example,  those  who  received  chemotherapy  reported  significant  increase  in 
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hair  loss  (p  =  0.0001)  and  sore  mouth  (p  =  0.003),  while  those  who  received 
radiotherapy  reported  increase  in  trouble  swallowing  (p  =  0.01). 
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- N Respiratory  Medicine  Day  Unit 
Stobhill  Hospital 
A  female  patient  with  lung  cancer  at  follow-up  assessment  of  quality  of 
life.  She  received  chemotherapy,  but  died  a  few  monthslater Results 
3.4  Small  and  non-small  cell  lung  cancer  and  quality  of  life 
In  this  section  analysis  is  restricted  to  small  and  non-small  cell  lung  cancer 
patients.  Two  methods  of  analyses  were  performed.  First,  comparison  was 
made  between  small  and  non-small  cell  lung 
.  cancer  patients'  baseline  and 
follow-up  scores.  This  provided  opportunity  to  examine  whether  patients  with 
different  cell  types  were  scored  differently  or  not.  Secondly,  small  and  non- 
small  cell  lung  cancer  patients'  baseline  scores  (before  treatment)  were 
compared  to  their  follow-up  scores  (after  treatment).  This  facilitated  the 
investigation  of  the  treatment  effects  on  these  two  groups  of  patients. 
3.4.1  Comparing  quality  of  life  in  small  and  non-small  cell  lung  cancer 
The  results  are  shown  in  Tables  6.27,,  6.28.,  and  6.29.  Although  there  were 
some  differences  between  small  and  non-small  cell  lung  cancer  patients' 
scores  on  the  NHP,  both  at  baseline  and  follow-up  assessments,  these 
differences  were  not  significant.  Non-small  cell  lung  cancer  patients  tended  to 
score  higher  than  small  cell  lung  cancer  patients  indicating  that  they  had  more 
perceived  health  problems  (Table  6.27). 
The  same  pattern  of  scoring  was  apparent  on  the  EORTC  QLQ-C30  indicating 
that  patients  with  non-small  cell  lung  cancer  had  a  lower  level  of  functioning 
and  quality,  of  life.  Only  on  one  measure  (emotional  functioning)  was  the 
difference  significant  (P:  --  0.01)  (Table  6.28). 
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At  baseline  assessments  there  were  no  significant  differences  between  small 
and  non-small  cell  lung  cancer  patients'  scores  on  symptom  subscales  on  the 
EORTC  QLQ-C30  and  QLQ-LC13,  although  on  some  of  the  measures  (for 
example,  haemoptysis,  dyspnoea,  pain,  pain  in  chest,  fatigue  and  appetite  loss) 
non-small  'cell  hing  cancer  patients  scored  higher  indicating  that  they  had  a 
greater  degree  of  symptoms.  However,  on  some  of  the  measures  small  cell 
lung  cancer  patients  had  higher  scores  such  as  scores  on  cough,  and  pain  in 
shoulder  (Table  6.29). 
At  follow-up  assessments  except  for  scores  on  pain  (p  =  0.005),  hair  loss  (p 
0.000),  and  sore  mouth  (p  =  0.006),  there  were  no  significant  differences 
between  small  cell  and  non-small  cell  lung  cancer  patients.  However,  there 
was  a  'clear  patter  `  of  scoring  indicating  that  non-small  cell  lung  cancer 
patients  had  higher  scores  on  disease-related  symptoms,  while  small  cell  lung 
cancer  patients  had  higher  scores  on  treatment-related  symptoms  (Table  6.29). 
14 
Finally,  it  is  important  to  note  that  the  difference  between  small  and  non-small  .P.  ti 
cell  lung  cancer  patients'  scores  may  be  due  to  the  different  treatments  they 
received  rather  than  the  difference  in  cell  type  (see  the  following  table). 
Treatment  Small  cell  Non-small  cell  Small  cell  Non-small  cell 
Baseline  Baseline  Follow-up+  Follow-up* 
n=23  -  n=6  n=1  n=44 
Chemotherapy  23  7  17  7 
Radiotherapy  0  24  -  0  18 
Surgery  0  6  0  6 
Supportive  care  0  30'  0  13 
+  At  10110W-UP  16  JI.  U.  paucuu  wcro  4UV  .  UL  Uucx,  ii  LUVL  par[  in  me  sway  ana  i  was 
terminally  ill. 
*  At  follow-up  53  NSCLC  patients  were  alive.  Of  these,  44  took  part  in  the  study,  6  refused  and  3 
were  terminally  ill. 
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Table  6.27  Comparison  of  small  and  non-small'  cell  lung  cancer  patients' 
scores  at  baseline  and  follow-up  assessments  on  NHP-Part  I  [the  higher 
values  indicate  more  perceived  health  problems,  min.:  0,  max.:  100,  all 
figures  are  mean  scores  (sd)] 
small  cell 
e-23 
Baseline 
non-small  cell 
n-6 
P* 
small  cell 
n-I 
Follow-up 
non-small  cell 
n  -44 
P' 
Energy  35.4  (36.0)  41.1  (42.4)  0.9  44.9  (33.2)  57.9  (40.2)  0.2 
Pain  17.7  (20.8)  24.4  (30.8)  0.7  17.3  (18.2)  29.8  (28.0)  0.1 
Emotional  reactions  17.5  (14.6)  27.7  (26.3)  0.2  14.1(16.5)  33.2  (31.3)  0.05 
Sleep  33.3  (27.4)  39.3  (32.3)  0.6  25.3  (21.6)  35.4  (33.6)  0.5 
Social  isolation  5.2  (10.8)  11.5  (19.7)  0.2  15.7  (23.5)  17.9  (28.0)  0.9 
Physical  mobility  27.9  (26.1)  28.1  (28.1)  0.9  39.4  (29.5)  36.4  (27.3)  0.8 
Table  6.28  Comparison  of  small  and  non-small  cell  lung  cancer  patients' 
functioning  and  global  quality  of  life  scores  at  baseline  and  follow-up 
assessments  on  EORTC  QLQ-C30  [the  higher  values  indicate  a  higher  level 
of  functioning  and  quality  of  life,  min.:  0,  max.:  100,  all  figures  are  mean 
scores  (sd)] 
Baseline 
small  cell  non-small  cell 
In  =M  !  n=671 
Follow-up 
small  cell  non-small  cell 
(n=171  (n  -"I 
Physical  functioning  63.5  (26.7)  64.5  (27.8)  0.9  48.2  (31.7)  57.7  (21.2)  0.3 
Role  functioning  56.5  (37.9)  62.7  (38.3)  0.5  35-3(34.3)  48.9(24.2)  0.1 
Emotional  functioning  88.0  (14.0)  76.4  (20.0)  0.01*  81.3  (18.3)  722  (23.9)  0.2 
Social  functioning  -  83.3  (29.7)  90.0  (17.9)  0.5  81.4  (26.9)  80.3  (24.5)  0.7 
Cognitive  functioning  90.6  (19.3)  84.1  (19.1)  0.06  75.5  (32.9)  82.6  (22.7)  0.7 
Global  quality  of  life  54.3  (24.3)  47.5  (23.6)  0.3  51.5  (29.0)  483  (242)  0.6 
+  2-tailed  probability  based  on  Mann-Whitney  U  test  (mean  rank). 
0  Significant  at  5%  level. 
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Table  6.29  Comparison  of  small  and  non-small  cell  lung  cancer  patients' 
symptoms  scores  on  EORTC  QLQ-C30  and  QLQ-LC13  at  baseline  and 
follow-up  assessments  [the  higher  values  indicate  a  greater  degree  of 
symptoms,  min.:  0,  max.:  100,  all  figures  are  mean  scores  (sd)] 
Baseline 
small  cell  non-small  cell 
In=211  Ina671 
Follow-up 
small  cell  non-small  cell 
(n-17)  (n-44) 
Cough  53.6  (31.4)  48.8  (32.5)  0.6  31.4  (34.3)  39.4  (29.9)  0.3 
Haemoptysis  8.7  (23.0)  13.9  (27.3)  0.4  2.0  (8.1)  2.3  (8.5)  0.9 
Dyspnoea  34.4  (24.4)  38.9  (27.5)  0.5  30.4  (27.5)  39.2  (26.4)  0.2 
Pain  21.7  (22.2)  26.4  (27,9)  0.7  14.7  (30.6)  31.4  (27.7)  0.005" 
Pain  in  chest  20.3  (28.0)  22.4  (29.2)  0.8  21.6  (35.2)  25.7  (30.4)  0.4 
Pain  in  shoulder  -  26.1  (31.7)  23.9  (33.2),  0.6  11.8  (20.2)  18.2  (27.3)  0.5 
Pain  elsewhere  27.5  (27.8)  26.4  (33.6)  0.6  21.6  (28.7)  23.5  (30.1)  0.9 
Sleep  difficulties  26.1  (37.5)  30.3  (35.2)  0.5  23.5  (30.7)  25.8  (32.8)  0.8 
Fatigue  32.9  (25.6)  37.5  (29.8)  0.6  37.9  (25.8)  43.9  (26.4)  0.4 
Appetite  loss  34.8  (34.1)  38.3  (33.5)  0.6  37.3  (37.0)  37.1  (33.1)  1.0 
Hair  loss 
. 
00.0  (00.0)  1  (5.7)  0.4  84.3  (26.7)  6.8  (19.8)  0.000" 
Nausea  and  vomiting  11.6  (13.7)  8.5  (18.0)  0.07  11.8  (18.4)  14.4  (22.9)  0.8 
Constipation  17.4  (28.2)  22.9  (33.9)  0.6  23.5  (30.7)  35.6  (40.3)  0.3 
Diarrhoea  10.1  (21.2)  4.5  (16.3)  0.07  7.8  (18.7)  3.8  (12.9)  03 
Peripheral  neuropathy  4.3  (15.3)  °  9.5  (23.1)  0.3  21.6  (31.0)  15.9  (25.4)  0.5 
Sore  mouth  1.4-(7.0)  4.0  (15.9)  0.6  29.4  (35.1)  8.3  (22.9)  0.006* 
Trouble  swallowing  14.5  (29.9)  8.0  (22.5)  0.2  7.8  (14.6)  15.2  (273)  0.6 
Financial  difficulties  5.8  (16.4)  10.4  (24.8)  0.5  19.6  (33.5)  9.1  (242)  0.2 
42-tailed  probability  based  on  Mann-Whitney  U  test  (mean  rank). 
*  Significant  at  5%  level. 
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3.4.2  Effect  of  treatment  on  small  cell  and  non-small  cell  lung  cancer  patients 
Small  and  non-small  cell  lung  cancer  patients'  scores  were  compared  to  their 
own,  follow-up  scores.  This  was  a  paired-matched  comparison,  that  is, 
comparing  baseline  and  follow-up  scores  where  data  were  available  for  the 
same  patients. 
Table  6.30  presents  both  small  and  non-small  lung  cancer  patients'  general 
health  status  as  measured  by  the  NHP.  Not  only  had  patients'  general  health 
status  not  improved,  but  there  were  also  significant  deterioration  on  measures 
such  as  social  isolation  (p  =  0.04),  and  physical  mobility  (p  =  0.03)-  for  small 
cell  lung  cancer  patients;  and  on  energy  (p  =  0.0004),  pain  (p  =  0.03),  and 
physical  mobility  (p  =  0.007)-  for  non-small  cell  lung  cancer  patients. 
However,  after  treatment  there  were  slight  improvements  for  small  cell  lung 
cancer  patients  with  lower  scores  on  emotional  reactions  and  sleep  difficulties. 
Similar  results  were  found  when  patients'  functioning  and  global  quality  of 
life  scores  were  measured  by  the  EORTC  QLQ-C30.  There  was  a  significant 
deterioration  in  patients  physical  and  role  functioning,  both  in  small  and  non- 
small  cell  lung  cancer  patients.  In  addition,  there  was  a  significant  reduction 
in  non-small  cell  lung  cancer  patients'  social  functioning,  while  small  cell 
lung  cancer  showed  slight  improvement  in  this  measure  (Table  6.31). 
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Table  6.32  shows  the  patients'  disease-  and  treatment-related  symptoms  as 
measured  by  the  EORTC  QLQ-C30  and  QLQ-LC13.  Except  on  two  measures 
(cough  in  small  cell  lung  cancer  patients  and  haemoptysis  in  non-small  cell 
lung  cancer  patients),  there  was  no  significant  symptom  relief.  However,  after 
treatment  small  cell  lung  cancer  patients  reported  a  lesser  degree  of  disease- 
related  symptoms.  Both  small-and  non-small  cell  lung  cancer  patients  scored 
higher  on  measures  related  to  side-effects  of  treatment  as  compared  to  their 
baseline  scores.  For  example,  non-small  cell  lung  cancer  patients  reported 
significant  increase  on  fatigue  (p  0.007),  constipation  (p  =  0.02),  peripheral 
neuropathy  (p  =  0.03),  sore  mouth  (p  =  0.04),  and  trouble  swallowing  (p  = 
0.01). 
,3.,, 
j  ,. 
s 
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Table  6.30  Small  and  non-small  cell  lung  cancer  patients'  mean  scores  (sd) 
on  NHP-Part  I  before  and  after  treatment  (the  higher  values  indicate  more 
perceived  health  problems,  min.:  0,  max.:  100) 
Small  cell  P'  Non-small  cell  P' 
(n  °  17)  (o  -  44) 
Before  After  Before  After 
Energy  34.7  (36.2)  44.9  (33.2)  0.2 
Pain  16.4  (22.1)  17.3  (18.2)  0.9 
Emotional  reactions  16.1  (12.2)  14.1(16.5)  0.5 
Sleep  29.5  (23.5)  25.3  (21.6)  0.6 
Social  isolation  7.1(12.2)  15.7  (23.5)  0.04" 
Physical  mobility  23.3  (23.7)  39.4  (29.5)  0.03* 
31.9  (37.9)  57.9  (40.2)  0.0004' 
19.8  (27.6)  29.8  (28.0)  0.036 
24.6  (26.0)  33.2  (31.3)  0.07 
34.8  (31.8)  35.4  (33.6)  0.8 
11.4  (21.4)  17.9  (28.0) 
. 
0.1 
23.5  (25.2)  36.4  (27.3)  0.007' 
Table  6.31  Small  and.  non-small  cell  lung  cancer  patients'  functioning  and 
global  quality  of  life  mean  scores  (sd)  on  EORTC  QLQ-C30  before  and  after 
treatment  (the  higher  values  indicate  a  higher  level  of  functioning  and 
quality  of  life,  min.:  0,  max.:  100) 
Small  cell  P+  Non-small  cell  P+ 
(n  17)  ßo  '  44) 
Before  After  Before  After 
Physical  functioning  63.5  (23.7)  482  (31.7)  0.03*  70.0  (25.0)  57.7  (21.2)  0.004' 
Role  functioning  55.9  (34.8)  35.3  (34.3)  0.04'  69.3  (36.1)  48.9  (24.2)  0.008' 
Emotional  functioning  88.7  (13.2)  813  (183)  0.2  78.6  (193)  72.2  (23.9)  0.2 
Social  functioning 
, 
77.5  (32.8)  81.4  (26.9)  0.5  90.9  (17.8)  80.3  (24.5)  0.004* 
Cognitive  functioning  89.2  (22.0)  75.5  (32.9)  0.05  85.6  (17.8)  82.6  (22.7)  0.4 
Global  quality  of  life  -  52.0  (26.3)  51.5  (29.0)  0.8  54.5  (19.3)  48.3  (24.2)  -  0.1 
+  Probability  based  on  Wilcoxon  matched-pairs  signed-ranks  test. 
0  Significant  at  5%  level. 
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Table  6.32  Small  and  non-small  cell  lung  cancer  patients'  symptoms  mean 
scores  (sd)  on  EORTC  QLQ-C30  and  QLQ-LC13  before  and  after 
treatment  (the  higher  values  indicate  a  greater  degree  of  symptoms,  min.:  0, 
mal.:  100) 
Small  cell  P+  Non-small  cell  P' 
(a-17)  (e  -  44) 
Before  After  Before  After 
Cough  56.9  (30.7)  31.4  (34.3)  0.03'  48.5  (32.5)  39.4  (29.9)  0.1 
Haemoptysis  9.8  (25.7)  2.0  (8.1)  0.3  14.4  (26.3)  2.3  (8.5)  0.0096 
Dyspnoea  40.2  (25.7)  30.4  (27.5)  0.08  34.5(25-3)  39.2  (26.4)  0.2 
Pain  22.5  (22.0)  14.7  (30.6)  0.3  23.9  (25.8)  31.4  (27.7)  0.07 
Pain  in  chest  17.6  (26.7)  21.6  (35.2)  0.8  22.7  (27.6)  25.7  (30.4)  0.7 
Pain  in  shoulder  25.5  (32.3)  11.8  (20.2)  0.06  23.5  (31.0)  18.2  (27.3)  0.2 
Pain  elsewhere  25.5  (27.7)  21.6  (28.7)  0.6  21.2  (28.8)  23.5  (30.1)  0.7 
Sleep  difficulties  27.5  (39.5)  23.5  (30.7)  0.8  27.3  (33.9)  25.8  (32.8)  0.8 
Fatigue  34.0  (28.2)  37.9  (25.8)  0.7  31.3  (26.3)  43.9  (26.4)  0.007' 
Appetite  loss  39.2  (37.7)  37.3  (37.0)  0.9  32.6  (31.7)  37.1  (33.1)  0.4 
Hair  loss  00.0  (00.0)  84.3  (26.7)  0.0004*  00.8  (5.0)  6.8  (19.8)  0.06 
Nausea  and  vomiting  11.8  (14.1)  11.8  (18.4)  0.9  7.6  (17.0)  14.4  (22.9)  0.08 
Constipation  23.5  (30.7)  23.5  (30.7)  1.0  17.4  (30.1)  35.6  (40.3)  0.02* 
Diarrhoea  13.7  (23.7)  7.8  (18.7)  0.4  53  (17.5)  3.8  (12.9)  0.6 
Peripheral  neuropathy  5.9  (17.6)  21.6  (31.0)  0.07  7.6  (21.4)  15.9  (25.4)  0.03' 
Sore  mouth  00.0  (00.0)  29.4  (35.1)  0.01*  1.5  (7.0)  83  (22.9)  0.04' 
Trouble  swallowing  17.6  (33.6)  7.8  (14.6)  0.1  3.8  (10.7)  15.2  (273)  0.010 
Financial  difficulties  7.8  (18.7)  19.6  (33.5)  0.1  8.3  (20.5)  9.1  (24.2)  0.7 
Probability  based  on  Wilcoxon  matched-pairs  signed-ranks  test. 
*  Significant  at  5%  level. 
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3.5  Limited  and  extensive  diseases  and  quality  of  life 
Two  approaches  were  chosen  to  examine  quality  of  life  in  patients  with 
limited  and  extensive  disease.  First,  analysis  was  performed  to  compare 
limited  and  extensive  disease  at  baseline  and  follow-up  assessments  to  look  at 
the  differences.  Secondly,  data  were  obtained  from  the  same  patients,  at 
baseline  (before  treatment)  and  follow-up  (after  treatment)  to  compare  the 
effects  of  treatment. 
3.5.1  Comparison  between  limited  and  extensive  disease 
At  baseline  and  follow-up,  assessments  patients  with  extensive  disease  had  a 
lower  quality  of  life  as  compared  to  patients  with  limited  disease.  These 
differences  were  more  profound  at  baseline.  Table  6.33  presents  patients' 
general  health  status  as  measured  by  the  NHP.  At  baseline,  patients  with 
extensive  disease  scored  significantly  higher  on  energy  (p  =  0.01),  pain  (p  = 
0.0004),  and  physical  mobility  (p  =  0.04),  indicating  that  they  had  more 
perceived  health  problems.  Again,  at  follow-up  while  patients  with  extensive 
disease  scored  higher,  none  of  the  scores  were  significantly  different. 
Table  6.34  presents  patients'  functioning  and  global  quality  of  life  scores. 
While  both  at  baseline  and  follow-up  patients  with  extensive  disease  had 
lower  functioning  and  quality  of  life,  on  most  measures  the  differences  were 
not  significant.  Only  at  baseline  assessments,  patients  with  extensive  disease 
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scored  lower  significantly  on  two  measures,  physical  functioning  (p  =  0.04) 
and  global  quality  of  life  (p  =  0.01). 
A  similar  pattern  of  scoring  was  found  in  patients'  evaluation  of  their  own 
disease-  and  treatment-related  symptoms  and  side-effects  as  measured  by  the 
EORTC  QLQ-C30  and  QLQ-LC13.  There  were  either  no  differences  at  all 
(cough)  or  the  directions  were  against  patients  with  extensive  disease 
indicating  that  they  had  more  symptoms  and  treatment-related  side-effects  as 
compared  to  the  patients  with  limited  disease.  However,  on  some  of  the 
measures  patients  with  limited  disease  scored  higher,  for  example,  diarrhoea 
(at  baseline)  and  haemoptysis  and  sore  mouth  (at  follow-up).  These  are  shown 
in  Table  6.35. 
t 
i 
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Table  6.33  Comparison  of  scores,  of,  patients  with  limited  and  extensive 
disease  on  NHP-Par  I  at  baseline  and  follow-up  [the  higher  values  indicate 
more  perceived  health  problems,  min.:  0,  max.:  100,  all  figures  are  mean 
scores  (sd)] 
Baseline 
Limited  Extensive 
n=101  n=24 
P`  Follow-up 
Limited  Extensive 
n-70  n-11 
P` 
Energy  37.4  (40.7)  62.2  (41.9)  0.01k  49.6  (39.7)  65.2  (26.7)  032" 
Pain  20.2  (26.8)  44.2  (33.0)  0.0004'  22.5  (23.6)  462  (39.0)  0.1 
Emotional  reactions  23.9  (22.9)  32.4  (29.1)  0.2  27.3  (29.3)  37.6  (30.2)  0.2 
Sleep  35.3  (31.7)  49.9  (33.9)  0.04'  32.7  (31.9)  44.4  (30.4)  0.2 
Social  isolation  11.9  (22.3)  15.0  (20.3)  0.2  18.8  (27.5)  19.3  (20.2)  0.5 
Physical  mobility  27.1  (26.6)  41.8  (31.6)  0.04*  33.7  (26.8)  43.9  (28.9)  0.2 
Table  6.34  Comparison  of  functioning  and  global  quality  of  life  scores  of 
patients  with  limited  and  extensive  disease  on_EORTC  QLQ-C30  at  baseline 
and  follow-up  [the  higher  values  indicate  a  higher  level  of  functioning  and 
quality  of  life,  min.:  0,  max.:  100,  all  figures  are  mean  scores(sd)] 
Baseline  P+  Follow-up  P* 
Limited  Extensive  Limited  Extensive 
(n=101)  (n=24)  (n=70)  (n-11) 
Physical  functioning  64.0  (28.1)  51.7  (24.3)  0.04  56.6  (25.9)  49.1  (16.4)  0.3 
Role  functioning  61.9  (35.5)  47.9  (42.9)  0.1  47.9  (31.2)  36.4  (23.4)  0.3 
Emotional  functioning  79.3  (22.0)  73.3  (20.3)  0.1  76.1(22.1)  73.5  (23.8)  0.7 
Social  functioning  . 
88.0  (23.6) 
. 
84.0  (18.7) 
., 
0.07  82.6  (23.6)  77.3  (18.7) 
., 
0.2. 
_ 
Cognitive  functioning  86.1  (20.3)  80.6  (23.9)  0.3  82.1  (23.6)  71.2  (27.0)  0.2 
Global  quality  of  life  52.5  (21.3)  37.8  (28.2)  0.01'  51.9  (25.9)  50.0  (25.8)  0.8 
`  2-tailed  probability  based  on  Mann-Whitney  U  test  (mean  rank) 
Significant  at  5%  level. 
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Table  6.35  Comparison  of  symptoms 
, 
scores  of  patients  with  limited  and 
extensive  disease  on  EORTC  QLQ-C30  and  QLQ-LC13  at  baseline  and 
follow-up  [the  higher  valued  indicate  a  greater  degree  of  symptoms,  min.:  0, 
max.:  100,  all  figures  are  mean  scores  (sd)] 
Baseline 
Limited 
(n-1O1 
Cough  46.5  (32.7) 
Haemoptysis  8.6  (20.9) 
Dyspnoea  36.8  (28.5) 
Pain  '-  °ri°  '  22.6  (25.0) 
Pain  in  chest  . 
20.1(27.5) 
pain  in  shoulder  24.1  (33.0) 
Pain  elsewhere  22.1  (31.7) 
Sleep  difficulties  27.4  (35.7) 
Fatigue  33.2  (28.1) 
Appetite  loss  30.4  (32.7) 
Hair  loss  00.7  (4.7) 
Nausea  and  vomiting  7.6  (16.6) 
Constipation  16.5  (30.8) 
Diarrhoea  -  7.3  (20.9) 
Peripheral  neuropathy  12.2  (27.4) 
Sore  mouth  2.0  (11.4) 
Trouble  swallowing  7.6  (20.5) 
Financial  difficulties  8.3  (21.8) 
Follow-up 
Extensive  Limited  Extensive 
(n  -  24)  (n  -  70)  (n  -  11) 
45.8  (33.8)  0.9  35.7  (29.1)  48.5  (34.5)  0.2 
15.3  (31.1)  0.4  4.8  (16.3)  00.0  (00.0)  0.3 
40.6  (22.4)  0.4  35.8  (27.5)  37.9  (28.2)  0.8 
45.1  (33.9)  0.003'  22.1(26.1)  40.9  (38.3)  0.2 
27.8  (33.6)  0.4  23.8  (31.2)  303  (37.9)  0.7 
37.5  (38.5)  0.1  17.6  (26.4)  27.3  (36.0)  0.4 
36.1  (36.7)  0.08  20.5  (28.5)  21.2  (37.3)  0.8 
44.4  (413)  0.07  24.3  (32.1)  30.3  (37.9)  0.7 
53.2  (30.0)  0.004'  383  (27.2)  53.5  (22.1)  0.07 
50.0  (35.4)  0.01'  29.0  (33.5)  54.5  (22.5)  0.008' 
1.4  (6.8)  0.5  21.9  (38.0)  303  (43.3)  0.6 
16.7  (21.4)  0.004"  11.2  (18.5)  19.7  (30.6)  0.5 
31.9  (36.0)  0.02'  27.1  (36.0)  42.4  (36.8)  0.2 
2.8  (9.4)  0.6  4.8  (14.2)  '00.0  (00.0)  0.2 
9.7  (25.0)  0.7  15.7  (23.9)  303  (37.9)  0.2 
4.2  (14.9)  0.4  143  (28.7)  6.1(20.1)  0.3 
9.7  (28.6)  0.8  11.9  (22.7)  182  (34.5)  0.7 
8.3  (20.3)  0.8  9.5  (24.8)  6.1  (20.1)  0.6 
-ý,  '  °ý 
+  2-tailed  probability  based  on  Mann-Whitney  U  test  (mean  rank). 
Significant  at  5%  level. 
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3.5.2  Effect  of  treatment  on  patients  with  limited  and  extensive  disease 
Eighty-two  patients  were  followed-up.  Of  these,  case  records  for  81  patients 
were  available  indicating  that  there  were  70  patients  with  limited  and  11  with 
extensive  diseases.  Thus,  the  baseline  and  follow-up  assessments  for  each  - 
group  were  matched  and  compared. 
Tables  6.36  and  6.37  presents  patients'  general  health  status  and  functioning 
scores  as  measured  by  the  NHP  and  the  EORTC  QLQ-C30.  Both  patients  with  s 
limited  and  extensive  disease  reported  deterioration  in  their  quality  of  life 
after  they  had  received  treatment.  However,  patients  with  limited  disease 
reported  slight  improvement  in  sleep,  and  patients  with  extensive  disease  in 
emotional  functioning. 
Table  6.38  presents  patients'  evaluation  of  their  own  disease  symptoms  and 
treatment  side-effects  as  measured  by  the  EORTC  QLQ-C30  and  QLQ-LC13. 
For  patients  with  limited  disease  the  only  significant  improvement  was  on 
cough  (p  =  0.005),  while  this  was  not  the  case  for  patients  with  extensive 
disease.  On  the  other  hand,  patients  developed  significant  treatment-related 
side-effects  such  as  hair  loss  (p  =  0.0001  in  limited  disease  and  p=0.04  in 
extensive  disease),  sore  mouth  (p  =  0.0005  in  limited  disease).  Overall,  as 
indicated  in  Tab1e  6.38  the  treatment  not  only  did  not  improve  patients' 
quality  of  life  significantly,  but  also  caused  them  several  new  problems  related 
to  the  treatment  they  had  received. 
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Table  6.36  Patients'  mean  scores  (sd)  on  *  the  NHP-Part  I  before  and  after 
treatment  by  those  who  had  limited  disease  and  those  with  extensive  disease 
(the  higher  values  indicate  more  perceived  health  problems,  min.:  0,  max.: 
100) 
Limited  disease  P+  Extensive  disease  P' 
(o°70)  (n.  '11) 
Before  After  Before  After 
Energy  32.0  (37.6)  49.6  (39.7)  0.0007*  42.9  (39.6)  65.2  (26.7)  0.1 
pain  19.2  (26.3)  22.5  (23.6)  0.2  34.9  (34.2)  46.2  (39.0)  0.4 
Emotional  reactions  21.1  (22.2)  27.3  (29.3)  0.08  31.2  (33.1)  37.6  (30.2)  0.6 
Sleep  34.3  (31.6)  32.7  (31.9)  0.7  41.6  (34.1)  44.4  (30.4)  0.3 
Social  isolation  11.1  (22.8)  18.8  (27.5)  0.02'  19.2  (23.9)  19.3  (20.2)  1.0 
Physical  mobility  23.0  (24.5)  33.7  (26.8)  0.001'  30.9  (29.5)  43.9  (28.9)  0.3 
Table  6.37  Patients'  functioning  and  global  quality  of  life  mean  scores  (sd) 
on  EORTC  QLQ-C30  before  and  after  treatment  by  those  who  had  limited 
disease  and  those  with  extensive  disease  (the  higher  values  indicate  a  higher 
level  of  functioning  and  quality  of  life,  min.:  0,  max.:  100) 
Limited  disease  P+  Extensive  disease  P' 
(n  =  70)  (n  =  11) 
Before  After  Before  After 
physical  functioningy  67.4  (26.0)  56.6  (25.9)  0.001*  61.8  (16.6)  49.1  (16.4)  0.08 
Role'  functioning  65.0  (33.4)  47.9  (31.2)  0.001*  59.1  (43.7)  36.4  (23.4)  0.2 
Emotional  functioning  80.6  (22.8)  76.1  (22.1)  0.2  68.2  (16.2)  73.5  (23.8)  0.3 
Social  functioning  86.4  (25.3)  82.6  (23.6)  0.09  83.3  (21.1)  77.3  (18.7)  0.4 
Cognitive  functioning  87.1  (20.1)  82.1  (23.6)  0.1  78.8  (24.8)  71.2  (27.0)  0.3 
Global  quality  of  life  54.2  (21.3)  51.9  (25.9)  0.6  50.8  (30.2)  50.0  (25.8)  0.9 
Probability  based  on  Wilcoxon  matched-pairs  signed-ranks  test. 
Significant  at  5%  level. 
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Table  638  Patients'  symptoms  mean  scores  (sd)  on  EORTC  QLQ-C30  and 
QLQ-LC13  before  and  after  treatment  by  those  who  had  limited  disease  and 
those  with  extensive  disease  (the  higher  values  indicate  a  greater  degree  of 
symptoms,  min.:  0,  max.:  100) 
Limited  disease 
(n  -  70) 
Before  After 
Cough  48.6  (30.4)  35.7  (29.1)  0.005' 
Haemoptysis  9.5  (21.3)  4.8  (16.3)  0.2 
Dyspnoea  35.2  (27.2)  35.8  (27.5)  1.0 
pain  22.4  (23.6)  22.1  (26.1)  0.9 
Pain  in  chest  21.4  (27.2)  23.8  (31.2)  0.7 
pain  in  shoulder  23.8  (31.2)  17.6  (26.4)  0.1 
Pain  elsewhere  18.6  (27.6)  20.5  (28.5)  0.7 
Sleep  difficulties  27.1(34.7)  24.3  (32.1)  0.6 
Fatigue  31.7  (27.8)  38.3  (27.2),  0.03* 
Appetite  loss  29.5  (32.9)  29.0  (33.5)  1.0 
Hair  loss  1.0  (5.6)  21.9  (38.0)  0.0001* 
Nausea  and  vomiting  5.7  (13.0)  11.2  (18.5)  0.04' 
Constipation  15.7  (29.3)  27.1(36.0)  0.03" 
Diarrhoea,  7.1  (19.6)  4.8  (14.2)  "  0.4 
Peripheral  neuropathy  12.9  (28.0)  15.7  (23.9)  0.3 
Sore  mouth  1.0  (5.6)  14.3  (28.7)  0.0005' 
Trouble  swallowing  6.7  (17.6)  11.9  (22.7)  0.1 
Financial  difficulties  8.1  (20.0)  9.5  (24.8)  0.6 
Extensive  disease 
(n-11) 
Before  After 
54.5  (37.3)  48.5  (34.5)  .7 
18.1  (34.3)  00.0  (00.0)  0.1 
42.4  (24.0)  37.9  (28.2)  0.8 
37.9  (30.0)  40.9  (38.3)  0.7 
27.3  (36.0)  30.3  (37.9)  0.8 
42.4  (45.0)  27.3  (36.0)  0.1 
30.3  (37.9)  21.2  (373)  0.6 
42.4  (44.9)  30.3  (37.9)  "  0.5 
40.4  (31.9)  53.5  (22.1)  0.2 
42.4  (36.8)  54.5  (22.5)  0.4 
00.0  (00.0)  30.3  (43.3)  0.04' 
21.2  (26.0)  19.7  (30.6)  0.9 
18.2  (27.3)  42.4  (36.8)  0.09 
6.1  (13.5)  00.0  (00.0)  0.2 
9.1  (302)  30.3  (37.9)  0.1 
00.0  (00.0)  6.1  (20.1)  03 
12.1(30.8)  18.2  (34.5)  0.6 
6.1  (20.1)  6.1  (20.1)  1.0 
Probability  based  on  Wilcoxon  matched-pairs  signed-ranks  test. 
Significant  a  5%  level. 
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3.6.  Pain  medication  at  follow-up 
Out  of  82  patients  who  were  followed-up,  33  lung  cancer  patients  (40%) 
indicated  that  they  did  not  take  any  pain  medications  during  the  last  week 
prior  to  the  interview,  and  the  remaining  49  (60%)  said  that  they  received  pain 
killers.  The  analysis  showed  that  the  pattern  of  pain  medication  in  these 
patients  as  compared  to  their  baseline  conditions  did  not  change  significantly 
(p  =  0.9): 
Of  those  who  received  pain  killers,  5  patients  (10%)  stated  that  it  did  not  help 
them  at  all,  29  (60%)  said  that  it  did  help  a  little,  10  (20%)  reported  that  it  did 
help  quite  a  bit,  and  finally  5  patients  (10%)  indicated  that  it  did  help  them 
very  much.  When  this  pattern  was  examined  against  the  baseline  pattern  in  the 
same  patients,  there  was  no  significant  difference  between  the  baseline  and  the 
follow-up  patterns  (p  =  0.4). 
3.7.  Prediction  of  global  quality  of  life  at  follow-up  assessments 
The  only  index  of  global  quality  of  life  was  that  of  the  EORTC  QLQ-C30 
which  consisted  of  two  ý7-point  scales  of  patients'  general  health  status  and 
quality  of  life.  Thus;  in  a-  follow-up  stage  to  investigate  which  variables 
predicted  global  quality  of  life,  a  similar  analysis  to  the  baseline  assessments 
(logistic  regression)  was  performed.  The  global  quality  of  life  at  follow-up 
assessment  was  chosen  as  an  outcome  (dependent  variable),  and  in  5  separate 
equations  6  groups  of  variables,  were  chosen  as  predictors  (independent 
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variables).  In  the  first  model  the  functioning  scales  (from  the  EORTC  QLQ- 
C30);  in  the  second  the  disease-  and  treatment  related  symptoms  (from  the 
EORTC  QLQ-C30  and  QLQ-LC13);  in  the  third  the  prognostic  factors,  these 
were  (age,  sex,  extent  of  disease,  weight  loss,  and  performance  status);  in  the 
fourth  the  NHP  scales,  in  the  fifth  some  related  socio-demographic,  clinical 
and  support  variables  and  finnaly,  all  above  variavles  were  chosen.  In  the 
following  sections  the  results  of  the  analysis  are  presented. 
(I)  Of  functioning  scores  the  social  and  physical  functioning  were  significant 
predictors  of  global  quality  of  life  at  follow-up  (Figure  6.13). 
(II)  Of  patients'  symptoms  two  were  significant  predictors  of  global  quality  of 
life  at  follow-up:  firstly  nausea  and  vomiting  and  secondly,  pain  in  other  sites 
in  the  body  (Figure  6.14) 
(III)  Of  prognostic  factors  -at  baseline,  only  the  performance  status  was  a 
significant  predictor  of  global  quality  of  life  at  follow-up  (Figure  6.15). 
(IV)  None  of  the  patients'  scores  on  the  NHP  were  significant  predictors  of 
global  quality  of  life  at  follow-up  (Figure  6.16). 
(V)  When  analysis  was  performed  based  on  socio-economic,  clinical  and 
support  variables,  Deprivation  Category  and  marital  status  were  significant 
predictors  of  patients'  global  quality  of  life  at  follow-up  predicting  that  those 
who  lived  in  deprived  areas  and  were  widowed,  separated,  and  divorced  had  a 
lower  global  quality  of  life  (p  =  0.03,  and  0.01  respectively).  Surprisingly, 
none  of  the  medical  factors  (diagnosis  and  treatment  modalities)  was 
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significant  in  predicting  what  might  happen  to  the  patients'  global  quality  of 
life  at  follow-up  (Figure  6.17). 
(VI)  Finally  all  the  above  variables  were  chosen  and  the  regression  analysis 
was  performed  by  selecting  the  `forward  conditional'  model.  Only  two 
variables  (fatigue,  nausea  and  vomiting)  were  found  to  be  significant 
predictors  of  global  quality  of  life  at  follow-up  (p  =  0.0002,  and  0.009 
respectively). 
The  analysis  also  indicated  that  fatigue  accounted  for  the  apparent  influence 
on  many  perceived  health  problems  (e.  g.  pain,  energy,  sleep  difficulties), 
performance  status,  functioning  (e.  g.  role,  and  social  functioning),  and 
symptoms  (e.  g.  loss  of  appetite,  dyspnoea,  cough).  Nausea  and  vomiting,  in 
turn,  accounted  for  the  apparent  effect  of  the  residual  variables  including 
physical  mobility,  emotional  functioning,  and  pain  in  other  sites  of  the  body. 
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Figure  6.13  Logistic  regression  analysis-Global  quality  of  life  and  functioning 
Number  of  cases  included  in  the  analysis:  82 
D  p.  ident  Variable..  aoilow-up,  Global  quality  of  lifte 
*  Constant  is  included  in  the  model. 
Beginning  Block  Number  1.  Method:  Enter 
Variable(s)  Entered  on  Step  Number 
1..  XPF2  Physical  functioning-follow  up 
XRF2  Role  functioning-follow  up 
XEF2  Emotional  functioning-follow  up 
XSF2  Social  functioning-follow  up 
XCF2  Cognitive  functioning-follow  up 
---------------------- 
Variables  in  the  Equation  ---------------------- 
Variable  B  S.  E.  Wald  df  Sig  R  Exp(B) 
XPF2  -.  0349  .  0172  4.1233  1  .  0423  -.  1371  .  9657 
XRF2  -.  0008  .  0133  .  0039  1  .  9500  .  0000  .  9992 
XEF2  -.  0115  .  0153  .  5683  1  .  4509  .  0000  .  9885 
XSF2  -.  0441  .  0194  5.1933  1  .  0227  -.  1682  .  9568 
XCF2  -.  0066  .  0156  .  1820  1  .  6697  .  0000  .  9934 
Constant  7.4525  1.9910  14.0110  1  .  0002 
Figure  6.14  Logistic  regression  analysis-Global  quality  of  life  and  symptoms 
Number  of  cases  included  in  the  analysis:  82 
Dependent  variable..  Follow-up  Global  quality  of  life 
*  Constant  is  included  in  the  model. 
Beginning  Block  Number  1.  Method:  Enter 
Variable(s)  Entered  on  Step  Number 
1￿  XAP2  Appetite  loss-follow  up 
XBR2  Dyspnoea-follow  up 
XC02  Constipation-follow  up 
XCOU2  Cough-follow  up 
XDI2  Diarrhoea-follow  up 
XFA2  Fatigue-follow  up 
XFI2  Financial  difficulties-follow  up 
XHL2  Hair  loss-follow  up 
XHP2  Haemoptysis-follow  up 
XNV2  Nausea  and  vomiting-follow  up 
XPA2  Pain-follow  up 
XPC2  Chest  pain-follow  up 
XPS2  Pain  in  arm  &  shoulder-follow  up- 
XPE2  Pain  elsewhere-follow  up 
XPN2  Peripheral  neuropathy-follow  up 
XSL2  Sleep-follow  up 
XSM2  Sore  mouth-follow  up 
XSW2  Trouble  swallowing-follow  up 
--------  -------------  Variables  in  the  Equation  ------  ---------  -------- 
Variable  B  S.  E.  Wald  df  Sig  R  Exp(B) 
XAP2  .  0364  .  0204  3.1854  1  .  0743  .  1025  1.0371 
XBR2  .  0107  .  0295  .  1310  1  .  7174  .  0000  1.0107 
XC02  -.  0194  .  0147  1.7393  1  .  1872  .  0000  .  9807 
XCOU2  .  0308  .  0176  3.0587  1  .  0803  .  0968  1.0313 
XD12  -.  0903  .  0557  2.6265  1  .  1051  -.  0745  .  9137 
XFA2  .  0182  .  0343  .  2811  1  .  5960  .  0000  1.0183 
XFI2  .  1373  .  7911  .  0301  1  .  8622  .  0000  1.1472 
XHL2  -.  0089  .  0126  .  4899  1  .  4840  .  0000  .  9912 
XHP2  .  0343  .  0424  .  6539  1  .  4187  .  0000  1.0349 
XNV2  .  1059  .  0407  6.7552  1  .  0093  .  2052  1.1117 
XPA2  -.  0135  .  0283  .  2285  1  .  6327  .  0000  .  9866 
XPC2  -.  0108  .  0173  .  3862  1  .  5343  .  0000  .  9893 
XPS2  .  0082  .  0159  .  2649  1  .  6068  .  0000  1.0082 
XPE2  .  0389-.,.  .  0181  4.6130  l  .  0317  .  1521  1.0397 
XPN2  -.  0231  .  0207  1.2455  1  .  2644  .  0000  .  9772 
XSL2  -.  0092  .  0150  .  3767  1  .  5394  .  0000  .  9908 
XSM2  .  0103  .  0169  .  3697  1  .  5432  .  0000  1.0103 
XSW2  .  0266  .  0226  1.3847  1  .  2393  .  0000  1.0270 
Constant  -3.2682  .  9628  11.5226  1  .  0007 
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Figure  6.15  Logistic  regression`  analysis-Global  quality  of  life  and  prognostic 
factors 
Number  of  cases  included  in  the  analysis:  81 
Parameter  coding  (categorical  data) 
Value  Freq  Coding 
(1)  (2)  (3) 
WEIGHT  LOSS 
significant  weight  loss  1.00  33  1.000 
. 
000 
. 
000 
weight  steady  2.00  26 
.  000  1.000 
. 
000 
possible  weight  loss  3.00  7 
.  000 
. 
000  1.000 
no  comment  4.00  15  .  000 
.  000 
. 
000 
EXTENT  OF  DISEASE 
limited  1.00  70 
.  000 
extensive  2.00  11  1.000 
SEX 
male  1  48  .  000 
female  2  33  1.000 
Dependent  variable..  Follow-up  Global  quality  of  life 
*  Constant  is  included  in  the  model. 
Beginning  Block  Number  1.  Method:  Enter 
Variable(s)  Entered  on  Step  Number 
1..  AGE  Age 
SEX  sex 
EXTENT  Extent  of  disease 
WEIGHLOS  Weight  loss 
ECOG2  Performance  status/ECOG2-  follow  up 
Variables  in  the  Equation 
Variable  B  S.  E.  Wald  df  Sig  R  Exp(B) 
AGE  .  0077  .  0310  .  0614  1 
.  8043  .  0000  1.0077 
SEX(1)  -.  8580  .  5784  2.2004  1  .  1380  -.  0424  .  4240 
EXTENT(1)  .  0338  .  8257  .  0017  1  .  9674  .  0000  1.0344 
WEIGHLOS  4.4933  3 
.  2129  .  0000 
WEIGHLOS(1)  -1.2614  .  7809  2.6096  1  .  1062  -.  0740  .  2832 
WEIGHLOS(2)  -.  2292  .  8081  .  0805  1  .  7767  .  0000  .  7952 
WEIGHLOS(3)  -1.4101  1.1923  1.3987  1  .  2369  .  0000  .  2441 
ECOG2  1.5089  .  4136  13.3089  1  .  0003  .  3188  4.5220 
Constant  -1.2118  2.2862  .  2809  1  .  5961 
Figure  6.16  Logistic  regression  analysis-Global  quality  of  life  and  NHP 
Number  of  cases  included  in  the  analysis:  82 
Dependent  Variable..  Follow-up  Global  quality  of  life 
*  Constant  is  included  in  the  model. 
Beginning  Block  Number  1.  Method:  Enter 
Variable(s)  Entered  on  Step  Number 
1..  TEM2  Emotional  reactions-follow  up 
TEN2  Energy-follow  up 
TP2  Pain-follow  up 
TPM2  Physical  mobility-follow  up 
TSL2  Sleep-  follow  up 
TS02  Social  isolation-follow  up 
----------------------  Variables  in  the  Equation  ----------------------- 
Variable  B  S.  E.  Wald  df  Sig  R  Exp(B) 
TEM2  . 
0264 
. 
0155  2.9038  1 
.  0884 
. 
0895  1.0267 
TEN2  . 
0145  .  0099  2.1260  1 
. 
1448 
. 
0334  1.0146 
TP2  . 
0039  . 
0151 
. 
0654  1 
. 
7981 
. 
0000  1.0039 
TPM2  . 
0261 
. 
0141  3.4013  1 
. 
0651 
. 
1114  1.0264 
TSL2  -.  0031  . 
0102 
. 
0936  1 
. 
7597 
. 
0000 
. 
9969 
TS02  -.  0265  .  0157  2.8388  1 
. 
0920  -.  0862 
. 
9738 
Constant  -1.5738  . 
5036  9.7671  1 
. 
0018 
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Figure  '  6.17  Logistic  regression  analysis-Global  quality  of  'life  and  socio- 
demographic,  clinical  and  social  support  variables 
Number  of  cases  included  in  the  analysis:  81 
Parameter  coding  (categorical  data)  ' 
Value  Freq  Coding 
(1)  (2)  (3) 
EMPLOYMENT  STATUS 
employed  1  12 
. 
000  .  000 
. 
000 
unemployed  271.000 
.  000 
. 
000 
housewife  3  15 
.  000  1.000 
.  000 
retired  4  47  .  000 
.  000  1.000 
TYPE  OF  ACCOMMODATION 
flat  1  30  1.000  .  000  .  000 
semi-detached  2  23  .  000  1.000  .  000 
4  in  Block  3  10  .  000  .  000  1.000 
terrace  house/house/others  4  18  .  000  .  000  .  000 
TREATMENT 
chemotherapy  1  25  1.000  .  000  .  000 
radiotherapy  2  29  .  000  1.000 
.  000 
surgery  36  .  000  .  000  1.000 
supportive  care  4  21  .  000  .  000  .  000 
NEIGHBOUR  SUPPORT 
never/almost  never  .1  61  1.000 
.  000 
sometimes  29 
.  000  1.000 
almost  always/always  3  11  .  000 
.  000 
MARITAL  STATUS 
married  1  49  .  000 
.  000 
single  241.000 
.  000 
widowed/separated/divorced  3  28  .  000  1.000 
DIAGNOSIS 
non-small  cell  1-  44  1.000 
.  000 
small  cell  2  17  .  000  1.000 
unspecified  3  20  .  000 
.  000 
FAMILY  SUPPORT 
never/almost  never  1  67  1.000 
.  000 
sometimes  25  .  000  1.000 
almost  always/always  39  .  000 
.  000 
CHILDREN  SUPPORT 
never/almost  never-  1  42  1.000 
.  000 
sometimes  24  .  000  1.000 
almost  always/always  3  35  .  000 
.  000 
DEPRIVATION  CATEGORY 
affluent  1  ',  16  .  000 
.  000 
middle  2  19  1.000 
.  000 
deprived  3  46  .  000  1.000 
Dependent  Variable..  Follow-up  Global  quality  of  life 
Constant  is  included  in  the  model. 
Beginning  Block  Number  1.  Method:  Enter 
Variable(s)  Entered  on  Step  Number 
I..  DEPCAT  Deprivation  Category 
EMPLOY  Employment  status 
TYPEHOM  Type  of  accommodation 
MARITAL  Marital  status 
DIAGNOS  Diagnosis 
TREATMEN  Types  of  treatment 
CHILHEL  Help  receiving  from  children 
FAMILYH  Help  receiving  from  family 
NEIGHBH  Help  receiving  from  neighbour 
-----------------------  Variables  in  the  Equation  -----------------------_-- 
Variable  B  S.  E.  Wald  df  Sig  R  Exp(B) 
DEPCAT  4.6858  2 
.  0960 
.  0785 
DEPCAT(1)  - 
1.5043  .  9720  2.3953  1 
.  1217 
,.  0596  4.5009 
DEPCAT(2)  2.0421"  .  9434  4.6857  1  .  0304 
.  1553  7.7065 
EMPLOY  2.3626  3  .  5006 
.  0000 
EMPLOY(1)  -1.7355  1.3651  1.6162  .  2036  .  0000  .  1763 
EMPLOY(2)  -.  4672  1.1473  .  1658...  .  6839 
.  0000  .  6268 
EMPLOY(3)  -.  0741  .  9922  .  0056  .  9404 
.  0000  .  9285 
TYPEHOM  4.5426  3 
.  2085 
.  0000 
TYPEHOM(l)  .  4038  .  8444  .  2287  1 
.  6325 
.  0000  1.4975 
TYPEHOM(2)  .  3350  .  8495  .  1555  1 
,... 
6933  .  0000  1.3979 
TYPEHOM(3)  -1.8170  1.2067  2.2674  1 
.  1321  -.  0490  .  1625 
MARITAL  5.5565  2 
.  0621 
.  1183 
MARITAL(1)  -.  9890  1.4685  .  4535  1  .  5007  .  0000  .  3720 
MARITAL(2)  -1.6854  -  .  7152  5.5528  1...  -  .  0185  -.  1787 
-  .  1854 
DIAGNOS  3.1604  2 
.  2059 
.  0000 
DIAGNOS(11  .  6851  .  7356  .  8673  1 
.  3517 
.  0000  1.9840 
DIAGNOS(2)  -1.5191  1.4528  1.0933  1 
.  2957 
.  0000  .  2189 
TREATMEN  4.61113  .  2026  .  0000 
TREATMEN(1)  1.6233  1.3278  1.4947  1 
. 
2215 
.  0000  5.0698 
TREATMEN(2)  -.  2304  .  7750  .  0883  1  .  7663  .  0000  .  7942 
TREATMEN(3)  -1.9733  1.3093  2.2716  1  .  1318  -.  0494  .  1390 
CHILHEL  '  .  0846-  2  .  9586'  .  0000 
CHILHEL(1)  .  1024  .  6472  .  0250  1  .  8743  .  0000  1.1078 
CHILHEL(2)  -.  2858  1.4285  .  0400  1  .  8414  .  0000  .  7514 
FAMILYH  4.3292  2  .  1148  .  0544 
FAMILYH(1)  1.4483  1.0217  2.0093  1  .  1563  .  0091  4.2558 
FAMILYH(2)  3.5853  1.7763  4.0741  1  .  0535  .  1365  36.0650 
NEIGHBH  .  7859  2  .  6750  .  0000 
NEIGHBH(l)  .  6692  .  8789  .  5798  1  .  4464  .  0000  1.9527 
NEIGHBH(2)  .  1145  1.3173  .  0076  1  .  9307  . 
0000  1.1213 
-,  ý 
"  {`5  "+" 
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The  remaining  9  patients  (4%)  who  found  being  interviewed  "not  very  or  not 
at  all"  acceptable,  stated  that  this  was  due  the'  following  reasons:  "It  was  too 
long"  (2  Patients),  "Because  of  my  health"  (3  patients),  "I  could  not  see  the 
relevance  of  the  questions  to  myself'  (2  patients),  "It  disturbed  me"  (1 
patient),  and  "I  just  did  not  like  it"  (1  patient). 
The  association  between  gender,  age,  deprivation  category,  diagnosis,  general 
health  status,  ,  global  quality  of,  life 
,  status,  and  interview  setting,  and  the 
patients'  preferences  and  the  reasons  they  stated  for  acceptability  were 
investigated.  These  are  shown  in  Tables  6.40  and  6.41.  There  were  no 
significant  associations  between  these  variables  except  for  age  where  there 
were  significant  differences  between  older  and  relatively  younger  patients  in 
the  reasons  they  gave  for  being  interviewed  acceptable. 
However,  the  evaluation  results  indicated  that:  patients  preferred  to  be 
interviewed  rather  than  to  fill  in  a  questionnaire,  and  that  interview  was 
acceptable  to  them  regardless  of  their  characteristics  including  socio- 
economic  status,  clinical  characteristics,  their  general  4ealth  status  and  global 
quality  of  life,  and  the  interview  setting.  Finally,  they  expressed  four  main 
reasons  for  the  acceptability  of  the  interviews.  All  these  are  considered  to  be 
components  of  an  effective  communication  indicating  that  understanding 
patients'  feelings  is  essential.  How  to  achieve  this  remains  the  major  question. 
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Table  6.39  Patients'  reactions  toward  the  study  (acceptability  questionnaire) 
Na 
Were  the  questions  easy  to  understand? 
very  easy  184  77 
moderately  easy  51  22 
not  very  easy  3  1 
not  at  all  000  00 
Did  you  find  the  questions  relevant? 
very  relevant  125  52 
moderately  relevant  92  39 
not  very  relevant  18  8 
not  at  all  3  1 
Do  you  prefer  to  fill  in  a  questionnaire  or  to  be 
interviewed? 
fill  in  a  questionnaire  23  10 
to  be  interviewed  168  70 
either  43  is 
don't  know  4  2 
Do  you  think  if  you  wanted  to  rill  in 
questionnaires,  you  might  had  difficulties? 
very  difficult  I1  5 
quite  difficult  27  11 
not  very  difficult  37  16 
not  at  all  163  69 
Do  you  find  being  interviewed  acceptable? 
very  acceptable  191  80 
quite  acceptable  38  16 
not  very  acceptable  7  3 
not  at  all  2  1 
Can  you  give  reasons? 
it  did  not  bother  me  56  24 
felt  at  ease  and  relaxed  62  26 
it  was  nice  to  talk  44  18 
it  was  conversational/the  way  of  interview  67  28 
other  reasons  (unacceptable)  9  4 
Do  you  prefer  to  be  interviewed  at  home  or  in 
the  clinic? 
clinic  55  23 
home  108  45 
either  71  28 
don't  know  4  2 
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Table  6.40  Patients'  preferences  by  their  demographic  characteristics, 
general  health  status,  global  quality  of  life,  and  interview  setting 
Fill  in  questionnaire  To  be  interviewed  Either  p 
(n=23)  (n-168)  (n-43) 
No.  (%)  No.  (%)  No.  (%) 
Sex 
male  15  (65)  89  (53)  28  (65) 
female  8  (35)  79(47)  15  (35) 
0.2 
Age 
65<  11(48)  72(43)  19(44) 
65>  12  (52)  96  (57)  24  (56) 
0.9 
Deprivation  category 
affluent  7(30)  40(24)  15  (35) 
deprived  16  (70)  128  (76)  28  (65) 
0.3 
Diagnosis 
lung  cancer  cases  10(44)  93  (55)  22  (51) 
respiratory  disease  controls  13  (56)  75  (45)  21(49) 
0.5 
General  health  status 
very  poor/poor  7  (30)  66  (39)  16(37) 
good  8(35)  53(32)  17(40) 
very  good/excellent  8  (35)  49  (29)  10(23) 
0.8 
Global  quality  of  life 
very  poor/poor  4  (17)  55  (33)  11(26) 
good  10(44)  57(34)  9(21) 
very  good/excellent  9(39)  56  (33)  23  (53) 
0.08 
Interview  setting 
home  8  (35)  38  (23)  14  (33) 
clinic  15  (65)  130  (77)  29(67) 
0.2 
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5.  Patients'  perceptions  of  quality  of  life 
Patients'  perceptions  of  quality  of  life  were  investigated.  Due  to  practical 
considerations  (patients'  time,  crowded  clinics,  etc.  ),  only  200  patients  were 
asked  to  define  quality  of  life,  to  identify  what  a  good  quality  of  life  is  for 
themselves,  and  to  indicate  the  importance  attached  to  the  components  parts  of 
their  quality  of  life.  Of  these,  108  were  cases  and  92  controls.  Fifty-six  percent 
(112)  of  the  patients  were  males  and  44%  (88)  females.  There  were  no 
significant  differences  between  cases  and  controls  in  socio-demographic 
characteristics  nor  with  the  original  sample  who  participated  in  the  study. 
5.1.  Definition  of  quality  of  life  by  patients 
When  patients  were  asked  to  define  quality  of  life,  contradictory  to 
expectation  they  identified  a  limited  number  of  areas  of  life.  In  total  8  areas  of 
life  were  extracted  from  patients'  responses.  All  patients  identified  at  least  one 
aspect  of  life,  87%  two  dimensions  of  life,  59%  mentioned  three  areas,  while 
only  21%  nominated  four  dimensions  of  life  as  definition  of  the  quality  of  life. 
The  highest  proportion  of  respondents  (42%)  mentioned  "health"  as  a 
definition  of  quality  of  life  while  only  5%  of  patients  indicated  that  "living 
longer"  mean  quality  of  life.  There  was  no  significant  difference  between 
cases  and  controls  in  most  dimensions  except  in  financial  security.  The 
controls  tend  significantly  to  consider  financial  security  as  one  of  the 
components  of  quality  of  life  more  than  cases.  In  contrast,  although  not 
significant,  the  cases  tended  to  nominate  health,  happiness,  and  survival  more 
and  family  life  less  than  controls  (Table  6.42). 
5.2.  A  good  quality  of  life  as  perceived  by  patients 
Respondents  were  asked  to  identify  what  a  good  quality  of  life  is  for 
themselves.  "Family  life",  was  mentioned  by  58%  of  the  respondents  as  an 
area  that  makes  life  better  for  them.  In  second  place  their  "own  health"  was 
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nominated  (51%),  and  "social  life"  by  43%.  Although  there  was  no  significant 
difference  between  cases  and  controls,  cases  mentioned  health  more  than 
controls  as  an  area  that  make  their  quality  of  life  better.  It  is  worth  noting  that 
when  cases  were  asked  to  define  quality  of  life  in  general  they  did  mention 
family  life  less  than  controls,  but  when  they  described  their  own  quality  of  life 
they  considered  family  life  as  important  as  their  own  health  (Table  6.43). 
5.3.  Order  of  importance 
Finally,  patients  were  asked  to  rank  nominated  items  in  order  of  importance. 
The  overall  results  are  shown  in  Table  6.44.  The  highest  proportion  of  patients 
nominated  family  life  as  the  most  important  factor  (27%),  followed  by  their 
own  health  (25%).  Health  was  mentioned  as  the  second  most  important  factor 
(21%),  followed  by  family  life  (18%),  and  financial  security  (18%).  This, 
however,  clearly  suggests  that  family  life  and  health  were  the  most  or  second 
most  important  factors.  As  described  earlier,  most  patients  considered  that  a 
good  quality  of  life  depends  on  only  two  factors.  In  contrast,  only  half  the 
patients  or  less  identified  third  and  fourth  factors.  For  example,  in  relation  to 
the  fourth  important  factor  for  a  good  quality  of  life  the  highest  proportion  of 
patients  nominated  social  life  (27%),  followed  by  happiness  (17%),  and 
enjoyment  of  life  (15%). 
The  stratified  analysis  indicated  that  in  almost  all  nominated  areas  there  were 
no  significant  differences  between  cases  and  controls.  Twenty  eight  cases  and 
26  controls  nominated  "family  life"  as  the  most  important  factor  of  a  good 
quality  of  life,  followed  by  their  own  health  (32  cases  and  18  controls).  Health 
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is  placed  second  by  22  cases  and  14  controls,  followed  by  family  life  (20  cases 
and  12  controls,  and  financial  security  (15  cases  and  17  controls).  The  results 
are  shown  in  Table  6.45. 
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Introduction 
This  chapter  discusses  the  study  findings  and  provides  explanations  relevant 
to  quality  of  life  in  patients  with  lung  cancer.  First,  a  general  discussion  is 
provided  and  then  based  on  the  study  findings,  several  topics  are  covered  and 
presented  in  the  following  sections. 
1.  General  discussion 
1.1  The  study  findings 
There  were  several  major  findings  in  this  study,  including  the  following:  - 
"  Global  quality  of  life  prior  to  diagnosis  was  a  predictor  of  length  of 
survival  in  lung  cancer  patients. 
"  There  was  a  difference  between  patients'  and  health  professionals' 
perception  of  quality  of  life 
"  There  was  no  significant  difference  between  the  socio-demographic 
characteristics  of  lung  cancer  cases  and  chronic  respiratory  disease 
controls. 
.  There  were  no  significant  differences  between  quality  of  life  in  cases  and 
controls  except  for  pain  and  loss  of  appetite. 
"  There  was  no  significant  difference  in  quality  of  life  of  lung  cancer 
patients  before  and  after  treatment. 
.  Social  support,  social  networks,  and  patients'  socio-economic  background 
were  found  to  be  important  determinants  of  their  baseline  quality  of  life. 
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is  Non-medical  factors  (Deprivation  Category  and  marital  status)  were  found 
to  be  significant  predictors  of  patients'  global  quality  of  life  at  follow-up, 
whereas  medical  factors  (cell  type  and  treatment  modalities)  were  not. 
"  Patients'  reactions  to  the  study  indicated  that  they  did  not  find  the  study 
intrusive.  However,  they  preferred  to  be  interviewed  at  home  rather  than  to 
fill  in  a  questionnaire  in  the  clinic. 
The  implications  of  the  above  findings  in  research,  and  management  of  lung 
cancer  are  explored  in  the  following  sections. 
1.2.  Quality  of  life 
Quality  of  life  is  difficult  to  define  and  varies  among  individuals.  The  findings 
of  this  study  are  advances  in  the  debate.  For  example,  most  recent  quality  of 
life  measures  are  developed  within  the  framework  proposed  by  the  European 
Organisation  for  Research  and  Treatment  of  Cancer  (EORTC)  which  has  its 
own  merit,  especially  since  it  is  necessary  to  provide  a  "common  language" 
and  prevent  haphazard  developments.  Yet,  these  instruments  carry  health 
professionals'  value  systems  rather  than  the  values  and  preferences  of  the 
public  including  healthy  individuals  and  patients. 
The  most  interesting  results  in  this  study  relate  to  the  role  of  family,  and 
importance  of  social  life,  leisure  activities  and  financial  security  in  patients' 
quality  of  life.  These  are  vital  issues  and  are  often  neglected  in  most  of  the 
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well-known  measures  of  quality  of  life  or  have,  at  best,  received  little 
attention.  Most  instruments  focus  on  health,  concentrate  on  feelings,  functions 
and  problems  associated  with  the  ill  health,  disability  or  disease.  This  study 
and  several  recent  studies  clearly  suggest  that  these  instruments  should  either 
be  reviewed  or  supplemented  with  additional  items  covering  family,  social 
life,  leisure  activities  and  other  areas  identified  in  this  study  and  other  studies. 
The  other  interesting  finding  in  this  study  was  that  patients  defined  quality  of 
life  in  one  way,  and  perceived  a  good  quality  of  life  for  themselves  in  another 
(Tables  6.42  and  6.43).  In  addition,  their  values  were  very  different  from 
those  of  health  professionals  as  found  from  the  literature,  and  most  existing 
quality  of  life  instruments.  The  number  of  available  quality  of  life  instruments 
is  a  reflection  of  such  differences,  where  expert-developed  tools  still  mainly 
focus  on  disease  or  treatment-related  symptoms.  In  terms  of  understanding  the 
complexity  of  the  individual  value  system  and  preferences,  these  differences 
are  noteworthy.  The  recent  studies  on  development  of  a  new  instrument,  the 
Subjective  Quality  of  Life  Profile  (SQLP),  confirms  that  these  differences  are 
real  and  should  be  understood  on  the  basis  of  difference  in  individuals'  values, 
that  is,  the  importance  they  attribute  to  each  area  of  their  lives  (Dazord,  1995). 
Delivery  of  effective  care  requires  a  much  better  understanding  of  patients' 
views  (Montazeri  et  al.,  1996c).  The  majority  of  patients  in  this  study  were 
from  deprived  areas,  with  low  levels  of  education  and  yet  it  seemed  that  they 
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had  wider  and  different  views  about  life  and  its  quality  as  compared  to  the 
clinicians  who  mainly  relate  quality  of  life  to  medical  dimensions  of  patients' 
daily  activities,  neglecting  the  other  important  aspects  of  their  lives. 
However,  there  are  two  major  problems  associated  with  this  and  other  studies 
on  the  subject.  First,  the  problem  of  change  over  time  and  the  course  of 
disease,  since  the  perception  of  patients  may  change  over  time.  For  example, 
the  wish  for  survival  (which  was  low  in  this  study,  9  out  of  200  patients,  also 
see  Table  6.42)  may  become  more  important  than  other  items  near  the  end  of 
life  (which  was  not  studied  because  the  study  was  not  designed  for  this 
purpose,  and  usually  at  this  stage  patients  are  very  ill  and  it  is  very  difficult  to 
ask  them  their  views).  Second,  the  problem  related  to  the  flexibility  of  the 
individual  judgement  due  to  fluctuating  defence  mechanisms  (Jenkinson, 
1994a).  For  example,  one  may  argue  that  the  relatively  low  rating  of  "one's 
own  health"  as  an  important  factor  of  quality  of  life  (see  Tables  6.43,  and 
6.44)  may  be  an  expression  of  denial  of  the  threat  that  cancer  and  its  treatment 
represents  to  the  individual.  Denial  may  fluctuate  over  the  course  of  disease 
and  a  patient  may  learn  to  live  with  the  threat.  Then,  "one's  own  health"  may 
become  a  very  important  domain. 
The  main  difference  in  this  study  from  previous  work  rests  on  the  fact  that  it 
was  observed  that  a  relatively  small  number  of  patients  identified  more  than 
three  areas  of  life  as  important  components  of  quality  of  life  or  they  perceived 
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to  be  important  for  their  own  quality  of  life.  One  explanation  is  that  in  this 
study  patients  did  not  receive  any  instructions  such  as  showcards  or  a  list  of 
suggested  dimensions  of  life  which  were  often  used  in  other  studies  (Ruta  et 
al.,  1994;  Bowling,  1995b).  This  however,  indicates  that  showcards  may  to 
some  extent  create  biased  results.  This  study  included  two  general  but  simple 
principles:  patients  were  allowed  to  identify  the  items  that  affect  their  quality 
of  life,  and  were  invited  to  rate  the  relative  importance  of  these  items  to  their 
quality  of  life. 
As  compared  to  controls,  cases  were  more  concerned  about  their  own  health. 
This  is  not  surprising  since  the  cases  were  newly  diagnosed  lung  cancer 
patients.  However,  they  were  concerned  about  family  as  much  as  their  own 
health.  These  findings  are  similar  to  previous  and  current  studies  (Bowling, 
1995b;  Belli  et  al.,  1996)  where  family  was  the  most  important  item  rated  by 
either  general  public,  or  patients  with  different  types  of  diseases  including 
cancer  patients. 
1.3.  Methodological  issues 
This  is  the  first  epidemiological  based  study  to  measure  health-related  quality 
of  life  in  patients  with  lung  cancer.  Eight  criteria  in  this  study  were  brought 
together  that  had  not  been  previously.  Although  these  have  been  listed  in  the 
introduction,  it  is  worthwhile  to  remind  readers  once  again  of  these  criteria: 
1.  Quality  of  life  was  the  main  outcome  measure. 
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2.  It  was  a  population-based  study  over  a  full  year  rather  than  a  clinic- 
based  study. 
3.  It  was  a  prospective  case-control  study. 
4.  At  the  baseline  assessment  of  quality  of  life  both  patients  and 
interviewer  were  blind  to  the  diagnosis. 
5.  There  was  a  detailed  investigation  of  the  socio-economic  status  of 
patients. 
6.  The  assessment  was  made  using  an  interviewer-administered  approach. 
7.  The  data  were  obtained  either  at  patients'  home  or  in  the  clinic. 
8.  Patients'  attitudes  toward  the  study  were  examined. 
This  was  a  double  blind  study.  At  the  time  of  baseline  assessment  of  quality  of 
life,  the  intention  was  to  keep  patients  and  the  researcher  blind  to  the 
diagnosis.  At  the  start  of  the  investigation  it  was  thought  this  might  not  be 
practicable.  The  investigator  was  able  to  interview  208  patients  (87%)  blind, 
less  than  intended.  From  this,  two  major  methodological  issues  became  clear. 
Firstly,  it  was  shown  that  it  was  possible  to  conduct  a  double-blind  case- 
control  assessment  of  quality  of  life.  This  was  apparently  the  first  time  this  has 
been  carried  out.  The  advantage  of  this  method  of  data  collection  is  that  it 
reduces  both  interviewee  and  interviewer  bias.  The  only  study  in  the  literature 
similar  in  design  to  this  project  was  that  of  Hughes  (1985a;  1985b).  Although 
that  was  a  prospective  case-control  study,  neither  patients  nor  the  researcher 
were  blind,  and  it  was  primarily  a  psychiatric  assessment  rather  than  a  quality 
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of  life  study  (see  Table  3.2).  Secondly,  until  now  it  was  not  clear  whether 
knowledge  of  cancer  diagnosis  could  affect  the  way  in  which  patients  respond 
to  the  quality  of  life  questionnaires  or  not.  This  was  examined  and  it  was 
found  that  knowledge  of  cancer  diagnosis  does  not  significantly  affect  the 
results. 
Another  feature  of  this  study  was  the  addition  of  a  study  to  find  out  reactions 
of  patients  to  having  their  quality  of  life  examined.  Having  searched  the 
literature  thoroughly,  this  appears  to  be  the  first  systematic  evaluation  of 
patients'  feelings  about  quality  of  life  studies  in  cancer,  since  previous 
researchers  have  mainly  reported  on,  for  example,  the  proportion  of  patients 
who  completed  the  scheduled  questionnaires  as  an  indicator  of  acceptability  or 
feasibility  in  conducting  quality  of  life  assessments  in  clinical  settings  (Hurny 
et  al.,  1992). 
Surprisingly  there  were  no  refusals  at  the  time  of  baseline  assessment.  Missing 
cases  resulted  in  a  response  rate  of  89%.  At  follow-up  assessments,  out  of  90 
patients  who  were  suitable  for  interview,  only  8  patients  refused  to  participate. 
Again,  the  response  rate  was  high  (91  %). 
More  interestingly,  there  were  no  refusals  from  GPs  both  at  baseline  and 
follow-up  assessments  of  patients'  quality  of  life.  This  was  due  to  several 
reasons  such  as  prior  discussion  with  their  representatives,  the  contribution  of 
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the  study  co-ordinator  to  seek  their  agreement  for  each  interview,  and  the 
importance  of  the  research  topic  which  is  one  of  the  main  public  health 
problems  in  the  area  with  a  50%  higher  incidence  rate  of  lung  cancer  than  the 
Glasgow  average. 
There  are  several  reasons  for  the  high  response  rates  in  this  study,  both  at 
baseline  and  at  follow-up.  First,  the  General  Practitioners  (GPs)  in  the  Stobhill 
catchment  area  were  well  informed  about  the  study.  Prior  to  the  start  of  the 
study  all  agreed  that  their  potential  patients  could  be  interviewed.  The  study 
had  a  high  profile  for  GPs  in  Stobhill  catchment  area.  Secondly,  the  chest 
physicians  in  the  Stobhill  Hospital  were  very  interested  in  the  project  and  they 
encouraged  recruitment  of  patients  into  the  study.  For  example,  during  the 
study  period  several  times  they  forgot  on  several  occasions  to  talk  to  the 
patients  about  the  study  during  the  medical  examination  in  their  clinics,  but  to 
include  these  missing  patients  in  the  study,  physicians  followed  them  through 
the  out-patient  department  explaining  about  the  study  and  asked  if  they 
wished  to  participate  in  the  study.  There  was  also  a  good  relationship  between 
researcher  and  nursing  staff,  both  in  the  out-patient  department  and  in  the 
ward.  This  led  the  researcher  to  have  much  easier  access  to  patients  and  the 
opportunity  to  talk  them  and  ask  for  their  consent.  Finally,  because  the 
researcher  was  not  a  native  investigator,  patients  may  have  wanted  to  co- 
operate  more  than  usual.  The  influence  of  researchers'  '  social  and  ethnic 
background  and  gender  in  outcome  of  interviewer-administered  studies  has 
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been  acknowledged  (Streiner  and  Norman,  1995).  For  example,  it  has  been 
observed  that  female  interviewers  usually  had  fewer  refusals  and  higher 
completion  rates  than  males. 
These  high  response  rates  are  important  in  supporting  the  robust  nature  of  the 
findings,  since  difficulties  with  data  collection  and  low  compliance  with 
quality  of  life  studies  among  patients  appear  to  be  the  most  significant  barriers 
to  the  successful  implementation  of  quality  of  life  investigations  in  clinical 
research  (Aaronson,  1991).  For  example,  Ganz  et  al.  (1989)  described  their 
experiences  in  a  quality  of  life  study  of  patients  with  lung  cancer  in  a  clinical 
trial  and  acknowledged  that  the  quality  of  life  data  from  the  trial  was  not 
suitable  for  evaluation  because  of  poor  quality  and  low  response.  Similar 
problems  were  reported  in  an  EORTC  study  of  patients  with  prostate  cancer, 
29  centres  randomised  171  patients  and  only  13  centres  participated  in  the 
complementary  quality  of  life  study,  randomising  a  total  of  90  patients.  Only 
72  of  these  patients  completed  baseline  questionnaire  and  only  43  patients  had 
at  least  one  post-treatment  questionnaire  (Fossa  et  al.,  1990).  As  one  might 
realise  here,  the  number  of  patients  in  the  trial  is  not  the  focus  of  discussion, 
but  the  emphasis  is  on  a  low  response  rate  in  the  quality  of  life  study. 
It  is  argued  that  there  are  five  possible  obstacles  in  collection  of  quality  of  life 
data.  These  were  identified  by  the  US  National  Cancer  Institute  (Yancik  et  al., 
1989);  administration  of  questionnaires  which  were  too  long,  variability 
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related  to  the  severity  of  patients'  illness,  variability  of  co-operation  with 
quality  of  life  studies  by  clinical  staff,  variability  of  the  place  of  the  interview, 
and  institutional  variables  (problems  of  the  data  collection).  Another  example 
of  poor  compliance  with  quality  of  life  assessment  was  reported  by  the  Swiss 
Group  for  Clinical  Cancer  Research  (Hurny  et  al.,  1992),  who  called  it  "a 
lesson  from  the  real  world".  Their  multicentre  trial  comparing  two  different 
chemotherapy  regimens  in  patients  with  small-cell  lung  cancer  recruited  188 
patients.  Their  compliance  rate  varied  between  21%  and  68%  among  the 
seven  participating  centres.  They  found  that  patients'  age,  sex,  education  and 
biological  prognostic  factors  were  not  predictors  of  compliance,  while  only 
institutional  variables  were  significant  factors  predicting  compliance. 
In  contrast,  extremely  high  compliance  rates  (95%)  have  been  reported  by  the 
Canadian  Clinical  Trials  Group  (Sadura  et  al.,  1992)  from  three  of  their 
current  trials  on  malignant  melanoma,  breast  cancer  and  on  the  effects  of  two 
antiemetics.  Their  success  have  been  attributed  to  a  set  of  specific  measures 
including  implementation  of  a  pre-trial  workshop  for  the  medical  staff  on  the 
procedure  of  data  collection. 
Above  all,  the  data  in  this  study  were  collected  by  means  of  interviewer- 
administered  approach.  This  even  by  itself  explains  why  the  response  rates 
were  high.  There  were  no  incomplete  questionnaires  at  all,  nor  was  there  any 
missing  information.  Thus,  no  individual  data  were  discarded. 
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The  interview  allowed  the  researcher  to  have  a  better  understanding  of 
patients'  concerns  and  on  the  other  hand,  helped  patients  to  understand  the 
study  and  purposes  of  the  investigation.  It  is  clear  that  when  one  leaves  a 
patient  alone,  especially  an  elderly  patient  with  a  low  educational  level,  and 
asks  him  or  her  to  complete  a  questionnaire,  the  quality  of  such  data  is 
questionable  despite  the  fact  that  the  interview  approach  may  also  carry  other 
drawbacks.  The  emphasis  here  is  to  show  why  interview-administered  method 
in  studies  such  as  quality  of  life  in  lung  cancer  patients  in  a  population  of 
elderly  people  usually  of  low  social  class  is  a  better  approach. 
It  is  essential  that  interviewers  are  properly  trained  in  order  to  reduce  bias  and 
that  questions  are  structured  in  order  to  avoid  ambiguity  (Bowling,  1995a). 
Prior  to  the  commencement  of  this  study,  practical  skills  in  these  areas  were 
acquired  through  participation  in  the  Tak  Tent  cancer  support  group  (see 
Appendices  I  and  II).  In  addition,  the  investigator  applied  himself  diligently  to 
the  study,  making  use  of  interpersonal  and  communication  skills  which  played 
a  major  role  in  this  project  to  be  conducted  successfully. 
1.4.  What  should  be  assessed? 
Studying  quality  of  life,  especially  in  patients  with  life  threatening  diseases 
such  as  cancer  is  becoming  increasingly  important.  It  is  argued  that  such 
understanding  may  help  to  deliver  effective  and  efficient  health  care. 
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As  many  researchers  seek  to  include  quality  of  life  measurements  in  their 
investigations,  the  initial  question  is:  what  should  be  assessed?  The  literature 
suggests  that  to  have  a  comprehensive  assessment  of  quality  of  life  in  cancer 
patients  it  is  better  to  use  one  generic  measure,  one  disease  specific  instrument 
and  one  study  specific  questionnaire  (Jonsson,  1987).  This,  however  has 
advantages  and  disadvantages.  While  including  different  instruments  in  a 
study  may  help  to  examine  a  broader  concept  of  quality  of  life,  administration 
of  lengthy  instruments  could  be  burdensome  both  to  patients  and  researchers. 
Such  a  problem  could  be  solved  by  using  simple  and  short  questionnaires. 
Thus,  in  this  project  to  provide  a  comprehensive  assessment,  three  valid, 
simple  and  short  instruments  were  chosen. 
The  use  of  the  NHP  alongside  the  EORTC  questionnaires  provided  useful 
information  to  interpret  the  results.  In  fact,  the  NHP  provided  a  very  realistic 
picture  of  patients'  general  health  status.  For  example,  it  showed  a  clear 
pattern  of  difference  between  health  status  of  patients  with  different  socio- 
economic  backgrounds  (Figure  6.4).  The  EORTC  quality  of  life 
questionnaires  were  also  appropriate  for  study,  since  according  to  the 
literature  (e.  g.,  Bowling,  1995a)  they  are  among  the  best  developed 
instruments  for  measuring  quality  of  life  in  patients-with  cancer. 
However,  one  may  argue  that  since  the  response  categories  on  NHP  are 
restricted  to  "yes"  and  "no",  this  may  result  in  losing  some  useful  information. 
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For  example,  if  a  patient  wants  to  respond  he  or  she  may  become  fatigued 
(one  of  the  NHP  questions),  there  is  no  option  of  saying  "sometimes". 
However,  an  apparent  danger  of  inclusion  of  an  extra  response  category  is  the 
likelihood  that  patients  would  always  lean  towards  "sometime".  In  this  regard 
therefore,  the  two  existing  response  categories  (yes  and  no)  would  be  an 
advantage.  Yet  the  question  remains,  how  could  one  possibly  resolve  this 
issue.  Replacing  the  NHP  with  one  of  emerging  generation  of  new  general 
health  measures  such  as  the  Medical  Outcomes  Study  Short  Form  36-item 
questionnaire  (known  as  SF-36,  a  new  general  health  measure)  is  definitely 
not  the  solution,  because  SF-36  also  has  its  own  limitations  such  as  low 
internal  reliability  of  the  "general  health"  and  "mental  health"  scales;  has 
difficult  questions  to  answer;  and  lacks  sensitivity  to  change  over  time  (Hill  et 
al.,  1996;  Jenkinson  et  al.,  1996). 
In  addition  to  loss  of  useful  information,  this  problem  equally  makes  the 
analysis  of  the  data  obtained  difficult.  The  difficulty  usually  arises  because 
such  data  are  not  normally  distributed  and  many  patients  were  at  extremes 
(Appendix  XIV).  This  was  the  reason  why  in  this  study  non-parametric  tests 
were  used.  The  most  interesting  feature  of  the  NHP  was  that  patients  found  it 
very  easy  to  understand  and  felt  at  ease  with  the  questions. 
The  EORTC  questionnaires  in  turn,  were  very  specific  and  therefore  at 
baseline  (pre-diagnosis)  interview  some  patients  were  surprised  by  the 
262 Discussion 
questions,  for  example  about  hair  loss  or  sore  mouth.  Furthermore,  it  was 
found  that  some  questions  do  not  make  sense  for  patients  in  the  UK  setting, 
for  example  the  question  about  financial  difficulties.  Most  elderly  people  were 
more  or  less  in  the  same  financial  positions.  In  other  words,  the  EORTC 
questionnaire  is  limited  in  indicating  patients'  needs  with  regard  to  financial 
difficulties,  or  even  issues  relating  to  the  patients'  family  and  social  life.  The 
wording  of  the  questions  are  inadequate  and  that  they  are  unlikely  to  identify 
patients'  needs  in  this  way.  In  addition,  it  was  found  that  the  EORTC 
questionnaires  were  not  very  specific  to  cancer  or  lung  cancer  as  intended, 
since  they  could  not  clearly  differentiate  between  controls  and  lung  cancer 
cases. 
1.5.  How  to  influence  clinical  practice 
One  of  the  challenging  issues  in  measuring  quality  of  life  relate  to  such 
practical  considerations  as,  whether  it  is  possible  to  use  these  measures 
routinely  in  day-to-day  practice,  or  how  quality  of  life  investigators  may 
influence  clinicians  to  use  these  measures  in  their  practices.  Some  of  the 
barriers  have  already  been  discussed  in  chapter  2,  section  3.6. 
To  overcome  these  problems  one  might  consider  the  following 
suggestions: 
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1.  Quality  of  life  data  should  be  collected  based  on  robust  methodological 
approaches  to  convince  clinicians  that  the  information  provided  by  these 
studies  is  valid. 
2.  Findings  from  quality  of  life  studies  should  be  disseminated  to  clinicians 
and  must  be  presented  in  simple  and  clear  ways.  Complicated  presentations 
of  data  make  clinicians  ignore  findings  because  they  might  think  that  these 
findings  are  just  manipulating  data  rather  than  real  patient-centred 
measures  of  health  care  and  clinical  outcomes. 
3.  There  should  be  short  and  easy-to-use  questionnaires  to  allow 
administration  in  busy  clinics.  Asking  clinicians  to  assess  quality  of  life 
comprehensively  to  meet  all  standard  criteria  is  not  realistic,  since 
clinicians  have  limited  time  even  for  satisfactory  management  of  their 
patients. 
4.  Quality  of  life  issues  should  be  recorded  in  case  notes  as  part  of  good 
clinical  practice.  This  may  help  clinicians  find  out  valuable  information 
and  enhance  their  communication  with  'their  patients  by  obtaining  such 
information. 
2.  Study  population 
2.1.  Representativeness 
The  findings  in  the  study  give  an  insight  to  the  characteristics  of  study 
population  including  lung  cancer  cases  and  patients  with  chronic  respiratory 
disease.  As  it  was  demonstrated  except  for  two  variables  (age,  and  children 
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support),  in  all  other  variables  studied  their  characteristics  were  similar.  In 
other  words,  the  study  findings  indicate  that  not  only  lung  cancer  patients,  but 
also  patients  with  chronic  respiratory  disease  are  those  who  mostly  live  in 
deprived  areas  in  rented  high  rise  flats,  about  40%  living  alone,  suffering  from 
a  weak  social  network  and  social  support  system. 
Since  the  study  population  were  elderly  patients,  it  could  be  well  explained 
why  some  characteristics  of  patients  differed  from  that  of  national  norms,  for 
example,  car  ownership,  educational  level,  and  employment  status.  However, 
compared  with  local  figures  (these  are  figures  from  the  northern  sector  of 
Glasgow,  see  Table  6.2  and  6.5),  it  seems  that  patients'  characteristics  in  this 
study  were  a  true  reflection  of  the  community  in  which  they  lived. 
Comparing  the  characteristics  of  the  1995  lung  cancer  patients  in  this  study 
with  those  registered  from  the  Stobhill  catchment  area  in  1994,  again  there 
was  a  reasonable  similarity  indicating  that  the  sample  was  representative  (see 
Tables  5.4  and  6.2). 
2.2.  Missing  cases 
There  were  13  cases  excluded  from  the  study  and  18  cases  who  were  missing 
(overall,  31  lung  cancer  cases).  In  Table  5.1  it  is  clear  that  there  were  no 
significant  differences  between  lung  cancer  patients  in  the  study  and  those 
who  were  excluded  or  missed.  For  example,  since  14  of  these  cases  had 
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unspecified  lung  cancer,  it  is  unlikely  to  expect  any  changes  in  the  results 
where  the  analysis  was  based  on  patients'  cell  type.  Thirteen  cases  were 
excluded  because  they  had  their  treatment  before  any  assessment  was  made. 
Thus,  to  adhere  to  the  study  protocol  they  were  excluded.  Excluding  such  a 
small  number  of  patients  would  not  make  any  difference  in  the  results. 
2.3.  Characteristics  of  cases  and  controls 
Two  characteristics  were  significantly  different  between  cases  and  controls. 
The  controls  tended  to  be  relatively  younger  (p  =  0.02,  Table  6.2)  and 
received  less  support  from  their  children  as  compared  to  lung  cancer  patients 
(p  =  0.007,  Table  6.3). 
Lung  cancer  patients  were  older  and  probably  reflecting  the  fact  that  lung 
cancer  is  the  disease  of  elderly  people.  Thus,  in  this  respect,  the  study  finding 
is  not  unexpected. 
Receiving  less  support  as  mentioned  by  controls  may  possibly  relate  to  being 
younger  and  able  to  manage  their  own  affairs  and  not  needing  help,  or  that 
they  had  chronic  disease  and  their  children  might  have  been  tired  of 
supporting  and  helping  them.  Finally,  contradictory  to  the  first  explanation,  it 
might  be  that  the  expectations  of  these  patients  were  higher  than  lung  cancer 
patients  considering  that  lung  cancer  cases  were  newly  diagnosed  and  did  not 
have  any  previous  experience  of  being  seriously  ill.  Such  an  argument  can  be 
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supported  by  the  data  where  it  was  found  that  lung  cancer  cases  had 
significantly  less  comorbidity  as  compared  to  the  controls  (see  Table  6.2).  The 
hospital  admission  was  used  as  a  proxy  of  comorbidity,  although  the  time 
frame  was  limited  only  to  one  year  prior  to  the  baseline  interview  and  might 
not  reflect  a  true  picture  of  the  lung  cancer  patients'  comorbidity. 
2.4.  Social  support 
One  of  the  most  important  findings  in  the  study  relates  to  the  fact  that  most 
patients,  both  lung  cancer  cases  and  chronic  respiratory  disease  controls, 
reported  that  they  did  not  receive  any  support  from  their  children,  families  and 
neighbours. 
Social  support  not  only  has  an  effect  on  adaptation  after  life  events,  but  can 
also  lead  to  a  reduction  of  health  problems  because  of  more  skill  in  avoiding 
and  coping  with  problems  (Wortman,  1984;  Cohen  and  Wills,  1985). 
There  are  two  explanations  of  social  support  and  its  relation  to  health:  the 
direct  effects  and  buffering  hypothesis.  The  former  identifies  social  support  as 
being  beneficial  both  during  normal  life  and  illness  while  the  later  argues  it  is 
beneficial  only  during  stressful  life  events. 
Direct  or  buffering  processes  are  established  in  empirical  research  when 
different  concepts  and  types  of  measurement  of  social  support  are  used.  Direct 
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effects  tend  to  be  found  when  support  is  measured  by  the  degree  to  which  a 
person  is  integrated  within  a  social  network,  while  buffering  effects  tend  to  be 
shown  when  support  is  indicated  by  the  availability  of  resources  that  help  one 
respond  to  stressful  events  (Northouse,  1989). 
Surprisingly  until  now  there  is  no  investigation  about  social  support  and  its 
relation  to  the  quality  of  life,  although  the  support  needs  of  cancer  patients 
have  been  studied  extensively  (e.  g.,  Broadhead  and  Kaplan,  1991,  Kobasa  et 
al.,  1991). 
In  this  study  the  relationship  between  social  support  and  quality  of  life  as 
measured  by  the  NHP  and  the  EORTC  QLQ-C30  was  examined  and  it  was 
found  that  social  support  variables  are  good  predictors  of  patients'  baseline 
quality  of  life.  This  will  be  discussed  in  more  detail  in  the  following  sections. 
3.  Baseline  quality  of  life 
At  baseline  assessments  (pre-diagnosis)  there  were  three  important  findings: 
first,  there  were  no  significant  differences  between  cases  and  controls, 
secondly  less  affluent  patients  had  poorer  quality  of  life,  and  finally  the  study 
of  the  relationship  between  quality  of  life  and  patients'  socio-economic 
characteristics  showed  significant  relationships  between  these  variables  and 
baseline  quality  of  life. 
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3.1.  Quality  of  life  in  cases  and  controls 
Baseline  quality  of  life  as  measured  by  the  NHP  and  the  EORTC 
questionnaires  showed  no  significant  differences  between  cases  and  controls. 
However,  some  differences  were  observed.  These  were  in  the  expected 
directions.  For  example,  cases  had  more  pain  since  lung  cancer  is  a  painful 
disease,  and  had  more  physical  mobility  problems  because  they  were  older.  In 
contrast,  chronic  respiratory  disease  controls  had  more  problems  with  energy 
and  social  isolation  because  of  dyspnoea  (Table  6.6). 
It  became  clear  that  the  NHP,  and  the  EORTC  questionnaires  (to  a  large 
extent),  could  not  differentiate  between  these  two  groups  of  patients  with 
sufficient  clarity,  although  they  highlighted  some  small  differences  between 
the  two  groups  (e.  g.  pain,  energy,  loss  of  appetite,  etc.  ).  There  are  several 
other  instruments  to  measure  quality  of  life  in  patients  with  chronic 
respiratory  disease  (see  for  example,  Curtis  et  al.,  1994).  The  fact  that  the 
chronic  respiratory  disease  controls  received  the  EORTC  questionnaires 
which  may  not  have  been  specific  to  their  conditions,  may  explains  the  failure 
to  demonstrate  statistically  significant  differences  between  these  two  groups. 
However,  if  different'  instruments  were  used  for  the  two  groups,  then 
comparison  between  them  would  have  been  fundamentally  flawed. 
Other  explanations  may  relate  to  the  selection  of  control  group.  The  question 
is,  could  the  selection  of  the  control  group  have  biased  the  outcome? 
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In  principle,  there  were  three  possibilities  for  the  selection  of  controls:  general 
population,  other  cancer  patients,  patients  with  respiratory  disease. 
Firstly,  selection  of  a  sample  of  the  general  population  has  some  inherent 
limitations,  especially,  since  the  administration  of  the  EORTC  questionnaires 
to  such  a  sample  would  be  problematic  on  methodological  grounds.  Secondly, 
selection  of  a  sample  of  patients  with  other  types  of  cancers  also  has 
limitations,  in  the  sense  that  it  would  be  largely  impracticable,  and  would 
result  in  conflicting  findings  since  most  of  their  symptoms  and  difficulties 
would  be  different.  Thirdly,  selection  of  a  sample  of  patients  with  similar 
symptoms  to  lung  cancer  at  presentation,  and  attending  the  same  department 
while  at  the  same  time,  keeping  the  researcher  blind.  This  had  advantages 
over  the  above  mentioned  possibilities,  and  was  therefore,  chosen  for  this 
study.  Thus,  the  issue  of  selection  of  inappropriate  controls  could  be  rejected. 
On  the  other  hand,  the  lack  of  significant  differences  between  these  groups, 
does  not  necessarily  reflect  inadequacy  of  the  questionnaires,  but  indicates 
that  quality  of  life  at  baseline  assessment  in  the  two  groups  was  very  similar. 
Both  suffered  from  low  levels  of  quality  of  life,  and  this  indeed,  shows  that 
assessment  of  quality  of  life  is  not  only  important  for  lung  cancer  patients,  but 
also  for  patients  with  chronic  respiratory  disease,  and  indeed  for  all  patients 
with  all  diseases! 
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Finally,  comparing  symptoms  in  lung  cancer  patients  with  chronic  respiratory 
disease  controls  as  measured  by  the  EORTC  QLQ-C30,  and  QLQ-LC13,  it 
was  found  that  lung  cancer  patients  had  significantly  more  pain  and  loss  of 
appetite.  These  findings  are  not  unexpected,  since  most  studies  of  symptoms 
in  cancer  patients  have  reported  that  pain  was  the  commonest  symptom  in 
advanced  cancer  (Curtis  et  al.,  1991).  Furthermore,  the  nature  of  pain  in  lung 
cancer  patients  and  patients  with  chronic  respiratory  disease  is  totally 
different.  The  most  frequent  aetiology  of  pain  in  lung  cancer  patients  is  bone- 
related  pain,  while  in  chronic  respiratory  disease  it  relates  to  muscular  pain 
(Cleeland  and  Syrjala,  1992). 
Suffering  from  pain  is  one  of  the  major  concerns  of  lung  cancer  patients.  In 
contrast  to  other  types  of  cancer,  patients  with  lung  cancer  may  experience 
pain  from  the  chest  lesion  or  metastatic  sites  in  the  bone  early  in  the  disease. 
Chronic  pain  is  frequently  associated  with  symptoms  such  as  sleep  disorder, 
and  loss  of  appetite  and  with  clinical  signs  and  symptoms  that  may  elaborate  a 
depressive  disorder  (Foley,  1985).  This  may  explain  why  lung  cancer  cases  in 
this  study  even  before  commencement  of  treatment,  reported  significantly 
more  loss  of  appetite  as  compared  to  controls. 
However,  patients'  pain  scores,  especially  lung  cancer  patients  on  the  NHP 
and  the  EORTC  questionnaires  were  lower  than  anticipated.  The  possible 
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explanations  for  such  an  observation  could  be  related  to  the  fact  that  a 
majority  of  patients  (52%)  indicated  that  they  took  pain  medication  (e.  g., 
Paracetamol)  prior  to  the  baseline  assessment.  Similar  results  have  been 
observed  by  Bergman  et  al.  (1994)  where  they  reported  that  lung  cancer 
patients'  pre-treatment  mean  pain  score  was  29.9  (SD  =  31.3).  This  was  27.1 
(SD  =  28.7)  in  this  study.  Also  it  has  been  observed  that  the  EORTC  lung 
cancer  questionnaire-  needs  some  refinement  of  its  pain  subscale  and  further 
testing  of  its  reliability  (Hollen  and  Gralla,  1996). 
The  NHP  has  been  applied  in  the  assessment  of  health  status  in  patients  with 
chronic  respiratory  disease,  and  found  to  be  valid  (Alonso  et  al.,  1992).  Their 
findings  in  a  study  of  67  patients  (mean  age  62.2,  SD  =  7.1),  are  relatively 
similar  to  those  of  this  study  since,  for  example,  the  mean  pain  score  (27;  SD 
not  included)  was  reported.  In  this  study  it  was  19.5  (SD  =  26.7). 
Again,  in  an  unpublished  study  of  63  new  cancer  patients  including  lung 
cancer  patients  (the  numbers  of  patients  with  different  cancer  sites  and  age  are 
not  identified),  Hunt  et  al.  (1986)  reported  findings  similar  to  those  of  this 
study.  For  example,  the  mean  pain  score  for  lung  cancer  patients  in  their  study 
was  about  32  (SD  not  included),  while  it  was  24.5  (SD  =  29.2)  in  this  study. 
Comparing  patients'  scores  on  the  NHP  with  that  of  the  UK  norms  for  general 
population  age  over  65  years  old  (Hunt  et  al.,  1993;  McEwen,  1993),  it  was 
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found  that  both  cases  and  controls  had  about  3  times  higher  mean  scores  on 
energy,  pain,  and  emotional  reactions,  and  about  2  times  higher  mean  scores 
on  sleep,  social  isolation  and  physical  mobility.  These  could  not  be 
substantiated  from  raw  data  from  these  investigations. 
3.2.  Quality  of  life  and  deprivation 
There  was  a  clear  pattern  of  difference  in  quality  of  life  of  the  patients  with 
different  socio-economic  deprivation  backgrounds.  It  was  found  that  in  most 
areas  as  measured  by  the  NHP  and  the  EORTC  questionnaires  the  patients  in 
deprived  groups  had  more  health  problems,  less  functioning,  and  more 
symptoms  as  compared  to  patients  in  the  affluent  groups.  This  clearly 
indicates  how  important  it  is  to  consider  patient's  socio-economic  status  when 
measuring  quality  of  life.  In  other  words,  the  findings  of  this  study  suggest 
that  quality  of  life  is  not  only  the  outcome  of  the  disease,  but  also  highly 
dependent  on  each  patient's  socio-economic  characteristics. 
In  studies  of  quality  of  life  in  lung  cancer  patients  the  only  investigation 
which  acknowledges  the  issue  of  patients'  socio-economic  status  is  that  of 
Sarna  (1993a;  1993b;  1994).  In  a  study  of  69  females  with  lung  cancer,  she 
reported  that  there  were  a  greater  disruption  in  quality  of  life  in  women  with 
low  income.  In  her  study  she  showed  that  income  was  a  statistically 
significant  predictor  of  baseline  quality  of  life. 
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Several  factors  may  explain  why  patients  in  lower  social  class  had  lower 
quality  of  life  as  compared  to  the  affluent.  First,  these  patients  lived  in 
deprived  areas,  and  therefore  their  social  environment  and  living  conditions 
were  not  as  good  as  their  more  affluent  counterparts.  The  relationship  between 
housing  and  quality  of  life  may  be  explained  by  the  hypothesis  that  housing 
environment  has  an  impact  on  social  relationships  and  therefore,  affects  health 
status  and  quality  of  life  (Martin  et  al.,  1987;  Hunt,  1990).  Secondly,  they 
might  had  been  referred  late  (though  not  cross-checked  because  of  time 
constraint)  and  this  had  a  significant  effect  on  their  baseline  quality  of  life 
where  their  disease  was  at  an  advanced  stage.  Since  there  was  no  evidence  of 
such  delay,  this  might  not  be  the  case.  In  fact,  if  there  were  considerable 
delays,  there  would  not  be  missing  cases  in  the  study.  Some  patients  in  this 
study  were  missed  because  they  had  been  referred  by  a  short  notice  and  they 
had  received  a  quick  hospital  appointment.  Basically  in  the  UK  setting,  access 
to  hospital  medical  care  for  lung  cancer,  is  equitable  irrespective  of  social 
class  (Angus  et  al.,  1995).  Finally,  the  lifestyle  and  health  behaviour  in  this 
group  of  patients  (deprived)  might  be  associated  with  a  lower  quality  of  life. 
For  example,  Macintyre  (1994)  in  her  review  of  socio-economic  variations  in 
Scotland's  health  observes  a  clear  gradient  by  socio-economic  status  for  the 
major  killers  in  Scotland,  heart  disease  and  cancer,  with  those  in  lower  social 
class,  living  in  more  deprived  areas,  with  less  education,  lower  income,  and 
rented  accommodation,  having  higher  rates  of  morbidity  and  mortality  than 
the  affluent. 
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From  the  researcher's  personal  observation  and  impression,  it  was  obvious 
that  the  poor  tended  to  be  more  emotionally  adjusted  to  their  condition  than 
the  affluent.  In  a  typical  example,  a  poor  patient  remarked,  `I  have  no  money, 
I  have  no  home,  and  now  that  I  have  lung  cancer,  I  see  it  as  yet  another 
problem  of  life;  but  life  is  for  living'.  On  the  other  hand,  the  affluent  tended  to 
be  rather  more  anxious,  yet  this  was  not  reflected  in  their  responses  to  the 
standard  questionnaires!  The  fact  that  these  observations  could  not  be 
supported  by  data  from  this  study,  again  underscores  the  limitations  of  quality 
of  life  instruments  in  capturing  certain  complex  issues  related  to  human  life. 
3.3.  What  predicts  the  baseline  quality  of  life? 
Three  outcome  measures  were  used  to  investigate  the  relationship  between  the 
baseline  quality  of  life  and  the  patients'  socio-economic  status  and  support 
systems.  It  was  hypothesised  that  the  disease  may  cause  emotional  reactions, 
social  isolation,  and  affect  the  patients'  global  quality  of  life.  When  these  were 
investigated,  it  was  found  that  marital  status,  and  family  support,  social 
isolation,  energy,  sleep  difficulties,  and  global  quality  of  life  were  all 
significant  predictors  of  the  patients'  baseline  emotional  reactions  as 
measured  by  the  NHP  at  fast  assessment  of  their  perceived  health  status 
(Figure  6.6). 
Emotional  reactions,  to  some  extent,  relate  to  psychological  well-being.  The 
study  findings  suggest  that  emotional  reactions  are  not  only  health-related,  but 
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A  male  patient  with  lung  cancer  at  follow-up  assessment  of 
quality  of  life 
After  completion  of  the  initial  treatment Discussion 
strongly  relate  to  the  patients'  social  support  and  social  network.  As  described 
earlier,  the  buffering  hypothesis  may  well  explain  why  patients  who  were 
single,  and  never  received  support  from  their  family,  had  more  emotional 
reactions.  According  to  this  hypothesis,  in  fact,  these  group  of  patients  when 
in  this  situation,  need  support  to  handle  crisis  and  cope  with  their  problems, 
but  do  not  have  any  support  resources  (Tijhuis  et  al.,  1995). 
Social  isolation  which  refers  to  one's  social  activities,  again  was  best 
predicted  by  the  social  network  variables.  It  was  found  that  marital  status 
(being  single  or  widowed),  visiting  family,  being  female,  emotional  reactions, 
pain,  energy,  and  physical  mobility  were  significant  predictors  of  the  patients' 
social  isolation.  Unfortunately  most  studies  of  quality  of  life  in  patients  with 
cancer  do  not  include  such  key  variables  in  their  analyses. 
There  are  several  explanations  for  the  contribution  of  these  variables  to  the 
patients'  quality  of  life.  It  has  been  observed  that  men  and  women  with  the 
fewest  social  connections  were  more  often  smokers  and  physically  inactive 
than  those  with  the  greatest  number  of  connections  as  estimated  by  a  score 
based  on  marital  status,  contact  with  friends  and  relatives  and  membership  of 
groups  (Berkman  and  Syme,  1979).  In  a  recent  study  of  an  elderly  Swedish 
population,  aspects  of  social  isolation  were  associated  with  smoking,  physical 
inactivity,  and  unhealthy  diet  (Hanson  and  Isacsson,  1992).  These  could 
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contribute  to  patients'  health  status  and  consequently  to  their  quality  of  life 
(Osler,  1995). 
The  baseline  global  'quality  of  life  was  best  predicted  by  the  patients'  age, 
Deprivation  Category,  and  employment  status.  Such  phenomena,  again, 
indicate  the  extent  to  which  patients'  socio-economic  status  contributes  to 
their  global  quality  of  life.  However,  as  "life"  in  general  cannot  be  evaluated, 
the  best  approach  is  to  evaluate  a  number  of  aspects  of  a  patient's  quality  of 
life  including  patient's  socio-economic  status.  In  addition,  `life'  has  spiritual 
and  material  components,  its  quality  therefore,  depends  on  a  balance  between 
these  important  dimensions. 
3.4.  Interview  setting 
Most  hospitals  and  clinics  are  not  particularly  suitable  places  for  patients  to 
reflect  adequately  on  their  quality  of  life.  For  example,  it  is  argued  that 
observation  of  social  activities  in  particular  is  likely  to  be  influenced  by  the 
hospital  environment.  It  is  to  be  expected,  therefore,  that  the  interview  at 
home  is  to  be  preferred  for  quality  of  life  assessments  (Bakker,  1986). 
The  difference  in  assessing  quality  of  life  in  different  settings,  that  is, 
interviewing  patients  at  home  or  in  the  clinic  was  investigated.  Except  for 
emotional  reactions  (NHP),  there  was  no  statistically  significant  difference 
between  home  or  clinic  settings.  Patients  at  home  reported  significantly  more 
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emotional  problems.  The  reason  for  such  a  difference  may  be  due  to  the  fact 
that  the  home  interviews  only  took  place  before  patients'  visits  to  hospital. 
This  may  be  a  reflection  of  their  anxiety,  especially  if  they  suspected  they  had 
a  serious  illness,  although  the  diagnosis  was  unknown  to  them  at  the  time. 
However,  although  not  significant,  it  was  observed  that  in  most  of  the 
measures  studied  patients  reported  more  problems  at  home. 
Two  explanations  may  be  put  forward.  Patients  at  home  may  have  over- 
reacted  to  their  problems  or  patients  in  the  clinic  may  have  under-estimated 
their  problems.  It  was  found  that  only  with  regard  to  pain  patients  in  the  clinic 
reported  more  problems.  This  is  exactly  what  one  may  expect  from  a  patient 
in  the  hospital  environment.  Others  (Ziebland  and  Fitzpatrick,  1992)  observed 
that  the  hospital  setting  itself  may  contaminate  the  results,  for  example  with 
questions  about  sleep  on  the  NHP,  which  because  this  refers  to  in-patient 
assessment  of  quality  of  life  rather  than  out-patient  assessment,  may  be 
irrelevant. 
van  Dam  and  Aaronson  (1987)  argue  that  the  place  where  the  data  collection 
takes  place  (at  home  or  in  the  clinic)  can  exert  a  strong  influence  on  the  way 
patients  respond  to  questions.  Thus,  they  recommend  that  one  should  try  to 
avoid  collecting  data  in  different  settings  within  a  single  study.  For  example, 
if  at  baseline  data  were  collected  in  the  clinic,  at  the  follow-up  also  data 
should  be  collected  in  the  clinic  not  for  example  at  home.  Such  a  statement 
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was  made  with  regard  to  self-reported  data  collection,  whereas  in  this  study 
data  were  collected  via  the  interviewer-administered  approach. 
3.5.  Knowing  the  diagnosis  of  cancer  and  its  relation  to  the  outcomes 
In  almost  all  studies  of  quality  of  life,  patients'  quality  of  life  was  first 
assessed  after  the  diagnosis  and  after  or  during  each  course  of  the  treatment. 
Therefore,  the  question  is  to  what  extent  does  knowing  the  diagnosis  affect  the 
results.  If  a  patient  has  recently  received  "bad  news"  indicating  that  he  or  she 
has  developed  lung  cancer,  any  assessment,  especially  on  psychological 
aspects  such  as  emotional  functioning,  may  be  biased.  No  previous  research 
on  this  topic  has  been  identified. 
A  comparison  was  made  between  results  obtained  from  quality  of  life 
assessment  in  two  groups  of  lung  cancer  patients:  those  who  did  not  know 
their  cancer  diagnosis  and  those  who  did,  to  find  out  how  this  may  contribute 
to  the  outcome.  For  example,  one  may  expect  a  significant  differences  in 
emotional  reactions  between  those  who  knew  their  diagnosis  and  those  who 
did  not.  The  study  results  indicated  that  there  was  no  evidence  to  suggest  that 
knowing  diagnosis  may  dramatically  affect  the  result,  because  there  were  no 
differences  between  these  two  groups'  emotional  reactions  or  social  isolation 
scores  at  all,  while  it  was  found  that  those  who  knew  their  diagnosis  reported 
more  physical  problems  (Tables  6.15,  and  6.16).  Certainly  this  was  not  due  to 
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their  age  differences,  since'those  who  knew  their  diagnosis  were  relatively 
younger  than  those  who  did  not  know  their  cancer  diagnosis. 
Looking  at  patients'  symptoms,  again  there  was  no  significant  difference 
between  these  two  groups  except  for  sleep  difficulties  indicating  that  those 
who  did  not  know  their  diagnosis  reported  significantly  more  problems  with 
sleep  (p  =  0.02).  Although  it  is  not  clear  why  a  significant  difference  emerged, 
it  is  possible  to  say  that  because  those  who  did  not  know  their  diagnosis  were 
older,  and  therefore  they  perceived  more  sleep  difficulties. 
4.  Follow-up  assessments 
4.1.  Baseline  quality  of  life  as  a  predictor  of  survival 
The  study  findings  suggest  that  the  baseline  quality  of  life  is  an  important 
prognostic  factor.  Two  types  of  analyses  were  carried  out:  simple  and  Cox's 
regression  analysis.  In  the  first  analysis  it  was  shown  that  most  measures  were 
significant  indicators  of  the  duration  of  patients'  survival.  For  example,  those 
who  were  dead  at  follow-up  had  significantly  more  problems  with  energy  (p  = 
0.007)  and  pain  (p  =  0.005)  at  baseline  as  measured  by  the  NHP  (Tables  6.19 
and  6.20).  In  the  second  analysis  (Cox  regression  analysis)  it  was  found  that 
patients'  aggregate  scores  on  the  NHP  and  EORTC  QLQ-C30  (functioning, 
and  global  quality  of  life  scores)  were  significant  predictors  of  survival  (p  = 
0.003,0.03,  and  0.03  respectively). 
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There  have  been  similar  findings  in  four  previous  quality  of  life  studies  of 
lung  cancer  patients.  Kassa  et  al.  (1989)  studied  quality  of  life  in  102  non- 
small  cell  lung  cancer  patients  and  found  that  psycho-social  well-being  was 
the  best  predictive  factor  of  survival.  Ruchdeschel  et  al.  (1989;  1991;  1994)  in 
a  series  of  quality  of  life  studies  using  the  Functional  Living  Index-Cancer 
(FLI-C)  reported  that  the  total  baseline  quality  of  life  score  (aggregate  score 
on  the  FLI-C)  alongside  performance  status,  weight  loss,  and  stage  of  disease 
were  significant  predictors  of  survival  in  438  lung  cancer  patients.  Ganz  et  al. 
(1991)  also  used  the  FLI-C  to  study  quality  of  life  in  40  lung  cancer  patients. 
Using  Cox  regression  analysis  and  dividing  the  patients  into  two  groups  (low 
and  high  quality  of  life),  they  found  that  baseline  quality  of  life  was  a 
significant  predictor  of  subsequent  survival.  Finally,  Gralla  et  al.  (1995)  in  a 
study  of  673  non-small  cell  lung  cancer  patients  using  the  Lung  Cancer 
Symptom  Scale  (LCSS)  observed  that  the  baseline  quality  of  life  not  only 
predicts  the  survival,  but  also  has  greater  impact  than  most  known  prognostic 
factors. 
Similar  findings  have  been  reported  both  for  other  cancers  for  example,  breast 
cancer  where  patients'  physical  well-being  scores  was  found  to  be  directly 
associated  with  survival  (Coates  et  al.,  1992),  and  for  other  diseases  such  as 
rheumatoid  arthritis.  Fitzpatrick  et  al.  (1992)  argue  that  quality  of  life 
instruments  have  been  shown  to  be  better  than  conventional  rheumatological 
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measures  as  a  predictors  of  long  term  outcomes  in  terms  of  both  morbidity  and 
mortality. 
In  contrast,  a  study  of  patients  with  malignant  melanoma  (Osoba  et  al.,  1993) 
found  that  pre-treatment  global  quality  of  life  scores  as  measured  by  the 
EORTC  QLQ-C30,  were  not  predictive  of  survival.  It  is  argued  that  because 
these  patients  did  not  have  advanced  disease,  as  did  the  lung  and  breast  cancer 
patients,  it  is  possible  to  suggest  that  pre-treatment  quality  of  life  may  not 
have  predictive  value  in  all  patients  with  all  cancers  (Osoba,  1994). 
This  study  by  using  a  prospective  design  and  performing  Cox's  regression 
analysis,  suggests  that  even  for  patients  in  the  early  stage  of  disease  initial 
quality  of  life  is  prognostic.  In  fact,  the  major  difference  between  the  present 
study  and  the  above  mentioned  studies  is  due  to  the  fact  that  they  measured 
quality  of  life  after  diagnosis,  but  in  this  study  quality  of  life  was  measured 
before  the  diagnosis.  Therefore,  the  concept  of  baseline  quality  of  life  in  this 
study  is  more  precise  than  others.  When  others  measured  quality  of  life  the 
disease  and  its  diagnosis  may  already  have  had  an  effect  on  it. 
These  however,  are  major  findings  and  have  important  implications. 
1.  Baseline  quality  of  life  is  a  significant  prognostic  factor  for  survival 
outcome  like  other  known  prognostic  factors  i.  e.  age,  gender,  disease  stage, 
weight  loss  and  performance  status. 
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2.  Baseline  assessment  of  quality  of  life  could  help  physicians  in  their  clinical 
decisions  as  it  directly  relates  to  the  patients'  survival  time.  Thus,  it  should  be 
integrated  into  clinical  practice  and  evaluated  prospectively. 
However,  one  should  be  aware  of  Cox's  regression  limitations.  One  of  the 
assumptions  of  the  Cox  regression  model  is  that  for  any  two  cases  or  any 
two  comparison  groups  (for  example,  in  this  study  those  with  high  and  low 
level  of  global  quality  of  life),  the  ratio  of  the  estimated  hazard  across  time 
is  a  constant  (Norusis,  1994).  For  example,  based  on  such  an  assumption 
for  two  patients  with  the  same  age  and  histology  but  different  levels  of 
global  quality  of  life,  the  ratio  of  their  estimated  hazard  rates  across  all 
time  is  considered  to  be  constant.  This  is  a  strong  assumption  which  may 
not  always  apply.  It  is  quite  possible  that  the  hazard  functions  of  patients 
with  low  and  high  level  of  global  quality  of  life  are  not  related  by  a 
constant  and  rather  depend  on  time.  It  is,  however,  possible  to  modify  the 
Cox  regression  model  to  overcome  the  problem,  but  this  was  not  feasible 
in  this  study  and  discussion  about  the  issue  is  beyond  the  scope  of  this 
section. 
4.2.  Baseline  versus  follow-up  quality  of  life 
At  follow-up  stage  82  patients  were  interviewed  and  their  quality  of  life 
scores  were  compared  with  their  baseline  scores.  In  general,  the  comparison 
indicates  that  patients'  quality  of  life  had  deteriorated.  The  only  improvement 
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was  seen  for  some  symptoms  such  as  coughing,  haemoptysis,  pain  in  the 
shoulder  and  sleep  difficulties.  These  improvements,  however,  were  not 
significant  except  for  coughing  which  was  possibly  controlled  by  medication. 
The  study  findings  indicate  that  in  addition  to  the  decrease  in  patients'  general 
health  status  (physical  health,  and  functioning),  they  developed  treatment- 
related  symptoms  such  as  fatigue,  hair  loss,  constipation,  and  sore  mouth. 
These  findings  are  similar  to  those  of  studies  conducted  by  Aaronson  et  al. 
(1993)  and  Bergman  et  al.  (1994).  They  used  the  EORTC  QLQ-C30  and  the 
EORTC  QLQ-LC  13  to  investigate  the  reliability  and  validity  of  the  EORTC 
questionnaires.  The  mean  scores  reported  in  their  studies  and  this  study  are 
very  similar.  For  example,  Aaronson  et  al.  (1993)  reported  the  mean  scores  of 
65.8  (SD  =  27.1)  and  62.3  (SD  =  28.3)  for  physical  functioning  before  and 
during  treatment.  In  this  study  these  were  67.1  (SD  =  25)  and  55.9  (24.9) 
respectively.  The  slight  difference  observed  could  have  resulted  from  the  fact 
that  while  they  administered  the  questionnaires  during  treatment,  in  this  study 
questionnaires  were  administered  after  initial  treatment. 
The  physical  symptoms  of  lung  cancer  have  a  serious  impact  on  the 
individual's  functional  or  performance  status  as  defined  by  the  ability  to  do 
certain  physical  activities.  At  present,  the  systematic  assessment  of  this  key 
concept  (performance  status)  continues  to  be  measured  in  patients  with  lung 
cancer  using  either  the  Karnofsky  Performance  Scale  (KPS),  or  Eastern 
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Cooperative  Oncology  Group  Performance  Status  (also  see  chapter  three, 
section  1.2.1). 
Performance  status  is  a  global  assessment  of  the  patients'  functioning  and 
ability  for  self-care,  and  should  not  therefore,  be  considered  to  be  equal  to 
assessment  of  quality  of  life  which  refers  to  a  broader  concept.  As  the  study 
results  suggest,  quality  of  life  in  lung  cancer  patients  is  not  limited  to  physical 
functioning,  but  also  other  symptoms  which  result  from  either  the  progression 
of  disease  or  side-effects  of  treatment.  In  addition,  these  types  of  instruments 
have  been  criticised  for  being  crude  measures  with  only  modest  reliability 
(e.  g.  Mor,  1984).  Thus,  comprehensive  assessment  of  physical  symptoms  as 
well  as  physical  functioning  are  important  in  evaluating  lung  cancer  patients' 
quality  of  life  both  before  and  after  treatment. 
4.3.  Effects  of  different  treatment  policies 
Treatments  for  lung  cancer  often  burden  the  patient  with  additional  physical 
symptoms.  Most  investigations  have  focused  on  the  side-effects  of 
chemotherapy.  Limited  information  is  available  about  radiotherapy,  surgery, 
and  supportive  care. 
To  show  the  effects  of  different  treatment  policies,  based  on  initial 
management,  patients  were  divided  to  four  groups:  patients  who  received 
chemotherapy  (n  =  25),  those  who  received  radiotherapy  (n  =  29),  those  who 
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underwent  surgery  (n  =  6)  and  those  who  were  treated  with  a  supportive  care 
policy  (n  =  21).  In  each  group,  patients'  baseline  scores  were  compared  to 
their  follow-up  assessments.  1 
In  general  not  only  were  there  no  improvements,  but  there  was  a  deterioration 
in  patients'  quality  of  life.  Chemotherapy  patients  reported  significant 
improvement  in  coughing  and  radiotherapy  patients  reported  significant 
improvement  for  pain  in  the  shoulder.  Apart  from  these,  there  was  no 
significant  disease-related  symptom  relief,  while  there  was  an  increase  in 
treatment-related  symptoms  such  as  hair  loss  in  chemotherapy  patients,  and 
constipation  in  radiotherapy  patients.  Although  the  sample  size  in  each  group 
was  rather  small,  the  findings  clearly  suggest  that  the  effects  of  different 
treatment  regimens  were  not  entirely  satisfactory,  but  without  treatment  their 
problems  could  have  been  worse.  For  example,  patients  who  received 
chemotherapy  reported  significant  problems  with  social  isolation.  In  clinical 
experience  and  empirical  research,  lung  cancer  patients  show  a  tendency 
toward  social  withdrawal.,  Symptoms  of  the  disease,  especially  impaired 
functional  status,  dyspnoea,  pain,  and  hair  loss  impose  limitations  on  the 
patients'  social  life.  Furthermore,  many  patients  seem  to  dislike  being 
dependent  on  others.  Thus,  they  prefer,  for  example,  to  stay  at  home  rather 
than  to  rely  on  the  help  of  others  to  help  them  be  socially  active  (McGeough 
et  al.,  1980). 
286 Discussion 
However,  it  seems  that  patients  who  received  surgery  had  a  better  quality  of 
life  as  compared  to  the  other,  groups,  while  patients  in  the  supportive  care 
group  reported  more  problems.  Comparing  radiotherapy  with  chemotherapy, 
radiotherapy  patients  reported  less  problems  (Tables  6.24,6.25,  and  6.26). 
Ideally,  the  goal  of  cancer  treatment  should  not  be  only  to  prolong  disease- 
free  survival,  but  to  enhance  the  patients'  ability  to  return  to  a  normal  life. 
Particularly  for  patients  with  -advanced-stage  disease,  one  can  question  the 
ability  of  cancer  therapy  to  improve  patients'  quality  of  life.  Clinical  trials 
thus,  can  not  sufficiently  document  the  continuing  impact  of  the  disease  and 
the  extent  to  which  treatment,  including  its  failure  to  manage  symptoms 
adequately,  diminishes  the  well-being  of  cancer  patients. 
4.4.  Small  cell  versus  non-small  cell  lung  cancer 
Overall,  there  were  no  significant  differences  between  small  cell  and  non- 
small  cell  lung  cancer.  patients  indicating  that  both  groups  showed  a  similar 
quality  of  life  either  at  baseline  assessments  or  at  follow-up  stage.  However, 
in  some  measures  such  as  haemoptysis  and  pain,  non-small  cell  lung  cancer 
patients  scored  higher  indicating  that  they  had  a  greater  degree  of  symptoms. 
The  study  findings  are  similar  to  these  of  Hopwood  et  al.  (1995)  who 
investigated  symptoms  on  232  small  cell  and  423  non-small  cell  lung  cancer 
patients.  They  reported  that  the  overall  pattern  of  symptom  prevalence  was 
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very  similar  for  the  two  disease  groups,  the  only  major  differences  being  the 
higher  level  of  chest  pain  and  coughing  up  blood  reported  in  patients  with 
non-small  cell  lung  cancer  patients. 
Considering  the  impact  of  treatment  on  patients'  quality  of  life,  the  study 
results  suggest  that  there  were  no  benefits  for  patients  with  non-small  cell 
lung  cancer,  while  there  were  some  palliative  improvements  for  small  cell 
lung  cancer  patients.  This  is  clearly  reflected  in  patients  scores  where  small 
cell  lung  cancer  patients  reported  more  treatment-related  symptoms,  while 
non-small  cell  lung  cancer  patients  reported  more  disease-related  symptoms. 
For  example,  small  cell  lung  cancer  patients  significantly  reported  more  hair 
loss,  and  sore  mouth  which  are  side-effects  of  chemotherapy,  whereas  non- 
small  cell  lung  cancer  patients  reported  significant  pain  distress  (Table  6.29). 
5.  Patients'  reactions  to  the  study 
One  of  the  most  interesting  experiences  in  this  study  relates  to  the  evaluation 
of  the  study  by  the  patients  themselves.  This  was  investigated  via  a  simple 
questionnaire.  First,  they  indicated  that  they  preferred  to  be  interviewed  rather 
than  to  fill  in  questionnaires.  Secondly  they  indicated  that  they  preferred  to  be 
interviewed  at  home  as  opposed  to  the  interview  in  the  clinic.  Thirdly  they 
found  being  interviewed  very  acceptable. 
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Communication  aspects  of  interviewing  patients  by  non-medical  qualified 
investigators  on  quality  of  life  is  not  well  documented.  This  becomes  more 
evident  when  one  considers  interviewing  a  cancer  patient.  With  regard  to 
quality  of  life  studies  and  interviewing  cancer  patients,  much  attention  in  the 
literature  has  instead  been  given  to  practical  and  methodological  issues 
(Montazeri  et  al.,  1996d). 
It  is  argued  that  the  advantages  of  face-to  face  interview  as  compared  to  self- 
administered  instruments  include  the  fact  that  the  interviewer  knows  about  the 
characteristics  of  who  is  answering.  Difficult  items  can  be  explained  to 
respondents,  is  more  flexible,  and  may  create  an  opportunity  for  researchers  to 
obtain  additional  and  vital  information  they  need  (Streiner  and  Norman, 
1995).  Thus,  in  many  respects  this  study  reinforce  the  view  that  interview  is  a 
more  convenient  way  of  data  collection,  although  the  drawbacks  should  not  be 
forgotten  including  the  costs  involved  and  the  risk  of  interviewer  bias,  as 
discussed  earlier. 
Usually,  there  is  an  impression  among  medical  staff  that  interviews  may 
disturb  patients  if  they  have  been  told  that  they  have  lung  cancer,  by  putting 
them  in  a  difficult  situation;  that  they  do  not  want  to  talk,  and  that  interviews 
are  not  a  useful  way  to  communicate  with  patients,  in  particular  with  cancer 
patients.  Data  obtained  in  this  study  indicates  that  the  majority  of  patients 
(96%)  found  being  interviewed  very  or  quite  acceptable.  Only  4%  of  patients 
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stated  that  they  found  being  interviewed  not  very  or  not  acceptable.  They 
expressed  four  main  reasons  for  their  feelings  with  the  majority  of  patients 
indicating  that  being  interviewed  did  not  bother  them,  they  felt  at  ease  and 
relaxed,  they  were  happy  to  talk,  the  interview  was  understandable  and  that 
they  were  satisfied  with  the  way  the  interview  had  been  carried  out. 
There  were  patients  who  felt  that  the  voice  and  behaviour  of  the  interviewer 
were  appealing  to  them  (Table  6.41).  Since  this  may  make  _the  patient  feel 
relaxed  and  comfortable,  the  issue  of  selecting  a  skilled  interviewer  in  quality 
of  life  studies  becomes  important.  Part  of  the  patients'  impression  of  pleasant 
behaviour  may  be  attributed  to  the  fact  that  the  traditional  question-answer 
interview  style  was  avoided.  In  traditional  style,  the  interviewee  usually  does 
not  find  a  chance  to  talk  and  it  is  argued  that  obtaining  accurate  and  complete 
understanding  of  the  patients'  health  status  in  this  way  is  very  unlikely 
(Marshall,  1988).  Many  of  the  patients  in  this  study  indicated  that  they  found 
being  interviewed  acceptable  because  they  had  a  chance  to  talk.  This  was 
apparent  from  the  patients'  statements  where  they  stated  that  "it  was  nice  to 
talk",  or  "it  was  nice  to  talk  to  somebody  who  is  not  superior",  or  "it  was  nice 
to  talk  to  somebody  who  is  listening".  Since  it  is  argued  that  clinical  teams 
including  researchers  mostly  talk  about  the  "case"  rather  than  the  person,  and 
that  in  clinical  medicine  the  eye  is  quicker  than  the  ear  (Spiro,  1992),  the  need 
for  more  effective  communication  and  consideration  of  patients'  experiences 
and  feelings  becomes  essential. 
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However,  allowing  patients  to  talk  unrestrained  has  disadvantages.  These 
include  deviation  from  the  main  study  questions,  a  lengthy  interview,  and  too 
much  involvement  with  patients'  problems.  A  balanced  approach  may  be  the 
reasonable  solution  to  the  problem  (May,  1991). 
Finally,  it  has  been  shown  that  proper  communication  with  patients  plays  an 
important  role  in  collecting  quality  information.  How  to  achieve  this  remains 
a  major  task  for  further  investigation.  Furthermore,  researchers  need  to 
communicate  effectively  with  medical  and  clinical  staff.  Without  such  links, 
there  is  no  means  of  recruitment  of  patients. 
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1.  Conclusions 
Several  conclusions  are  made  based  on  the  study  findings. 
1.  Lung  cancer  patients'  quality  of  life  prior  to  diagnosis  was  found  to  be  a 
significant  predictive  factor  of  length  of  survival  indicating  the  importance  of 
quality  of  life  as  a  prognostic  factor,  even  after  adjusting  for  known 
prognostic  factors,  these  are,  age,  sex,  extent  of  disease,  weight  loss,  and 
performance  status. 
2.  Patients'  perception  of  quality  of  life  was  different  from  the  perceptions  of 
health  professionals.  This  suggests  that  doctor-patient  communication  should 
be  further  developed.  To  -  achieve  this,  a  better  understanding  of  patients' 
concerns  by  knowing  their  values  and  preferences  is  needed. 
3.  There  was  surprisingly  no  significant  difference  between  lung  cancer  cases 
and  chronic  respiratory  disease  controls  with  regard  to  their  demographic  and 
socio-economic  status.  This,  may  have  implications  for  health  care 
professionals.  For  example,  both  diseases  are  related  to  health  behaviour  and 
lifestyles.  They  are,  to  a  large  extent,  some  of  the  consequences  of  smoking, 
manifesting  later  in  life.  This  underscores  the  need  for  appropriate  targeting  of 
health  education  and  promotion  programmes  on  adolescents,  taking  account  of 
the  socio-economic  and  demographic  variables  highlighted  in  this  study.  Such 
programmes  must  use  an  adequate  constellation  of  methods  (e.  g.,  ban  on 
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advertising,  increased  taxation  on  tobacco,  different  health  education 
approaches,  etc.  )  which  seek  to  prevent  youngsters  from  taking  up  smoking. 
4.  At  baseline,  there  was  no  significant  difference  between  quality  of  life  in 
lung  cancer  cases  and  chronic  respiratory  disease  controls.  This  observation 
highlights  the  extent  to  which  patients  with  chronic  respiratory  disease  'suffer 
from  their  disease,  and  indicates  the  fact  that  health  professionals  might  be 
under-estimating  quality  of  life  in  patients  with  chronic  respiratory  disease. 
5.  Quality  of  life  was  found  to  be  different  in  patients  with  different 
Deprivation  Categories.  This'  indicates  the  extent  to  which  socio-economic 
status  of  patients  contributes  to  their  quality  of  life.  The  poor  experience  a 
lower  level  of  quality  of  life  as  compared  to  their  affluent  counterparts. 
Although  it  was  felt  that  the  poor  may  have  better  quality  of  life  by  virtue  of 
their  supposedly  stronger  family  ties  (Atkinson,  1996),  this  was  not  supported 
by  the  data.  Thus,  the  findings  are  in  line  with  those  previous  studies  on 
inequalities  in  health,  which  show  markedly  poorer  health  for  those  on  the 
lower  fringes  of  the  socio-economic  scale  (e.  g.,  Davey  Smith  and  Egger, 
1993). 
6.  Patients'  social  support  and  social  networks  were  important  determinants  of 
patients'  quality  of  life,  as  they  were  predictive  factors  for  social  isolation  and 
emotional  reactions,  all  of  which  are  important  components  of  psychological 
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health.  This  clearly  suggests  that  not  only  disease  and  treatment-related 
factors  contribute  to  the  patients'  health-related  quality  of  life,  but  that  other 
non-medical  components  `also  play  an  important  role  in  shaping  patients' 
quality  of  life.  Available  data  did  not  highlight  which  of  medical  and  non- 
medical  'components  was  a  more  important  predictor  of  psychological  health. 
This  however,  marks  an  important  area  for  consideration  in  future  studies  on 
quality  of  life. 
It  is  worth  noting  that  . 
the  findings  from  this  study  indicated  that  .  non- 
medical  factors  such  -  as  Deprivation  Category  and  marital  status  were 
significant  predictors  of  global  quality  of  life  at  follow-up,  while  medical 
factors  such  as  cell  type  and  treatment  modalities  were  not. 
7.  Comparing  patients'  baseline  quality  of,  life  with  their  follow-up 
assessments,  the  findings  from  this  study  showed  that  patients'  quality  of  life 
had  deteriorated  indicating  that  overall,  treatment  is  ineffective  in  improving 
lung  cancer  patients'  quality  of  life  regardless  of  cell  type  and  stage  of 
disease.  Although  one  must  realise  the  importance  of  treatment  in  palliation  of 
symptoms,  this  finding  detracts  greatly  from  observations  (see  summary  tables 
in  chapter  three)  which  suggest  improvements  in  quality  of  life  as  a  result  of 
treatment. 
iTi 
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8.  There  was  no  significant  difference  in  quality  of  life  between  lung  canccr 
patients  who  did  not  know  their  cancer  diagnosis  and  those  who  knew  their 
diagnosis.  This  suggests  that  knowing  diagnosis  did  not  significantly  affect 
the  way  in  which  patients  responded  to  the  questionnaires.  This  is  a  crucial 
methodological  finding  which  negates  the  current  hypothesis  that  patients' 
awareness  of  their  cancer  'diagnosis  may  influence  the  way  in  which  they 
respond  to  quality  of  life  questionnaires. 
9.  There  was  no  significant  difference  in  quality  of  life  between  patients  who 
were  interviewed  at  their  homes  and  patients  who  were  interviewed  in  the 
clinic.  This  indicates  the  place  of  interview  does  not  significantly  affect  the 
results. 
10.  It  was  feasible  to  conduct  quality  of  life  studies  based  on  robust 
epidemiological  methods.  This  has  allowed  a  more  representative  assessment 
to  be  made  than  clinical  trials  and  clinical-based  studies. 
11.  Reactions  of  patients  to  the  study  indicate  that: 
(i)  A  majority  of  the  patients  preferred  to  be  interviewed  rather  than  to  fill  in  a 
questionnaire.  There  was  no  significant  association  between  this  preference 
and  patients'  age,  gender,  diagnosis,  place  of  interview,  patients'  general 
health  status  and  global  quality  of  life. 
(ii)  A  majority  of  the  patients  did  not  find  the  interview  an  intrusion. 
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(iii)  The  highest  proportion  of  patients  preferred  to  be  interviewed  at  home 
rather  than  in  the  clinic. 
12.  Overall,  the  study  findings  indicate  that  considering  patients'  views  when 
collecting  quality  of  life  data  offers  the  advantage  of  improving  the  quality  of 
data,  reducing  missing  information  and  minimising  refusals,  thus  ensuring 
efficient  use  of  resources. 
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2.  Recommendations  `.  - 
This  study  has  provided  useful  information  about  quality  of  life  in  paticnts 
with  lung  cancer.  Based  on  the  findings  and  experiences  gained  through  the 
study  the  following  are  recommended  both  for  consideration  in  lung  cancer 
care  and  for  further  research. 
1.  Since  quality  of  life  measures  could  have  prognostic  value,  they  should  be 
included  in  clinical  trials  and  epidemiological  studies  of  outcomes  in  patients 
with  lung  cancer.  However,  such  benefits  from  quality  of  life  measures  would 
be  better  enhanced  if  the  limitations  of  current  instruments  as  highlighted  in 
the  work  are  taken  into  account. 
2.  Doctor-patient  communication  needs  to  be  further  improved,  since  efective 
health  care  delivery  requires  a  better  understanding  of  patients'  concerns.  To 
achieve  this  it  is  recommended  to  provide  resources  available  to  make 
communication  training  part  of  post-graduate  and  continuing  medical 
education.  '' 
3.  Measuring  quality  of  life  in  patients  with  lung  cancer  is  essential  and  is 
recommended.  This  may  provide  additional  psycho-social  information  likely 
to  indicate  individuals  or  sub-groups  of  patients  who  may  benefit  from 
particular  treatment  regimens.  Purchasers  of  lung  cancer  care  may  rely  on 
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such  information  to  provide  appropriate  services  which  address  specific 
psycho-social  needs  of  patients. 
4.  Any  assessment  of  quality  of  life  needs  to  be  considered  in  relation  to 
patients'  socio-economic  status.  Without  such  considerations  it  is  difficult  to 
provide  a  realistic  picture  of  patients'  quality  of  life. 
5.  The  inclusion  of  general  health  measures  such  as  the  Nottingham  Health 
Profile  (NHP)  in  studies  of  quality  of  life  is  recommended  since  these 
instruments  provide  useful  information  on  patients'  perceived  health  status. 
However;  there  is  a  need  for  further  development  of  the  NIIP  in  relation  to  its 
response  category  (yes  and  no)  format.  How  to  achieve  this  remains  to  be 
resolved.  An  ordinal  response  category,  that  is,  a  4-point  Likert  scale  format 
(not  at  all,  a  little,  quite  a  bit,  very  much),  may  be  the  solution  and  is  worth 
examining. 
6.  The  EORTC  questionnaires  which  are  cancer  specific  were  administered  to 
both  lung  'cancer  cases  and  chronic  respiratory  disease  controls.  It  was 
surprising  that  the  instruments  could  not  distinguish  between  these  two 
populations.  The  fact  that  the  instruments  proved  applicable  to  patients  with 
chronic  respiratory  disease  challenges  the  validity  of  the  questionnaires,  and 
underscores  the  need  for  their  further  developments.  Specifically,  there  is  need 
to  improve  their  pain,  family  and  social  life  subscales  and  to  further 
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investigate  their  reliability  and  validity  in  the  UK  setting.  Supplementation  of 
a  valid  pain  questionnaire  may  help  to  overcome  the  problem  arising  from  the 
EORTC  QLQ-LC  13  pain  subscale. 
"  7.  Clinical  staff  have  an'  important  role  in  quality  of  life  studies.  Thus, 
effective  communication  between  researchers  and  clinical  staff  is  essential  and 
should  be  established  if  not  present,  since  part  of  the  high  response  rate  in  this 
study  could  be  attributed  to  the  rapport  which  existed  between  the  researcher 
and  clinical  stafff. 
8.  Assessment  of  quality  of  life  should  be  acceptable  to  patients.  Interview- 
administered  approach  is  recommended  to  achieve  this.  This  may  improve  the 
quality  of  data,  reduce  missing  information  and  decrease  the  burden  on 
patients.  These  may  help  to  justify  the  cost  associated  with  this  method, 
although  this  study  was  not  designed  to  answer  such  a  question. 
9.  The  study  design  in  this  project  proved  feasible  and  desirable.  Thus,  it  is 
recommended  that  this  experience  be  used  in  future  research  since  it  has  the 
potential  of  ensuring  a  more  representative  result. 
10.  This  study  should  be  repeated  with  a  larger  sample  in  Glasgow  and 
elsewhere.  For  such  a  research  programme  the  following  are  recommended: 
(i)  The  controls  should  also  be  included  in  the  follow-up  assessments. 
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(ii)  A  better  way  for  enrolling  all  emergency  admissions,  and  internal  referrals 
is  needed  to  enter  all  cases  in  the  study. 
(iii)  There  is  need  to  use  standard  measures  instead  of  ad  hoc  questionnaires 
when  assessing  social  support  and  social  networks.  This  would  allow  to 
provide  valid  and  comparable  data. 
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The  letter  to  Tak  Tent 
334 WEST  OF  SCOTLAND  CANCER  SURVEILLANCE  UNIT 
GREATER  GLASGOW  HEALTH  BOARD, 
RUCHILL  HOSPITAL, 
Dire,  s-  .r:  Dr.  C.  R.  GILLIS  GLASGOW,  G20  9Nß 
Telephone:  041.946  7120  Ent.  270 
Mrs.  Eileen  Smith,  17th  March,  1994. 
TAK  TENT, 
Western  Infirmary, 
GLASGOW, 
G11  6NT. 
Dear  er  Smit  , 
- 
JU 
Re  :  Mr.  Ali  Montazeri,  B.  Sc.  1984  Teheran,  MPH  1993  Glasgow 
The  above  is  presently  an  enrolled  student  at  the  University  of 
Glasgow  for  the  degree  of  PhD  under  my  supervision  and  is  a 
member  of  the  University  Department  of  Public  Health. 
The  subject  of  his  proposed  thesis  is  'Insights  on  the  quality  of 
life  of  cancer  patients  with  particular  reference  to  ovarian 
Cancer  in  relation  to  optimal  treatment'.  Ultimately,  he  will 
carry  out  a  study  on  ovarian  cancer  trying  to  determine 
instruments  for  measuring  whether  the  optimal  therapy  we  have 
found  by  research  benefits  quality  of  life. 
However,  I  feel  he  should  first  learn  to  talk  to  patients  with 
cancer  and  therefore  thought  of  your  Organisation  as  not  only 
playing  a  guiding  role  in  this  project  but  offering  him  the 
possibility  of  talking  to  some  of  your  members  attending  group 
meetings  and  gradually  absorbing  the  use  of  Tak  Tent. 
I  am  sorry  to  trouble  you  with  this  request  but  feel  sure  you 
will  be  interested.  Mr.  Montazeri  can  be  contacted  at  this 
addres 
Yours 
/incerely, 
1,4 
4e  Y,  -.,  -, ý  /4- 
I 
ýý Appendix  II 
Tak  Tent:  does  cancer  support  work? 
Studies  of  a  cancer  support  group 
336 Abstract 
A  descriptive  study  using  two  interviewer-administered  questionnaires  was 
conducted  to  know  more  about  cancer  support  groups  and  the  people  who  are 
using  these  services.  All  seventy  one  patients  and  relatives  attending  six  cancer 
support  groups  at  the  time  of  investigation  in  the  West  of  Scotland  were 
interviewed.  They  were  asked  about  their  satisfaction  with  care  and  support, 
past  and  current  concerns,  global  health  and  quality  of  life,  and  needs.  The 
majority  of  participants  were  married  females,  middle  class,  aged  50  to  65  years 
old,  and  were  long  time  survivors.  Fifty-two  per  cent  of  cancer  patients  and 
70%  of  their  families  stated  that  they  were  very  satisfied  with  support  were 
receiving.  Nearly  90%  of  patients  reported  that  they  did  not  receive  any 
counselling  either  during  their  treatment  from  their  cancer  specialists  or  at 
present  from  a  professional  counsellor.  The  "general  perceived  health",  and 
"global  quality  of  life"  among  patients  and  relatives  were  found  to  be 
moderately  good  or  good.  Concerns  of  patients  and  their  families  were  studied. 
Patients  reported  optimistic  changes  while  relatives  were  more  negative.  Needs 
assessment  indicated  that  52%  of  patients  require  symptom  relief  and  family 
support,  whereas  53%  of  relatives  need  counselling  with  a  professional 
counsellor  and  informational  support.  One-third  of  patients  reported  that  they 
had  no  problem  at  present  and  the  rest  identified  difficulties  with  home  duties, 
shopping  and  transportation,  and  financial  problems.  The  study  suggests  that 
there  is  value  in  encouraging  cancer  patients  and  their  relatives  to  take  part  in 
existing  cancer  support  groups.  This  may  help  to  reduce  the  burden  of  disease 
and  care-burden  imposed  on  families. 
Key  words  Social  support.  Cancer  support  group.  Concerns.  Needs  assessment. 
Quality  of  life. 
337 Introduction 
The  stigma  associated  with  cancer  may  explain  why  some  patients  evaluate 
their  life  as  being  negative  and  often  conclude  that  "life  is  not  worth  living". 
Thus,  it  is  argued  that  for  many  patients  with  cancer,  treatment  alone,  is  not 
enough  and  support  from  family  and  friends  may  help  them  to  cope  with 
stressful  life  events  [17].  In  addition,  families  of  cancer  patients  also  suffer. 
Studies  in  the  past  decade  have  revealed  that  outside  help  is  necessary  for  such 
families  [25].  A  longitudinal  study  of  the  adjustment  patterns  to  breast  cancer 
reported  that  patients  and  their  families  experienced  the  same  amount  of 
psychological  morbidity  [27].  The  association  between  psychological  morbidity 
of  cancer  patients  and  their  next-of-kin  is  well  documented  [6]. 
Supportive  care  is 
. 
becoming  recognised  as  critical  in  cancer  medicine.  It 
includes  all  rational  forms  of  support  ranging  from  basic  cancer  therapy  to 
spiritual  help  [28].  In  this  respect,  psychological  interventions  are  being  widely 
used  to  influence  coping  behaviour  and  improve  both  patients'  and  their 
relatives'  perception  of  personal  control  during  the  course  of  the  disease  [35].  In 
doing  so,  individual  or  group  therapy  are  considered  to  be  a  useful  approach  to 
reduce  patients'  distress,  anxiety  and  depression  [10,24].  Spiegel  [31]  argues 
that  group  experience  enables  patients  to  take  control  over  their  lives,  it  helps 
them  to  establish  a  social  network  and  tolerate  strong  emotions,  including 
negative  affect,  express  their  anger  directly,  and  make  use  of  available  social 
supports.,.,  . 
338 Two  types  of  group  therapy  in  cancer  medicine  can  be  identified: 
professionally-run  groups  and  self-help  or  lay-led  support  groups.  It  is  argued 
that  the  group  setting  can  provide  a  supportive  atmosphere  to  share  feelings  and 
experiences  with  others  who  "are  in  the  same  boat".  This  means  that  the  use  of 
support  groups  can  be  viewed  as  an  effective  intervention  to  help  cancer 
patients  and  their  families  [3,36].  People  participate  in  support  groups  because 
of  the  benefits  of  seeing  and  talking  with  others  experiencing  the  same  problem 
[2].  Support  groups  are  being  formed  increasingly  and  it  is  felt  that  these  groups 
are  a  potential  resource  for  individuals  living  with  chronic  illness  -  individuals 
with  potential  risk  of  developing  psychological  morbidity.  Only  a  few  studies 
have  reported  that  support  groups  are  of  little  value  to  patients  and  their  families 
[15].  Fewer  still,  demonstrate  that  support  group  attenders  may  suffer  from 
negative  experiences  [12]. 
To  explore  the  issue,  this  paper  reports  the  results  of  a  descriptive  study  carried 
out  in  the  West  of  Scotland.  The  main  purpose  of  the  study  was  to  investigate 
the  views  of  people  who  participated  in  a  cancer  support  group  known  as  "Talc 
Tent"  which  is  the  Old  Scots  for  "Take  Care".  It  sought  to  look  at  attenders 
characteristics  to  find  out:  who  they  are,  their  clinical  background,  their 
concerns,  needs,  and  problems,  and  how  they  evaluate  their  own  health  status 
and  quality  of  life. 
Tak  Tent  began  in  the  University  Department  of  Clinical  Oncology,  Glasgow 
Gartnavel  General  Hospital  in  1980,  then  spread  to  other  parts  of  the  West  of 
339 Scotland  [4].  There  are  14  Tak  Tent  groups  and  their  membership  is  made  up  of 
patients,  relatives  and  friends,  and  professionals.  The  mission  statement  of  the 
group  is:  "to  promote  the  care  of  cancer  patients,  their  families,  friends,  and  the 
staff  involved  professionally  in  cancer  care  by  providing  practical  and 
emotional  support".  Usually,  the  size  of  the  groups  range  from  10  to  20 
members  in  each  monthly  meeting  [32). 
Tak  Tent  offers  the  following  support  programmes: 
1.  Informational  support:  Tak  Tent  provides  up-to-date  information  for  all  those 
affected  by  cancer  which  can  be  used  to  help  them  cope  with  everyday  problems 
which  they  might  face. 
2.  Counselling  support:  this  is  a  service  for  patients  and  their  families  both  via 
telephone  services  and  face-to-face  individual  counselling  by  trained 
counsellors.  Counselling  is  based  on  conventional  psychotherapy  methods  with 
regard  to  each  individual's  circumstances  [21].  These  include  discussion  of 
feelings,  problems  and  solutions;  teaching  basic  relaxation  techniques; 
emphasising  patients'  ability  to  help  self;  giving  suggestions  on  communication 
of  feelings;  etc. 
3.  Regular  group  meetings:  usually  in  each  meeting  there  is  an  invited  speaker 
who  discusses  about  different  topics  ranging  from  cancer-related  topics  to 
issues  related  to  participants'  daily  life.  Sometimes  a  group  member  may 
present  a  specific  topic  related  to  his  or  her  experience.  If  patients  or  other 
group  members  choose  to  talk  about  their  experience  of  cancer,  the  rest  of  the 
group  will  treat  this  in  confidence  [30]. 
340 4.  Emotional  support:  recently,  the  Tak-Tent  Resource  Centre  has  opened  and 
the  co-ordinator,  formerly  a  MacMillan  Nurse,  sees  patients  and  relatives  in  the 
centre,  giving  emotional  support. 
5.  Social  activities:  this  includes  social  evenings,  excursions,  and  visiting  other 
groups.  The  groups  also  act  for  practical  help  in  the  community. 
However,  of  these,  counselling  and  emotional  support  and  group  meetings  are 
the  most  important  components  of  the  Tak  Tent  activities. 
Methods 
Data  collection 
A  descriptive  study  was  carried  out  by  means  of  a  structured  interview  with 
patients  and  relatives  participating  in  Tak  Tent  meetings  in  the  West  of 
Scotland.  To  interview  people,  after  permission  by  the  Executive  Committee, 
one  of  us  (A.  M)  took  part  in  all  active  groups  on  several  occasions.  The 
following  groups  were  active  at  the  time  of  investigation:  Campbeltown,  East 
Kilbride,  Glasgow  Southern  General,  Glasgow  South  Side,  Hamilton,  and 
Paisley.  In  each  group  the  study  was  explained  to  participants,  and  those  who 
wished  to  participate  in  the  study  were  interviewed  using  study-specific 
questionnaires. 
Subjects 
Initially  the  study  population  was  divided  into  two  sub-groups:  "patients"  and 
"relatives".  All  present  members  in  the  six  Tak  Tent  groups  at  the  time  of 
341 investigation  agreed  to  take  part  in  the  study  and  there  were  no  refusals,  giving 
a  response  rate  of  100%  -  31  patients  and  40  relatives. 
Measures 
Although  standardised  measures  are  available  to  assess  satisfaction  with  health 
care  and  service  programmes,  two  questionnaires  were  constructed:  one  for 
patients,  consisting  of  22  questions  and  the  other  for  relatives  with  20  questions. 
The  aim  was  to  develop  a  study-specific  questionnaire  for  using  in  a  larger 
study  on  quality  of  life  in  patients  with  cancer  (using  standards  measures).  The 
questions  was  governed  by  a  combination  of  previous  research  findings  and  the 
desire  to  take  advantage  from  face-to  face  interviewing  of  study  subjects. 
Demographic  status.  Demographic  variables  included  sex,  age,  marital  status 
and  Deprivation  Category  (Depcat)  as  an  indicator  of  socio-economic  status 
(Carstairs  and  Morris  Depcat  Index)  [5].  The  deprivation  categories  range  from 
I  (affluent)  to,  7  (deprived). 
Clinical  status.  Clinical  background  was  investigated  by  asking  participants  to 
identify  cancer  type,  treatment  modality,  and  time  since  the  disease  was 
diagnosed. 
Psychological  effects.  To  study  the  psychological  effects  of  diagnosis  and 
consequent  outcomes  on  patients  and  relatives  three  measures  were  applied:  the 
time  it  took  to  cope  with  diagnosis;  their  most  important  concern  both  at  past 
and  present.  These  were  open-ended  questions. 
Satisfaction.  The  satisfaction  with  care  and  support  were  measured  on  a4  point 
Likert  scale  ranging  from  1  to  4  (very  satisfied  to  not  at  all).  In  addition, 
342 patients  but  not  relatives  were  asked  to  indicate  whether  they  received  any 
counselling  during  the  course  of  treatment  and  at  present.  Furthermore,  patients 
were  asked  about  support  they  were  receiving  from  their  family  (either  within 
the  household  or  outside  the  home),  and  from  friends  or  neighbours. 
Global  health  and  quality  of  life.  There  were  two  questions  on  health  and  global 
quality  of  life.  The  respondents  were  asked  to  rate  their  perceived  health  on  a5 
point  scale  ranging  from  0  to  4  (very  poor  to  very  good).  They  rated  their 
quality  of  life  on  a7  point  scale  ranging  from  0  to  6  (extremely  poor  to 
excellent).  Relatives  were  asked,  in  addition,  to  describe  their  associated 
patients'  health  and  quality  of  life.  The  above  scale  was  used  with  the  additional 
category-dead. 
Needs  assessment.  Finally,  respondents  were  asked  to  identify  their  own 
important  needs  by  ranking  several  topics  including  symptom  relief,  emotional 
support,  social  support,  family  support,  informational  support,  counselling 
support,  and  better  treatment.  Questions  on  symptom  relief  and  treatment  issues 
were  not  asked  of  patients'  relatives.  Apart  from  these  topics,  patients  (not 
relatives)  were  asked  to  indicate  their  problems  with  regard  to  home  duties, 
shopping,  transportation,  finance,  and  other  problems. 
Analysis 
The  data  were  analysed  in  a  descriptive  fashion  using  Epi-info  version  5,  a 
multi-purpose  computer  programme  for  epidemiological  researchers,  produced 
jointly  by  the  Centres  for  Disease  Control,  Atlanta,  and  the  World  Health 
Organisation,  Geneva  [26].  Based  on  the  study  objectives  and  due  to  the  small 
343 sample  size,  analysis  was  limited  to  a  descriptive  method  containing  numbers 
and  percentages  (mean  scores  and  standard  deviations  where  necessary)  of 
responses  for  each  response  category  of  each  variable. 
Results 
Demographic  and  clinical  status 
The  demographic  and  clinical  characteristics  of  patients  (n  =  31),  and  relatives 
(n  =  40)  are  shown  in  Table  1.  The  majority  of  both  were  females-87%  and  72% 
respectively.  The  mean  age  for  patients  was  55.5  years  ranging  from  25  to  77, 
and  for  relatives  was  56.5  years  ranging  from  24  to  78.  The  study  results 
suggest  that  the  majority  of  people  attending  Tak  Tent  are  from  middle  class 
background-  24  patients  (77%)  and  28  relatives  (69%).  Twelve  patients  (39%) 
survived  more  than  five  years.  Sixteen  relatives  stated  the  same  proportion  of 
survival  (40%)  for  their  ill  family  members.  Six  patients  (19%)  were  newly 
diagnosed  (less  than  1  year).  This  figure  for  those  of  relatives  was  very  similar 
(20%).  In  eleven  of  the  patients  interviewed,  breast  cancer  was  the  main. 
diagnosis  (36%),  while  seven  of  the  relatives  interviewed  reported  lung  cancer 
(18%)  as  the  main  diagnosis  of  their  patients. 
Since  twenty-six  relatives  (65%)  reported  that  their  patients  had  died,  there  is 
not  a  direct  match  between  patients  and  relatives  and  this  influences  the 
findings  that  follow.  Eleven  patients  (36%)  stated  that  they  were  under 
treatment  at  present  time,  while  relatives  reported  that  five  of  their  associated 
patients  were  under  treatment  (13%).  Seventeen  patients  (55%)  reported  that 
344 they  received  combined  therapy.  Relatives  said  that  eleven  of  their  associated 
patients  received  surgery  (28%). 
The  relationship  of  relatives  to  their  patients  was  studied.  Nine  of  the  relatives 
(23%)  were  wives  and  the  same  proportion  were  husbands  (23%),  three  mothers 
(8%),  four  sisters  (10%),  four  daughters  (10%),  and  eleven  fell  in  the  category 
of  others  which  included  friends,  nurses,  sisters-in-law,  brothers-in-law,  etc. 
(26%). 
Satisfaction  with  care  and  support 
The  respondents  were  asked  to  identify  whether  they  were  satisfied  with  the 
care  and  support  they  received.  Eighteen  patients  (58%)  stated  that  they  were 
"very  satisfied"  with  the  care  they  received  or,  were  receiving,  whereas  most 
relatives  (60%)  claimed  that  they  were  "fairly"  satisfied  with  the  care  their 
relatives  had  received  or  were  receiving.  Sixteen  patients  (52%)  and  twenty- 
eight  relatives  (70%)  stated  that  they  were  "very  satisfied"  with  the  support  they 
were  receiving  from  Talc  Tent.  Five  patients  (16%)  and  six  relatives  (15%) 
identified  that  apart  from  Tak  Tent  they  receive  support  from  other  sources 
including  GP,  Church,  and  other  support  groups  (Table  2). 
Support  from  family  and  friends 
When  patients  were  asked  whether  they  were  receiving  any  support  from  their 
families,  21  patients  (68%)  responded  "always/almost  always",  5  (16%) 
345 "sometimes",  and  5  (16%)  "almost  never/never".  Twelve  patients  (39%)  stated 
that  they  received  support  from  friends  and  neighbours  "always/almost  always", 
13  (42%)  "sometimes",  and  6  (19%)  "almost  never/never".  Only  five  patients 
(16%)  indicated  that  they  had  received  counselling  support  from  their  cancer 
specialists  during  their  treatment,  and  three  (10%)  stated  that  they  received 
counselling  from  a  professional  counsellor  at  present. 
Coping  with  diagnosis 
To  find  out  how  long  it  took  to  cope  with  the  diagnosis,  patients  and  relatives 
described  different  feelings.  Nine  patients  (29%)  stated  that  they  coped 
"immediately"  (less  than  one  month),  14  (45%)  said  it  took  "several 
months/quite  long  time",  6  (19%)  stated  that  it  was  "on-going  process",  and  two 
patients  (7%)  reported  that  they  "never"  coped  with  their  cancer  diagnosis.  On 
the  other  hand,  4  relatives  (10%)  claimed  that  they  coped  "immediately",  19 
(47%)  stated  for  "quite  long  time"  they  did  not  cope  with  the  situation,  10 
(25%)  reported  it  was  "on-going  process",  and  7  (18%)  said  "never/forever".  As 
it  is  clear,  the  relatives  showed  a  quite  different  pattern  of  coping  style,  and 
compared  to  the  patients  it  took  longer  time  for  the  relatives  to  cope  with  the 
cancer  diagnosis. 
Most  important  concern  at  past  and  present 
The  main  concern  of  eleven  patients  at  the  time  of  diagnosis  of  disease  was  fear 
of  dying  (36%),  while  at  present  time  ten  patients  (32%)  claimed  that  their  main 
concern  was  fear  of  recurrence.  Ten  patients  (32%)  stated  that  they  wanted  to 
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diagnosis  were  worried  about  how  to  cope  with  the  disease  while  at  the  time  of 
interview,  five  patients  (16%)  hoped  to  be  cured.  Relatives  reported  different 
features  for  their  most  important  concern.  Ten  relatives  (25%)  indicated  that  at 
present  they  feel  depressed,  while  eleven  relatives  (27%)  stated  that  they  were 
worried  at  the  time  of  the  diagnosis.  Seven  relatives  (18%)  reported  that  they 
had  some  hopes  that  their  patients  would  get  better,  whereas  as  time  went  on, 
this  figure  reduced  to  five-13%  (Table  3). 
Perceived  health  and  global  quality  of  life 
The  mean  score  of  perceived  health  for  patients  was  2.5  (SD  =  0.85)  and  3.4 
(SD  =  1.05)  for  relatives,  indicating  that  they  perceived  their  own  health  as 
being  good  (patients)  and  very  good  (relatives).  Since  a  low  score  indicates  poor 
health,  this  means  patients  rated  their  health  poorer  as  compared  to  the  relatives. 
The  mean  scores  of  global  quality  of  life  for  patients  and  relatives  were  the 
same-  4.5  (SD  =  0.96)  and  4.4  (SD  =  1.2)  respectively.  This  indicates  both 
patients  and  relatives  rated  their  own  quality  of  life  between  moderately  good 
and  good. 
When  relatives  were  asked  to  describe  the  health  and  quality  of  life  of  their 
patients,  the  mean  scores  became  3.6  and  4.8,  indicating  that  the  survivors  have 
good  health  and  moderately  good  quality  of  life  as  perceived  by  their  relatives 
(relatives  who  reported  that  their  patients  had  died  were  excluded  from 
analysis). 
347 Needs  assessment 
Sixteen  patients  (52%)  indicated  that  symptom  relief  and  family  support  were 
their  important  needs,  while  twenty-one  relatives  (53%)  stated  that  they  needed 
counselling  (with  a  professional  counsellor)  and  informational  support.  The 
remaining  15  patients  stated  that  they  need  emotional  support  (13%), 
informational  support  (13%),  better  treatment  (13%)  and  counselling  support 
(100/9),  whereas  the  remaining  19  relatives  reported  that  they  need  family 
support  (18%),  emotional  support  (15%),  and  15%  told  that  they  have  no 
special  needs. 
In  addition  patients  were  asked  to  identify  their  main  problems  at  the  present 
time.  Ten  patients  (32%)  reported  that  they  have  no  problem,  five  (16%) 
responded  difficulties  in  doing  home  duties,  four  (13%)  financial,  three  (10%) 
shopping  and  transportation,  and  six  (29%)  claimed  that  they  had  other 
problems  including  pain,  lack  of  support  from  GP,  other  physical  disability, 
psychological  distress  and  adjustment  problems. 
Discussion 
This  paper  presents  data  collected  from  patients  and  relatives  who  take  part 
every  month  in  a  cancer  support  group.  The  results  show  that  married  females, 
middle  class  people,  aged  50  to  69  years  old  mostly  attend  Tak  Tent  cancer 
support  group.  This  result  is  in  line  with  that  of  Chesler  et  al.  [7]  and  Slevin  et 
al.  [29]  which  indicated  that  women  are  more  likely  than  men  to  use  cancer 
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characteristics  between  patients  who  attend  cancer  support  group  and  relatives' 
patients  (see  Table  1).  Studies  have  shown  that  female  survivors  will  come 
primarily  from  patients  with  breast  cancer  while  among  men  the  largest 
numbers  of  survivors  would  be  patients  with  prostate,  colorectal,  and  bladder 
cancers.  Lung  cancer  survivors  for  both  males  and  females  are  few  [1].  Thus, 
since  in  this  study  most  participants  were  female,  both  as  patients  and  relatives, 
it  is  possible  to  say  that  within  the  patient  group  the  prevalence  of  breast  cancer 
was  high  whereas  most  relatives  reported  their  patients  had  lung  cancer-who 
already  have  died  of  their  disease.  Obviously,  this  also  explains  why  there  were 
differences  in  the  pattern  of  treatment. 
The  findings  of  this  study  suggest  that  for  relatives  a  longer  process  of  coping 
was  apparent.  However,  some  patients  and  relatives  stated  that  coping  with  the 
diagnosis  is  a  continuing  process.  This  means  that  as  time  passes,  they  being  to 
come  to  terms  with  the  idea  of  having  cancer.  A  patient  reported  that  "the  initial 
shock  could  take  up  to  6  months,  then  eases,  but  never  really  goes  away". 
Another  patient  stated  that  "I  guess  it  would  always  be  at  the  back  of  my  mind, 
but  life  is  for  living". 
The  most  important  concern  of  patients  at  the  time  of  diagnosis  and  at  the 
present  time  may  explain  why  coping  is  a  continuing  process.  For  example,  it 
was  found  that  some  patients  were,  at  the  time  of  diagnosis,  worried  how  to 
cope  with  the  disease  while  now  hoped  to  be  cured.  It  appears  that  "hope"  and 
349 "coping"  to  some  extent  are  related.  Coping  can  be  seen  as  strategies  used  to 
deal  with  threat  and  it  is  argued  that  variables  that  affect  coping  include: 
interpersonal,  environmental,  and  illness-related  factors  [22].  On  the  other  hand, 
hope  is  multi-dimensional,  process  oriented,  and  a  complex  of  many  thoughts, 
feelings,  and  actions  that  change  with  time  [8].  Relatives  showed  different 
responses  to  hope  and  coping.  Some  relatives  reported  that  they  had  initial 
hopes  that  their  patients  would  be  cured,  but  with  time,  their  hopes  diminished 
and  instead,  they  began  to  experience  depression,  and  only  a  few  stated  that  they 
were  managing  to  cope  with  the  situation  (see  Table  3).  Recent  studies  have 
shown  that  relatives  of  newly  diagnosed  cancer  patients  report  high  levels  of 
concerns  and  psychological  distress  and  deserve  greater  attention  than  they 
currently  receive  [14]. 
It  was  found  that  fear  of  dying  changed  to  fear  of  recurrence.  Cancer  is  feared 
perhaps  because  in  many  cases  after  all  it  is  a  fatal  disease  [18]  and  concern 
about  fear  of  recurrence  at  present  time  can  be  easily  understood.  Recurrence 
may  cause  the  past  experiences  to  be  remembered  for  example  the  difficult  time 
of  being  in  hospital  or  treatment  period  [20].  Others  observed  that  many  cancer 
survivors  worry  about  suffering  a  recurrence  and  about  developing  a  secondary 
cancer  [16].  According  to  one  patient  "hoping  I  never  need  be  in  hospital.  Being 
at  hospital  scares  me".  In  a  study  on  attitudes  of  cancer  patients  a  similar  finding 
was  reported.  The  study  described  that  a  continuous  remembering  of  the 
treatment  experience  was  evident  among  cancer  patients;  sometimes  called 
flash-back  phenomena  [34]. 
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life  were  found  to  be  good  for  both  patients  and  their  relatives.  One  might  argue 
that  global  measurement  does  not  reflect  the  problems  patients  and  their 
families  are  facing.  However,  several  studies  indicate  that  quality  of  life 
improved  with  a  cancer  diagnosis  [11,13].  This  was  attributed  to  the  fact  that 
cancer  patients  might  experience  increased  empathy  and  understanding  from 
others  as  well  as  a  positive  image  of  life  after  their  cancer  diagnosis.  In  a  study 
in  the  Netherlands  [33]  it  was  found  that  cancer  patients  had  more  positive 
social  experiences  than  the  normal  population.  It  is  argued  that  cancer 
experience  often  brings  with  it  benefits  including  strengthened  relationships, 
appreciation  of  life,  and  enhancement  of  self-concept  [19,34]. 
Compared  to  other  studies,  patients  in  our  study  showed  fewer  problems.  For 
example,  in  the  Home  Care  study  [23]  the  authors  reported  that  14%  of  patients 
needed  help  with  personal  care,  51%  needed  help  with  household  tasks,  and 
58%  reported  needing  help  with  transportation  while  in  this  study  the  most 
common  response  (32%)  indicated  that  the  patients  had  no  problem. 
Finally,  as  patients  and  their  relatives  indicated,  one  might  conclude  that  cancer 
support  groups  could  be  seen  as  a  useful  means  of  allowing  cancer  survivors  to 
share  their  experiences  and  at  least  overcome  some  of  their  own  problems  and 
develop  their  own  social  networks.  It  is  also  interesting  to  note  the  continued 
attendance  of  relatives 
.  of  deceased  cancer  patients  who  presumably  are  still 
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suggested  that  with  the  increasing  care-burden  imposed  on  families,  the  level  of 
distress  they  experience  and  their  importance  for  patients'  well-being,  non- 
provision  of  support  services  for  relatives  may  be  short-sighted  [9]. 
It  is  difficult  to  come  to  a  general  conclusion  from  such  a  small  study.  However, 
since  the  majority  of  participants  indicated  that  they  were  very  or  fairly  satisfied 
with  the  support  they  received,  it  seems  that  there  is  need  to  encourage  cancer 
patients  and  their  families  to  take  part  in  one  of  the  existing  cancer  support 
groups  and  they  should  be  informed  about  the  existence  of  cancer  support 
groups.  This  may  help  to  reduce  the  burden  of  disease  and  enhance  quality  of 
life  in  individuals  who  are  suffering.  In  contrast,  a  rather  sizeable  percentage  of 
the  respondents  appeared  not  to  be  entirely  satisfied  with  the  support  they  were 
received  (Table  2).  This,  however,  need  to  be  taken  as  a  signal  that  programmes 
are  not  working  optimally.  It  would  seem  essential  that  Tak  Tent  co-ordinators 
devote  more  attention  to  identifying  aspects  of  their  programmes  where 
participants  were  relatively  dissatisfied. 
Those  who  are  attending  Tak  Tent  groups  are  not  representative  of  the  larger 
population  of  patients  and  their  relatives.  Thus,  it  is  not  clear  whether  those  who 
chose  not  to  take  part  in  support  groups  would  benefit  from  doing  so.  It  would 
be  interesting  to  carry  out  a  study  on  non-member  or  non-attendance  for  these 
support  groups.  It  may  be  that  the  majority  of  patients  and  relatives  feel  no  need 
for  such  support  groups  or  that  they  prefer  other  approaches  based  on  individual 
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earlier,  Tak  Tent  provides  telephone  services  and  individual  counselling  and 
many  of  patients  and  relatives  use  these  services  and  do  not  attend  group 
meetings.  The  study  of  the  characteristics  of  these  people  could  be  a  potential 
area  for  further  investigation.  This  may  also  explain  why  relatively  a  few 
numbers  of  people  attend  group  meetings.  It  would  be  stimulating  to  investigate 
why  so  few  patients  take  advantage  of  the  availability  of  support  groups.  Is  it  a 
problem  of  accessibility,  lack  of  awareness  of  their  availability,  lack  of  interest 
in  this  approach  to  providing  support,  or  a  combination  of  such  factors?  These, 
however,  remain  to  be  answered. 
On  the  other  hand,  cancer  support  groups  require  to  develop  their 
communication  network  to  inform  patients  and  their  families  more  effectively 
and  efficiently.  Also  in  order  to  offer  appropriate  support  and  information  to 
patients  and  their  families  it  is  important  that  at  least  some  members  of  support 
groups  have  received  training  in  group  dynamics  and  listening  and 
communication  skills. 
It  seems  that  symptom  relief  and  family  support  for  patients,  and  counselling 
and  informational  support  for  relatives  are  the  most  important  needs  which 
should  be  considered.  For  those  who  do  not  have  a  support  system,  more 
psychosocial  care  may  be  necessary  and  counselling  services  should  be 
provided. 
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357 Table  1.  Respondents  demographic  and  clinical  characteristics 
Patients  (n  =  31)  Relatives  (n  =  40) 
%  (No.  )  %  (No.  ) 
Sex: 
Male  13(4)  28(11) 
Female  87(27)  72(29) 
Age: 
Mean  (SD)  55.5  (12.8)  56.5  (11.7) 
Range  -  25-77  24-78 
Marital  Status: 
Married  58  (18)  65  (26) 
Single  13  (4)  3  (1) 
Widowed/Divorced/Separated  29  (9)  33  (13) 
Deprivation  Category: 
Affluent  10  (3)  13  (5) 
Middle  77(24)  69(28) 
Deprived  13  (4)  18  (7) 
Type  of  Cancer:  * 
Breast  36(11)  15  (6) 
Lymphoma  20  (6)  5  (2) 
Lung  7  (2)  18  (7) 
Prostate  0  8  (3) 
Bowel  0  10  (4) 
Other  37  (12)  46  (18) 
Time  since  diagnosis: 
Less  than  1  year  19  (6)  20  (8) 
1-5  years  42(13)  40(16) 
More  than  5  years  39(12)  40  (16) 
Receiving  Treatment: 
Yes  36(11)  13  (5) 
No  64(20)  87(35) 
Type  of  treatment: 
Radiotherapy  7  (2)  15  (6) 
Chemotherapy  10  (3)  18  (7) 
Surgery  29  (9)  28(11) 
Combined  55  (17)  25  (10) 
Other  0  15  (6) 
*  This  information  identified  by  relatives  are  those  refers  to  of  the  patients  in  their  own  family 
members. 
358 Table  2.  Satisfaction  with  care  and  support 
Patients  (n  =  31) 
%  (No.  ) 
Relatives  (n  =  40) 
%  (No.  ) 
Satisfaction  with  care: 
Very  58(18)  38(15) 
Fairly  39  (12)  60(24) 
A  little  3  (1)  2  (1) 
Not  at  all  0  0 
Support  receiving: 
From  one  source  (Tak  Tent  only)  84  (26)  85  (34) 
From  more  than  one  source  (Ta  16  (5)  15  (6) 
Tent  and  others) 
Satisfaction  with  support: 
Very  52  (16)  70(28) 
Fairly  45  (14)  27(11) 
A  little  3  (1)  0 
Not  at  all  0  3  (1) 
359 Table  3.  Patients'  and  relatives'  the  most  important  concern  at  the  time  of 
diagnosis  and  the  present  time 
Concern  at  diagnosis 
%  (No.  ) 
Concern  at  present 
%  (No.  ) 
(a)  Patients  (n  =  31): 
How  to  cope  19  (6)  0 
Hopes  0  16  (5) 
Fear  of  dying  36(11)  0 
Fear  of  recurrence  0  32(10) 
Life  and  health  16  (5)  0 
Good  life  and  living  0  32(10) 
Family  29  (9)  10  (3) 
None  0  10  (3) 
(b)  Relatives  (n  =  40): 
Hopes  18  (7)  13  (5) 
Worries  27(11)  20  (8) 
Fear  of  loss  13  (5)  0 
Depression  0  25  (10) 
Patients'  ability  to  cope  25  (10)  0 
Coping  myself  0  20  (8) 
Patients'  suffering  15  (6)  0 
Patients'  well-being  0  15  (6) 
Providing  support  3  (1)  0 
None  0  10  (4) 
360 Appendix  III 
Letter  sent  to  General  Practitioners  in 
Stobhill  Hospital  catchment  area 
361 STOBHILL 
NHS  TRUST 
Stobhill  NHS  Trust 
Balomock  Road,  Glasgow  G21  3UW 
Telephone:  0141-201  3000  Dr  Mi] 
Irax  Numbers  041.557.0468 
Dear 
DKPARTMSMT  OF  RZ8PIRATORY  M=DICIKZ  kA 
Consultant  Physicians 
NHS  TRUST  Dr  Gavin  Boyd  ý}  41  201  3716 
Dr  Robert  Milroy  0141  201  3714 
Stobhill  NHS  Trust 
Balomock  Road,  Glasgow  G21  3UW 
Telephone:  0141-201  3000  Dr  Milroy'  a  secretary  0141  201  3715 
Fax  Numbers  041.557.0468 
RM.  ZM 
22nd  December  1994 
A  survey  of  the  needs  and  quality  of  life  of  patients  with  chronic 
respiratory  problems  and  who  attend  the  Stobhill  Respiratory  Department, 
is  planned.  The  Department  of  Public  Health,  Glasgow  University  in 
association  with  the  Health  Gains  Commissioning  programme  of  GGHB  and  with 
support  from  the  Area  Clinical  Audit  Committee  are  helping  Stobhill  Hospital 
with  this  study.  This  prospective  audit  will  act  as  a  pilot  for  a  broader 
assessment  throughout  Greater  Glasgow  of  quality  of  life  issues  in  patients 
with  chronic  respiratory  disease,  especially  lung  cancer. 
we  would  like  your  assistance  in  this  Stobhill  audit  project  (protocol 
enclosed).  With  your  permission,  patients  you  consider  to  have  chronic 
respiratory  problems  and  who  have  been  referred  to  the  Respiratory  Clinic  at 
Stobhill  Hospital  will  be  asked  to  complete  3  questionnaires  (samples 
enclosed). 
Mr  Ali  Montazeri  (BSc,  MPH,  Dept  Public  Health)  has  considerable  insight 
into  studying  the  problems  with  assessing  quality  of  life.  He  will  visit 
patients  in  their  own  homes  to  administer  these  questionnaires  which  take 
about  20  minutes  to  complete.  He  will  be  blind  to  the  nature  of  their 
diagnosis. 
In  the  case  of  patients  who  subsequently  transpire  to  have  lung  cancer, 
further  estimations  of  quality  of  life  will  be  made  immediately  following 
diagnosis  and  3  months  after  diagnosis,  allowing  the  effects  of  diagnosis 
and  treatment  on  quality  of  life  to  be  assessed.  These  subsequent 
assessments  will  be  performed  at  the  Stobhill  Hospital  respiratory  clinic  or 
at  the  patients  own  home. 
This  prospective  audit  will  be  preceded  by  a  pilot  survey  to  determine  the 
most  practical  arrangements  for  organising  the  logistics  of  the  study. 
Could  you  please  indicate  on  the  enclosed  tear-off  slip  that  you  are  happy 
for  your  patients  to  be  included  and  return  it  to  me  in  the  envelope 
provided.  If  any  of  your  patients  are  actually  included  then  you  will  be 
contacted  by  our  Research  Coordinator,  Mrs  Jeanette  Henderson,  to  obtain 
your  approval. 
Thank  you  very  much  in  anticipation. 
Y  re  eine  y, 
ROBERT  MILROY 
Consultant  Physician 
Adk qVV 
W.  W  Ewo". 
N 
Hum 
1MdM  t'iot  "a  06 
OrgWtrAOw  Handel  Iblobw To:  Dr  Robert  Milroy 
Consultant  Physician 
Stobhill  NHS  Trust 
I  agree 
Q/ 
do  not  agree 
Q 
for  my  patients  to  be  included  in  a 
prospective  audit  addressing  quality  of  life  issues  in  patients  with  chronic 
respiratory  disease,  including  lung  cancer.  I  understand  I  will  be  informed 
of  any  patients  identified  for  inclusion  in  this  study  before  the  patients 
are  asked  to  participate. 
Please  print  Signature 
Name 
Practice  Address Appendix  IV 
Patient  introductory  format 
364 Study  Number: 
QUALITY  OF  LIFE  STUDY 
Chronic  Respiratory  Disease 
Consultant  :  Dr  R  Milroy  /  Dr  G  Boyd 
Date  of  Referral: 
Patient  Information 
Surname: 
First  Names: 
Unit  Number: 
Date  of  Birth: 
Address: 
Post  Code: 
Telephone  Number: 
Date  of  Stobhill  Appointment: 
Name  of  General  Practitioner: 
Address: 
Post  Code: 
Telephone  Number: 
Date  GP  contacted:  Cleared  Yes/No 
Date  patient  contacted: 
Date  and  time  of  Mr  Montazeri  Interview: 
Date  copy  sent  to  Ali  Montazeri: Appendix  V 
The  Nottingham  Health  Profile  Part  I 
366 THE  NOTTINGHAM  HEALTH  PROFILE 
©  HUNT,  McKENNA  &  McEWEN  1989 Please  do 
not  write 
In  this  margin 
LISTED  BELOW  ARE  SOME  PROBLEMS  PEOPLE  MIGHT  HAVE 
IN  THEIR  DAILY  LIVES. 
READ  THE  LIST  CAREFULLY  AND  PUT  A  TICK  IN  THE  BOX 
UNDER  YES  FOR  ANY  PROBLEM  THAT  APPLIES  TO  YOU 
AT  THE  MOMENT.  TICK  THE  BOX  UNDER  1  FOR  ANY 
PROBLEM  THAT  DOES  NOT  APPLY  TO  YOU. 
PLEASE  ANSWER  EVERY  QUESTION.  IF  YOU  ARE  NOT  SURE 
WHETHER  TO  ANSWER  YES  OR  NOT,  TICK  WHICHEVER  ANSWER 
YOU  THINK  IS  MOST  TRUE  AT  THE  MOMENT. 
YES 
YJ 
NO 
I'm  tired  all  the  time 
I  have  pain  at  night 
Things  are  getting  me  down 
YES  NO 
I  have  unbearable  pain 
I  take  tablets  to  help  me  sleep 
I've  forgotten  what  it's  like  to  enjoy  myself 
YES  NO 
I'm  feeling  on  edge 
I  find  it  painful  to  change  position 
I  feel  lonely 
Please  turn  over 
1) Please  do 
not  write 
In  this  margin 
I  can  only  walk  about  indoors 
I  find  it  hard  to  bend 
Everything  is  an  effort 
I'm  waking  up  in  the  early  hours 
of  the  morning 
I'm  unable  to  walk  at  all 
I'm  finding  it  hard  to  make  contact 
with  people 
r, 
YES  NO 
YES  NO 
REMEMBER  IF  YOU  ARE  NOT  SURE  WHETHER  TO  ANSWER  "YES"  OR  "NO" 
TO  A  PROBLEM,  TICK  WHICHEVER  ANSWER  YOU  THINK  MORE  TRUE  AT 
THE  MOMENT. 
YES  NO 
The  days  seem  to  drag 
I  have  trouble  getting  up  and  down 
stairs  or  steps 
I  find  it  hard  to  reach  for  things 
YES  NO 
I'm  in  pain  when  I  walk 
I  lose  my  temper  easily  these  days 
I  feel  there  is  nobody  I  am  close  to 
Please  turn  over 
3 Please  do 
not  write 
in  this  margin 
YES  NO 
I  lie  awake  for  most  of  the  night 
I  feel  as  if  I'm  losing  control 
I'm  in  pain  when  I'm  standing 
YES  NO 
I  find  it  hard  to  dress  myself  _ 
I  soon  run  out  of  energy 
I  find  it  hard  to  stand  for  long  (e.  g.  at 
the  kitchen  sink,  waiting  for  a  bus) 
YES  NO 
I'm  in  constant  pain 
It  takes  me  a  long  time  to  get  to  sleep 
I  feel  I  am  a  burden  to  people 
YES  NO 
Worry  is  keeping  me  awake  at  night 
I  feel  that  life  is  not  worth  living 
I  sleep  badly  at  night 
Please  turn  over 
4 Please  do 
not  write 
in  this  margin 
YES  NO 
I'm  finding  it  hard  to  get  on  with  people 
I  need  help  to  walk  about  outside  (e.  g.  a 
walking  aid  or  someone  to  support  me) 
YES  NO 
I'm  in  pain  when  going  up  and  down 
stairs  or  steps 
I  wake  up  feeling  depressed 
I'm  in  pain  when  I'm  sitting 
v1 
NOW  PLEASE  GO  BACK  TO  PAGE  1  AND  MAKE  SURE  THAT  YOU 
HAVE  ANSWERED  "YES"  OR  "NO"  TO  EVERY  QUESTION,  ON 
ALL  FOUR  PAGES  OF  THE  QUESTIONNAIRE. 
THANK  YOU  FOR  YOUR  HELP 
a 
5 Appendix  VI 
The  EORTC  QLQ-C30  and  QLQ-LC13 
372 EORTC  QLQ-C30 
We  are  interested  in  some  things  about  you  and  your  health.  Please  answer  all  of  the 
questions  yourself  by  circling  the  number  that  best  applies  to  you.  There  are  no  "right" 
or  "wrong"  answers.  The  information  that  you  provide  will  remain  strictly  confidential. 
Please  fill  in  your  inititals: 
Your  birthdate  (Day,  Month,  Year): 
Today's  date  (Day,  Month,  Year): 
No  Yes 
1.  Do  you  have  any  trouble  doing  strenuous  activities, 
like  carrying  a  heavy  shopping  bag  or  a  suitcase?  1  2 
2.  Do  you  have  any  trouble  taking  a  long  walk?  1  2 
3.  Do  you  have  any  trouble  taking  a  short  walk  outside  of  the  house?  1  2 
4.  Do  you  have  to  stay  in  a  bed  or  a  chair  for  most  of  the  day?  .1  2 
5.  Do  you  need  help  with  eating,  dressing,  washing  yourself  or 
using  the  toilet?  1  2 
6.  Are  you  limited  in  any  way  in  doing  either  your  work  or  doing 
household  jobs?  1  2 
7.  Are  you  completely  unable  to  work  at  a  job  or  to  do  household  jobs?  1  2 
During  the  past  week:  Not  at  A  Quite  Very 
All  Little  a  Bit  Much 
8.  Were  you  short  of  breath?  1  2  3  4 
9.  Have  you  had  pain?  1  2  3  4 
10.  Did  you  need  to  rest?  1  2  3  4 
11.  Have  you  had  trouble  sleeping?  1  2  3  4 
12.  Have  you  felt  weak?  1  2  3  4 
13.  Have  you  lacked  appetite?  1  2  3  4 
14.  Have  you  felt  nauseated?  1  2  3  4 
15.  Have  you  vomited?  1  2  3  4 
16.  Have  you  been  constipated?  1  2  3  4 
Please  Qo  on  to  the  next  aaae During  the  past  week:  Not  at  A  Quite  Very 
All  Little  a  Bit  Much 
17.  Have  you  had  diarrhea?  1  2  3  4 
18.  Were  you  tired?  1  2  3  4 
19.  Did  pain  interfere  with  your  daily  activities?  1  2  3  4 
20.  Have  you  had  difficulty  in  concentrating  on  things, 
like  reading  a  newspaper  or  watching  television?  1  2  3  4 
21.  Did  you  feel  tense?  1  2  3  4 
22.  Did  you  worry?  1  2  3  4 
23.  Did  you  feel  irritable?  1  2  3  4 
24.  Did  you  feel  depressed?  1  2  3  4 
25.  Have  you  had  difficulty  remembering  things?  1  2  3  4 
26.  Has  your  physical  condition  or  medical  treatment 
interfered  with  your  family  life?  1  2  3  4 
27.  Has  your  physical  condition  or  medical  treatment 
interfered  with  your  social  activities?  1  2  3  4 
28.  Has  your  physical  condition  or  medical  treatment 
caused  you  financial  difficulties?  1  2  3  4 
For  the  following  questions  please  circle  the  number  between  1  and  7  that 
best  applies  to  you 
29.  How  would  you  rate  your  overall  Dhvsical  condition  during  the  past  week? 
1234567 
Very  poor  Excellent 
30.  How  would  you  rate  your  overall  uali  of  life  during  the  past  week? 
1234567 
Very  poor  Excellent 
0  Copyright  1992  EORTC  Study  Group  on  Quality  of  Ufe.  All  rights  reserved. EORTC  OLO-LC13 
Patients  sometimes  report  that  they  have  the  following  symptoms.  Please  indicate  the  extent  to  which 
you  have  experienced  these  symptoms  during  the  past  week. 
During  the  past  week:  Notat  A  Quite  Very 
al  little  abit  much 
31.  How  much  did  you  cough?  1  2  3  4 
32.  Did  you  cough  blood?  1  2  3  4 
33.  Were  you  short  of  breath  when  you  rested?  1  2  3  4 
34.  Were  you  short  of  breath  when  you  walked?  1  2  3  4 
35.  Were  you  short  of  breath  when  you  climbed  stairs?  1  2  3  4 
36.  Have  you  had  a  sore  mouth  or  tongue?  1  2  3  4 
37.  Have  you  had  trouble  swallowing?  1  2  3  4 
38.  Have  you  had  tingling  hands  or  feet?  1  2  3  4 
39.  Have  you  had  hair  loss?  1  2  3  4 
40.  Have  you  had  pain  in  your  chest?  1  2  3  4 
41.  Have  you  had  pain  in  your  arm  or  shoulder?  1  2  3  4 
42.  Have  you  had  pain  in  other  parts  of  your  body?  1  2  3  4 
If  yes,  where?  .........................................  ........................  .. 
43.  Did  you  take  any  medicine  for  pain? 
1  No  2  Yes 
44.  If  yes,  how  much  did  it  help?  1  2  3  4 
Please  use  the  space  below  for  additional  comments  you  may  have: 
®Copyright  EORTC  Study  Group  on  Quality  of  Life.  NI  rights  reserved. 
3 
0 Appendix  VII 
Correspondence  with  the  EORTC  Quality  Of  Life  Unit 
and  user's  agreement 
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UNIVERSITY 
of 
GLASGOW 
26  July  1994 
Dr  Said  Serbouti 
Statistician 
EORTC  Data  Centre 
Ave  E  Mounier  83,  Bte  11 
1200  Brussels 
Belgium 
Dear  Dr.  Serbouti, 
As  a  Ph.  D.  student  in  the  Public  Health  Department,  University  of  Glasgow,  I 
am  writing  to  request  for  materials  on  Quality  of  Life  Studies.  Based  on  advice 
I  received  from  Dr.  Cull  I  would  like  to  ask  your  help.  Would  you  please 
kindly  send  me  relevant  literature,  supporting  documents,  and  the  EORTC 
QLQ-C30.  My  project  is  an  unsponsored  academic  work.  Therefore,  I  would 
be  most  grateful  if  you  could  arrange  for  me  to  be  able  to  use  EROTC  QLQ- 
C30. 
Thank  you. 
Yours  sincerely 
Ali  Montazeri 
DEPARTMENT  OF  PUBLIC  HEALTH 
University  of  Glasgow,  2  Lilybank  Gardens,  Glasgow  G12  8RZ 
Telephone:  0141-339  8855  Ext  Fax:  0141-330  5018 tEORTC 
ý 
t-tJn11M\Yl  (  )fj:  YLV.  au  M1  GW  RLV\al  11 
tl  I  M%1tniml  (A  Gumv 
International  Association  under  Belgian  law 
Said  Serbouti,  M.  S. 
Statistician  Quality  of  Life  Unit 
Tel  :  32.2.774.16.06 
EORTC  Data  Center 
Dear  Mr.  Montazeri, 
Mr.  Ali  Montazcri 
University  of  Glasgow 
Department  of  Public  Health 
2,  Lilybank  Gardens 
GB  -Glasgow  G128RZ 
Brussels,  5  August  1994. 
Thank  you  for  your  interest  in  the  EORTC  approach  to  quality  of  life  assessment  but  we  would  like  to 
have  some  more  information  about  your  unsponsored  academic  work  and  to  know  how  you  will  utilize 
our  information. 
We  have  recently  completed  an  international  field  study  of  the  most  recent  version  the  EORTC  quality  of 
life  questionnaire  the  EORTC  QLQ-C30.  This  questionnaire  is  designed  for  use  with  a  wide  range  of 
cancer  patient  populations,  and  is  intended  to  be  supplemented  by  tumor-specific  questionnaire  modules 
or supplements  (e.  g.,  lung  cancer,  breast  cancer,  head  and  neck  cancer,  etc.  ). 
The  empirical  results  to  date  are  quite  promising.  The  EORTC  QLQ-C30  has  proven  to  be  a  reliable 
and  valid  instrument  and,  importantly,  appears  responsive  to  changes  in  health  status  over  time. 
Please  note  that  the  QLQ-C30  is  a  copyrighted  instrument,  with  all  rights  reserved.  Written,  prior 
consent  of  the  EORTC  Study  Group  on  Quality  of  Life  is  required  for  its  use.  Conditions  for  its  use  are 
dependent  on  whether  it  will  be  employed  in  a  university-based  investigation,  in  which  case  its 
distribution  is free.  Or  in  a  study  that  is  carried  out  or  sponsored  by  the  pharmaceutical  industry,  its  use 
is  then  subject  to  a  royalty  fee.  The  current  fees  are  $2.500  for  studies  with  less  than  50  patients,  $5.000 
for  studies  with  50  patients  and  $10,000  for  studies  with  200  or  more  patients.  The  royalty  fee  is 
required  per  clinical  study.  The  funds  that  are  generated  through  the  copyright  arrangement  will  be  used 
exclusively  to  support  the  on-going  research  of  the  Study  Group  on  the  development  and  refinement  of 
quality  of  life  instruments. 
Enclosed  please  find  the  paper  entitled  "The  EORTC  QLQ-C30:  A  quality  of  life  instrument  for  use  in 
international  clinical  trials  in  oncology".  In  the  appendix  of  this  paper  you  will  find  the  English-language 
version  of  the  QLQ"C30.  The  questionnaire  is  available  in  most  European  languages. 
Thank  you  again  for  your  interest  in  our  work  and  for  your  reply. 
encl.:  3 
Sincerely  yo  rs, 
" 
k 
Said  Serbouti 
Avenue  E.  Mounier,  83  -  Bte  II"  1200  Brussels  "  Belgium  "  Tel.:  (02)  774.16.11  "  Telefax:  (02)  772.35.45 4 
ýý   +`' 
UNIVERSITY 
of 
GLASGOW 
12  August  1994 
Dr  Said  Serbouti 
Statistician  Quality  of  Life  Unit 
EORTC  Data  Centre 
Ave  E  Mounier,  83  -  Bte  11 
1200  Brussels 
Belgium 
Dear  Dr.  Serbouti, 
Thank  you  very  much  for  your  letter  of  5  August  1994,  and  for  the  enclosed 
materials. 
As  I  explained  before  I  am  doing  my  Ph.  D.,  in  the  Public  Health  Department, 
University  of  Glasgow,  on  quality  of  life  in  patients  with  ovarian  cancer.  I  am 
going  to  use  the  EORTC  QLQ-C30  alongside  the  Nottingham  Heath  Profile 
(NHP)  and  the  Rotterdam  Symptom  Checklist  (RSCL)  in  a  study  which  will  be 
carried  out  in  the  West  of  Scotland.  I  will  use  these  instruments  as  outcome 
measures  (not  in  a  clinical  trial)  to  provide  my  thesis.  These  questionnaires  are  not 
going  to  be  used  other  than  for  academic  purposes.  Thus,  again  I  would  like  ask 
your  permission  to  be  able  to  use  the  EORTC  QLQ-C30. 
I  hope  to  develop  computer-based  versions  of  these  tools  and  compare  them  with 
a  paper  and  pen  method.  I  wonder  if  you  have  any  information  on  computer-based 
quality  of  life  studies  in  general,  and  about  the  EORTC  QLQ-C30  in  particular.  If 
so  I  would  be  very  grateful  if  you  would  forward  it  to  me. 
Thank  you  once  more  for  your  assistance. 
Yours  sincerely 
Ali  Montazeri 
DEPARTMENT  OF  PUBLIC  HEALTH 
University  of  Glasgow,  2  Lilybank  Gardens,  Glasgow  G12  8RZ 
Telephone:  0141-359  8855  Ext  Fax:  0141-330  5018 ,,. 
EORTC LinýIx'.  un(kl  uxiiIpi  Ii  tivtimh 
afxlTnutnxi4iI  (anur 
International  Asxrciation  under  Belgian  law 
Said  Seibouti,  M.  S. 
Statistician  Quality  of  Life  Unit 
Tel  :  32.2.774.16.06 
EORTC  Data  Center 
Dear  Mr.  Montazeri, 
Mr.  Ali  Montazcri 
University  of  Glasgow 
Department  of  Public  Health 
2,  Lilybank  Gardens 
GB  -  Glasgow  G  128RZ 
Brussels,  30  August  1994. 
We  thank  you  for  your  letter  dd.  12  August  1994  and  in  order  to  make  the  User's  agreement  we  need  the 
exact  title  of  your  PhD  thesis. 
We  thank  you  in  advance  and  remain, 
Sincerely  yours, 
/\  ' 
ft  Said  Serbouti 
Avenue  E.  Mounier.  83  -  Bte  11  "  1200  Brussels  "  Belgium  "  Tel.:  (02)  774.16.11  "  Telefax:  (02)  772.35.45 amp 
UNIVERSITY 
of 
GLASGOW 
15  September  1994 
Dr.  Said  Serbouti 
Statistician  Quality  of  Life  Unit 
EORTC  Data  Centre 
Ave  E  Mounier,  83  -  Bte  11 
1200  Brussels 
Belgium 
Dear  Dr.  Serbouti, 
Thank  you  very  much  for  your  letter  of  30  August.  I  am  writing  to  inform  you 
about  my  new  proposed  study.  After  careful  consideration  I  find  that  I  am  unable 
to  recruit  enough  patients  with  ovarian  cancer  in  the  West  of  Scotland.  Instead,  I 
decided  to  continue  my  study  with  lung  cancer  patients.  As  you  know  the  West  of 
Scotland  has  the  highest  incidence  of  lung  cancer  in  the  world.  Thus,  I  am  going 
to  use  the  EORTC  QLQ-C30  and  EORTC  QLQ-LC13  alongside  the  Nottingham 
Heath  Profile  (NHP).  I  remind  you  that  I  will  use  these  instruments  as  outcome 
measures  (not  in  a  clinical  trial)  for  my  Ph.  D.  thesis.  These  questionnaires  are  not 
going  to  be  used  other  than  for  academic  purposes.  I  would  like  to  ask  your 
permission  to  be  able  to  use  the  EORTC  QLQ-C30  and  EORTC  QLQ-LC13.  Still 
I  hope  to  develop  computer-based  versions  of  these  tools  and  compare  them  with 
a  paper  and  pen  method. 
The  title  of  my  Ph.  D.  thesis  is:  "The  contribution  of  the  clinical  care  to  the  quality 
of  life  in  patients  with  cancer".  In  this  study  the  process  of  care  will  be  examined 
against  outcome,  with  outcome  measured  in  terms  of  quality  of  life  instead  of 
survival.  Subjects  are  patients  with  lung  cancer.  Thank  you  for  your  assistance. 
Yours  sincerely 
Ali  Montazeri 
DEPARTMENT  OF  PUBLIC  HEALTH 
University  of  Glasgow,  2  Lilybank  Gardens,  Glasgow  G12  8RZ 
Telephone:  0141-339  8855  Ext  Fax:  0141-330  5018 0`  EORTC IUIIMMLNl(  ý111411NN1kIf  I4N\111  It 
NXi  W%11111114111  19  (.  NN  IM 
International  Association  under  Belgian  61w 
EORTC  QLQ-C30  USER'S  AGREEMENT 
The  EORTC  Quality  of  Life  Study  Group  grants  permission  to  A.  Montazeri  to  employ 
the  EORTC  QLQ-C30  in  a  study  entitled  "The  contribution  of  the  clinical  care  to  the 
quality  of  life  in  patients  with  cancer  ". 
The  Study  Group  will  supply  A.  Montazeri  with:  (1)  the  QLQ-C30  in  the  currently 
available  languages;  and  (2)  the  standard  algorithms  for  scoring  the  QLQ-C30.  Use  of 
the  EORTC  QLQ-C30  in  the  above-mentioned  investigation  is  subject  to  the  following 
conditions: 
1.  A.  Montazeri  confirms  that  this  study  is  being  conducted  without  direct  or  indirect 
sponsorship  or  support  from  pharmaceutical,  medical  appliance  or  related,  for-profit 
health  care  industries. 
2.  A.  Montazeri  will  not  modify,  abridge,  condense,  translate,  adapt  or  transform  the 
QLQ-C30  or  the  basic  scoring  algorithms  in  any  manner  or  form,  including  but  not 
limited  to  any  minor  or  significant  change  in  wording  or  organization  of  the  QLQ-C30. 
3.  A.  Montazeri  will  not  reproduce  the  QLQ-C30  or  the  basic  scoring  algorithms  except 
for  the  limited  purpose  of  generating  sufficient  copies  for  its  own  use  and  shall  in  no 
event  distribute  copies  of  the  QLQ-C30  to  third  parties  by  sale,  rental,  lease,  lending,  or 
any  other  means.  Reproduction  of  the  QLQ-C30  as  part  of  any  publication  is  strictly 
prohibited. 
4.  Analysis  and  reporting  of  QLQ-C30  data  by  A.  Montazeri  should  follow  the  written 
guidelines  for  scoring  of  the  QLQ-C30  as  provided  by  the  EORTC  Study  Group  on 
Quality  of  Life. 
5.  This  agreement  holds  for  the  abovementioned  study  only.  Use  of  the  QLQ-C30  in  any 
additional  studies  of  A.  Montazeri  will  require  a  separate  agreement. 
Signed  and  dated  by: 
Said  Serbouti,  for  the 
EORTC  Quality  of  Life  Group 
£L").  Sq 
gned  and  dated  by: 
All  Montazeri,  for 
C  Department  of  Public  Health 
University  of  Glasgow 
3 
Registered  Office  avenue  E  Mounier  83  Bte  11  e  1200  Brussels  a  Belgium  a  Phone:  f32  2  774  16a  Fax.  f  32  2  772  35  45 
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UNIVERSITY 
of 
GLASGOW 
7  October  1994 
Dr.  Said  Serbouti 
Statistician  Quality  of  Life  Unit 
EORTC  Data  Centre 
Ave  E  Mounier,  83  -  Bte  11 
1200  Brussels 
Belgium 
Dear  Dr.  Serbouti, 
Thank  you  very  much  for  your  letter  of  22  September,  and  for  the  enclosed 
materials.  Please  find  enclosed  one  singed  user's  agreement.  As  I  mentioned 
before  I  am  going  to  use  the  EORTC  QLQ-C30  and  EORTC  QLQ-LC13 
alongside  the  Nottingham  Heath  Profile  (NHP).  Thus,  would  you  please  kindly  let 
me  know  whether  I  need  another  user's  agreement  on  QLQ-LC  13  or  not.  I  will 
collect  data  as  soon  as  possible  and  hopefully  I  shall  send  you  a  copy  of  my 
proved  protocol. 
Thank  you  in  advance. 
Yours  sincerely 
All  Montazeri 
DEPARTMENT  OF  PUBLIC  HEALTH 
University  of  Glasgow,  2  Lilybank  Gardens,  Glasgow  G12  8RZ 
Telephone:  0141-339  8855  Ext  Fax:  0141-330  5018 '  EORTC  nqxýinOr  inv.  iI  NtNtRtMVnh 
uxl  lnutnxvtt  tA  aixt  Y 
International  Association  under  Belgian  law 
i 
Said  Serbouti,  M.  S. 
Statistician  Quality  of  Life  Unit 
Tel  :  32.2.774.16.06 
EORTC  Data  Center 
Mr.  All  Montazeri 
University  of  Glasgow 
Department  of  Public  Health 
2,  Lilybank  Gardens 
GB-Glasgow  G12  8RZ 
Brussels,  12  October  1994. 
Dear  Mr.  Montazeri, 
Please  find  enclosed  the  key-scoring  algorithm  for  the  analysis  of  the  EORTC  questionnaire 
QLQ-C30.  No  other  user's  agreement  will  be  requested  by  us  if  you  use  the  QLQ-LC13  as 
well. 
Do  not  hesitate  to  contact  me  if  you  have  any  question  regarding  the  use  or  interpretation  of 
the  QLQ-C30 
I  wish  you  great  success  with  your  project  and  I  look  forward  to  hearing  from  you  as  the  study 
progresses. 
￿,, 
Sincerely  yours, 
Said  Serbouti 
Enc.  1 
Avenue  E.  Mounier.  83  -  Bte  11  "  1200  Brussels  "  Belgium  "  Tel.:  (02)  774.16.  )?.  Telefax:  (02)  772.35.45 Ad 
`t, 
ýY  ýý 
UNIVERSITY 
of 
GLASGOW 
16  February  1995 
Dr.  Said  Serbouti 
Statistician  Quality  of  Life  Unit 
EORTC  Data  Centre 
Ave  E  Mounier  , 
83  -  Bte  11 
1200  Brussels 
Belgium 
Dear  Dr.  Serbouti, 
Since  our  last  correspondence  I  was  preparing  for  the  study  to  begin.  I  started 
collecting  data  from  Ist  January  1995  and  this  will  continue  up  to  December.  I 
wish  to  inform  you  that  I  received  the  key-scoring  algorithm  for  the  analysis  of  the 
EORTC  QLQ-C30,  but  not  for  the  QLQ-LC13.  I  would  be  most  grateful  if  you 
could  help  me  with  a  copy.  Please  fined  enclosed,  a  copy  of  my  study  protocol. 
Your  comments  and  assistance  with  further  relevant  literature  will  be  most 
welcome. 
Yours  sincerely 
Ali  Montazeri 
DEPARTMENT  OF  PUBLIC  HEALTH 
University  of  Glasgow,  2  Lilybank  Gardens,  Glasgow  G12  8RZ 
Telephone:  0141-339  8855  Ext  Fax:  0141-330  5018 EORTC 
ýý 
Eu  Ckgarozatxm  kx  Re  wart  h 
and  ment  o(  Cancer 
International  Association  under  Belgian  Law 
Gwendoline  Kiebert 
Head  Quality  of  Life  Unit 
Tel  :  32.2.774.16.61 
Brussels,  February  20,1995 
Dear  Dr.  Montazeri, 
Thank  you  for  your  letter  and  outlines  of  your  study.  It  seems  a  very  interesting  study  to 
me.  I  did  not  know  that  Glasgow  is  the  leading  city  I  in  the  world  with  regard  to  the 
incidence  of  lung  cancer.  How  sad. 
I  enclose  a  copy  of  the  key  scoring  algorithm  of  the  lung  module.  Good  luck  with  your 
study,  and  please  keep  us  informed  about  your  study. 
For  your  information,  Dr.  Said  Serbouti  has  left  the  EORTC  since  last.  January 
Sincerely  yours, 
Gwendoline  Kiebert 
Registered  Office:  avenue  E.  Mounier  83  Bte  11.1200  Brussels  "  Belgium  "  Phone:  +  32  2  774  16  11  "  Fax:  +32  2  772  35  45 
E-mail:  eortc  @eoric.  be Appendix  VIII 
Study  specific  questionnaire 
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UNIVERSITY 
of 
GLASGOW 
Quality  of  Life  in  Patients  with  Chronic  Respiratory  Disease 
1995 
Dear  Sir/Madam, 
We  are  trying  to  study  how  to  improve  the  effectiveness  of  the  health  service  in 
improving  people's  quality  of  life.  But  before  any  action  can  be  taken  we  must 
know  what  people  think  about  their  own  health  and  what  they  think  their  quality 
of  life  is. 
The  following  questions  and  enclosed  questionnaires  are  designed  to  seek  your 
personal  experiences.  Your  GP  already  has  agreed  with  this  investigation.  It  is 
hoped  that  data  gained  from  you  and  other  people  who  have  agreed  to  help,  will 
improve  the  delivery  of  health  and  enhance  the  quality  of  life.  We  hope  you  will  be 
able  to  help  us  by  co-operating  with  this  research  project  and  are  grateful  to  you 
for  doing  so. 
The  information  you  give  will  be  treated  in  confidence-  Thank  you. 
No. 
Date  of  interview 
Address 
........................................................................................................................................ 
............................................................................................................. 
Post  code.......... 
Date  of  birth 
MF  Sex 
Marital  status 
Married 
Single 
Widowed 
Separated 
Divorced 
Living  with  a  partner 
Employment 
Employed  (full  time  or  part  time) 
Unemployed 
Housewife 
Retired 
Other 
DEPARTMENT  OF  PUBLIC  HEALTH 
University  of  Glasgow,  2  Lilybank  Gardens,  Glasgow  G12  8RZ 
Telephone:  0141-539  8855  Ext  Fax:  0141-330  5018 Education  111-.  1 
No  school  leaving  certificate 
School  certificate 
College/University  qualification 
Other 
House  ownership 
Owner  occupied 
Private  rented 
Rented  from  Council 
Rented  from  Housing  Association 
Other 
Type  of  accommodation 
Number  of  rooms  available 
Number  of  children 
How  often  do  your  children  who  left  home  visit  you? 
Always  (daily) 
Almost  always  (2-3  times  in  a  week/weekly) 
Sometimes  (monthly) 
Almost  never  (yearly) 
Never 
Do  they  help  you  in  any  way  (for  example  shopping,  cooking,  cleaning,  etc.  ) 
Always 
Almost  always 
Sometimes 
Almost  never 
Never 
Do  you  see  your  other  members  of  family  or  other  relatives? 
Always  (daily) 
Almost  always  (2-3  times  in  a  week/weekly) 
Sometimes  (monthly) 
Almost  never  (yearly) 
Never 
Do  they  help  you  in  any  way(for  example  shopping,  cooking,  cleaning,  etc.  ) 
Always 
Almost  always 
Sometimes 
Almost  never 
Never 
389 How  often  do  you  contact/visit  your  neighbours? 
Always  (daily) 
Almost  always  (2  or  3  times  in  a  week/weekly) 
Sometimes  (monthly) 
Almost  never  (yearly) 
Never 
Do  they  help  you  in  any  way?  (for  example  shopping,  cooking,  etc.  ) 
Always 
Almost  always 
Sometimes 
Almost  never 
Never 
Home  distance  from  Hospital  Mile  F1 
Have  you  been  admitted  to  hospital  for  any  treatment  during  the  last  year? 
Yes 
No  R 
Do  you  have  any  problems  travelling  for  your  treatment? 
Yes  B 
No 
What  are  they? 
........................................................................................................................................ 
Means  of  transport 
........................................................................................................................................ 
Do  you  have  a  car? 
Yes 
No  R 
"  Thank  you  very  much  for  your  help. 
To  be  completed  after  interview: 
Interview  setting 
Home 
Clinic 
Any  comments 
........................................................................................................................................ 
........................................................................................................................................ 
........................................................................................................................................ 
390 Appendix  IX 
Acceptability  questionnaire 
391 Study  Number: 
Acceptability  Questionnaire 
Q1.  Are  the  questions  easy  to  understand  in  general? 
Very  easy 
Moderately  easy 
Not  very  easy 
Not  at  all 
Q2.  Please  identify  difficult  questions? 
................................................................................................................................  .............. 
................................................................................................................................ 
Q3.  Are  the  options  provided  as  answers  adequate? 
.. 
Yes 
No 
Q4.  Did  you  find  the  questions  relevant  to  yourself? 
Very  relevant 
Moderately  relevant 
Not  very  relevant 
Not  at  all 
Q5.  Please  identify  questions  you  think  are  irrelevant: 
................................................................................................................................  .............. 
................................................................................................................................ 
Q6.  Do  you  prefer  to  rill  in  a  questionnaire  or  to  be  interviewed? 
.. 
Fill  in  a  questionnaire 
To  be  interviewed 
Either 
Don't  know 
Q7.  Do  you  find  it  difficult  to  fill  in  a  questionnaire  by  yourself? 
Very  difficult 
Quite  difficult 
Not  very  difficult 
Not  at  all 
Q8.  Can  you  give  reasons? 
............................................................................................................................... 
Q9.  Do  you  find  being  "interviewed"  comfortable? 
......... 
Very  comfortable 
Quite  comfortable 
Not  very  comfortable 
Not  at  all 
Q10.  Can  you  give  reasons? 
............................................................................................................................... 
Q11.  Do  you  prefer  to  be  interviewed  at  home  or  clinic? 
......... 
Home 
Clinic 
Either 
Don't  know 
Q12.  Any  other  comments? 
.............................................................................................................................. 
.............................................................................................................................. 
.............................................................................................................................. 
.............................................................................................................................. 
................ 
................ 
................ 
................ 
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Letter  sent  to  lung  cancer  patients  at  follow-up 
by  the  chest  physician 
393 STOBHILL 
Süd 
--a"ý1  rte'  "S 
. ý"  ý 
NHS  TRUST 
Stobhip  NHS  Trust 
Balornock  Road,  Glasgow  G21  3UW 
Telephone:  0141.2013000  Dr  MI 
Fax  Numbers  0141.557.046E 
RM.  EM 
7th  April  1995 
(Dictated  7.4.95) 
DIPARTMZNT  Ct  RZ8PIRATORY  MLDICINZ 
Consultant  Physicians  iiiý71ifl 
NHS  TRUST  Dr  Gavin  Boyd  0141  201  3716 
, 
Dr  Robert  Milroy  0141  201  3714 
Stobhip  NHS  Trust 
Balornock  Road,  Glasgow  G21  31  W 
Telephone:  0141.2013000  Dr  Milroy's  secretary  0141  201  3715  (Dirsot  lins) 
Fax  Numbers  0141.557.0468 
Dear 
You  may  remember  completing  a  questionnaire  with  Mr  Ali  Montazeri  around  the 
time  you  first  visited  the  Stobhili  Chest  Clinic  about  3  months  ago. 
I  am  interested  to  know  how  you  are  feeling  now.  I  would,  therefore,  like 
Mr  Montazeri  to  see  you  again  and  assess  how  you  are  feeling. 
If  you  have  no  objections  I  would  like  Mr  Montazeri  to  intereview  you  again 
in  the  near  future.  If  you  do  not  want  to  see  Mr  Montazeri  again  please 
telephone  Mrs  Jeanette  Henderson,  our  Research  Co-ordinator,  on 
0141.201.3973.  If  we  do  not  hear  from  you  in  the  next  week,  Mr  Montazeri 
will  either  telephone  you  or  write  to  you  to  arrange  an  appointment  to  see 
you  again.  This  appointment  will,  of  course,  be  tailored  for  your 
convenience. 
Thank  you  again  for  your  help.  We  hope  other  patients  will  benefit  in  the 
future  from  your  participation  in  this  important  research. 
Yours  sincerely, 
ROBERT  MILROY 
Consultant  Physician 
l 
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Letter  sent  to  lung  cancer  patients  at  follow-up 
by  the  researcher 
395 STO  BHI  LL 
NHS  TRUST  -- 
Stobhill  NHS  Trust 
Balornock  Road,  Glasgow  G21  3UW. 
Telephone:  041558  0111 
Dear 
.......................... 
You  will  recently  have  received  a  letter  from  Dr.  Robert  Milroy  regarding  my 
proposed  visit  to  assess  how  you  are  feeling.  I  am  unable  to  contact  you  by 
telephone,  but  propose  to  visit  you  at  home  on  .....................  at  .......... 
(a.  m.  /p.  m.  ). 
If  this  arrangement  does  not  suit  you,  please  telephone  me  at  ........................  and 
we  can  arrange  a  more  convenient  time  for  you. 
Thank  you  for  your  help. 
Yours  sincerely 
Ali  Montazeri 
Clinical  Research  Assistant  to  Dr.  Milroy Appendix  XII 
The  Nottingham  Health  Profile  user's  guide  for  data  analysis 
397 TABLE  V.  Weighted  Scores  for'YES'  Responses  on  Part  I 
Statement  Weight  Code 
I'm  tired  all  the  time  ..........................  39.20  EN1 
I  have  pain  at  night  ...........................  12.91  P1 
I  take  tablets  to  help  me  sleep  ...................  22.37  SL1 
Things  are  getting  me  down 
....................  10.47  EM1 
I  find  it  painful  to  change  position  ................  9.99  P3 
I'm  feeling  on  edge  ...........................  7.22  EM3 
I  feel  lonely  .................................  22.01  SOl 
I  can  only  walk  about  indoors 
...................  11.54  PM1 
I  have  unbearable  pain  ........................  19.74  P2 
I  find  it  hard  to  bend 
..........................  10.57  PM2 
Everything  is  an  effort  ......................... 
36.80  EN2 
I'm  unable  to  walk  at  all  .......................  21.30  PM3 
I'm  waking  up  in  the  early  hours  of  the  morning  ....  12.57  SL2 
I've  forgotten  what  is't  like  to  enjoy  myself  ......... 
9.31  EM2 
I'm  finding  it  hard  to  make  contact  with  people  .....  19.36  S02 
I'm  in  pain  when  I  walk  .......................  11.22  P4 
The  days  seem  to  drag 
.........................  7.08  EM4 
I  have  trouble  getting  up  and  down  stairs  or  steps  ... 
10.79  PM4 
I  find  it  hard  to  reach  for  things  .................  9.30  PM5 
I  lose  my  temper  easily  these  days 
............... 
9.76  EM5 
I  lie  awake  for  most  of  the  night  .................  27.26  SL3 
I  feel  as  if  I'm  losing  control  ....................  13.99  EM6 
I'm  in  pain  when  I'm  standing  ..................  8.96  P5 
I  feel  there  is  nobody  I  am  close  to  ...............  20.13  S03 
I  find  it  hard  to  dress  myself  ....................  12.61  PM6 
I  soon  run  out  of  energy  ....................... 
24.00  EN3 
I  find  it  hard  to  stand  for  long 
(eg  at  the  kitchen  sink,  waiting  for  a  bus)  ........  11.20  PM7 
I'm  in  constant  pain  ...........................  20.86  P6 
It  takes  me  a  long  time  to  get  to  sleep  ............. 
16.10  SL4 
I  feel  I  am  a  burden  to  people  ...................  22.53  S04 
Worry  is  keeping  me  awake  at  night  ..............  13.95  EM7 
I  feel  that  life  is  not  worth  living 
.................  16.21  EM8 
I  sleep  badly  at  night  ..........................  21.70  SL5 
I  need  help  to  walk  about  outside 
(eg  a  walking  aid  or  someone  to  support  me)  ..... 
12.69  PM8 
I'm  in  pain  when  going  up  and  down  stairs  or  steps  .. 
5.83  P7 
I  wake  up  feeling  depressed 
....................  12.01  EM9 
I'm  finding  it  hard  to  get  on  with  people  ........... 
15.97  S05 
I'm  in  pain  when  I'm  sitting  ....................  10.49  P8 
NB  It  should  be  noted  that  the  variable  code  is  not  related  to  the  ordering  of  items 
on  the  questionnaire. Coding  of  Part  1  Responses  by  Computer  Programme  (SPSS  Format) 
RECODE  EN1(1-39.2)/P1(1-12.91)/EM1(1-10.47)/P2(1-19.74) 
/SL1(1-22.37)/EM2(1-9.31)/EM3(1-7.22)/P3(1=9.99) 
/SO1(1=22.01)/PM1(1-11.54)/PM2(1-10.57)/EN2(1-36.8) 
/SL2(1-12.57)/PM3(1-21.3)/SO2(1-19.36)/EM4(1-7.08) 
/PM4(1-10.79)/PM5(1-9.3)/P4(1=11.22) 
RECODE  EM5(1-9.76)/SO3(1-20.13)/SL3/(1-27.26)/EM6(1=13.99) 
/P5(1-8.96)/PM6(1-12.61)/EN3(1-24)/PM7(1-11.2)/P6 
(1-20.86)/SL4(1-16.1)/SO4(1=22.53)/EM7(1-13.95)/EM8 
(1=16.21)/SL5(1-21.7)/SO5(1-15.97)/PM8(1=12.69)/ 
P7(1-5.83)/EM9(1-12.01)/P8(1-10.49) 
COMPUTE  TEN-EN1+EN2+EN3 
COMPUTE  TP=P1+P2+P3+P4+P5+P6+P7+P8 
COMPUTE  TEM-EM1+EM2+EM3+EM4+EM5+EM6+EM7+EM8+EM9 
COMPUTE  TSL-SL1+SL2+SL3+SL4+SL5 
COMPUTE  TSO-SO1+SO2+SO3+SO4+SOS 
COMPUTE  TPM=PMI+PM2+PM3+PM4+PM5+PM6+PM7+PMS 
MISSING  VALUES  EN1  to  P8  (9) 
ASSIGN  MISSING  TEN  TO  TPM(200) 
VARIABLES  EN1,  TIRED  ALL  THE  TIME/ 
P1,  PAIN  AT  NIGHT/ 
EM1,  THINGS  ARE  GETTING  HIM  DOWN/ 
P2,  UNBEARABLE  PAIN/ 
SL1,  NEEDS  TABLETS  TO  SLEEP/ 
EM2,  HAS  FORGOTTEN  HOW  TO  ENJOY  HIMSELF/ 
EM3,  FEELING  ON  EDGE/ 
P3,  PAINFUL  TO  CHANGE  POSITION/ 
SO1,  FEELS  LONELY/ 
PM1,  CAN  ONLY  WALK  INDOORS/ 
PM2,  HARD  TO  BEND/ 
EN2,  EVERYTHING  IS  AN  EFFORT/ 
SL2,  WAKES  UP  EARLY/ 
PM_,  IS  UNABLE  TO  WALK  AT  ALL/ 
SO2,  FINDS  IT  HARD  TO  CONTACT  F  )PLE/ 
EM4,  THE  DAYS  DRAG/ 
PM4,  FINDS  STAIRS  OR  STEPS  DIFFICULT/ 
PMS,  FINDS  IT  HARD  TO  REACH  FOR  THINGS/ 
P4,  HAS  PAIN  WHEN  WALKS/ 
EM5,  LOSES  TEMPER  EASILY/ 
S03,  CANNOT  GET  CLOSE  TO  ANYONE/ 
SL3,  LIES  AWAKE  FOR  MOST  OF  THE  NIGHT/ 
EM6,  THINKS  HE  IS  LOSING  CONTROL/ 
P5,  HAS  PAIN  WHEN  STANDING/ 
PM6,  FINDS  IT  HARD  TO  DRESS/ 
EN3,  SOON  LOSES  ENERGY/ 
PM7,  FINDS  IT  HARD  TO  STAND  FOR  LONG/ 
P6,  IS  IN  CONSTANT  PAIN/ 
SL4,  TAKES  A  LONG  TIME  TO  GET  TO  SLEEP/ 
$04,  FEELS  HE  IS  A  BURDEN  TO  OTHERS/ 
EM7,  WORRY  KEEPS.  HIM  AWAKE/ 
EM8,  FEELS  THAT  LIFE  IS  NOT  WORTH  LIVING/ 
SL5,  SLEEPS  BADLY  AT  NIGHT/ 
SO5,  FINDS  IT  HARD  TO  GET  ON  WITH  OTHERS/ 
PM8,  NEEDS  HELP  TO  WALK  OUTSIDE/ 
P7,  HAS  PAIN  WHEN  USING  STAIRS  OR  STEPS/ 
EM9,  WAKES  UP  DEPRESSED/ 
P8,  HAS  PAIN  WHEN  SITTING/ Appendix  XIII 
The  EORTC  Quality  Of  Life  Questionnaires  user's  guide  for 
data  analysis 
400 Scoring  Procedures  for  the 
EORTC  Core  Quality  of  Life  Questionnaire  (EORTC  QLQ-C30) 
The  questionnaire  includes  6  functional  scales: 
"  Physical  functioning  (PF) 
"  Role  functioning  (RF) 
"  Emotional  functioning  (EF) 
"  Cognitive  functioning  (CF 
"  Social  functioning  (SF) 
"  Global  health  status/quality  of  life  (QL) 
These  6  scales  are  all  constructed  in  a  similar  manner:  (1)  the  raw  scores  for  the  individual 
items  within  a  scale  are  first  summed,  and  then  divided  by  the  number  of  items  within  the 
scale;  and  (2)  these  scale  scores  are  then  linearly  transformed  auch  that  all  scales  range 
from  0  to  100,  with  a  higher  scale  score  representing  a  higher  level  of  functioning. 
Following  are  the  scoring  algorithms  for  the  5  functional  scales,  including  the  SPSS 
computational  language  (note:  the  two-letter  abbreviations  employed  for  the  various 
scales  and  items  are  arbitrary;  alternative  abbreviations  can,  of  course,  be  used). 
Physical  functioning  (questionnaire  items  1  through  5) 
1  Compute  an  additive  scale  (PF)  by  adding  the  questionnaire  items  1-5  (Q1  to  Q5) 
and  dividing  this  sum  by  the  number  of  items  (5): 
COMPUTE  PF=(Q1  +  Q2  +  Q3  +  Q4  +  Q5)/5. 
2  Carry  out  a  linear  transformation  to  convert  the  physical  functioning  scale  (PF)  to  a 
0-100  scale  (XPF): 
COMPUTE  XPF=100-((PF-1)  100). 
Role  functioning  (questionnaire  items  6  and  7) 
1  Compute  an  additive  scale  (RF)  by  adding  the  questionnaire  items  6  and  7  (Q6  and 
Q7)  and  dividing  this  sum  by  the  number  of  items  (2): 
COMPUTE  RF=(Q6+Q7)12. 
2  Carry  out  a  linear  transformation  to  convert  the  role  functioning  scale  (RF)  to  a 
0-100  scale  (XRF): 
COMPUTE  XRF  =100-((RF-1)'  100). 
Emotional  functioning  (questionnaire  items  21-24) 
1  Compute  an  additive  scale  (EF)  by  adding  the  questionnaire  items  21-24  (Q21  to 
Q24)  and  dividing  this  sum  by  the  number  of  items  (4): 
COMPUTE  EF=(Q21  +Q22+Q23+Q24)/4. 2  Carry  out  a  linear  transformation  to  convert  the  emotional  functioning  scale  (EF)  to  a 
0-100  scale  (XEF): 
COMPUTE  XEF  =100-((EF-1)'  10013). 
Cognitive  functioning  (questionnaire  items  20  and  25) 
1  Compute  an  additive  scale  (CF)  by  adding  the  questionnaire  items  20  and  25  (Q20 
and  Q25)  and  dividing  this  sum  by  the  number  of  items  (2): 
COMPUTE  CF=(Q20+Q25)/2. 
2  Carry  out  a  linear  transformation  to  convert  the  cognitive  functioning  scale  (CF)  to  a 
0-100  scale  (XCF): 
COMPUTE  XCF=100-((CF-1)'100/3). 
Social  functioning  (questionnaire  items  26  and  27) 
1  Compute  an  additive  scale  (SF)  by  adding  the  questionnaire  items  26  and  27  (Q26 
and  Q27)  and  dividing  this  sum  by  the  number  of  items  (2): 
COMPUTE  SF=(Q26+Q27)/2. 
2  Carry  out  a  linear  transformation  to  convert  the  social  functioning  scale  (SF)  to  a 
0-100  scale  (XSF): 
COMPUTE  XSF=100-((SF-1)  "  100/3). 
Global  health  status/qt'  aý  litt'  of  life  (questionnaire  items  29  and  30) 
1  Compute  an  additive  scale  (QL)  by  adding  the  questionnaire  items  29  and  30  (Q29 
and  Q30)  and  dividing  this  sum  by  the  number  of  items  (2): 
COMPUTE  QL=(Q29+Q30)12. 
2  Carry  out  a  linear  transformation  to  convert  the  global  quality  of  life  scale  (QL)  to  a 
0-100  scale  (XQL): 
COMPUTE  XQL=(QL-1)'100/6. 
The  questionnaire  includes  a  number  of  multi-item  scales  and  single  items  assessing  a 
range  of  physical  symptoms  common  among  patients  with  cancer.  An  additional  single 
item  assesses  the  financial  impact  of  the  disease  and  treatment.  These  scales  and  single 
items  are  linearly  transformed  such  that  all  scalesrtems  range  from  0  to  100,  with  a 
higher  score  representing  a  higher  level  of  symptomatology/problems. 
_ 
Fatigue  (FA) 
_ 
Appetite  loss  (AP) 
Nausea  and  vomiting  (NV) 
_ 
Constipation  (CO) 
Pain  (PA) 
_ 
Diarrhea  (DI) 
_  Dyspnea  (DY)  Financial  impact  (FI) 
_ 
Sleep  disturbance  (SL) Fatigue  (questionnaire  items  10,12  and  18) 
1  Compute  an  additive  scale  (FA)  by  adding  the  questionnaire  items  10,12  and  18 
(Q10,  Q12  and  Q181  and  dividing  this  sum  by  the  number  of  items  (3): 
COMPUTE  FA=(Q10+Q12+Q18)/3. 
2  Carry  out  a  linear  ttansformation  to  convert  the  fatigue  scale  (FA)  to  a  0-100  scale 
(XFA): 
COMPUTE  XFA=(FA-1)"100/3. 
Nausea  and  vomiting  (questionnaire  items  14  and  15) 
1  Compute  an  additive  scale  (NV)  by  adding  the  questionnaire  items  14  and  15  (Q14 
and  Q15)  and  dividing  this  sum  by  the  number  of  items  (2): 
COMPUTE  NV=(Q14+Q15)/2. 
2  Carry  out  a  linear  transformation  to  convert  the  nausea  and  vomiting  scale  (NV)  to  a 
0-100  scale  (XNV): 
COMPUTE  XNV=(NV-1)  100/3. 
P_aja  (questionnaire  items  9  and  19) 
1  Compute  an  additive  scale  (PA)  by  adding  the  questionnaire  items  9  and  19  (Q9  and 
Q19)  and  dividing  this  sum  by  the  number  of  items  (2): 
COMPUTE  PA=(Q9+Q19)/2. 
2  Carry  out  a  linear  transformation  to  convert  the  pain  scale  (PA)  to  a  0-100  scale 
(XPA): 
COMPUTE  XPA=(PA-1)'100/3. 
Single  items  (questionnaire  items  8,11,13,16,17  and  28) 
The  remaining  questionnaire  items  -  assessing  dyspnea  (DY),  sleep  disturbance  (SL), 
appetite  loss  (AP),  constipation  (CO),  diarrhea  (DI),  and  financial  difficulties  (F))  are  treated 
individually.  These  items  should  also  be  linearly  transformed  to  a  0-100  scale. 
COMPUTE  XDY=(DY-1)"100/3. 
COMPUTE  XSL=(SL-1)"100/3. 
COMPUTE  XAP=(AP-1)"10013. 
COMPUTE  XCO  =  (CO-1)  "  100/3. 
COMPUTE  XDI=(DI-1)'100/3. 
COMPUTE  XFI=(Fl-1)'100/3. 
Further  inquiries  regarding  the  scoring  algorithms  for  the  EORTC  QLQ-C30  can  be  directed 
to:  Said  Serbouti,  Head,  Quality  of  Life  Unit,  The  EORTC  Data  Center,  Avenue  Emmanuel 
Mounier  83111,1200  Brussels,  Belgium.  Telephone:  32-2-774-1606;  Telefax: 
32-2-772-3545. J 
0 
Scoring  procedures  for  the 
EORTC  QUALITY  OF  LIFE  QUESTIONNAIRE 
LONG  CANCER  MODULE 
The  questionnaire  module  includes  twelve  items  in  disease-  and  treatment-related 
symptoms,  and  one  conditional  item  on  effects  of  pain  medication. 
A  multi-item  scale  on  dyspneu  is  created,  while  the  remaining  symptoms  and  side- 
effects  are  measured  by  single  items.  All  raw  scores  are  linearly  transformed  to  a 
score  ranging  from  0  to  100,  with  a  higher  score  representing  more  complaints. 
Dyspneu  (items  33-35  in  QLQ-LC13  +  item  8  in  QLQ-C30) 
1.  Compute  an  additive  scale  (DY)  by  adding  the  scores  of  items  33,34,  and  35 
in  QLQ-LC13,  and  item  8  in  QLQ-C30.  Divide  the  sum  of  the  raw  scores 
by  the  number  of  items.  (4). 
COMPUTE  DY  -  (LC33+LC34+LC35+C8)  /4 
2.  Carry  out  a  linear  transformation  of  the  scale  score  (DY)  to  a  1-100  scale 
(XDY): 
COMPUTE  XDY  -  (DY"1)*  100/3 
Cough  (CO-LC31),  Haemoptysis  (HP-LC32),  Sore  mouth  (SM-LC36),  Trouble 
swallowing  (SW-LC37),  Peripheral  neuropathy  (PN-LC41),  Hair-loss 
(HL-LC39),  Pain_in_chest  (PC-LC40),  Pain_in_shoulder  (PS-LC41), 
Pain  elsewhere  (PE-LC42) 
COMPUTE  XCO  -  (CO-1)*100/3 
COMPUTE  XHP  -  (HP-1)  *  100/3 
COMPUTE  XSM  -  (SM-1)*100/3 
COMPUTE  XSW  -  (SW-1)*100/3 
COMPUTE  XPN  -  (PN-1)*100/3 
COMPUTE  XHL  -(HL-1)*100/3 
COMPUTE  XPC  -  (PC-1)*100/3 
COMPUTE  XPS  -  (PS-1)*100/3 
COMPUTE  XPE  -  (PE-1)*100/3 
Pain  medication  (PMa  -LC43,  PMb  -  LC44) 
COMPUTE  XPA  -  (PMa-1)*100 
if  XPMa  *0  (PMb  *  1): 
COMPUTE  XPMb  -  100-((PMb-1)*100/3) Appendix  XIV 
Distribution  of  patients'  scores  on  the  NHP 
405 Key:  vertical  axis  shows  number  of  patients  and  horizantal  axis  indicates  patients'  scores 
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